| 1189 | Aarnoutse R, Brinkman K, Benetucci J, et al. Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients. AIDS. 2004 Feb 20;18(3):565-7. | 15090812 |
| 1120 | Aarnoutse R, Droste J, van Oosterhout J, et al. Influence of once-daily nevirapine on the pharmacokinetics of OD nelfinavir/ritonavir combinations in healthy volunteers [abstract 7.5]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | |
| 945 | Aarnoutse RE, Grintjes KJT, Telgt D, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clinical Pharmacology and Therapeutics 2002;71:57-67. | 11823758 |
| 2591 | Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2005 Dec;78(6):664-74. | 16338282 |
| 1049 | Aarnoutse RE, Droste JA, Van Oosterhout JJ et al. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. British Journal of Clinical Pharmacology 2003; 55: 115–125. | 12580982 |
| 1602 | Abbott Laboratories. ProSom (estazolam) Prescribing Information. North Chicago, IL. December, 2004. | https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=97656 |
| 2586 | AbbVie Corporation. Holkira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) Product Monograph. St-Laurent, QC. August 10, 2017. | http://www.abbvie.ca/content/dam/abbviecorp/ca/english/docs/HOLKIRA_PAK_PM_EN.pdf |
| 3330 | Abbvie Corporation. Humira (adalimumab) Product Monograph. St-Laurent, QC. April 21, 2021. | https://pdf.hres.ca/dpd_pm/00052133.PDF |
| 175 | AbbVie Corporation. Kaletra (lopinavir/ritonavir) Product Monograph. St-Laurent, QC. July 5, 2021. | http://www.abbvie.ca/content/dam/abbviecorp/ca/english/docs/KALETRA_PM_EN.pdf |
| 2848 | AbbVie Corporation. Maviret (glecaprevir and pibrentasvir tablets) Product Monograph. St-Laurent, QC. April 7, 2022. | http://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/MAVIRET_PM_EN.pdf |
| 2847 | AbbVie Corporation. Mavyret (glecaprevir and pibrentasvir tablets) Prescribing Information. North Chicago, IL. August 2017. | http://www.rxabbvie.com/pdf/mavyret_pi.pdf |
| 899 | AbbVie Corporation. Norvir (ritonavir) Product Monograph. St-Laurent, QC. July 5, 2021. | http://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/NORVIR_PM_EN.pdf |
| 3331 | Abbvie Corporation. Rinvoq (upadacitinib) Product Monograph. St-Laurent, QC. July 26, 2021. | |
| 2652 | AbbVie Corporation. Technivie (ombitasvir, paritaprevir and ritonavir tablets) Prescribing Information. North Chicago, IL. November, 2017. | http://www.rxabbvie.com/pdf/technivie_pi.pdf |
| 2764 | AbbVie Corporation. Technivie (ombitasvir, paritaprevir and ritonavir tablets) Product Monograph. St-Laurent, QC. August 10, 2017. | http://www.abbvie.ca/content/dam/abbviecorp/ca/english/docs/TECHNIVIE_PM_EN.pdf |
| 3338 | Abbvie Corporation. Venclexta (venetoclax) Product Monograph. St-Laurent, QC. January 21, 2021. | |
| 2779 | AbbVie Corporation. Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) Prescribing Information. North Chicago, IL. November 2017. | http://www.rxabbvie.com/pdf/viekirapak_pi.pdf |
| 2871 | Abbvie Inc. Kaletra (lopinavir/ritonavir) Product Monograph. North Chicago, IL. April 2023. | http://www.rxabbvie.com/pdf/kaletratabpi.pdf |
| 3202 | Abbvie Inc. Norvir (ritonavir) Prescribing Information. North Chicago, IL. December 2022. | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022417s000TOC.cfm |
| 2679 | Abel S, al. E. Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK 427,857) in healthy volunteers [abstract LBPE4.3/15]. 10th European AIDS Conference, November 17-20, 2005, Dublin. | |
| 2677 | Abel S, Back D, Vourvahis M. Maraviroc: Pharmacokinetics and drug interactions. Antiviral Therapy. 2009;14(5):607-618. | 19704163 |
| 1408 | Abel S, Ridgway C, Hamlin J, et al. An open, randomised, 2-way crossover study to investigate the effect of darunavir/ritonavir on the pharmacokinetics of maraviroc in healthy subjects [abstract 55]. 8th International Workshop on Pharmacology of HIV Therapy, April 16-18, 2007, Budapest, Hungary. | |
| 2133 | Abel SR, Russell D, Whitlock L, et al. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):19-26. | 18333862 |
| 2619 | Aberg JA, Rosenkranz S, Fichtenbaum CJ, et al. Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS 2006;20(5):725-9. | 16514303 |
| 1977 | Abgrall S, Le Bel J, Lele N, et al. Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV patients. . HIV Clinical Trials 2013;14(6):313-8. | 24334184 |
| 1846 | Aboud M, Castelino S, Back DJ, et al. Etravirine plasma levels in a patient with decompensated liver disease. AIDS 2009;23(10):1293-5. | 19455013 |
| 228 | Aboulker JP, Swart AM. Preliminary analysis of the Concorde trial. Lancet 1993;341:889-90. | 8096582 |
| 2067 | Abrass C, Appelbaum J, Boyd C, et al. The HIV and Aging Consensus Project. Recommended treatment strategies for clinicians managing older patients with HIV. In: American Academy of HIV Medicine, AIDS Community Research Initiative of America, Society AG, editors. November, 2011. p. 1-76 Available from: www.aahivm.org/hivandagingforum.com. | http://www.aahivm.org/hivandagingforum.com |
| 3381 | AcelRx Pharmaceuticals, Inc. Dsuvia (sufentanil) sublingual tablet Package Insert. Redwood City, CA. November 2018. | |
| 2147 | Acle S, Roca F, Vacarezza M, et al. Ergotism secondary to ergotamine-ritonavir association. Report of three cases. Rev Med Chil 2011;139(12):1597-600. | 22446707 |
| 1855 | Acosta E, Kendall MA, Gerber JG, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007;51(9):3104-10. | 17576825 |
| 788 | Acosta EP, Gulick R, Katzenstein D, et al. Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus–Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359. The Journal of Infectious Diseases. 2000;182(5):1375-1384. | 11023461 |
| 957 | Acosta EP, Havlir DV, Richman DD, et al. Pharmacodynamics of indinavir in protease-naive HIV-infected patients receiving zidovudine and 3TC [abstract 455]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco. | |
| 341 | Acosta EP, Henry K, Baken L, et al. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999;19(6):708-12. | 10391416 |
| 2612 | Actelion Pharmaceuticals Canada Inc. Opsumit (macitentan) Product Monograph. Laval, QC November, 2015. | https://www1.actelion.com/documents/ca/ca-opsumit-procuct-monograph-en.pdf |
| 2004 | Actelion Pharmaceuticals Ltd. Tracleer (bosentan) Product Monograph. Laval, QC December 14, 2015. | https://pdf.hres.ca/dpd_pm/00033042.PDF |
| 2611 | Actelion Pharmaceuticals US I. Opsumit (macitentan) Product Monograph. South San Francisco, CA March, 2017. | https://opsumit.com/opsumit-prescribing-information.pdf |
| 2625 | Adamczyk R, Lubin S, Hesney M, et al. Effect of daclatasvir with asunaprevir and beclabuvir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norethindrone acetate in women [abstract 78]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC. | |
| 2977 | Adams JL, Patterson KB, Prince HMA, Sykes C, Greener BN, Dumond JB, Kashuba ADM. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. Antiviral Therapy 2013;18:1005-13. | 23899439 |
| 2014 | Adiwijaya B, Chandorkar G, Van Heeswijk RPG, et al. Effect of mild and moderate hepatic impairment on telaprevir pharmacokinetics [abstract PK_1]. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 22-23, 2011, Cambridge, MA. | http://regist2.virology-education.com/2011/6HEPPK/docs/05_Garg.pdf |
| 3111 | Adkison et al. Effect of sorbitol on 3TC PK afte administration of lamivusine solution in adults. CROI 2017. Seattle, Washington. Abstract #428. | http://www.croiconference.org/sites/default/files/posters-2017/428_Adkison.pdf |
| 227 | Advice for the Patient: Drug Information in Lay Language. Rockville, MD: The United States Pharmacopoeal Convention, Inc.; 1992. | |
| 2694 | Agarwala S, Eley T, Child M, et al. Pharmacokinetic effects of coadministration of atazanavir and tenofovir at steady state [poster WePe3.3C07]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, July 24-27, 2005, Rio de Janeiro. | http://www.medadvocates.org/resources/conferences/3rd%20_ias/05-156a_agarwala_086.pdf |
| 2906 | Agarwala S, Eley T, Child M, Wang Y, Persson A, Filoramo D, et al. Pharmacokinetics of atazanavir in severely renally impaired subjects including those on hemodialysis [abstract 2]. 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary, April 16-18, 2007. | http://www.natap.org/2007/pharm/Pharm_08.htm |
| 1390 | Agarwala S, Eley T, Villegas C, et al. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects [abstract 16]. 6th International Workshop on Clinical Pharmacology of HIV Therapy April 28-30, 2005, Quebec. | |
| 1218 | Agarwala S, Grasela D, Child M, et al. Characterization of the steady-state pharmacokinetic profile of atazanavir beyond the 24-hour dosing interval [abstract 845]. Antiviral Therapy 2003;8(S1):S422. | http://www.medadvocates.org/resources/conferences/iasconfpath/ias2003/atv%20pk%20past%2024%20hour%20interval.pdf |
| 2631 | Agarwala S, Gray K, Eley T, et al. Pharmacokinetic interaction between atazanavir and omeprazole in healthy subjects [poster WePe3.3C08]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, July 24-27, 2005, Rio de Janeiro. | http://www.medadvocates.org/resources/conferences/3rd%20_ias/05-156b_agarwala_109.pdf |
| 2570 | Agarwala S, Gray K, Nettles R, et al. Lack of pharmacokinetic interaction between atazanavir, ritonavir and fluconazole dosed to steady-state in healthy subjects [abstract A-0382]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27-30 2006, San Francisco, CA. | |
| 1381 | Agarwala S, Gray K, Wang Y, et al. Pharmacokinetic effect of omeprazole on atazanavir with ritonavir in healthy subjects [abstract 658]. 12th Conference on Retroviruses and Opportunistic Infections, February 22-25, 2005, Boston. | |
| 1106 | Agarwala S, Mummaneni V, Randall D, et al. Pharmacokinetic effect of rifabutin on atazanavir with and without ritonavir in healthy subjects [abstract 445-W]. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA. | |
| 1177 | Agarwala S, Russo R, Mummaneni V, et al. Steady-state pharmacokinetic interaction study of atazanavir with ritonavir in healthy subjects [abstract H1716]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. | |
| 1380 | Agarwala S. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects [abstract 11]. 6th International Workshop on Clinical Pharmacology of HIV Therapy, April 28-30, 2005, Quebec City, Canada. | |
| 2765 | Akamine Y, Miura M, Sunagawa S, et al.Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. Xenobiotica. 2010 Nov;40(11):782-9.. | 20839930 |
| 301 | Akingbehin T, Villada JR, Walley T. Metipranolol-induced adverse reactions: I. The rechallenge study. Eye 1992;6(Pt 3):277-9. | 1359978 |
| 302 | Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis [see comments]. British Journal of Ophthalmology 1991;75(9):519-23. | 1680389 |
| 421 | Akula SK, Ma PE, Peyman GA, et al. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. British Journal of Ophthalmology 1994;78(9):677-80. | 7947546 |
| 87 | Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993;34:161-2. | 8422851 |
| 859 | Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Safety 1998;18(2):83-97. | 9512916 |
| 1690 | Alberts DS, Chang SY, Chen HS, et al. Comparative pharmacokinetics of chlorambucil and melphalan in man. Recent Results Cancer Res 1980;74:124-31. | 7444135 |
| 1749 | Alberts DS, Chang SY, Chen HS, et al. Kinetics of intravenous melphalan. Clin Pharmacol Ther 1979;26:73-80. | 445964 |
| 3414 | Alidoost M, Conte GA, Agarwal K, et al. Iatrogenic Cushing’s Syndrome Following Intra-Articular Triamcinolone Injection in an HIV-Infected Patient on Cobicistat Presenting as a Pulmonary Embolism: Case Report and Literature Review. Int Med Case Rep J 2020;13:229-35. | 32607001 |
| 3185 | Allavena C, Dailly E, Reliquet V, et al. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1 infected subjects. J Antimicrob Chemother 2014;69:2804-2808 | 24907142 |
| 2850 | Allavena C, Volteau C, Andre-Garnier E et al. Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study). Med Mal Infect 2018 Dec 21 | 30583867 |
| 3307 | Allergan Pharmaceutical International Limited. Ubrelvy (ubrogepant) Prescribing Information. Madison, NJ. December 2019. | |
| 1388 | Almond L, Gibbons SE, Davies G, et al. A retrospective survey of the Liverpool TDM service: factors influencing efavirenz concentrations in patients taking rifampicin [abstract 19]. 6th International Workshop on Clinical Pharmacology of HIV Therapy April 28-30, 2005, Quebec. | |
| 833 | Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers [published erratum appears in Pharm Res 1998 Jun;15(6):958]. Pharmaceutical Research 1998;15(3):423-8. | 9563072 |
| 792 | Altice FL, Friedland GH, Cooney E. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999;13:957-62. | 10371177 |
| 1117 | Alvarez-Amao D, Pace W, Gold M. Switch from high to low dose amprenavir in combination with efavirenz and ritonavir [abstract 2.7]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | |
| 2584 | ALZA Corporation. Invega (paliperidone) Prescribing Information. Vacaville, CA. June 2017 | https://www.invegasustenna.com/important-product-information |
| 202 | Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrobial Agents and Chemotherapy 1991;35(6):1186-90. | 1656856 |
| 1185 | Amantea M, Raber S, Pesano R, et al. Pharmacokinetic model of capravirine, a novel non-nucleoside reverse transcriptase inhibitor, co-administered with Kaletra in healthy and HIV-infected subjects [abstract 8.3]. 4th International Workshop on Clinical Pharmacology of HIV Therapy, March 27-29, 2003, Cannes, France. | |
| 1294 | Amantea M, Raber S, Zhou J, et al. Effect of capravirine (CPV) on the safety and pharmacokinetics (PK) of atorvastatin (ATV) with and without lopinavir/ritonavir (LPV/r) in healthy volunteers [abstract TuPeB4630]. XV International AIDS Conference, July 11-16, 2004, Bangkok, Thailand. | |
| 1746 | Amantea MA, Forrest A, Northfelt DW, et al. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. Clin Pharmacol Ther 1997;61:301-11. | 9084455 |
| 2205 | American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT). Position Paper: Single-Dose Activated Charcoal. Clin Toxicol 2005;43:61–87. | 15822758 |
| 2206 | American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT). Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol 1999;37(6):731-51. | 10584586 |
| 207 | American Hospital Formulary Service Drug Information. McEvoy GK, editor. Bethesda MD: American Society of Health-System Pharmacists, Inc.,; 1995. | |
| 226 | American Society of Hospital Pharmacists. Medication Teaching Manual: The Guide to Patient Drug Information. 6th ed. Bethesda: American Society of Hospital Pharmacists, Inc.; 1994. | |
| 3664 | Amgen Canada Inc. Sensipar (cinacalcet) Product Monograph. Mississauga, ON. October 11, 2019. | https://pdf.hres.ca/dpd_pm/00053588.PDF |
| 3562 | Ammar H, Govindu RR. A dangerous and unrecognized interaction of apixaban. Cureus 2021;13:e19688. | 34934565 |
| 3625 | Amouyal C, Buyse M, Lucas-Martini L, et al. Sleeve gastrectomy in morbidly obese HIV patients: focus on anti-retroviral treatment absorption after surgery. Obes Surgery. 2018;28:2886-2893. | 29781044 |
| 976 | Amsden GW, Nafziger AN, Foulds G. A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1522-7. | 11185676 |
| 3021 | An G, Morris ME. A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. AAPS J 2012;14:352-64. | 22451016 |
| 426 | Anand R, Font RL, Fish RH, et al. Pathology of cytomegalovirus retinitis treated with sustained release intravitreal ganciclovir [see comments]. Ophthalmology 1993;100(7):1032-9. | 8391675 |
| 463 | Anand R, Nightinglage SD, Fish RH, et al. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Long term results. Archives of Ophthalmology 1993;111:223-7. | 8141855 |
| 1285 | Ananworanich J, Siangphoe U, Mahanontharit A, et al. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. Antivir Ther. 2004 Dec;9(6):1035-6. | 15651763 |
| 2469 | Ancrenaz V, Deglon J, Samer C, et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic & clinical pharmacology & toxicology 2013 Feb;112(2):132-7. | 22900583 |
| 312 | Anderson B, Anderson B. Necrotizing uveitis incident to perfusion of intercranial malignancies with nitrogen mustard and related compounds. Transactions of the American Ophthalmological Society 1960;58:95-105. | 13683174 |
| 1441 | Anderson MS, Hanley WD, Moreau A, et al. Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. Br J Clin Pharmacol 2011;71(4):616-20. | 21395656 |
| 1401 | Anderson MS, Kakuda TN, Hanley WD, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008;52(12):4228-32. | 18838586 |
| 3098 | Anderson MS, Kaufman D, Castronuovo P et al. Effect of Doravirine (MK-1439) on the Pharmacokinetics of an Oral Contraceptive (Ethinyl Estradiol and Levonorgestrel) [abstr 34].16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy May 26-28, 2015 Washington, DC. | |
| 3147 | Anderson MS, Khalilieh S, Yee KL, et al. A two-way steady-state pharmacokinetic interaction study of doravirine (MK-1439) and dolutegravir. Clin Pharmacokinetic 2017;56:661-9. | 27699622 |
| 1663 | Anderson MS, Mabalot Luk JA, Hanley WD, et al. Effect of raltegravir on the pharmacokinetics of methadone. J Clin Pharmacol 2010;12(1461-6). | 20173085 |
| 1515 | Anderson MS, Sekar V, Tomaka F, et al. Pharmacokinetic evaluation of darunavir/ritonavir and raltegravir in healthy subjects [abstract A-962]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington, DC. | http://www.hivandhepatitis.com/2008icr/icaac_idsa/posters/3_Anderson.pdf |
| 1240 | Anderson PL, Lamba J, Schuetz E, et al. MDR1 genotypes associated with antiviral dynamics and indinavir (IDV) disposition in HIV-infected patients [abstract 2.1]. 4th International Workshop on Clinical Pharmacology of HIV Therapy, March 27-29, 2003, Cannes, France. | |
| 3668 | Andrade A, Fuchs EJ, Marzinke MA, et al. EVG/cobi/FTC/TAF bioequivalence comparing whole tablets with tablets dissolved in tap water. AIDS Res Hum Retr 2023;39:38-43. | 36301928 |
| 2282 | Andrade A, Hendrix CW, Fuchs EJ, et al. Steady-state plasma and intracellular ribavirin concentrations are not significantly altered by abacavir co-administration in hepatitis C virus infected patients [abstract 538]. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA. | |
| 1611 | Andrade RA, Evans RT, Hamill RJ, et al. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated Histoplasmosis. Ann Pharmacother 2009;43:908-13. | 19401476 |
| 2182 | Andreasen AH, Brosen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on CYP3A4. Epilepsia 2007 Mar;48(3):490-6. | 17346248 |
| 1872 | Andrews E, Glue P, Fang J, et al. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol 2010;69:51-7. | 20078612 |
| 1524 | Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48(12):4680-6. | 15561844 |
| 2838 | Ankrom W, Sanchez RI, Yee KL et al. Investigation of pharmacokinetic interactions between doravirine and elbasvir-grazoprevir and ledipasvir-sofosbuvir. Antimicrob Agents Chemother 2019;63:e02491-18. | 30782982 |
| 2837 | Ankrom W, Sanchez RI, Yee KL, et al. Investigation of Pharmacokinetic Interactions Between Doravirine and Elbasvir/Grazoprevir and Ledipasvir/Sofosbuvir. Antimicrob. Agents Chemother 2019;63(5):e02491-18. | 30782982 |
| 3143 | Ankrom W, Yee KL, Sanchez RI, et al. Severe renal impairment has minimal impact on doravirine pharmacokinetics. Antimicrob Agents Chemother 2018;62. pii: e00326-18. | 29891610 |
| 331 | Anonymous. New guidance on post exposure prophylaxis of health care workers exposed to HIV at work. Communicable Disease Report CDR Weekly 1997;7(27):239. | 9223769 |
| 273 | Anonymous. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349(9063):1413-21. | 9164314 |
| 568 | Anonymous. Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group (ACTG). American Journal of Ophthalmology 1997;124(1):61-70. | 9222234 |
| 221 | Anonymous. Talk about prescriptions month. Planning Guide 1991;October:1-20. | |
| 2559 | Ansdell VE, Wright SG, Hutchinson DB. Megaloblastic anaemia associated with combined pyrimethamine and co-trimoxazole administration. Lancet 1976 Dec 4;2(7997):1257. | 63088 |
| 1184 | Antoniou A, Tseng AL, van Heeswijk RP, et al. Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients. Ther Drug Monit. 2005 Dec;27(6):779-81. | 16306854 |
| 2633 | Antoniou A, Yoong D, Beique LC, et al. Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series. Journal of Acquired Immune Deficiency Syndromes 2005;39(1):126-8. | 15851924 |
| 2719 | Antoniou T, Gough K, Yoong D, et al. Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. Clin Infec Dis 2004;38(5):e38-40. | |
| 2039 | Antoniou T, Tseng A. Interactions between antiretrovirals and antineoplastic agents. Clin Pharmacokinet 2005;44:111-45. | 15656694 |
| 2040 | Antoniou T, Tseng A. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002;36:1598-613. | 12243611 |
| 3317 | Anzenbacherova E, Spicakova A, Jourova L, et al. Interaction of rocuronium with human liver cytochromes P450. J Pharmacol Sc 2015;127:190-5. | 25727956 |
| 886 | Apseloff G, Foulds G, LaBoy-Goral L, et al. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. Journal of Clinical Pharmacology 1998;38(9):830-5. | 9753212 |
| 39 | Apseloff G, Hilligoss DM, Gardner MJ, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. Journal of Clinical Pharmacology 1991;31:358-61. | 2037709 |
| 2992 | Aralez Pharmaceuticals Trading DAC. Blexten (Bilastine) Product Monograph. Dublin, Ireland. April 20, 2016. | |
| 3568 | Arbor Pharmaceuticals. Nymalize (nimodipine) Prescribing Information. Atlanta, GA. May 2013. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203340lbl.pdf |
| 475 | Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. Journal of Infectious Diseases 1995;172(4):951-6. | 7561215 |
| 2512 | Arguin PM, Tan KR. Infectious Diseases Related to Travel: Malaria. In: Centers for Disease Control and Prevention, editor. CDC Health Information for International Travel 2014: Oxford University Press; 2014. | |
| 2762 | Armstrong SC, Wynn GH, Sandson NB. Pharmacokinetic drug interactions of synthetic opiate analgesics. (Psychosomatics 2009; 50:169–176) | 19377028 |
| 1645 | Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can Journal Cardiol 2006;22(1):23-45. | 16450016 |
| 3035 | Arora N, Gupta A, Sadeghi N. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma. BMJ Case Rep 2017 Oct 9. pii:bcr2017-222063. | 28993364 |
| 3521 | Arora P, Collins S.E, Martin H et al. Drug Interactions with once daily B/F/TAF in combination with once-weekly rifapentine [abstract 369]. Conference on Retroviruses and Opportunistic Infections (virtual CROI), March 6-10, 2021. | |
| 3279 | Asari A, Iles-Smith H, Chen YC et al. Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure. Br J Clin Pharmacol 2007;64:738-44. | 17662093 |
| 1479 | Aschmann YZ, Kummer O, Linka A, et al. Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors. Therapeutic Drug Monitoring 2008;30(1):130-4. | 18223477 |
| 842 | Asgari M, Back DJ. Effect of azoles on the glucuronidation of zidovudine by human liver UDP-glucuronosyltransferase [letter; comment]. Journal of Infectious Diseases 1995;172(6):1634-6. | 7594735 |
| 1921 | Ashby J, Garvey L, Erlwein O, et al. The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers [abstract O315]. Tenth International Congress on Drug Therapy in HIV Infection, November 7-11, 2010, Glasgow, UK. | |
| 2525 | Asimus S, Elsherbiny D, Hai TN, et al. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundamental & clinical pharmacology 2007 Jun;21(3):307-16. | 17521300 |
| 479 | Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. New England Journal of Medicine 1996;334(5):316-8. | 8532029 |
| 3315 | Aspen Pharmacare Canada Inc. Naropin (ropivacaine HCl) Product Monograph. Oakville, ON. March 25, 2019. | |
| 3123 | Astellas Pharma Canada Inc. Xtandi (enzalutamide) Product Monograph. Markham, ON. June 28, 2017. | http://www.cmsastellas.ca/uploads/pdf/Xtandi_PM_EN.pdf |
| 3155 | Astellas Pharma Canada, Inc. Myrbetriq (mirabegron) Product Monograph. Markham, ON. June 2, 2016. | |
| 3153 | Astellas Pharma Canada, Inc. Vesicare (solifenacin) Product Monograph. Markham, ON. September 19, 2013. | |
| 473 | Astra Pharmaceutical Products Inc. Foscavir Product Monograph. Westborough, MA 2000. | |
| 2470 | Astra Zeneca Canada Inc. Brilinta (ticagrelor) Product Monograph. Mississauga, ON. May 27, 2016. | https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/BRILINTA%20-%20Product-Monograph.pdf |
| 1808 | Astra Zeneca Canada Inc. Iressa (gefitinib) Product Monograph. Mississauga, ON. September 25, 2017. | http://www.astrazeneca.ca/en/Our-Medicines/en-Products-AZ |
| 3027 | Astra Zeneca Pharmaceuticals LP. Iressa (gefitinib) Prescribing Information. Wilmington, DE. July 2015. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206995s000lbl.pdf |
| 3336 | AstraZeneca Canada Inc. Calquence (acalabrutinib) Product Monograph. Mississauga, ON. November 28, 2019. | |
| 2724 | AstraZeneca Canada Inc. Diprivan 1% w/v (propofol injection) Prescribing Information. Mississauga, ON. July, 2012. | |
| 3274 | AstraZeneca Canada Inc. Faslodex (fulvestrant) Product Monograph. Mississauga, ON. November 7, 2017. | https://pdf.hres.ca/dpd_pm/00042059.PDF |
| 3232 | AstraZeneca Canada Inc. Lynparza (olaparib) Product Monograph. Mississauga, ON. March 19, 2019. | https://pdf.hres.ca/dpd_pm/00050332.PDF |
| 2183 | AstraZeneca Canada Inc. Seroquel (quetiapine) Product Monograph. Mississauga, ON. March 2, 2017. | http://www.astrazeneca.ca/en/Our-Medicines/en-Products-AZ |
| 3001 | AstraZeneca Canada Inc. Zomig (zolmitriptan) Product Monograph. Mississauga, ON. November 1, 2012. | |
| 1144 | AstraZeneca Canada Ltd. Seroquel Product Monograph. Mississauga, Ontario. March 2, 2017. | http://www.astrazeneca.ca/en/Our-Medicines/en-Products-AZ |
| 3488 | AstraZeneca Canada. AstraZeneca COVID-19 Vaccine (ChAdOx1-s [recombinant]) Product Monograph. Mississauga, ON. February 26, 2021. | https://covid-vaccine.canada.ca/info/pdf/astrazeneca-covid-19-vaccine-pm-en.pdf |
| 3337 | AstraZeneca Pharmaceuticals LP. Calquence (acalabrutinib) Package Insert. Wilmington, DE. October, 2017. | |
| 3231 | AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) Prescribing Information. Wilmington, DE. September 2018. | |
| 3009 | AstraZeneca Pharmaceuticals LP. Onglyza (saxagliptin) Prescribing Information. Wilmington, DE. April 2016. | |
| 3573 | AstraZeneca Pharmaceuticals LP. Seroquel (quetiapine) Prescribing Information. Wilmington, DE. June 2016. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020639s064lbl.pdf |
| 3659 | AstraZeneca Pharmaceuticals. Daliresp (roflumilast) Prescribing Information. Wilmington, DE. April 2017. | |
| 1681 | ATAC Trialists’ Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘ArimidexTM and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 2001;85:317-24. | 11487258 |
| 2325 | ATC/DDD Index [database on the Internet]2012 [cited September 2011]. Available from: http://www.whocc.no/atc_ddd_index/. | |
| 2361 | Atrio J, Stanczyk F, Neely M, et al. Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women. J Acq Immune Def Syndr 2014;65:72–77. | 24025339 |
| 2381 | Atrio J, Stanczyk FZ, Neely M, et al. Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women. J Acquir Immune Defic Syndr 2014 Jan 1;65(1):72-7. | 24025339 |
| 2610 | Atsmon J, Dingemanse J, Shaikevich D, et al. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet 2013 Aug;52(8):685-92. | 23568224 |
| 3422 | Atwine D, Baudin E, Gele T, et al. Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial. J Antimicrob Chemother 2020; 75:1250-1258. | 31999314 |
| 2153 | Aung GL, O'Brien JG, Tien PG, et al. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother 2010;44(11):1850-4. | 20978219 |
| 1445 | Autar R, Wit FWNM, Sankote J, et al. Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients AIDS 2007;21:1535-9. | 17630547 |
| 1345 | Aventis Pharma Inc. Frisium Product Monograph. Laval, QC 2001. | |
| 146 | Aversa SL, Kimberlin C. Psychosocial aspects of antiretroviral medication use among HIV patients. Patient Education and Counseling 1996;29:207-19. | 9006237 |
| 3637 | Avihingsanon A, Gatechompol S, Ueaphongsukkit T, et al. Safety and pharmacokinetic of daily isoniazid/rifapentin (1HP) in adults with standard dose of dolutegravir [abstract 7378]. 24th International AIDS Conference, July 29 - August 2, 2022; Virtual and Montreal, Canada | https://programme.aids2022.org/Abstract/Abstract/?abstractid=7378 |
| 3693 | Avihingsanon A, Jirajariyavet S, Treebupachatsakul P, et al. 24 week efficacy and safety of efavirenz- and dolutegravir-based antiretroviral therapy with isoniazid and rifapentine for tuberculosis preventive therapy (1HP and 3HP) in Thai people living with HIV. IAS 2023 Conference, Brisbane, Australia. July 23-26, 2023. | https://programme.ias2023.org/Abstract/Abstract/?abstractid=3650 |
| 2372 | Avihingsanon A, Ramautarsing RA, Suwanpimolkul G, et al. Ergotism in thailand caused by increased access to antiretroviral drugs: A global warning. Top Antivir Med 2014;21(5):165-8. | 24531557 |
| 3638 | Avihingsanon A, Ueaphongsukkit T, Gatechompol S, et al. Pharmacokinetic and 48 week efficacy of once-daily vs twice-daily dolutegravir among patients with human immunodeficiency virus/tuberculosis coinfection receiving rifampicin based tuberculosis therapy: a randomized control trial [abstract 7329]. 24th International AIDS Conference, July 29 - August 2, 2022; Virtual and Montreal, Canada. | https://programme.aids2022.org/Abstract/Abstract/?abstractid=7329 |
| 2896 | Avihingsanon A, van der Lugt J, Kerr SJ, Gorowara M, Chanmano S, Ohata P, Lange J, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther. 2009 Apr;85(4):402-8. doi: 10.1038/clpt.2008.244. Epub 2008 Dec 31. | 19118378 |
| 1629 | Avihingsanon A, van der Lugt J, Singphore U, et al. Pharmacokinetics Safety and 24 weeks efficacy of ritonavir-boosted indinavir (600/100 mg BID) in HIV/TB co-infected Thai patients receiving rifampin [abstract TUPEB144]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Capetown, South Africa. | |
| 866 | Aweeka FT, Brody SR, Jacobson M, et al. Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration? Clinical Therapeutics 1998;20(2):232-43. | 9589815 |
| 571 | Aweeka FT, Gambertoglio JG, Kramer F, et al. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. Clinical Pharmacology & Therapeutics 1995;57(4):403-12. | 7712668 |
| 855 | Aweeka FT, Gambertoglio JG, van der Horst C, et al. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). Antimicrobial Agents & Chemotherapy 1992;36(8):1773-8. | 1416864 |
| 497 | Bach MC, Bagwell SP, Knapp NP, et al. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 1985;103(3):381-2. | 2992335 |
| 516 | Bach MC, Hedstrom PS. CMV retinitis treated with ganciclovir [9(1,3-dihydroxy-2-propoxymethyl) guanine] in patients with AIDS. Annals of Ophthalmology 1987;19(10):369-73,75. | 2825580 |
| 57 | Bach MC. Possible drug interaction during therapy with azidothymidine and acyclovir for AIDS [letter]. New England Journal of Medicine 1987;317:547. | 3468354 |
| 1715 | Bachur NR. Adriamycin (NSC-123127) pharmacology. Cancer Chemother Rep 1975;6:153-8. | |
| 107 | Baciewicz AM, Ashar BH, Locke TW. Interaction of ofloxacin and warfarin [letter]. Annals of Internal Medicine 1993;119:1223. | 8239258 |
| 121 | Back D, Haworth S, Hoggard P, et al. Drug interactions with d4T phosphorylation in vitro [abstr]. XI International Conference on AIDS, July 1996, 1996, Vancouver. | |
| 1128 | Back DJ, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002;16(suppl 1):S5-S37. | 12035820 |
| 1490 | Back DJ, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monitor 2006;28(3):468-73. | 16778736 |
| 983 | Back DJ, Khoo SH, Gibbons SE, et al. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Therapeutic Drug Monitoring 2000;22(1):122-6. | 10688274 |
| 1651 | Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-6. | 1659439 |
| 1213 | Badaro R, DeJesus E, Lazzarin A, et al. Efficacy and safety of atazanavir with ritonavir or saquinavir versus lopinavir/ritonavir in combination with tenofovir and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16 week results from BMS AI424-045 [abstract 118]. Antiviral Therapy 2003;8(S1):S212-13. | |
| 3456 | Badell ML, Sheth AN, Momplaisir F, et al. A multicenter analysis of elvitegravir use during pregnancy on HIV viral suppression and perinatal outcomes. Open Forum Infect Dis 2019;6(4):1-7. | 31037241 |
| 3629 | Badowski M, Kassem S, Taylor C et al. Virologic outcomes of antiretroviral therapy in HIV-1 infected patients following bariatric surgery: a case series. Open Forum Infect Dis 2016;3(Suppl_1). | |
| 2689 | Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 2015 May;15(5):1313-22. | 25708713 |
| 2673 | Badri PS, King JR, Polepally AR et al. Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clin Pharmacokinet. 2015 Sep 2. [Epub ahead of print] | |
| 2665 | Badri PS, Dutta S, Wang H, et al. Drug interactions with direct acting antiviral combination of paritaprevir/ritonavir + ombitasvir [abstract 55]. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 26-28, 2015, Washington, DC. | |
| 1172 | Baede P, Piscitelli S, Graham N, et al. Drug interactions with TMC125, a potent next generation NNRTI [abstract A1827]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. | |
| 2198 | Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67. | 21812507 |
| 3648 | Baettig V, Courlet P, Tarik D et al. Boosted darunavir, emtricitabine, and tenofovir pharmacokinetics in the early and late postgastric bypass surgery periods. AIDS 2018;32:1903-1905. | |
| 2145 | Baeza MT, Merino E, Boix V, et al. Nifedipine-lopinavir/ritonavir severe interaction: a case report. AIDS 2007;21(1):119-20. | 17148983 |
| 30 | Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-9. | 1671113 |
| 24 | Bailey DG. Food-drug interactions: emphasis on grapefruit juice effects. Canadian Journal of Clinical Pharmacology 1995;2:10-14. | |
| 1662 | Baker J, Rainey PM, Moody D, et al. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors didanosine, lamivudine and tenofovir. Am J Addict 2010 Jan 1;19(1):17-29. | 20132118 |
| 908 | Baldwin JR, Borin MT, Ferry JJ, et al. Pharmacokinetic interaction between the HIV protease inhibitors tipranavir and ritonavir [abstract 657]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-28, 1999, San Francisco, CA. | |
| 150 | Balestra P, Ferri F, Galgani S, et al. Clinical, psychological and behavioural characteristics of HIV patients reporting low compliance to treatments [abstr. Tu. B.2148]. XI International Conference on AIDS, July, 1996, Vancouver. | |
| 540 | Balfour HH, Jr., Drew WL, Hardy WD, et al. Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary. JAIDS 1992;5(Suppl 1):S37-44. | 1318367 |
| 1682 | Balis FM, Holcenberg JS, Bleyer WA. Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 1983;8:202-32. | 6189661 |
| 346 | Ballard C, Toerner JG, Colwell B, et al. Early CD4, viral load, and quality of life response to salvage treatment with nelfinavir: the UCSD Owen Clinic nelfinavir expanded access experience [abstr. I-192]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 3333 | Ballent M, Lifschitz A, Virkel G et al. Involvement of P-glycoprotein on ivermectin kinetic behaviour in sheep: itraconazole-mediated changes on gastrointestinal absorption. J Vet Pharmacol Ther 2007;30:242-8. | 17472656 |
| 3332 | Ballent M, Lifschitz A, Virkel G, et al. Pretreatment with the inducers rifampicin and phenobarbital alters ivermectin gastrointestinal disposition. J Vet Pharmacol Ther 2010;33:252-9. | 20557442 |
| 329 | Bangsberg D, Zolopa AR, Bamberger J, et al. Protease inhibitors in HIV-infected homeless and marginally housed adults [abstr. I-180]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 1066 | Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-3. | 11416722 |
| 1214 | Bangsberg DR, Wu Y, Yuan Y, et al. Pill burden predicts adherence regimen discontinuation or switch, viral load and CD4 cell response in a nationwide US sample of HIV+ antiretroviral naive people on protease inhibitor therapy [abstract 757]. Antiviral Therapy 2003;8(S1):S395. | |
| 385 | Banker AS, Arevalo JF, Munguia D, et al. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. American Journal of Ophthalmology 1997;124(2):168-80. | 9262540 |
| 1874 | Barau C, Blouin P, Creput C, et al. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. Fundam Clin Pharmacol 2009;23(4):423-5. | 19709321 |
| 3085 | Barbarini G, Villani P, Cusato M, Sangiovanni L, Carbonara S, Ciraci E, et al. Free and total plasma concentrations of amprenavir in HIV-positive patients with hepatitis co-infection treated with unboosted fosamprenavir [abstract P_38]. 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, the Netherlands, April 15-17, 2009. | |
| 2601 | Barco S, Coppens M, van den Dool EJ, et al. Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation. Thromb Haemost 2014 Oct;112(4):836-8. | 24990596 |
| 577 | Barditch-Crovo P, Toole J, Hendrix CW, et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. Journal of Infectious Diseases 1997;176(2):406-13. | 9237705 |
| 764 | Baril L, Jouan M, Agher R, et al. Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS. AIDS. 2000 Nov 10;14(16):2593-6. | 11101072 |
| 2416 | Barrail-Tran A, Braun J, Vincent C, et al. Atazanavir and ritonavir pharmacokinetics with telaprevir-based HCV treatment (ANRSHC26) [abstract MOPE42]. 20th International AIDS Conference, July 20-25, 2014, Melbourne, Australia. | |
| 1424 | Barrail-Tran A, Furlan V, Blouin P, et al. Effect of coadministered protease inhibitor regimen on tacrolimus blood concentration in 3 kidney transplanted HIV-infected patients [abstract 58]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2007, Budapest, Hungary. | |
| 1877 | Barrail-Tran A, Yazdanpanah Y, Goldwirt L, et al. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients. AIDS 2010;24(16):2581-3. | 20960678 |
| 1324 | Barrios A, Rendon A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS. 2005 Mar 24;19(6):569-75. | 15802975 |
| 242 | Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clinical Pharmacokinetics 1997;32(3):194-209. | 9084959 |
| 1022 | Barry M, Howe J, Back D, et al. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. British Journal of Clinical Pharmacology 1993;36:82-5. | 8373716 |
| 1016 | Barry M, Howe JL, Ormesher S, et al. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with acquired immunodeficiency syndrome. British Journal of Clinical Pharmacology 1994;37:421-6. | 8054247 |
| 2471 | Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clinical pharmacokinetics 1999 Apr;36(4):289-304. | 10320951 |
| 1155 | Bart PA, Rizzardi PG, Gallant S, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Therapeutic Drug Monitoring 2001;23(5):553-5. | 11591903 |
| 2927 | Bartels H, Decosterd L, Battegay M et al. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. Journal of Antimicrobial Chemotherapy 2017, 72(9):2574–2577 | 28575323 |
| 268 | Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Annals of Internal Medicine 1996;125(3):161-72. | 8686973 |
| 1207 | Bartlett JA, DeMasia R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-77. | 11504958 |
| 15 | Bass JB, Jr., Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Journal of Respiratory and Critical Care Medicine 1994;149:1359-74. | 8173779 |
| 2441 | Bastida C, Also MA, Pericas JM, et al. [Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?]. Enferm Infecc Microbiol Clin 2014 Jun 6. | 24913991 |
| 579 | Bates CM, Carey PB, Hind CRK. Anaphylaxis due to liposomal amphotericin (AmBisome). Genitourinary Medicine 1995;71:414-5. | 8566990 |
| 2472 | Bates D, Dalton B, Gilmour J, et al. Venous thromboembolism due to suspected interaction between rivaroxaban and nevirapine. The Canadian journal of hospital pharmacy 2013 Mar;66(2):125-9. | 23616677 |
| 2179 | Bates DE, Herman RJ. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ann Pharmacother 2006;40(6):1190-5. | 16720703 |
| 408 | Baudouin C, Chassain C, Caujolle C, et al. Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Ophthalmologica 1996;210(6):329-35. | 8887389 |
| 3 | Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. Journal of the Acquired Immune Deficiency Syndrome 1992;5:1237-57. | 1453334 |
| 3391 | Bayer Inc. Adempas (riociguat) Product Monograph. Mississauga, ON. March 31, 2020 | https://pdf.hres.ca/dpd_pm/00055581.PDF |
| 3216 | Bayer Inc. Androcur (cyproterone acetate) Product Monograph. Toronto, Canada. February 25, 2011. | https://pdf.hres.ca/dpd_pm/00012618.PDF |
| 2009 | Bayer Inc. Levitra (vardenafil) Product Monograph. Mississauga, ON. June 4, 2015. | http://omr.bayer.ca/omr/online/levitra-pm-en.pdf |
| 1813 | Bayer Inc. Nexavar (sorafenib) Product Monograph. Mississauga, ON. December 17, 2014. | http://omr.bayer.ca/omr/online/nexavar-pm-en.pdf |
| 3269 | Bayer Inc. Stivarga (regorafenib) Product Monograph. Mississauga, ON. January 30, 2019. | https://pdf.hres.ca/dpd_pm/00049537.PDF |
| 2473 | Bayer Inc. Xarelto (rivaroxaban) Product Monograph. Mississauga, ON. September 1, 2016 | http://omr.bayer.ca/omr/online/xarelto-pm-en.pdf |
| 2273 | Bayer Inc. Xarelto (rivaroxaban) Product Monograph. Mississauga, ON. September 1, 2016. | http://omr.bayer.ca/omr/online/xarelto-pm-en.pdf |
| 2006 | Beau-Salinas F, Garot D, Le Guellec C, et al. Possible reduction in indinavir serum concentrations by bosentan. Ther Drug Monitor 2005;27(6):822-3. | 16306862 |
| 933 | Beauverie P, Taburet AM, Dessalles MC, et al. Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. AIDS 1998;12(18):2510-1. | 9875597 |
| 645 | Beck RW, Moke P, Blair RC, et al. Uveitis associated with topical beta-blockers. Archives of Ophthalmology 1996;114(10):1181-2. | 8859074 |
| 3496 | Begley R, Lutz J, Dvory-Sobol H, et al. Clinical evaluation of drug interactions with oral lenacapavir and probe drugs [abstract 89]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, March 6-10, 2021. | |
| 2440 | Begley R, Martin H, Lawson EB, et al. Pharmacokinetics and safety of tenofovir alafenamide in subjects with mild or moderate hepatic impairment [abstract P_39]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 3146 | Behm MO, Yee KL, Levine V, et al. The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects. Clin Drug Investig 2017;37:571-9. | 28349328 |
| 1991 | Beinema M, Brouwers JRBJ, Schalekamp T, et al. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008;100:1052-7. | 19132230 |
| 2733 | Bekhti A, Pirotte J. Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts. Br J Clin Pharmacol. 1987;24(3):390-2. | |
| 3509 | Bekker A, Capparelli E, Violari A, et al. Abacavir dosing in neonates from birth: a pharmacokinetic analysis [abstract 605]. Conference on Retroviruses and Opportunistic Infections (CROI) 2021. Virtual | https://www.croiconference.org/abstract/abacavir-dosing-in-neonates-from-birth-a-pharmacokinetic-analysis/ |
| 3644 | Bekker A, Capparelli, Violari A et al. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. Lancet HIV 2022;9(1):e24-31. | 34883066 |
| 3347 | Bekker A, Violari A, Cababasay M, et al. Pharmacokinetics of Nevirapine prophylaxis in HIV-exposed low birth weight infants [abstract 758]. Conference on Retroviruses and Opportunistic Infections (CROI), March 8-11, 2017. Seattle, WA | http://www.croiconference.org/sessions/pharmacokinetics-nevirapine-prophylaxis-hiv-exposed-low-birth-weight-infants |
| 1007 | Bellibas SE. Ritonavir-fluoxetine interaction. Antimicrobial Agents and Chemotherapy 1999;43(7):1815. | 10438337 |
| 878 | Benedek IH, Fiske WD, White SJ, et al. Pharmacokinetic interaction between multiple doses of efavirenz and rifabutin in healthy volunteers [abstract]. Clinical Infectious Diseases 1998;27:1008. | |
| 380 | Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction studies in healthy volunteers with efavirenz and the macrolide antibiotics, azithromycin and clarithromycin [abstr. 347]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 703 | Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers [abstract 42280]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 1842 | Benhamida J, Chappey C, Coakley E, et al. HIV-1 genotype algorithms for prediction of etravirine susceptibility; novel mutations and weighting factors identified through correlations to phenotype. Antiviral Ther 2008;13:A142. | |
| 941 | Benichou C, Danan G. A new method for drug causality assessment: RUCAM. In: Benichou C, editor. Adverse drug reactions: a practical guide to diagnosis and management. Chichester, England: John Wiley & Sons Ltd.,; 1994. p. 277-83. | |
| 1717 | Benjamin RS, Riggs CE, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal renal and hepatic function. Cancer Res 1977;37:1416-20. | 856462 |
| 32 | Benton R, Honig P, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of Qtc [abstr]. Clinical Pharmacology and Therapeutics 1994;55:146. | 8612381 |
| 1009 | Berbel GA, Latorre IA, Porta EJ, et al. Protease inhibitor-induced carbamazepine toxicity. Clinical Neuropharmacology 2000;23(4):216-8. | 11020127 |
| 141 | Berg JS, Dischler J, Wagner DJ, et al. Medication compliance: a healthcare problem. Annals of Pharmacotherapy 1993;27:S3-19. | 8400462 |
| 2827 | Berger JL, Nguyen Y, Lebrun D, et al. Early neuropsychological adverse events after switching from PI/r to dolutegravir could be related to hyperthyroidism in patients under levothyroxine. Antivir Ther. 2016 Nov 11. [Epub ahead of print] | 27834772 |
| 1058 | Bergshoeff AS, Wolfs TFW, Geelen SPM, et al. Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. Annals of Pharmacotherapy 2003;37:521-5. | 12659608 |
| 2332 | Bernstein B, Menon RM, Klein CE, et al. Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers [abstract 58]. HepDART, December 6-10, 2009, Kohala Coast, Hawaii. | |
| 1830 | Berretta M, Di Benedetto F, Bearz A, et al. FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. Cancer Invest 2008;26(6):610-4. | 18584352 |
| 2795 | Berretta M, Lleshi A, Cappellani A, et al. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr HIV Res 2010;8:218-22. | 20158458 |
| 1802 | Berretta M, Lleshi A, Di Benedetto F, et al. Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients. Ann Oncol 2006;17(7):1176-7. | 16798837 |
| 2346 | Bertelsen K, Montes M, Horban A, et al. Efficacy, safety and pharmacokinetics of telaprevir, peg-IFN-alfa-2a, and ribavirin in combination with darunavir/ritonavir-based HAART in HCV/HIV-1 co-infected patients (INSIGHT substudy) [abstract PE7/11]. 14th European AIDS Conference (EACS), October 16-19, 2013, Brussels, Belgium. | |
| 398 | Berthe P, Baudouin C, Garraffo R, et al. Toxicologic and pharmacokinetic analysis of intravitreal injections of foscarnet, either alone or in combination with ganciclovir. Investigative Ophthalmology & Visual Science 1994;35(3):1038-45. | 8125715 |
| 1794 | Berthou F, Dreano Y, Belloc C, et al. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 1994;47:1883-95. | 8204106 |
| 3578 | Berton M, Bettonte S, Decosterd L et al. Pharmacokinetics of dolutegravir and bictegravir in obese people living with HIV [abstract 436]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, February 12-16, 2022. | |
| 1276 | Bertz R, Ashbrenner E, Foit C, et al. Assessment of steady-state pharmacokinetics of three dosing regimens of saquinavir administered as hard gelatin capsules in combination with lopinavir/ritonavir to HIV-infected adults [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 1169 | Bertz R, Foit C, Ashbrenner E, et al. Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects [abstract A1822]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. | |
| 1121 | Bertz R, Foit C, Burt D, et al. Assessment of the multiple-dose pharmacokinetic interaction between Kaletra (lopinavir/ritonavir) and amprenavir in healthy volunteers [abstract 7.6]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | |
| 1099 | Bertz R, Foit C, Chiu Y-L, et al. Multiple-dose Kaletra (lopinavir/ritonavir) does not affect the pharmacokinetics of the CYP2D6 probe, desipramine [abstract 433-W]. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA. | |
| 1123 | Bertz R, Foit C, Ye X, et al. Pharmacokinetics of once-daily vs. twice-daily Kaletra (lopinavir/ritonavir) in HIV+ subjects [abstract 126]. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA. | |
| 1156 | Bertz R, Hsu A, Lam W, et al. Pharmacokinetic interactions between Kaletra and other non-HIV drugs [abstract 438]. 5th International Congress on Drug Therapy in HIV Infection, October 22-26, 2000, Glasgow, Scotland. | |
| 920 | Bertz R, Lam W, Brun S, et al. Multiple-dose pharmacokinetics of ABT-378/ ritonavir in HIV-positive subjects [abstract 327]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-28, 1999, San Francisco, CA. | |
| 967 | Bertz R, Lam W, Hsu A, et al. Assessment of the pharmacokinetic interaction between ABT-378/ritonavir and efavirenz in healthy volunteers and in HIV+ subjects [abstract 424]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. | |
| 1261 | Bertz R, Li J, King M, et al. Lopinavir inhibitory quotient predicts virologic response in highly antiretroviral-experienced patients receiving high-dose lopinavir/ritonavir [abstract 134]. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco CA. | |
| 1050 | Bertz R, Renz C, Foit C, et al. Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100 mg BID) in HIV-infected subjects when taken with food [abstract 3.10]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4, 2001, Noordwijk, the Netherlands. | |
| 261 | Bertz RJ, Cao G, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of desipramine [abstr]. XI International Conference on AIDS, July 7-12, 1996, Vancouver. | |
| 262 | Bertz RJ, Cao G, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of trimethoprim/sulfamethoxazole [abstr]. XI International Conference on AIDS, July 7-12, 1996, Vancouver. | |
| 1377 | Bertz RJ, Chiu Y-L, Naylor C, et al. Lack of effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients [abstract P279]. 7th International Congress on Drug Therapy in HIV Infection, November, 2004, Glasgow. | |
| 1170 | Bertz RJ, Foit C, Ashbrenner E, et al. Effect of amprenavir on the steady-state pharmacokinetics of lopinavir/ritonavir in HIV+ and healthy subjects [abstract A1823]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. | |
| 244 | Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics 1997;32(3):210-58. | 9084960 |
| 151 | Besch CL, Morse E, Simon P, et al. Preliminary results of a compliance study within CPCRA 007 combination nucleoside study (NuCombo) [abstract 254]. 4th National Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 213 | Besch CL. Compliance in clinical trials. AIDS 1995;9:1-10. | 7893432 |
| 3466 | Best BM, Burchett S, Li H, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med 2015;16(8):502-511. | 25959631 |
| 3204 | Best BM, Capparelli EV, Diep H,et al. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. J Acquir Immune Defic Syndr 2011;58(4):385-91. | 21876444 |
| 2902 | Best BM, Letendre SL, Brigid E, et al. Low atazanavir concentrations in cerebrospinal fluid. AIDS (London, England). 2009;23(1):83-87. doi:10.1097/QAD.0b013e328317a702. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2642983/ |
| 366 | Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrobial Agents & Chemotherapy 1995;39(7):1546-53. | 7492102 |
| 3428 | BGP Pharma ULC. Dymista (azelastine and fluticasone) Product Monograph. Etobicoke, ON. May 31, 2018. | |
| 287 | Bhalla K, Birkhofer M, Li GR, et al. 2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity. Blood 1989;74(6):1923-8. | 2572282 |
| 1997 | Bickel M, Anadol E, Vogel M, et al. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother 2010;65(5):999-1004. | 20202988 |
| 2451 | Bickel M, Khaykin P, Stephan C, et al. Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. HIV Med 2013 Nov;14(10):633-8. | 23980564 |
| 2603 | Bidon D, Bauler S, Venon M, Dupont C. Cobicistat-vinblastine interaction and severe peripheral neuropathy. AIDS 2015;29(9):1120-21. | 26125146 |
| 2356 | Bifano M, Adamczyk R, Hwang C, et al. Daclatasvir pharmacokinetics in healthy subjects: no clinically-relevant drug-drug interactions with either cyclosporine or tacrolimus [abstract 1081]. Hepatology 2013;58(4 suppl):730A. | |
| 2316 | Bifano M, Hwang C, Oosterhuis B, et al. Assessment of HIV ARV drug interactions with the HCV NS5A replication complex inhibitor BMS-790052 demonstrates a pharmacokinetic profile which supports co-administration with tenofovir disoproxil fumarate, efavirenz, and atazanavir/ritonavir [abstract 618]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA. | |
| 2317 | Bifano M, Sevinsky H, Bedford B, et al. Coadministration of BMS-790052 and BMS-650032 does not result in a clinically meaningful pharmacokinetic interaction in healthy subjects [abstract 827]. 61st Annual Meeting of the American Association for the Study of Liver Diseases, October 29-November 2, 2010, Boston, MA. | |
| 2430 | Bifano M, Sevinsky H, Persson A, et al. Daclatasvir (DCV; BMS-790052) has no clinically significant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects [abstract]. 62th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 6-9, 2011, San Francisco, CA. | |
| 2318 | Bifano M, Sevinsky H, Persson A, et al. Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects [abstract]. 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 6-9, 2011, San Francisco. | http://www.natap.org/2011/AASLD/AASLD_78.htm |
| 2311 | Bifano M, Sevinsky H, Stonier M, et al. Daclatasvir, an HCV NS5A replication complex inhibitor, has minimal effect on pharmacokinetics of midazolam, a sensitive probe for cytochrome P450 3A4 [abstract O_15]. 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 26-27, 2013, Cambridge, MA. | |
| 784 | Bilello JA, Bilello PA, Symonds W, et al. Amprenavir (141W94) in combination with 1592U89 is highly synergistic in vitro [abstract I-21]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24-27, 1998, San Diego. | |
| 2537 | Bindschedler M, Lefevre G, Degen P, et al. Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants. The American journal of tropical medicine and hygiene 2002 Mar;66(3):293-8. | 12139223 |
| 2534 | Bindschedler M, Lefevre G, Ezzet F, et al. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. European journal of clinical pharmacology 2000 Aug;56(5):375-81. | 11009045 |
| 3235 | Biocodex. Diacomit (stiripentol) Full Prescribing Information. France. August 2018. | |
| 2178 | Birbeck GL, French JA, Perucca E, et al. Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee on the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology 2012;78(2):139-45. | 22218281 |
| 622 | Biron KK, Davis MG, Stanat SC, et al. Antiviral activity and mechanism of action of 1263 W94, a benzimidazole riboside inhibitor of human cytomegalovirus [abstract H085]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 15-18, 1996, New Orleans. | |
| 2252 | Black A, Dunn S, Guilbert É, et al. Canadian Contraception Consensus—Update on depot medroxyprogesterone acetate (DMPA). J Obstet Gynaecol Can 2006;28(4):305-8. | 16776909 |
| 1639 | Black DJ, Kunze KL, Wienkers L, et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996;24:422-8. | 8801057 |
| 82 | Black PN. Probable interaction between fluoxetine and itraconazole. Annals of Pharmacotherapy 1995;29:1048-9. | 8845547 |
| 3365 | Blackman AL, Heil EL, Devanathan AS, et al. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: A case report. Antivir Ther 2020 Apr 28 [Epub ahead of print]. | https://pubmed.ncbi.nlm.nih.gov/32341207/ |
| 3183 | Blair C, Li S, Chau G et al. Brief report: Hormonal contraception use and cabotegravir pharmacokinetics in HIV-uninfected women enrolled in HPTN 077. JAIDS 2020;85:93-7. | 32452972 |
| 1375 | Blanchard JN, Wohlfeiler M, Canas A, et al. Pancreatitis with didanosine and tenofovir disoproxil fumarate. Clinical Infectious Diseases 2003;37(5):e57-62 [Erratum in: Clin Infect Dis. 2003 Oct 1;37(7):995]. | 12942419 |
| 1566 | Blanco JL, Martinez-Rebollar M, Calvo M, et al. Pharmacokinetic interaction between raltegravir and tipranavir/ritonavir in HIV-1 infected patients [abstract P_23]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam, The Netherlands. | |
| 1757 | Blanz J, Mewes K, Ehninger G, et al. Evidence for oxidative activation of mitoxantrone in human, pig, and rat. Drug Metab Dispos 1991;19:871-80. | 1686230 |
| 2645 | Bloch M, Quan D, Kaufmann G, et al. Pharmacokinetics, tolerability and therapeutic response of double boosted protease inhibitor antiretroviral therapy with lopinavir/ritonavir and atazanavir administered once and twice daily in patients with HIV-1 infection [abstract TUPE0075]. XVI International AIDS Conference August 13-18 2006, Toronto, Canada | |
| 93 | Block SH. Carbamazepine-isoniazid interaction. Pediatrics 1982;69:494-5. | 7070898 |
| 2373 | Blondin MC, Beauregard H, Serri O. Iatrogenic Cushing syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir: two cases and literature review. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2013 Nov-Dec;19(6):e138-41. | 23807527 |
| 2370 | Blonk M, Beek Mv, Colbers A, et al. Pharmacokinetic drug-drug interaction study between raltegravir and atorvastatin 20 mg in healthy volunteers. J Acq Immune Def Syndr 2015;69(1):44-51. | 25942458 |
| 2749 | Blonk M, Colbers A, Poirters A, et al. Effect of Ginkgo Biloba on the pharmacokinetics of raltegravir in healthy volunteers. Antimicrob Agents Chemother 2012;56(10):5070-5075. | 22802250 |
| 2898 | Blonk M, Colbers EPH, Child M, et al. The influence of tobacco smoking on atazanavir pharmacokinetics [abstract P_34]. 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA, April 13-15, 2011. [page 56] | http://regist2.virology-education.com/abstractbook/2011_3.pdf |
| 2626 | Blonk M, Langemeijer C, Colbers A, et al. Pharmacokinetic drug-drug interaction study between raltegravir and citalopram in healthy volunteers [abstract 53]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DS. | |
| 3069 | Blum et al. Steady-state pharmacokinetic evaluation of emtricitabine in neonates exposed to HIV in utero [abstract 568]. Presented at the 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006, Denver, CO. | |
| 1327 | Blum MR, Begley J, Zong J, et al. Lack of a pharmacokinetic interaction between emtricitabine and tenofovir DF when coadministered to steady state healthy volunteers [abstract A-1621]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003, Chicago, IL. | |
| 70 | Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Annals of Internal Medicine 1991;114:755-7. | 2012358 |
| 64 | Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on the disposition of phenytoin. Clinical Pharmacology and Therapeutics 1991;49:420-5. | 2015731 |
| 362 | Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourinary Medicine 1997;73(2):110-6. | 9215092 |
| 3236 | Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) Product Monograph. Burlington, ON. June 6, 2019. | https://pdf.hres.ca/dpd_pm/00051644.PDF |
| 2274 | Boehringer Ingelheim (Canada) Ltd. Pradaxa (dabigatran) Product Monograph. Burlington, ON. December 15, 2016. | https://www.boehringer-ingelheim.ca/sites/ca/files/documents/pradaxapmen.pdf |
| 2571 | Boehringer Ingelheim (Canada) Ltd. Aptivus (tipranavir) Prescribing Information. Burlington, ON. March 5, 2014 | https://www.boehringer-ingelheim.ca/sites/ca/files/documents/aptivuspmen_1.pdf |
| 1601 | Boehringer Ingelheim (Canada) Ltd. Aptivus (tipranavir) Product Monograph. Burlington, ON March 5, 2014. | https://www.boehringer-ingelheim.ca/sites/ca/files/documents/aptivuspmen_1.pdf |
| 188 | Boehringer Ingelheim (Canada) Ltd. Viramune and Viramune XR (nevirapine) Product Monograph. Burlington, ON. November 18, 2013. | https://www.boehringer-ingelheim.ca/sites/ca/files/documents/viramunexrpmen.pdf |
| 3237 | Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) Prescribing Information. Ridgefield, CT. January 2018. | |
| 2776 | Boehringer Ingelheim. Jardiance (empagliflozin) Product Monograph. Burlington, ON. January 9, 2017. | https://www.boehringer-ingelheim.ca/sites/ca/files/productpmen.pdf |
| 1363 | Boelaertt JR, Dom GM, Huitema ADR, et al. The boosting of didanosine by allopurinol permits a halving of the didanosine dosage. AIDS 2002;16(16):2221-3. | 12409745 |
| 3116 | Boerhinger Ingelheim. Striverdi Respimat (olodaterol) Product Monograph. Burlington, ON. July 5, 2016. | |
| 3006 | Boerhinger Ingelheim. Trajenta (linagliptin) Product Monograph. Burlington, ON. December 22, 2016. | |
| 1118 | Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002 Dec;50(6):1081-4. | 12461038 |
| 1287 | Boffito M, D'Avolio A, Di Perri G, et al. Repeated pharmacokinetics of tenofovir disoproxil fumarate in HIV-infected adults receiving saquinavir hard gel/ritonavir 1000/100 mg BID [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 1266 | Boffito M, Dickinson L, Hill A, et al. Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1376-84. | 15483467 |
| 2259 | Boffito M, Jackson A, Amara A, et al. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation. Antimicrob Agents Chemother 2011;55(9):4218-23. | 21709075 |
| 1669 | Boffito M, Jackson A, Lamorde M, et al. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers J Acquir Immune Defic Syndr 2009;52(2):222-7. | 19620877 |
| 1265 | Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004;18(9):1291-7. | 15362661 |
| 3397 | Boffito M, Lucchini A, Maiello A et al. Lopinavir/ritonavir absorption in a gastrectomized patient. AIDS. 2003;17(1):136‐137. | 12478084 |
| 1318 | Boffito M, Maitland D, Dickinson L, et al. Simultaneous administration of saquinavir hard gel and ritonavir is required for optimal saquinavir absorption [abstract A-453]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC. | |
| 2931 | Boffito M, Moyle G, Hill A, Sekar V, Lefebvre E, De Pauw M, et al. The pharmacokinetic profile of darunavir with low-dose ritonavir in various multiple-dose regimens over 120 hours [abstract P31]. 9th Int Workshop Clin Pharmacol HIV Ther: New Orleans, April 7-9, 2008. | http://www.natap.org/2008/Pharm/Pharm_13.htm |
| 2698 | Boffito M, Pozniak A, Kearney BP, et al. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate Antimicrob Agents Chemother 2005;49:4386-9. | |
| 1077 | Boffito M, Rossati A, Dal Conte I, et al. Opiate withdrawal syndrome in new efavirenz recipients under methadone maintenance regimen (abstr). 1st IAS Conference on HIV Pathogenesis and Treatment, July 8-11, 2001, Buenos Aires. | |
| 1159 | Boffito M, Rossati A, Reynolds HE, et al. Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS Research and Human Retroviruses 2002;18(5):341-2. | 11897035 |
| 1440 | Boffito M, Singh K, Higgs C, et al. Effect of different meals on the pharmacokinetic profile of saquinavir 500mg tablet/ritonavir 1000/100mg BID in HIV-infected individuals [abstract A-1423]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, IL. | |
| 1180 | Boffito M, Tija J, Reynolds HE, et al. Simultaneous determination of rifampicin and efavirenz in plasma. Ther Drug Monit. 2002 Oct;24(5):670-4. | 12352941 |
| 1531 | Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007;21(11):1449-55. | 17589191 |
| 1045 | Bohjanen PR, Johnson MD, Szczech LA, et al. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother. 2002 Aug;46(8):2387-92. | 12121909 |
| 3112 | Bohjanen PR, Johnson MD, Szczech LA, Wray DW, Petros WP, Miller CR, Hicks CB. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother. 2002 Aug;46(8):2387-92. | 12121909 |
| 1796 | Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995;71:311-2. | 8534764 |
| 3104 | Bollen P, Colbers A, Schalkwijk S, et al. First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women [abstract 8]. 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, May 22-24, 2018, Baltimore, MD. | |
| 3198 | Bollen P, Prins H, colbers A, Velthoven K, et al. The dolutegravir/valproic acid drug-drug interaction is primarily based on protein displacement. J Antimicrob Chemother 2021;76:1273-6. | 33544819 |
| 137 | Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. American Journal of Health-System Pharmacy 1991;48:1978-88. | 1928147 |
| 1825 | Boni J, Abbas R, Leister C, et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol 2009;64(2):263-70. | 19015855 |
| 1824 | Boni J, Leister C, Burns J, et al. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 2008;98:1797-802. | 18458675 |
| 1823 | Boni J, Leister C, Burns J, et al. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications. J Clin Pharmacol 2007;47:1430-9. | 17913896 |
| 1631 | Bonnet M, Bhatt NB, Jani IV, et al. Pharmacokinetic (pk) parameters of nevirapine (NVP) when initiated without 2-weeks leading dose in tuberculosis (TB)-HIV co-infected patients receiving rifampicin (RMP): substudy of the CARINEMO- ANRS 12146 trial in Maputo (Mozambique) [abstract WEPEB253]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Capetown, South Africa. | |
| 1476 | Bonora S, Calcagno A, Fontana S, et al. Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. Clinical Infectious Diseases 2007;45:1654-5. | 18190336 |
| 2893 | Bonora S, D'Avolio A, Tettoni C, Siccardi M, Gonzalez de Requena D, Baietto L, et al. A pilot study evaluating plasma and intracellular pharmacokinetics of switching from atazanavir 400 mg QD to atazanavir 200 mg BID in HIV+ patients [abstract O17]. 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, USA, April 7-9, 2008. | |
| 2894 | Bonora S, D'Avolio A, Tettoni C, Siccardi M, Gonzalez de Requena D, Baietto L, et al. A pilot study evaluating plasma and intracellular pharmacokinetics of switching from atazanavir 400 mg QD to atazanavir 200 mg BID in HIV+ patients [abstract O17]. 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, USA, April 7-9, 2008. | |
| 2910 | Bonora S, Gonzalez de Requena D, D'Avolio A, Calcagno A, Tettoni M, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G. Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. Antivir Ther. 2011;16(4):499-504. | 21685537 |
| 1882 | Bonora S, Lanzafame M, D’Avolio A, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 2008;46:146-7. | 18171231 |
| 2026 | Bonora S, Nozza S, González de Requena D, et al. Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens [abstract CDB293] 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 17-20, 2011, Rome, Italy. | |
| 1779 | Boocock DJ, Brown K, Gibbs AH, et al. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002;23:1897-901. | 12419838 |
| 1076 | Booker B, Smith P, Forrest A, et al. Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) & N-delavirdine [abstract A 490]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 694 | Borin MT, Chambers JH, Carel BJ, et al. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Research 1997;35(1):53-63. | 9224961 |
| 250 | Borin MT, Chambers JH, Carel BJ, et al. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clinical Pharmacology and Therapeutics 1997;61(544-53). | 9164416 |
| 1498 | Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004;5:352-9. | 15369510 |
| 2431 | Bouatou Y, Samer CF, Ing Lorenzini KR, et al. Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity. AIDS Res Ther 2014;11:25. | 25120580 |
| 3665 | Boucoiran I, Roy M, Poliquin V et al. Evaluation of cabergoline for lactation inhibition in women living with HIV. Int J STD AIDS 2021;32:654-61. | 33612017 |
| 1188 | Boulanger C, Ha B, Desrosiers M, et al. Rifabutin given twice weekly with ritonavir-boosted amprenavir in a once-daily HAART regimen may result in sub-therapeutic levels of rifabutin despite directly observed treatment [abstract 8.5]. 4th International Workshop on Clinical Pharmacology of HIV Therapy, March 27-29, 2003, Cannes, France. | |
| 1860 | Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infec Dis 2009;49:1305-11. | 19807276 |
| 2184 | Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002 May 31;71(2):163-9. | 12031686 |
| 2963 | Bourgeois S, Horsmans Y, Nevens F et al. Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.Antimicrob Agents Chemother. 2017 Nov 22;61(12): e01217-17 | 28971875 |
| 2592 | Bow D, Liu J, Kavetskaia O et al. A Mechanistic Non-clinical Assessment of Drug-Drug Interactions (metabolism and transporters) with the Hepatitis C Virus (HCV) Regimen: ABT-450/r, Ombitasvir and Dasabuvir. 2014 AASLD/EASL Special Conference on Hepatitis C, September 12–13, 2014, New York, NY | |
| 1239 | Boyd MA, Aarnoutse RE, Ruxrungtham K, et al. Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. JAIDS 2003;34(2):134-9. | 14526202 |
| 1282 | Boyd MA, Autar R, Burger D, et al. Saquinavir 1000 mg bid boosted with ritonavir 200 mg in the presence of efavirenz 600 mg results in adequate saquinavir minimum concentrations: HIV-NAT 012 pharmacokinetic study [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 2079 | Boyd S, Hadigan C, McManus M, et al. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. J Acq Immune Def Syndr 2013;63(3):355-61. | 23535292 |
| 2080 | Boyd S, Penzak S, Nieman L, et al. Coadministration of orally inhaled beclomethasone dipropionate and HIV protease inhibitor does not significantly alter adrenal function in healthy volunteers [abstract 610]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA. | |
| 1664 | Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol 2011 Jun;51(6):943-50. | 20852006 |
| 1337 | Bratt G, Stahle L. Sildenafil does not alter nelfinavir pharmacokinetics. Therapeutic Drug Monitoring 2003;25(2):240-2. | 12657921 |
| 638 | Brauchli P, Reuteler I, Burki B, et al. [Use of complimentary medical therapies in HIV/AIDS in Switzerland]. Schweizerische Medizinische Wochenschrift Journal Suisse de Medecine 1996;126(30):1297-305. | 8765770 |
| 3192 | Bravo I, Alvarez H, Marino A, Clotet B, Molto J. Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions. Br J Clin Pharmacol 2018, 84(7):1617-1619. | 29663482 |
| 1311 | Breilh D, Rouzes A, Djabarouti S, et al. Pharmacokinetic drug interaction of lopinavir/ritonavir in combination with tenofovir in experienced HIV+ patients [abstract A-445]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC. | |
| 2514 | Brentlinger PE, Behrens CB, Micek MA. Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. The Lancet Infectious diseases 2006 Feb;6(2):100-11. | 16439330 |
| 2686 | Breske A, al. E. Nevirapine trough concentrations in HIV-infected patients treated with or without tenofovir [abstract 4.3/10]. 10th European AIDS Conference, November 17-20, 2005, Dublin. | |
| 3436 | Brill MJE, Svensson EM, Pandie M, et al. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Int J Antimicrob Agents 2017;49:212-7. | 28038962 |
| 1072 | Brinkman K, Huysmans F, Burger DM. Pharmacokinetic interaction between saquinavir and cyclosporine [letter]. Annals of Internal Medicine 1998;129:914-5. | 9867740 |
| 890 | Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [editorial]. Aids 1998;12(14):1735-44. | 9792373 |
| 2720 | Bristol-Myers Squibb Canada. Baraclude (entecavir) Product Monograph. Montreal, QC November 19, 2010. | http://www.bmscanada.ca/static/products/en/pm_pdf/Baraclude_EN_PM.pdf |
| 3017 | Bristol-Myers Squibb Canada. CeeNU (lomustine) Product Monograph. St-Laurent, QC. February 17, 2016. | |
| 2638 | Bristol-Myers Squibb Canada. Daklinza (daclatasvir) Product Monograph. Montreal, QC, May 26, 2017. | https://pdf.hres.ca/dpd_pm/00039487.PDF |
| 2566 | Bristol-Myers Squibb Canada. Evotaz (atazanavir/cobicistat) Product Monograph. Montreal, QC. Sept 8, 2017. | https://pdf.hres.ca/dpd_pm/00041224.PDF |
| 196 | Bristol-Myers Squibb Canada. Fungizone (amphotericin B) Product Monograph. Montreal, QC. June 1, 2009. | http://www.bmscanada.ca/static/products/en/pm_pdf/Fungizone_EN_PM.pdf |
| 1231 | Bristol-Myers Squibb Canada. Reyataz (atazanavir) Product Monograph. St-Laurent, QC. April 28, 2020. | http://www.bmscanada.ca/static/products/en/pm_pdf/REYATAZ_EN_PM.pdf |
| 681 | Bristol-Myers Squibb Canada. Sustiva (efavirenz) Prescribing Information. Montreal, QC. December 12, 2019. | https://pdf.hres.ca/dpd_pm/00039540.PDF |
| 1035 | Bristol-Myers Squibb Canada. Videx EC (didanosine enteric coated) Product Monograph. Montreal, QC. June 16, 2017. | http://www.bmscanada.ca/static/products/en/pm_pdf/VIDEX_EN_PM.pdf |
| 1229 | Bristol-Myers Squibb Canada. Zerit (stavudine) Product Monograph. Montreal, QC. February 13, 2018. | http://www.bmscanada.ca/static/products/en/pm_pdf/Zerit_EN_PM.pdf |
| 3402 | Bristol-Myers Squibb Company USA. Evotaz (atazanavir/cobicistat) package insert. Princeton, NJ. May 2023. | https://packageinserts.bms.com/pi/pi_evotaz.pdf |
| 2889 | Bristol-Myers Squibb Company USA. Evotaz package insert. Princeton, NJ. May 2023. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206353s001lbl.pdf |
| 2890 | Bristol-Myers Squibb Company USA. Evotaz package insert. Princeton, NJ. May 2023. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206353s001lbl.pdf |
| 2870 | Bristol-Myers Squibb Company. Eliquis (apixaban) Product Monograph. Princeton, NJ, November 2017. | https://packageinserts.bms.com/pi/pi_eliquis.pdf |
| 2605 | Bristol-Myers Squibb Company. Videx (didanosine) Pediatric Oral Solution Prescribing Information. Princeton, NJ. June 2009. | http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020156s044lbl.pdf |
| 1033 | Bristol-Myers Squibb Company. Videx EC (didanosine) Prescribing Information. Princeton, NJ. December 2018. | http://packageinserts.bms.com/pi/pi_videx_ec.pdf |
| 2888 | Bristol-Myers Squibb USA. Reyataz® (atazanavir) Product Monograph. Princeton, NJ. September 2020. | https://packageinserts.bms.com/pi/pi_reyataz.pdf |
| 1806 | Bristol-Myers-Squibb Canada. Sprycel (dasatinib) Product Monograph. Montreal, QC. July 31, 2017. | http://www.bmscanada.ca/static/products/en/pm_pdf/SPRYCEL_EN_PM.pdf |
| 2450 | Bristol-Myers-Squibb. Daklinza (daclatasvir) Summary of Product Characteristics. European Union Feb 19,2019. | https://www.medicines.org.uk/emc/product/3300/smpc |
| 2267 | British HIV Association. British HIV Association guidelines for the management of HIV infection in pregnant women. HIV Medicine 2012;13(Suppl 2):87-157. | 22830373 |
| 2814 | Britnell SR, Willets AE, Vanderman AJ, Woodard CL, Britt RB. Influence of successful chronic hepatitis C virus treatment with ledipasvir/sofosbuvir on warfarin dosing requirements in four veterans. Pharmacotherapy 2016 Oct 7. doi: 10.1002/phar.1845. [Epub ahead of print] | 27716978 |
| 766 | Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-8. | 9386808 |
| 3461 | Brogly SB, Abzug MJ, Watts H, et al. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J 2010;29(8):721-7. | |
| 3221 | Brooks K, Pinilla M, Shapiro D, et al. Pharmacokinetics of tenofovir alafenamide 25mg with PK boosters during pregnancy and postpartum. [Abstract 12]. 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and other Antiviral Drugs. May 14-16, 2019, Noordwijk, The Netherlands. | http://regist2.virology-education.com/abstractbook/2019/abstractbook_20ANTIVIRAL.pdf |
| 3310 | Brooks KM, Castillo-Mancilla JR, Morrow M, et al. Plasma and intracellular PK and renal safety of TAF 25 mg with boosted PI and LDV/SOF [abstract 449]. Conference on Retroviruses and Opportunistic Infections (CROI). March 8-11, 2020, Boston, MA. | http://www.croiconference.org/sessions/plasma-intracellular-pk-and-renal-safety-taf-25mg-boosted-pi-and-ldvsof |
| 2990 | Brooks KM, Garrett KL, Kuriakose SS, George JM, Balba G, Bailey B, Anderson M, Lane HC, Maldarelli F, Pau AK. Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration. Pharmacotherapy. 2017 Aug;37(8):e82-e89. | 28556353 |
| 3130 | Brooks KM, George JM, Pau AK, et al. Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine. Clin Infect Dis 2018;67:193-201. | 29415190 |
| 3486 | Brooks KM, Momper JD, Pinilla M, et al. Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. AIDS 2021;35(3):407-417. | 33252495 |
| 3696 | Brooks KM, Pau AK, Swaim D et al. Pharmacokinetics, safety and tolerability of once-daily darunavir with cobicistat and weekly isoniazid/rifapentine. JAIDS 2023;94:468-73. | 37955446 |
| 937 | Brophy DF, Israel DS, Pastor A, et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrobial Agents and Chemotherapy 2000;44(4):978-84. | 10722500 |
| 275 | Brown BA, Wallace RJ, Jr., Griffith DE, et al. Clarithromycin-associated digoxin toxicity in the elderly. Clinical Infectious Diseases 1997;24(1):92-3. | 8994761 |
| 621 | Brown F, Arum I, Francis G, et al. Ganciclovir prodrug (RS-79070): multiple dose, dose-ranging study with effect of food [abstract LB-19]. 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 2864 | Brown K, Thomas D, McKenney K, et al. Impact of splitting or crushing on the relative bioavailability of the darunavir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. Clin Pharmacol Drug Dev 2019;8(4):541-548. | 30508308 |
| 2654 | Brown LS, Chu M, Aug C, et al. The use of nelfinavir and two nucleosides concomitantly with methadone is effective and well-tolerated in HepC co-infected patients [abstract I-206]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 2115 | Brown MC. An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature. Chemotherapy 1999;45(5):392-5. | 10473927 |
| 1521 | Bruce R, Altice F, Moody D, et al. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend 2009;105:234-9. | 19726139 |
| 1879 | Bruce RD, Altice F, Moody D, et al. Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. J Acquir Immune Defic Syndr 2010;54:511-14. | 20672450 |
| 1605 | Bruce RD, Altice FL, Gourevitch MN, et al. Pharmacokinetic drug interactions between opiod agonist therapy and antiretroviral medications: implications and management for clinical practice. . J Acquir Immune Defic Syndr 2006;41:563-72. | 16652030 |
| 2754 | Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 2006;20:783-4. | |
| 2028 | Bruce RD, Moody D, Chodkowski D, et al. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir [abstract MOPE176]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 17-20, 2011, Rome, Italy. | |
| 2202 | Bruce RD, Winkle P, Custodio J, et al. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. J Acq Immune Def Syndr 2013;63(4):480-4. | 23599011 |
| 2386 | Bruce RD, Winkle P, Custodio JM, et al. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. Antimicrob Agents Chemother 2013 Dec;57(12):6154-7. | 24080665 |
| 2613 | Bruderer S, Aanismaa P, Homery MC, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J 2012 Mar;14(1):68-78. | 22189899 |
| 1641 | Bruggemann RJM, Alffenaar J-WC, Blijlevens NMA, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other co-administered agents. Clin Infec Dis 2009;48:1441-58. | 19361301 |
| 1878 | Brüggemann RJM, van Luin M, Colbers EPH, et al. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J Antimicrob Chemother 2010;65(10):2188-94. | 20667889 |
| 152 | Brundage RC, Acosta EP, Page LM, et al. An Approach for Quantitating Medication Compliance in HIV-Infected Patients Using Pharmacokinetic Principles. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 1722 | Bruning PF. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 1992;28A(1404-7). | 1515258 |
| 1369 | Bruno R, Sacchi P, Filice G. Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo. AIDS 2003;17(18):2674-5. | 14685062 |
| 1026 | Bruzzese VL, Gillum JG, Israel DS, et al. Effect of fluconazole on pharmacokinetics of 2',3'-didioxyinosine in persons seropositive for human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 1995;39:1050-3. | 7625787 |
| 2167 | Buchacz K, Baker RK, Palella FJJ, et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010;24(10):1549-59. | 20502317 |
| 511 | Buchi ER, Fitting PL, Michel AE. Long-term intravitreal ganciclovir for cytomegalovirus retinitis in a patient with AIDS. Case report. Archives of Ophthalmology 1988;106(10):1349-50. | 2845902 |
| 961 | Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-82. | 10969720 |
| 1688 | Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996;16:2083-8. | 8712747 |
| 510 | Buhles WC, Jr., Mastre BJ, Tinker AJ, et al. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Reviews of Infectious Diseases 1988;10(Suppl 3):S495-506. | 2847286 |
| 2932 | Buijs BS, van den Berk GE, Boateng CP, Hoepelman AI, van Maarseveen EM, Arends JE. Cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS. 2015 Apr 24;29(7):785-91 | 25985401 |
| 3543 | Bukkems V, Hidalgo-Tenorio C, Garcia C, et al. First pharmacokinetic data of bictegravir in pregnant women living with HIV. AIDS 2021;35:2405-10. | 34723856 |
| 3534 | Bukkems V, Hidalgo-Tenorio C, Garcia C, van Hulzen A, Richel O, Burger D, Colbers A. First pharmacokinetic data of bictegravir in pregnant women living with HIV. AIDS 2021;35:2405-6. | 34723856 |
| 3533 | Bukkems V, Necsoi C, Hidalgo-Tenorio C, Garcia C, Alba Alejandre I, Weiss F, et al. Tenofovir alafenamide concentrations are reduced by half in pregnant women living with HIV: data from the PANNA Network [abstract 11]. 22nd International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, Sept 20-22, 2021, Virtual Meeting | |
| 3416 | Bukkems V, Post T, Colbers A, Burger D, Svensson E. A population pharmacokinetic analysis assessing the exposure of raltegravir once-daily 1200mg in pregnant women living with HIV [abstract 7]. 21st International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, Sept 28-30, 2020, Virtual Meeting. | |
| 3502 | Bukkems VE, Post TM, Colberts A, Burger DM, Svensson EM. A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV. CPT Pharmacometrics Syst Pharmacol 2021;10(2):161-172. | 33369217 |
| 1989 | Bundow D, Aboulafia DM. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. Am J Clin Oncol 2004;27(1):81-4. | 14758138 |
| 1992 | Bungard TJ, Yakiwchuk E, Foisy M, et al. Drug interaction involving warfarin: practice toll and practical management tips. Can Pharm J 2011;144(1):21-25. | |
| 1486 | Burger D, Huisman A, Van Ewijk N, et al. The effect of atazanavir and atazanavir/ritonavir on UDP-Glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther 2008;84(6):698-703. | 18528434 |
| 2642 | Burger DM, Agarwala S, Child M, et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrobial Agents and Chemotherapy 2006 October;50(10):3336-42. | http://aac.asm.org/content/50/10/3336.full.pdf |
| 746 | Burger DM, Hoetelmans RMW, Mulder JW, et al. Low plasma levels of Indinavir are related to virological treatment failure in HIV-1 -infected patients on indinavir-containing triple therapy. Antiviral Therapy 1998 June 28-July 3;3(4):215-20. | 10682141 |
| 948 | Burger DM, Hugen P, Aarnoutse R, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):218-24. | 11242194 |
| 1193 | Burger DM, Hugen PWH, Aarnoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Therapeutic Drug Monitoring 2003;25(1):73-80. | 12548148 |
| 781 | Burger DM, Hugen PWH, Prins J, et al. Pharmacokinetics of indinavir in a BID regimen with or without a low-dose ritonavir [abstract P38]. 4th International Congress of Drug Therapy in HIV Infection, November 7-12, 1998, Glasgow, Scotland. | |
| 787 | Burger DM, Hugen PWH, Prins JM, et al. Pharmacokinetics of an indinavir/ritonavir 800/100mg BID regimen [abstract 363]. 6th Conference on Retroviruses and Opportunistic Infections, January 31-February 4, 1999, Chicago IL. | |
| 1194 | Burger DM, Hugen PWH, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003;17(8):1157-65. | 12819517 |
| 915 | Burger DM, Hugen PWH, TerHofstede HJM, et al. Dose-finding study of a once daily indinavir/ritonavir regimen in healthy volunteers [abstract 321]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-28, 1999, San Francisco, CA. | |
| 1956 | Burger DM, Jacobs BS, Colbers A, et al. Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers [abstract P_10]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13-15th, 2011, Miami, USA. | |
| 342 | Burger DM, Koopmans PP, Brinkman K, et al. Therapeutic drug monitoring of the HIV-protease inhibitor indinavir [abstr. A-19]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 1871 | Burger DM, Magis-Escurra C, van den Berk GEL, et al. Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis. AIDS 2010;24(2):328-30. | 20029272 |
| 1023 | Burger DM, Meenhorst PL, Koks CH, et al. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrobial Agents and Chemotherapy 1993;37:1426-31. | 8363370 |
| 22 | Burger DM, Meenhorst PL, Koks CHW, et al. Drug interactions with zidovudine. AIDS 1993;7:445-60. | 8507410 |
| 1122 | Burger DM, Prins JM, van der Ende ME, et al. The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID. Journal of the Acquired Immune Deficiency Syndrome 2004;35(1):97-98. | 14707800 |
| 1183 | Burger DM, Schmitz K, Schneider K, et al. Pharmacokinetics of lopinavir and reduced-dose indinavir as part of a salvage therapy regimen [abstract 8.2]. 4th International Workshop on Clinical Pharmacology of HIV Therapy, March 27-29, 2003, Cannes, France. | |
| 3108 | Burger DM, Verweel G, Rakhmanina N, Verwey-Van Wissen CP, La Porte CJ, Bergshoeff AS, Lyall H, Hartwig NG, Green H, Soldin S, Gibb DM, de Groot R. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther. 2007 Apr;81(4):517-20. | 17329994 |
| 1147 | Burman W, Orr L. Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz. AIDS 2000;14(17):2793-4. | 11125901 |
| 875 | Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clinical Infectious Diseases 1999;28:419-30. | 10194057 |
| 1245 | Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. American Journal of Respiratory & Critical Care Medicine 2001;164(1):7-12. | 11435232 |
| 3683 | Buscemi L, Mossholder B. Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature. Am J Health Syst Pharm 2023; 80 (4): 196-199. | 36306472 |
| 2991 | Buscemi L. Virological suppression after use of crushed tenofovir-emtricitabine and dolutegravir tablets in a patient with HIV infection. Am J Health Syst Pharm. 2016 Aug 1;73(15):1125-6. | 27440618 |
| 374 | Buss N. Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions [abstr. 354]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 1514 | Busse K, Hadigan C, Chairez C, et al. Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. J Acquir Immune Defic Syndr 2009;52(2):235-9. | 19648824 |
| 1509 | Busti AJ, Bain AM, Hall RG, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2008;51(6):605-10. | 18520949 |
| 565 | Butler KM, De Smet MD, Husson RN, et al. Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus. Journal of Pediatrics 1992;120(3):483-6. | 1311378 |
| 1248 | Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.[see comment]. AIDS Reader 2003;13(7):344-8. | 12889452 |
| 1680 | Buzdar AU, Robertson JFR, Eirmann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane. Cancer 2002;95:2006-16. | 12404296 |
| 2538 | Byakika-Kibwika P, Lamorde M, Mayito J, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. The Journal of antimicrobial chemotherapy 2012 Sep;67(9):2213-21. | 22687893 |
| 2545 | Byakika-Kibwika P, Lamorde M, Okaba-Kayom V, et al. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. The Journal of antimicrobial chemotherapy 2012 May;67(5):1217-23. | 22316571 |
| 277 | Caballero-Granada F, Viciana P, Cordero E, et al. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. Antimicrobial Agents and Chemotherapy 1997;41:1207. | 9145904 |
| 2474 | Cabral KP. Pharmacology of the new target-specific oral anticoagulants. Journal of thrombosis and thrombolysis 2013 Aug;36(2):133-40. | 23645472 |
| 2148 | Cagatay A, Guler O, Guven K. Ergotism caused by concurrent use of ritonavir and ergot alkaloids: a case report. Acta Chir Belg 2009;109(5):639-40. | 19994812 |
| 1536 | Cahn P, Molina JM, Towner W, et al. 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virologic response to etravirine [abstract TUPE0047]. XVIIth International AIDS Conference, August 3-8, 2008, Mexico City, Mexico. | |
| 1221 | Cahn P, Piliero P, Giordano M, et al. Atazanavir: Antiretroviral efficacy in HIV-infected patients co-infected with hepatitis B and/or C viruses [abstract H-1730]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. | |
| 1728 | Cairo MS, Toy C, Sender L, et al. Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin. J Leukoc Biol 1990;47:224-33. | 2155275 |
| 2433 | Calcagno A, Baietto L, Pagani N, et al. Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. Pharmacogenomics 2014 Jul;15(10):1281-6. | 25155930 |
| 3626 | Calcagno A, Conte ID, Catttaneo D, et al. Low tenofovir plasma exposure in HIV oral preexposure prophylaxis recipients with gastrointestinal disorders. Antimicrob Agents Chemother. 2020;65:e01902-20. | 33106270 |
| 2093 | Calcagno A, D'Avolio A, Simiele M, et al. Pharmacokinetics of raltegravir 400 mg once-daily in combination with atazanavir/ritonavir plus two NRTIs [abstract P_05]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 2933 | Calcagno A, Yilmaz A, Cusato J, Simiele M, Bertucci R, et al. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS 2012;26:1529-33. | 22555164 |
| 1161 | Calvo R, Lukas JC, Rodriguez M, et al. Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz. British Journal of Clinical Pharmacology 2002;53(2):212-4. | 11851649 |
| 1735 | Camaggi CM, Strocchi E, Carisi P, et al. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 1992;30:307-16. | 1643700 |
| 253 | Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [abstr]. 3rd National Conference on Human Retroviruses and Related Infections, January 28-February 1, 1996, Washington. | |
| 691 | Cameron DW, Japour A, Mellors J, et al. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor-naive patients in year two follow-up [abstract 388]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 702 | Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 1999 Feb 4;13(2):213-24. | 10202827 |
| 796 | Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999;13:213-24. | 10202827 |
| 53 | Campagna KD, Torbert A, Bedsole GD, et al. Possible induction of indinavir metabolism by phenytoin [abstr]. Pharmacotherapy 1997;17:182. | |
| 1071 | Campana C, Regazzi MB, Buggia I, et al. Clinically significant drug interactions with cyclosporin. An update. Clinical Pharmacokinetics 1996;30:141-79. | 8906896 |
| 1673 | Campbell T, Grinsztejn B, Hartikainen J, et al. Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials [abstract MOPEB038]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Capetown, South Africa. | |
| 2123 | Canadian Pharmacists Association. Thiazide diuretics monograph. Compendium of Pharmaceuticals and Specialties, online version (e-CPS). 2011. | |
| 2511 | Canadian recommendations for the prevention and treatment of malaria among international travellers. Canada communicable disease report = Releve des maladies transmissibles au Canada 2004 Jun;30 Suppl 1:1-62. | 15382371 |
| 2452 | Canalejo E, Pacheco MS. Cushing syndrome due to ritonavir-fluticasone interaction. Cmaj 2012 Oct 16;184(15):1714. | 22586335 |
| 1275 | Canta F, Marrone R, Gonzalez de Requena D, et al. Pharmacokinetics of atazanavir alone and coadministered with saquinavir hard gel once daily [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 930 | Cantilena L, et al. Lack of a pharmacokinetic interaction between indinavir and methadone [abstract PI-74]. Clinical Pharmacology and Therapeutics 1999;65(2):135. | |
| 306 | Cantrill HL, Henry K, Jackson B, et al. Recovery of human immunodeficiency virus from ocular tissues in patients with acquired immune deficiency syndrome [see comments]. Ophthalmology 1988;95(10):1458-62. | 2852338 |
| 465 | Cantrill HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. Ophthalmology 1989;96:367-74. | 2540470 |
| 506 | Cantrill HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. Ophthalmology 1989;96(3):367-74. | 2540470 |
| 3176 | Cao W, Vyboh K, Routy B, et al. Imatinib for highly chemoresistant Kaposi sarcoma in a patient with long-term HIV control: a case report and literature review. Curr Oncol 2015;22:e395-9. | 26628884 |
| 1418 | Cao Y, Smith PF, Wire MB, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy. 2008 Jul;28(7):863-74. | 18576901 |
| 2882 | Capparelli EV, Letendre SL, Ellis RJ, Patel P, Holland D, McCutchan JA. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2005;49:2504-2506. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1140502/pdf/1090-04.pdf |
| 1481 | Carbonara S, Regazzi M, Ciraci E, et al. Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis. Ann Pharmacother 2009;43:978-84. | 19383934 |
| 977 | Cardiello P, Kroon E, Hoetelmans R, et al. Steady-state pharmacokinetics of saquinavir with and without two doses of itraconazole in HIV-1+ Thai patients: HIV NAT001.2 substudy [abstract WeOrB545]. XIII International AIDS Conference, July 9-14, 2000, Durban, South Africa. | |
| 1112 | Cardiello P, Monhaphol T, Mahanontharit A, et al. Pharmacokinetics of once daily saquinavir-hard gel caps and saquinavir-soft gel caps boosted with ritonavir in HIV-1+ Thai patients: HIV NAT001.4 substudy [abstract 1.2]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | 12640194 |
| 1109 | Cardiello P, Samor T, Burger D, et al. Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. Antivir Ther. 2003 Jun;8(3):245-9. | 12924542 |
| 158 | Carmel S. The Health Belief Model in the research of AIDS-related preventive behaviour. Public Health Reviews 1990-91;18:73-85. | 2132884 |
| 340 | Carmichael JM, O'Connell MB, Devine B, et al. Collaborative drug therapy management by pharmacists: American College of Clinical Pharmacy Position Statement. Pharmacotherapy 1997;17(5):1050-61. | |
| 297 | Carney MD, Combs JL, Waschler W. Cryptococcal choroiditis. Retina 1990;10(1):27-32. | 2343188 |
| 2620 | Caro L, Marshall WL, Feng HP, et al. Coadministration of HCV protease inhibitor grazoprevir with HCV NS5A inhibitor elbasvir has no effect on pravastatin but increases rosuvastatin exposure in healthy subjects [abstract 17]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC. | |
| 2425 | Caro L, Talaty JE, Guo Z, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and IV and oral rifampin in healthy volunteers [abstract 495]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC. | |
| 2420 | Caro L, Talaty JE, Guo Z, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and midazolam, pitavastatin, and atorvastatin in healthy volunteers [abstract 477]. Hepatology 2013;58(4 (Suppl) AASLD Abstracts):437A. | |
| 2422 | Caro L, Talaty JE, Guo Z, et al. Pharmacokinetic interactions between the HCV protease inhibitor MK-5172 and ritonavir-boosted hiv protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers [abstract 487]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC. | |
| 2771 | Caro L, Wolford D, Dunnington K, et al. Coadministration of grazoprevir (MK-5172) HCV protease inhibitor with elbasvir (MK-8742) HCV NS5A inhibitor increases atorvastatin exposure in healthy subjects [abstract 62]. HEPDART 2015, December 6-10, 2015, Maui, Hawaii. | |
| 2427 | Caro L, Yeh W, Ho M, et al. Pharmacokinetics of hepatitis c virus protease inhibitor MK-5172 in volunteers with mild and moderate hepatic impairment [abstract P_37]. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 19-21, 2014, Washington, DC. | http://www.natap.org/2014/Pharm/Pharm_43.htm |
| 581 | Carosi G, Castelli F, Lernestedt JO, et al. Convenient twice daily foscarnet in induction therapy of AIDS-associated cytomegalovirus retinitis. AIDS 1997;11(2):258-60. | 9030380 |
| 712 | Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association 1998;280:78-86. | 9660368 |
| 235 | Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 1997;277:1962-9. | 9200638 |
| 8 | Carr A, Cooper DA, Penny R. Allergic manifestations of human immunodeficiency virus (HIV) infection. Journal of Clinical Immunology 1991;11:55-64. | 1676034 |
| 974 | Carr RA, Andre AK, Bertz RJ, et al. Concomitant administration of ABT-378/ritonavir results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin [abstract 1644]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. | |
| 1880 | Carten M, Kiser J, Kwara A, et al. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and efavirenz. Infect Dis Obstet Gynecol 2012;2012:Epub 2012 Feb 28. | 22536010 |
| 2921 | Carvalho AS, Osorio Valente R, Almeida Morais L, et al. HIV and coronary disease - when secondary prevention is insufficient. Rev Port Cardiol 2017;36:569.e1-569.e8. | 28697899 |
| 3535 | Carvalho S, Sheehan N, Valois S, Kakkar F, Boucher M, Ferreira E, Boucoiran I. Relationship between raltegravir trough plasma concentrations and virologic response and the impact of therapeutic drug monitoring during pregnancy [abstract 16]. 22nd International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, Sept 20-22, 2021. Virtual Meeting. | |
| 2444 | Castagna A, Spagnuolo V, Galli L, et al. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: the MODAt trial. AIDS 2014;28(15):2269-79. | 25058680 |
| 1075 | Castelao AM, Sabate I, Grino JM, et al. Cyclosporine-drug interactions. Transplantation Proceedings 1988;20(5 Suppl 6):66-9. | 3051593 |
| 954 | Castillo E, Palepu A, Beardsell A, et al. Outpatient pharmacy care and HIV viral load response among patients on HAART. AIDS Care. 2004 May;16(4):446-57. | 15203413 |
| 56 | Cato A, Qian J, Carothers L, et al. Evaluation of the pharmacokinetic interaction between ritonavir and didanosine [abstr]. Clinical Pharmacology and Therapeutics 1996;59:144. | |
| 1032 | Cato A, Qian J, Vomvouras S, et al. Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infection patients. Journal of the Acquired Immune Deficiency Syndrome 1998;18:466-72. | 9715843 |
| 1135 | Cato Ar, Qian J, Hsu A, et al. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 1998;42(7):1788-93. | |
| 3206 | Cattaneo D, Baldelli S, Cerea M, et al. Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. Antimicrob Agents Chemother 2012;56(12):6132-6. | https://www.ncbi.nlm.nih.gov/pubmed/22964253 |
| 3287 | Cattaneo D, Baldelli S, Cozzi M, et al. Drug-drug interactions between antiretrovirals and carbamazepine or oxcarbazepine: a real-life investigation. [poster PE27/6]. 17th European AIDS Conference, November 6-9, 2019, Basel, Switzerland. | http://europeanaidsconference.eacs.cyim.com/mediatheque/media.aspx?mediaId=78375&channel=28172 |
| 2843 | Cattaneo D, Baldelli S, Minisci D, et al. Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials? [abstract O_02]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL. | http://regist2.virology-education.com/Abstractbook/2017_5.pdf |
| 3207 | Cattaneo D, Cossu MV, Fucile S, et al. Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers: a randomized, open-label, 2-period, single-dose, crossover phase 1 study. Ther Drug Monit 2015;37(1):119-25. | 24988438 |
| 3525 | Cattaneo D, Formenti T, Minisci D, et al. Lack of clinically relevant interactions between bictegravir and metformin in persons with diabetes and HIV. J Antimicrob Chemother 2021 Mar 17;dkab077. doi: 10.1093/jac/dkab077. Online ahead of print. | 33729482 |
| 3654 | Cattaneo D, Giacomelli A, Gervasoni C. Loss of control of HIV viremia with OTC weight-loss drugs: a call for caution? Obesity (Silver Spring) 2018; 26(8): 1251– 1252. | 30070075 |
| 2687 | Cattaneo D, Sollima S, Charbe N, et al. Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. Eur J Clin Pharmacol 2016;72(3):365-7. | 26362279 |
| 3541 | Cattani V, Jalil E, Torres T, et al. No impact of tenofovir/emtricitabine in estradiol exposure among transwomen on oral PrEP: results from the 12-week drug-drug interaction PrEParadas substudy. 11th IAS 2021 Conference, July 18-21 2021 (virtual) | https://theprogramme.ias2021.org/Abstract/Abstract/2207 |
| 2376 | CDC. Updated guidelines on managing drug interactions in the treatment of HIV-related tuberculosis. MMWR 2014;63(12):272. | http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm |
| 3444 | Celgene Inc. Inrebic (fedratinib) Product Monograph. Mississauga, ON. July 23, 2020. | https://pdf.hres.ca/dpd_pm/00057170.PDF |
| 3222 | Celgene Inc. Istodax (romidepsin) Product Monograph. Mississauga, ON. December 13, 2016. | |
| 3268 | Celgene Inc. Otezla (apremilast) Product Monograph. Mississauga, ON. November 2, 2017. | |
| 3219 | Celgene Inc. Pomalyst (pomalidomide) Product Monograph. Mississauga, ON. June 28, 2019. | https://pdf.hres.ca/dpd_pm/00051994.PDF |
| 1826 | Celgene Inc. Revlimid (lenalidomide) Product Monograph. Mississauga, ON. October 15, 2015. | http://www.celgenecanada.net/pdfs/Revlimid%20Product_Monograph_-_English_Version.pdf |
| 234 | Centers for Disease Control and Prevention. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Morbidity and Mortality Weekly Report 1997;46 (RR-12):1-44. | 9214702 |
| 2050 | Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR 2009 March 24;58:1-209. Last update Nov 4, 2015 at: https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/318/introduction | https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/318/introduction |
| 869 | Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Morbidity and Mortality Weekly Report 1998;47(RR-20). | 9809743 |
| 1234 | Centers for Disease Control and Prevention. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. Morbidity and Mortality Weekly Report 2003 June 26;52(RR-11):1-88. | 12836625 |
| 2138 | Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use. MMWR Early Release 2010;59:May 28. | 20559203 |
| 953 | Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. Morbidity and Mortality Weekly Report 2000;49(9):185-9. | 11795500 |
| 1259 | Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors [version 1.20.04]. Morbidity and Mortality Weekly Report 2004 January 23;53(2):37. | |
| 174 | Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus : a summary. Morbidity and Mortality Weekly Report 1995;44(R-8):1-34. | 7565547 |
| 3005 | Cerrone M, Alfarisi O, Neary, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother 2019;74:1670-8. | 30815689 |
| 1791 | Cersosimo RJ. Topotecan: a new topoisomerase I inhibiting antineoplastic agent. Ann Pharmacother 1998;32:1334-43. | 9876816 |
| 2975 | Chaikin, P., Gillen, M. S., Malik, M., Pentikis, H., Rhodes, G. R. and Roberts, D. J. (2005), Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. British Journal of Clinical Pharmacology, 59: 346–354. | 15752381 |
| 2024 | Chakilam A, Chavan A, Smith G, et al. Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and ritonavir or warfarin [abstract PK_20]. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 22-23, 2011, Cambridge, MA. | |
| 758 | Chan S, Zhang M, Pithavala Y, et al. Potential early predictors of long-term virologic response to nelfinavir mesylate (Viracept): plasma drug concentration, baseline viral load, and initial 4-week change in viral load [abstract A-11]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24-27, 1998, San Diego. | |
| 2915 | Chan-Tack KM, Truffa MM, Struble KA, et al. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration’s adverse event reporting system. AIDS 2007 May 31;21(9):1215-8. | 17502736 |
| 2914 | Chang HR and Pella PM. Atazanavir urolithiasis. New England Journal of Medicine 2006 Nov 16;355(20):2158-9. | 17108352 |
| 1787 | Chang TK, Chen G, Waxman DJ. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. J Pharmacol Exp Ther 1995;274:270-5. | 7616408 |
| 1694 | Chang TK, Weber GF, Crespi CL, et al. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-37. | 8242617 |
| 1609 | Chang Y, Moody D, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos 2006;34(3):440-8. | 16381669 |
| 2810 | Chaparro M, Trapero-Marugan M, Moreno-Otero R, Gisbert JP. Azathioprine plus ribavirin treatment and pancytopenia. Aliment Pharmacol Ther. 2009;30(9):962-963. | 19807727 |
| 3295 | Chaponda M, Hachizovu S, Kabuya JB, et al. Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz based antiretroviral therapy in Zambia: an open label non-randomized interventional trial [abstract PE27/1]. 17th European AIDS Conference, November 6-9, Basel, Switzerland. | |
| 1902 | Chaponda M, Nyirenda W, Watson V, et al. Altered plasma levels of nevirapine after commencing rifampicin containing TB regimens in Malawi [abstract 46]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7, 2010, Sorrento, Italy. | |
| 2808 | Chappell C, Lamorde M, Nakalema S, Scarsi K, et al. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. AIDS 2017;31:1965-72. | 28692531 |
| 3580 | Chappell CA, Lamorde M, Nakalema S et al. Double-dose etonogestrel contraceptive implant overcomes interaction with efavirez [abstract 884]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, February 12-16, 2022. | |
| 407 | Charles NC, Steiner GC. Ganciclovir intraocular implant. A clinicopathologic study [see comments]. Ophthalmology 1996;103(3):416-21. | 8600417 |
| 2589 | Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan;148(1):108-17. | 25304641 |
| 2104 | Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents — A potentially lethal cocktail. Hepatology 2011;54(1):3-5. | 21710471 |
| 858 | Chave JP, Munafo A, Chatton JY, et al. Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. Antimicrobial Agents & Chemotherapy 1992;36(5):1013-8. | 1324635 |
| 289 | Chavez-de la Paz E, Arevalo JF, Kirsch LS, et al. Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention. Ophthalmology 1997;104(3):539-44. | 9082286 |
| 713 | Checkley GE, Thompson SC, Crofts N, et al. HIV in the mentally ill. Australia and New Zealand Journal of Psychiatry 1996;30(2):184-94. | 8811261 |
| 695 | Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. Journal of the Acquired Immune Deficiency Syndrome 1995;8(2):141-51. | 7530585 |
| 3601 | Chen B, Zhou D, Wei H et al. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. Br J Clin Pharmacol 2022 Feb 15. doi: 10.1111/bcp.15278. Online ahead of print. | 35165925 |
| 3125 | Chen L, Boinpally R, Gad N, et al. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects. Clin Drug Investig. 2015 Oct;35(10):601-12. | 26315684 |
| 3695 | Chen RQ, Zino L, Geerlings S et al. Exposure to doravirine, lamivudine, tenofovir, and raltegravir in a patient with HIV after a Roux-en-Y gastric bypass. AIDS 2023; 37: 1769-1771. | 37534729 |
| 575 | Cherrington JM, Fuller MD, Chen MS. Antiviral effects of adefovir (PMEA) against in vitro replication of wild type and drug resistant human cytomegalovirus (HCMV) clinical isolates. 3rd International Congress on Drug Therapy in HIV Infection, November 3-7, 1996, Birmingham, UK. | |
| 486 | Cherrington JM, Miner R, Hitchcock MJ, et al. Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug. Journal of Infectious Diseases 1996;173(4):987-92. | 8603981 |
| 280 | Chesney M. Mental health issues surrounding compliance. HIV and Compliance Conference, April 7, 1997, Harrisburg, PA. | |
| 343 | Chesney MA. New antiretroviral therapies: adherence challenges and strategies. Evolving HIV Treatments: Advances and the Challenge of Adherence (a satellite symposium), September 27, 1997, Toronto, Ontario. | |
| 2025 | Cheung MC, Hicks LK, Leitch HA. Excessive neurotoxicity with ABVD when combined with protease inhibitor–based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clinical Lymphoma, Myeloma & Leukemia 2010;10(2):E22-E25. | 20371439 |
| 3677 | Cheung NW, Liddle C, Coverdale S, et al. Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man. J Clin Endocrinol Metab 1995;81:1999-2001. | 8626872 |
| 580 | Cheung TW, Jayaweera DT, Pearce D, et al. Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections. Int J STD AIDS. 2000 Oct;11(10):640-7. | 11057934 |
| 1755 | Chiccarelli FS, Morrison JA, Cosulich DB, et al. Identification of human urinary mitoxantrone metabolites. Cancer Res 1986;46:4858-61. | 3731132 |
| 2969 | Chien C, Persson A, Sevinsky H, Dudley J, Lu M, Kaul S et al. Single-Dose pharmacokinetics of enteric-coated didanosine in subjects with hepatic impairment compared to healthy adult subjects [abstract P9]. 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, USA, April 7-9, 2008. | http://www.natap.org/2008/Pharm/Pharm_16.htm |
| 871 | Chin DP, DeRiemer K, Small PM, et al. Differences in contributing factors to tuberculosis incidence in U.S. -born and foreign-born persons. American Journal of Respiratory & Critical Care Medicine 1998;158(6):1797-803. | 9847270 |
| 120 | Chin T. Effects of an acidic beverage (Coca Cola) on the absorption of ketoconazole. Antimicrob Agents Chemother 1995;39(8):1671-5. | 7486898 |
| 2788 | Chinello P, Cicalini S, Pichini S, Pacifici R, Tempestilli M, Cicini MP, Pucillo LP, Petrosillo N. Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. Infect Dis Rep. 2015 Mar 16;7(1):5822. | 25874072 |
| 3370 | Chinula L, Brummel SS, Ziemba L, et al. Safety and efficacy of DTG vs EFV and TDF vs TAF in pregnancy: IMPAACT 2010 trial. [abstract 130]. Conference on Retroviruses and Opportunistic Infections (CROI). March 8-11, 2020, Boston, MA. | https://www.croiconference.org/abstract/safety-and-efficacy-of-dtg-vs-efv-and-tdf-vs-taf-in-pregnancy-impaact-2010-trial/ |
| 2699 | Chittick G, Zong J, Blum MR, et al. Boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother 2006;50(4):1304-10. | |
| 1011 | Chittick GE, Gillotin C, McDowell JA, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 1999;19:932-42. | 10453964 |
| 750 | Chodakewitz J, Deutsch P, Leavitt R, et al. Relationships between indinavir (IDV) pharmacokinetics and antiviral activity in phase I/II trials [abstract 42266]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 3212 | Chrdle A, Jerhotová Z, Vacík M, et al. Crushed dolutegravir/abacavir/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression. Int J STD AIDS 2019 Jan;30(1):94-98. | 30231834 |
| 590 | Chrisp P, Clissold SP. Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991;41(1):104-29. | 1706982 |
| 3666 | Christensen J, Dupont E, Ostergaard K. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole. Mov Disord 2022;17:1360-2. | 12465083 |
| 1434 | Chung E, Eley T, Nettles R, et al. Effect of nevirapine on atazanavir with ritonavir in HIV+ subjects [abstract A-1414]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, IL. | |
| 2099 | Chung E, Zhu L, Sims K, et al. An increase in atazanavir to 400 mg mitigates the effects of famotidine when given with ritonavir and tenofovir DF in HIV-infected patients [abstract P_14]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 3612 | Chupradit S, Wamalwa D, Maleche-Obimbo E, et al. Pharmacokinetics of abacavir in African children <14 kg dosed per WHO weight-bands. [abstract 735]. CROI 2022, Feb 12-24, 2022. Hybrid virtual/Denver CO. | |
| 2496 | Churchill FC, Patchen LC, Campbell CC, et al. Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. Life sciences 1985 Jan 7;36(1):53-62. | 3965841 |
| 1968 | Cianfrocca M, Lee S, Von Roenn J, et al. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi\'s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. Cancer Chemother Pharmacol 2011;68:827-33. | 21207228 |
| 2000 | Cicalini S, Almodovar S, Grilli E, et al. Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. Clin Microbiol Infect 2011;17(1):25-33. | 20545962 |
| 1028 | Cimoch PJ, Lavelle J, Pollard R, et al. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects. Journal of the Acquired Immune Deficiency Syndrome 1998;17(3):227-34. | 9495222 |
| 1916 | Cingolani A, Torti L, Pinnetti C, et al. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin’s lymphoma. AIDS 2010;24(15):2408-12. | 20671541 |
| 3360 | CIPLA LTD. Lopinavir and ritonavir Oral Pellets 40 mg/10 mg Product Monograph. Verna Indl. Estate, Goa, India. May 2015. | https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/205425PI.pdf |
| 2322 | Cited September 2011. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php | |
| 862 | Clark AB, Lobo BL, Gelfand MS. Fluconazole and amphotericin B for cryptococcal meningitis. Annals of Pharmacotherapy 1996;30(12):1408-10. | 8968453 |
| 931 | Clarke S, Mulcahy F, Back D, et al. Managing methadone and non-nucleoside reverse transcriptase inhibitors: guidelines for clinical practice [abstract 88]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco. | |
| 1157 | Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clinical Infectious Diseases 2002;34(8):1143-5. | 11915005 |
| 1162 | Clarke SM, Mulcahy FM, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clinical Infectious Diseases 2001;33(9):1595-7. | 11568856 |
| 1163 | Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. British Journal of Clinical Pharmacology 2001;51(3):213-7. | 11298066 |
| 3078 | Clavel C, Peytavin G, Tubiana R, et al. Etravirine penetration in cervicovaginal compartment exceed the median inhibitory concentration in HIV-1 infected women treated with etravirine-containing regimen (DIVA- 02 study) [abstract MOPE177]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. | |
| 1355 | Clay PG, Adams MM. Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction. Annals of Pharmacotherapy 2003;37:202-5. | 12549947 |
| 2615 | Clay PG, Anderson PL, Smith P, et al. Pharmacokinetics of once-daily fosamprenavir 1400 mg plus atazanavir 400 mg without ritonavir in HIV-negative subjects [abstract 587]. 13th Conference on Retroviruses and Opportunistic Infections February 5-8, 2006, Denver, CO. | |
| 171 | Clepper I. Noncompliance. The invisible epidemic. Drug Topics 1992. | |
| 1043 | Clevenbergh P, Durant J, Halfon P, et al. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antiviral Therapy 2000;5(1):65-70. | 10846595 |
| 1499 | Clevenbergh P, Garraffo R, Durant J, et al. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic drug monitoring of protease inhibitors: 12 week results. AIDS 2002;16:2311-5. | 12441803 |
| 2155 | ClinicalTrials.gov. TMC125-TiDP2-C188: A Phase I, Open-label trial to investigate the pharmacokinetic effect of multiple-dose TMC125 on buprenorphine and norbuprenorphine administered in HIV-negative patients on stable buprenorphine/naloxone maintenance therapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00828815 (Accessed 17 July 2012). 2012. | |
| 761 | Clumeck N, for the Avanti Study Group. AVANTI 3. A randomised, double blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/nelfinavir in anti-retroviral naive patients [abstract 8]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 198 | Cobb M, Desai J, Brown LS, et al. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998;63(6):655-62. | 9663180 |
| 469 | Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991;98:1348-55. | 1658703 |
| 1776 | Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982;42:317-23. | 7053859 |
| 2043 | Cohen C, Davis KL, Meyers J. Association between daily antiretroviral pill burden and hospitalization risk in a medicaid population with HIV [abstract H2-791]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2011, Chicago, IL. | |
| 711 | Cohen C, Siemon-Hryczyk P, Pilson R, et al. Potent and convenient Fortovase-sgc BID regimens in combination with two nucleosides or nelfinavir plus one nucleoside in HIV-infected patients [abstract 12314]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 298 | Cohen JI, Saragas SJ. Endophthalmitis due to Mycobacterium avium in a patient with AIDS. Annals of Ophthalmology 1990;22(2):47-51. | 2316950 |
| 336 | Cohen V, Maggio C, Triplett JW, et al. Relationship between antiretroviral prescription compliance and immunologic, virologic, and clinical outcomes [abstr.]. Pharmacotherapy 1997;17(5):1091. | |
| 1886 | Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007;81(2):222-7. | 17192768 |
| 2211 | Coilly A, Furlan V, Roche B, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012;56(11):5728-34. | 22908172 |
| 566 | Coker RJ, Tomlinson D, Horner P, et al. Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet [letter; comment]. Lancet 1991;338(8766):574-5. | 1678829 |
| 38 | Coker RJ, Tomlinson DR, Parkin J, et al. Interaction between fluconazole and rifampicin [letter]. British Medical Journal 1990;301:818. | 2224282 |
| 168 | Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Archives of Internal Medicine 1990;150:841-5. | 2327844 |
| 3476 | Colbers A, Hawkins D, Hidalgo-Tenorio C, et al. Atazanavir exposure is effective during pregnancy regardless of tenofovir use. Antivir Ther 2015;20(1):57-64. | 24992294 |
| 3070 | Colbers A, Hawkins DA, Gingelmaier A, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS 2013; 27:739–748. | 23169329 |
| 3103 | Colbers A, Jourdain G, Hawkins D, et al. Tenofovir exposure during pregnancy and postpartum in hepatitis B mono-infected women on TDF monotherapy compared to HIV-infected women on TDF-containing antiretroviral therapy [abstract 1]. 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, May 22-24, 2018, Baltimore, MD. | |
| 2934 | Colbers A, Molto J, Ivanovic J, Hidalgo Tenori C, Weizacker K, van der Ende I et al. A Comparison of the Pharmacokinetics of Darunavir, Atazanavir and Ritonavir during Pregnancy and Post-partum [abstract]. CROI 2012. | http://www.natap.org/2013/HIV/011613_03.htm |
| 3105 | Colbers A, Schalkwijk S, Konopnicki D, et al. [abstract 17]. Elvitegravir pharmacokinetics during pregnancy and postpartum. 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, May 22-24, 2018, Baltimore, MD. | |
| 180 | Collaborative AZT Study Group. Tolerance of AZT in association with trimethoprim-sulfamethoxazole, pyrimethamine, or rifampin [abstr]. IV International Conference on AIDS, June 12-16, 1988, Stockholm. | |
| 525 | Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. New England Journal of Medicine 1986;314(13):801-5. | 3005861 |
| 462 | Collazos J, Diaz F, Mayo J, et al. Endophthalmitis as a complication of intravitreal treatment for cytomegalovirus retinitis. AIDS 1995;9(8):980-1. | 7576342 |
| 2530 | Colmenero JD, Fernandez-Gallardo LC, Agundez JA, et al. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrobial agents and chemotherapy 1994 Dec;38(12):2798-802. | 7695265 |
| 1211 | Colonno R, Rose R, Cianci C, et al. Emergence of atazanavir resistance and maintenance of susceptibility to other PIs is associated with an I50L substitution in HIV protease [abstract 597]. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston. | |
| 1212 | Colonno RJ, Thiry A, Limoli K, et al. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrobial Agents and Chemotherapy 2003;47(4):1324-33. | 12654666 |
| 2646 | Columbo S, al. E. In vivo pharmacokinetic interaction study between boosted atazanavir and lopinavir for cellular, total and unbound plasma exposures in HIV-infected patients [abstract 4.3/12]. 10th European AIDS Conference, November 17-20, 2005, Dublin. | |
| 1650 | Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330(4):263-72. | 8272088 |
| 2747 | Compendium of Pharmaceuticals and Specialties, on-line version (CPS). Chloroquine phosphate Monograph. Canadian Pharmacists Association, September 2012. | |
| 2832 | Compendium of Pharmaceuticals and Specialties, on-line version (CPS). Isoniazid Monograph. Canadian Pharmacists Association, October 2013. | |
| 229 | Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343(871-81). | 7908356 |
| 54 | Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature London 1995;374:569-71 [letter]. | 7700387 |
| 90 | Cone LA, Woodward DR, Simmons JC, et al. Drug interactions in patients with AIDS [letter]. Clinical Infectious Diseases 1992;15:1066-8. | 1457653 |
| 2358 | Cooper C, Conway B, Ghesquiere W, et al. Pharmacokinetic interactions of faldaprevir and deleobuvir (BI 207127) and their individual and combined effect on selected cytochrome P450 (CYP) probe substrates in genotype 1 hepatitis C infected patients [abstract 1083]. Hepatology 2013;58(4 suppl):732A. | |
| 851 | Cooper DA, Pedersen C, Aiuti F, et al. The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group. Aids 1991;5(8):933-43. | 1777174 |
| 849 | Cooper DA, Pehrson PO, Pedersen C, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group. Aids 1993;7(2):197-207. | 8096703 |
| 3410 | Cope RJ, Fischetti BS, Kavanagh RK et al. Safety and efficacy of weight-loss pharmacotherapy in persons living with HIV: a review of the literature and potential drug-drug interactions with antiretroviral therapy. Pharmacotherapy 2019;39:1204-15. | 31602703 |
| 3652 | Cope RJ, Fischetti BS, Kavanagh RK, et al. Safety and efficacy of weight-loss pharmacotherapy in persons living with HIV: a review of the literature and potential drug-drug interactions with antiretroviral therapy. Pharmacotherapy 2019; 39: 1204-1215. | 31602703 |
| 1227 | Corales RB, Coffey C, Gordon F, et al. Lipid improvement with atazanavir therapy in an antiretroviral-experienced population: experience in the atazanavir Early Access Program [abstract 64]. Antiviral Therapy 2003;8(4):L46-7. | |
| 2637 | Corallo CE, Grannell L, Tran H. Postoperative bleeding after administration of a single dose of rivaroxaban to a patient receiving antiretroviral therapy. Drug Saf Case Rep 2015;2:11. | 27747723 |
| 1268 | Corbett AH, Davidson L, Park JJ, et al. Dose separation strategies to overcome the pharmacokinetic interaction of a triple protease inhibitor regimen containing fosamprenavir, lopinavir, and ritonavir [abstract 611]. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco CA. | |
| 1376 | Corbett AH, Eron J, Fiscus SA, et al. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. JAIDS 2004;36:921-8. | 15220698 |
| 1961 | Corcione S, Calcagno A, Bonora S, et al. Clinical pharmacology of complex regiment of antiretroviral therapy including etravirine, maraviroc and raltegravir [abstract P_29]. 12th International Conference on Clinical Pharmacology of HIV Therapy, April 13-15th, 2011, Miami, USA. | |
| 3684 | Cordova E, Garibaldi F, Bono L, Rodriguez C. Severe hyperkalaemia due to a potential drug-drug interaction between eplerenone and antiretrovirals in a HIV-positive patient after a myocardial infarction. Int J STD AIDS 2021;32:771-3. | 33629924 |
| 3033 | Cordova E, Morganti L, Odzak A, et al. Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS 2017;28:1259-62. | 28403692 |
| 2302 | Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977 [abstract 1101]. 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22, 2012, Barcelona, Spain. | |
| 1584 | Corona G, Vaccher E, Sandron S, et al. Lopinavir-Ritonavir Dramatically Affects the Pharmacokinetics of Irinotecan in HIV Patients With Kaposi's Sarcoma. Clin Pharmacol Ther 2008;83(4):601-6. | 17713471 |
| 2285 | Corona G, Vaccher E, Spina E, et al. Potential hazard drug–drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin’s lymphoma. AIDS 2013;27:1033-9. | 23698067 |
| 414 | Coroneo MT, Young S. High dose intravitreal ganciclovir [letter; comment]. Retina 1995;15(3):265-6. | 7569358 |
| 3599 | Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 2019;380:1597-1605. | 30969503 |
| 1625 | Corti N, Heck A, Rentsch K, et al. Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers. Eur J Clin Pharmacol 2009;65(10):999-1006. | 19562329 |
| 1786 | Cotreau MM, von Moltke LL, Harmatz JS, et al. Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen. Pharmacology 2001;63:210-9. | 11729359 |
| 3128 | Cotton MF, Liberty A, Rodriguez CA, et al. Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single-tablet regimen in children (6 to <12 years) living with HIV-1. [WEAB0204] 22nd International AIDS Conference (AIDS 20118), Amsterdam, Netherlands. July 23-27, 2018. | |
| 2978 | Cottrell ML, Hadzic T and Kashuba ADM. Clinical pharmacokinetic, pharmacodynamic and drug- interaction profile of the integrase inhibitor dolutegravir. Clinical Pharmacokinetics 2013: 1-14. | 23824675 |
| 3499 | Cottura N, Montanha MC, Bunglawala FS et al. In silico prediction of long-acting cabotegravir PK in liver-impaired patients [abstract 374]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, March 6-10, 2021. | |
| 1745 | Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi’s Sarcoma. Drugs 1997;53:520-38. | 9074848 |
| 2916 | Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clinical Infectious Diseases 2007 15 Oct; 45(8):e105-8. | 17879904 |
| 130 | Cox S, Batts D, Stewart F, et al. Evaluation of the pharmacokinetic interaction between saquinavir and delavirdine in healthy volunteers. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 1087 | Cox S, Conway B, Freimuth W, et al. Pilot study of BID and TID combinations of saquinavir-SGC, delavirdine, zidovudine and lamivudine as initial therapy: pharmacokinetic interaction between saquinavir & delavirdine [abstract 82]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco. | |
| 649 | Cox S, Sargent S, Para M, et al. Plasma viral load reduction in an open-label randomized study of Rescriptor in combination with zidovudine and two dose levels of indinavir compared to zidovudine, lamivudine, and indinavir in HIV-1 infected individuals [abstract 427]. 7th Annual Canadian Conference on HIV/AIDS Research, April 30-May 3, 1998, Quebec City, PQ. | |
| 377 | Cox SR, Herman BD, Batts DH, et al. Delavirdine and rifabutin: pharmacokinetic evaluation in HIV-1 patients with concentration-targeting of delavirdine [abstr. 344]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 378 | Cox SR, Schneck DW, Herman BD, et al. Delavirdine and nelfinavir: a pharmacokinetic drug-drug interaction study in healthy adult volunteers [abstr 345]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 3687 | CPhA Monograph. Colchicine monograph. CPS, April 22, 2020. | |
| 739 | Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scandinavian Journal of Infectious Diseases - Supplementum 1990;74:63-70. | 2097720 |
| 166 | Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995;49(3):321-7. | 7774509 |
| 84 | Crane JK, Shih HT. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. American Journal of Medicine 1993;95:445-6. | 8213879 |
| 2936 | Crauwels H, Baugh B, Ryan B, et al. Total and unbound pharmacokinetics of once-daily darunavir/ritonavir in HIV-1 infected pregnant women [abstract O_15]. 15th International Workshop on Clinical Pharmacology of HIV Therapy, May 19-21, 2014, Washington, DC. | http://www.natap.org/2014/Pharm/Pharm_28.htm |
| 2935 | Crauwels H, Baugh B, Van Landuyt E, et al. Impact of food on the bioavailability of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (DCFTAF), the first protease inhibitor-based, single-tablet complete HIV-1 regimen [abstract P310]. HIV Drug Therapy 2016, Glasgow, UK. | http://programme.aids2016.org/PAGMaterial/eposters/0_3076.pdf |
| 2221 | Crauwels H, Deckx H, Enweonye I, et al. Absence of a pharmacokinetic interaction of rilpivirine with the P-glycoprotein substrate digoxin in healthy volunteers [abstract P71]. 11th International Congress on Drug Therapy in HIV Infection, November 11-15, 2012, Glasgow, Scotland. | |
| 2343 | Crauwels H, Deckx H, Stevens M, et al. Absence of a pharmacokinetic interaction between rilpivirine, a non-nucleoside reverse transcriptase inhibitor and metformin [abstract PE10/4]. 14th European AIDS Conference (EACS), October 16-19, 2013, Brussels, Belgium. | |
| 1484 | Crauwels H, Van Heeswijk RP, Bollen A, et al. The effect of different types of food on the bioavailability of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) [abstract P32]. 9th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9 2008, New Orleans, LA. | |
| 3106 | Crauwels HM, Osiyemi O, Zorrilla C, et al. Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen. HIV Med 2019;20:337-43. | 30873741 |
| 2077 | Crauwels HM, Stevens M, De La Rosa G, et al. Absence of pharmacokinetic interaction between the NNRTI rilpivirine (TMC278) and the integrase inhibitor raltegravir [abstract 617]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA. | |
| 1856 | Crauwels HM, Van Heeswijk R, Cornelis L, et al. Pharmacokinetic interaction study between TMC278, an NNRTI, and the contraceptives norethindrone plus ethinylestradiol [abstract PE 4.3/3]. 12th European AIDS Conference, November 11-14, 2009, Cologne, Germany. | |
| 1529 | Crauwels HM, Van Heeswijk R, Kestens D, et al. The pharmacokinetic interaction between rifabutin and TMC278, an investigational NNRTI [abstract TUPE0080]. XVIIth International AIDS Conference, August 3-8, 2008, Mexico City, Mexico. | |
| 1577 | Crauwels HM, Van Heeswijk R, Stevens M, et al. TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), does not alter the pharmacokinetics of sildenafil [abstract P_22]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 1582 | Crauwels HM, Van Heeswijk R, Stevens T, et al. The effect of TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) on CYP3A activity in vivo [abstract P_28]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 1900 | Crauwels HM, van Heeswijk RPG, Vandevoorde A, et al. Pharmacokinetic interaction study between TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor and methadone [abstract 33]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7, 2010, Sorrento, Italy. | |
| 1927 | Crauwels HM, Vingerhoets J, Ryan R, et al. Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir Ther 2012;17(3):439-6. | 22293086 |
| 3689 | CredibleMeds. Risk categories for drugs that prolong QT & induce Torsades de Pointes (TdP). Updated June 26, 2023. | https://crediblemeds.org/index.php/druglist |
| 3474 | Cressey TR, Bekker A, Cababasay M, et al. Abacavir safety and pharmacokinetics in normal and low birth weight infants with HIV [abstract 843]. Conference on Retroviruses and Opportunistic Infections (CROI), March 8-11, 2020. Boston, MA. | https://www.croiconference.org/abstract/abacavir-safety-and-pharmacokinetics-in-normal-and-low-birth-weight-infants-with-hiv/ |
| 3088 | Cressey TR, Best BM, Achalapong J, Stek A, Wang J, Chotivanich N, Yuthavisuthi P, Suriyachai P, Prommas S, Shapiro DE, Watts DH, Smith E, Capparelli E, Kreitchmann R, Mirochnick M; IMPAACT P1026s team. Reduced indinavir exposure during pregnancy. Br J Clin Pharmacol. 2013 Sep;76(3):475-83. | 23305215 |
| 1762 | Cresteil T, Monsarrat B, Alvinerie P, et al. Taxol metabolism by human liver microsomes: identification of cytochrome P450 involved in its biotransformation. Cancer Res 1994;54:386-92. | 7903909 |
| 1760 | Cresteil T, Monsarrat B, Dubois J, et al. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002;30:438-45. | 11901098 |
| 1772 | Crewe HK, Ellis SW, Lennard MS, et al. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997;53:171-8. | 9037249 |
| 1774 | Crewe HK, Notley LM, Wunsch RM, et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4’-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002;30:869-74. | 12124303 |
| 3321 | Crichton S, Collins IJ, Turkova A, et al. Abacavir dosing, effectiveness, and safety in young infants living with HIV in Europe [abstract 844]. Conference on Retroviruses and Opportunistic Infections (CROI), March 8-11, 2020. Boston, MA. | http://www.croiconference.org/sessions/abacavir-dosing-effectiveness-and-safety-young-infants-living-hiv-europe |
| 3645 | Crichton S, Collins IJ, Turkova A, et al. Abacavir dosing, effectiveness, and safety in young infants living with HIV in Europe [abstract 844]. Conference on Retroviruses and Opportunistic Infections (CROI), March 8-11, 2020. Boston, MA. | https://www.croiconference.org/abstract/abacavir-dosing-effectiveness-and-safety-in-young-infants-living-with-hiv-in-europe/ |
| 3369 | CROI | |
| 1334 | Crommentuyn KM, Mulder JW, Sparidans RW, et al. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clinical Infectious Diseases 2004;38(8):e73-75. | 15095234 |
| 1057 | Crommentuyn KML, van Heeswijk RPG, Veldkamp AI, et al. Nevirapine once daily versus twice daily: implications for drug-drug interactions [abstract 1.11]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4, 2001, Noordwijk, the Netherlands. | |
| 1752 | Crooke ST, Henderson M, Samson M, et al. Phase I study of oral mitomycin C. Cancer Treat Rep 1976;60:1633-6. | 1035507 |
| 538 | Crumpacker CS. Ganciclovir. New England Journal of Medicine 1996;335(10):721-9. | 8786764 |
| 1754 | Cummings J, Spanswick VJ, Tomasz M, et al. Enzymology of mitomycin C metabolic activation in tumour tissue. Biochem Pharmacol 1998;56:405-14. | 9763215 |
| 390 | Cundy KC, Lynch G, Shaw JP, et al. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Current Eye Research 1996;15(5):569-76. | 8670758 |
| 487 | Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy 1995;39(6):1247-52. | 7574510 |
| 2900 | Curran A, Guiu J, Lopez RM, van den Eynde E, Marti R, Crespo M, Perez M, et al. Atazanavir total and unbound plasmatic concentrations in HIV-HCV coinfected patients with hepatic cirrhosis [abstract P_20]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24th, 2013, Amsterdam. [page 51] | http://regist2.virology-education.com/abstractbook/2013_3.pdf |
| 2693 | Curran A, Lopez R, Pou L, et al. Pharmacokinetic evaluation of potential interaction between tipranavir and enfuvirtide [abstract 53]. 7th International Workshop on Clinical Pharmacology of HIV Therapy April 20-22, 2006, Lisbon. | |
| 2347 | Curran A, Marti R, Lopez RM, et al. Darunavir and telaprevir drug interaction: total and unbound plasmatic concentrations in HIV-HCV coinfected patients [abstract PE10/16]. 14th European AIDS Conference (EACS), October 16-19, 2013, Brussels, Belgium. | |
| 2937 | Curran A, Marti R, Lopez RM, Perez M, van den Eynde E, Crespo M et al. Darunavir and ritonavir total and unbound concentrations in HIV-HCV coinfected patients with hepatic cirrhosis [abstract O_16]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18th, 2012, Barcelona, Spain. | http://regist2.virology-education.com/2012/13hivpk/docs/29_Curran.pdf |
| 2938 | Curran A, Ocana I, Deig E, Guiu J, Lopez RM, Perez M et al. Darunavir/ritonavir once daily total and unbound plasmatic concentrations in HIV-infected pregnant women [abstract P_19]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. [page 49] | http://regist2.virology-education.com/abstractbook/2013_3.pdf |
| 2295 | Custodio J, Garner W, Jin F, et al. Evaluation of the drug interaction potential between the pharmacokinetic enhancer cobicistat and tenofovir disoproxil fumarate in healthy subjects [abstract O_07]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | |
| 2415 | Custodio J, Guo S, Lawson EB, et al. Lack of clinically relevant drug interactions between elvitegravir plus ritonavir boosted-atazanavir and telaprevir [abstract MOPE041]. 20th International AIDS Conference, July 20-25, 2014, Melbourne, Australia. | |
| 2337 | Custodio J, Guo S, Lawson EB, et al. Lack of clinically relevant drug Interactions between elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and telaprevir [abstract A-1576]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 10-13, 2013, Denver, CO. | |
| 2417 | Custodio J, Shao Y, Begley R, et al. Pharmacokinetics of boosted-elvitegravir in combination with rifabutin, utilizing twice daily administration of cobicistat to overcome induction [abstract THPDB0102]. 20th International AIDS Conference, July 20-25, 2014, Melbourne, Australia. | http://pag.aids2014.org/abstracts.aspx?aid=6114 |
| 2627 | Custodio J, West S, Das M, et al. Evaluation of the drug interaction potential between elvitegravir/cobicistat/emtrictabine/tenofovir alafenamide and sertraline [abstract 73]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC. | |
| 2830 | Custodio J, West S, SunGupta D, et al. Evaluation of the drug-drug interaction potential between cobicistat-boosted protease inhibitors and statins [abstract O_04]. 18th International Workshop on Clinical Pharmacology of HIV Therapy, June 14-16, 2017, Chicago, USA. | http://regist2.virology-education.com/2017/18AntiviralPK/05_Custodio.pdf |
| 2873 | Custodio J, West S, Yu A, et al. Lack of clinically relevant effect of bictegravir on metformin pharmacokinetics and pharmacodynamics. Open Forum Infect Dis 2017;4:S429. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631370/ |
| 2775 | Custodio JM, Chuck SK, Chu H, et al. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide. Pharmacology Research & Perspectives. 2017;5(5):e00353. | |
| 3107 | Custodio JM, Fordyce M, Garner W, et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob agents Chemother 2016;60(9):5135-5140. | 27216057 |
| 3053 | Custodio JM, Liu Y, Graham H, et al. Bioequivalence of two pediatric formulations vs adult tablet formulation of elvitegravir [abstract]. Conference on Retroviruses and Opportunistic Infections, Boston MA, March 3-6, 2014. | http://www.croiconference.org/sites/all/abstracts/902.pdf |
| 3052 | Custodio JM, Rhee M, Shen G, Ling KH, Kearney BP, Ramanathan S. Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment. Antimicrob Agents Chemother. 2014 May;58(5):2564-9. doi: 10.1128/AAC.02180-13. | 24550332 |
| 2437 | Custodio JM, Shao Y, Begley R, et al. Pharmacokinetics and drug interaction profile of cobicistat-boosted elvitegravir with carbamazepine [abstract H-1011]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, 2014, Washington, DC. | |
| 2087 | Custodio JM, Wang H, Hao J, et al. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. J Clin Pharmacol 2014; 54(6):649-56. | 24375014 |
| 2860 | Custodio JM, West S, Lutz, J, et al. Twice daily administration of tenofovir alafenamide in combination with rifampin: potential for tenofovir alafenamide use in HIV-TB coinfection [abstract PS13/4]. 16th European AIDS Conference, October 25-27, 2017, Milan, Italy. | http://www.professionalabstracts.com/eacs2017/iplanner/#/grid |
| 3004 | Custodio JM, West SK, Collins S et al. Pharmacokinetics of bictegravir administered twice daily in combination with rifampin. [abstract 34]. Conference on Retroviruses and Opportunistic Infections (CROI), March 4-8, 2018, Boston, MA. | |
| 2806 | Custodio JM, West SK, Gupta D et al. Evaluation of the Drug Interaction Potential between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Atorvastatin [abstract P306]. HIV Drug Therapy, October 22-26, 2016, Glasgow UK. | |
| 1684 | Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996;24:1015-9. | 8886613 |
| 1030 | D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Annals of Internal Medicine 1996;124:1019-30. | 8633815 |
| 2130 | Daali Y, Ancrenaz V, Bosilkovska M, et al. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. Metabolism 2011;60(11):1584-9. | 21550074 |
| 515 | Daikos GL, Pulido J, Kathpalia SB, et al. Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression. British Journal of Ophthalmology 1988;72(7):521-4. | 2843218 |
| 2629 | Dailly E, Allavena C, Gregoire M, et al. Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. J Antimicrob Chemother 2015 Dec;70(12):3307-10. | 26271944 |
| 1591 | Dailly E, Raffi F, Perre P, et al. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach. HIV Med 2009;10(9):586-9. | 19486187 |
| 3099 | Dalgard O., Conway B., Cunningham E.B., et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology and Hepatology; 3(3):153-161. | |
| 884 | Dalton K, Dalton MJ. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurologica Scandinavica 1987;76(1):8-11. | 3630649 |
| 1679 | Damia G, D’Incalci M. Clinical pharmacokinetics of altretamine. Clin Pharmacokinet 1995;28:439-48. | 7656502 |
| 1139 | Damle B, Hess H, Kaul S, et al. Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Biopharm Drug Disposition 2002;23(2):59-66. | 11932960 |
| 1614 | Damle B, LaBadie R, Crownover P, et al. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008;65(4):523-30. | 18294336 |
| 969 | Damle BD, Mummaneni V, Kaul S, et al. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrobial Agents and Chemotherapy 2002;46:385-91. | 11796346 |
| 1082 | Damle BD, Yan J, Behr D, et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol. 2002 Apr;42(4):419-27. | 11936567 |
| 1971 | Danaher PJ, Salsbury TL, Delmar JA. Metabolic derangement after injection of triamcinolone into the hip of an HIV-infected patient receiving ritonavir. Orthopedics 2009;32(6):450. | 19634808 |
| 1649 | Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34. | 3280211 |
| 2177 | Dangerous supplements: what you don't know about these 12 ingredients could hurt you. Consum Rep 2010;75(9):16-20. | 20712098 |
| 1784 | Daniel PC, Gaskell J, Bishop H, et al. Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur J Cancer Clin Oncol 1981;17:1183-9. Eur J Cancer Clin Oncol 1981;17:1183-9. | 7199465 |
| 551 | Danner SA, Matheron S. Cytomegalovirus retinitis in AIDS patients: a comparative study of intravenous and oral ganciclovir as maintenance therapy. Aids 1996;10(Suppl 4):S7-11. | 9110064 |
| 2576 | Dao, C. et al. Assessment of vitamin D levels among HIV-infected patients in the study to understand the natural history of HIV/AIDS in the era of effective therapy: SUN study. Abstract. 2010. 17th Conference on Retroviruses and Opportunistic Infections. | |
| 1253 | Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997;350(9089):1425-31. | 9371165 |
| 809 | Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter]. Annals of Pharmacotherapy 1997;31(5):647. | 9161669 |
| 838 | Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clinical Infectious Diseases 1998;26:259-74. | 9502438 |
| 2170 | Darque A, Enel P, Ravaux I, et al. Drug interactions in elderly individuals with the human immunodeficiency virus [letter]. JAGS 2012;60(2):382-4. | 22332689 |
| 1523 | Das K, Clark ADJ, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004 May 6;47(10):2250-60. | 15115397 |
| 553 | Davies L, Maynard A. An economic exploration of oral and intravenous ganciclovir in the induction and maintenance treatment of AIDS-related cytomegalovirus retinitis. International Journal of STD & AIDS 1996;7(6):415-21. | 8940670 |
| 387 | Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Archives of Ophthalmology 1997;115(6):733-7. | 9194724 |
| 3517 | Dawood AA, Nooh MZ, Elgamal AA. Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian Type 2 diabetes mellitus patients with chronic hepatitis C genotype 4. Diabetes Metab J 2017;41:316-21. | 28868829 |
| 459 | De Antoni A, Foli A, Lisziewicz J, et al. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis. 1997 Oct;176(4):899-903. | 9333147 |
| 1550 | De Bethune M, Andries K, Azijn H, et al. TMC-278, a new potent NNRTI, with an increased barrier to resistance and good pharmacokinetic profile [abstract 556]. 12th Conference on Retroviruses and Opportunistic Infections, February 22-25, 2005, Boston, MA. | |
| 2305 | De Kanter C, Colbers A, Blonk M, et al. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. J Antimicrob Chemother 2013;68(6):1415-22. | 23429642 |
| 2127 | De Kanter C, Keuter M, Van der Lee MJ, et al. Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir. Antivir Ther 2011;16(3):435-7. | 21555828 |
| 2152 | De Maat MM, Huitema ADR, Mulder JW, et al. Drug interaction of fluvoxamine and fluoxetine with nevirapine in HIV-1-Infected individuals. Clin Drug Invest 2003;23(10):629-37. | 17535078 |
| 3520 | De Nicolo A, Calcagno A, Motta I, et al. Intracellular disposition of darunavir/ritonavir and dolutegravir with rifampin [abstract 371]. Conference on Retroviruses and Opportunistic Infections (virtual CROI), March 6-10, 2021. | |
| 777 | Deayton J, Wilson P, Sabin C, et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS. 2000 Jun 16;14(9):1163-70. | 10894280 |
| 2813 | DeCarolis DD, Westanmo AD, Chen Y-C, et al. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. Ann Pharmacother 2016;50(11):909-17. | 27465881 |
| 1903 | Decloedt EH, McIlleron H, Smith P, et al. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampicin with adjusted doses of lopinavir/ritonavir tablets. Antimicrob Agents Chemother 2011;55(7):3195-200. | 21537021 |
| 2818 | Deeken JF, Beumer JH, Anders NM, et al. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirnez, and the tyrosine kinase inhibitor erlotinib. Cancer Chemother Pharmacol 2015;76(4):813-9. | 26330331 |
| 1810 | Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opinion Oncology 2009;21:445-54. | 19606034 |
| 347 | Deeks S, Grant R, Horton C, et al. Virologic effect of ritonavir plus saquinavir in subjects who have failed indinavir [abstr. I-205]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 327 | Deeks S, Loftus R, Cohen P, et al. Incidence and predictors of virologic failure to indinavir or/and ritonavir in an urban health clinic [abstr. LB-2]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 576 | Deeks SG, Collier A, Lalezari J, et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. Journal of Infectious Diseases 1997;176(6):1517-23. | 9395363 |
| 211 | Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. Journal of the American Medical Association 1997;277:145-53. | 8990341 |
| 2166 | Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009;17(4):118-23. | 19890183 |
| 613 | Dega H, Eliaszewica M, Gisselbrecht M, et al. Infections associated with totally inplantable venous access devices (TIVAD) in human immunodeficiency virus-infected patients. Journal of the Acquired Immune Deficiency Syndrome 1996;13:146-54. | 8862279 |
| 992 | Degen O, Kurowski M, Van Lunzen J, et al. Amprenavir and ritonavir: intraindividual comparison of different doses and influence of concomitant NNRTI on steady-state pharmacokinetics in HIV-infected patients [abstract 739]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago IL. | |
| 2456 | DeJesus E, Lalezari JP, Osiyemi OO, et al. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther 2010;15(5):711-20. | 20710052 |
| 1313 | DeJesus E, Piliero P, Summers K, et al. Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2006 Sep;50(9):3157-9. | 16940117 |
| 3577 | DeJesus E, Richmond G, Berhe M et al. IV push administration of ibalizumab: pharmacokinetics, safety and efficacy [abstract 429]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, February 12-16, 2022. | |
| 3390 | DeJesus E, Saleh S, Cheng S et al. Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults. Pulm Circ 2019;9:2045894019848644. | 30997864 |
| 3385 | Dekkers BGJ, Bierman WFW, Touw DJ, Alffenaar J-WC. Relevance of the drug-drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat. AIDS 2019;33:1100-1102. | 30946167 |
| 2105 | Delaborde L, Logerot S, Baudrant-Boga M, et al. Tacrolimus-Telaprevir interaction monitoring : case report in a liver transplant patient with recurrence of hepatitis C virus (HCV) [abstract P507]. VII eme Congrès de Physiologie de Pharmacologie et de Thérapeutique, 4-6 Avril, 2012, Dijon, France. | |
| 2522 | Dellicour S, Hall S, Chandramohan D, et al. The safety of artemisinins during pregnancy: a pressing question. Malaria journal 2007;6:15. | 17300719 |
| 2287 | DeMaio W, Kane CP, Nichols AI, et al. Metabolism studies of desvenlafaxine. J Bioequiv Availab 2011;3(7):151-60. | |
| 973 | Demarles D, Gillotin C, Bonaventure-Paci S, et al. Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice. Antimicrob Agents Chemother 2002;46:1589-90. | |
| 1501 | Demeter L, Jiang H, Mukherjee L, et al. A prospective, randomized, controlled, open-label trial evaluating the effect of therapeutic drug monitoring and protease inhibitor dose escalation on viral load responses in antiretroviral-experienced, HIV-infected patients with a normalized inhibitory quotient [abstract 35]. 15th Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, MA. | 19114860 |
| 3026 | Deng J, Shao J, Markowitz JS, An G. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. Pharm Res 2014;31:2237-55. | 24842659 |
| 300 | Denning DW, Armstrong RW, Fishman M, et al. Endophthalmitis in a patient with disseminated cryptococcosis and AIDS who was treated with itraconazole. Reviews of Infectious Diseases 1991;13(6):1126-30. | 1663651 |
| 80 | Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. New England Journal of Medicine 1991;324:654-62. | 1994248 |
| 2300 | Denning J, Cornpropst M, Clemons D, et al. Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone pharmacokinetics and pharmacodynamics [abstract 372]. 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 4-8, 2011, San Francisco. | |
| 1081 | Depestel D, Kazanjian P, Cinti SK, et al. Magnitude and duration of elevated gastric pH in patients infected with human immunodeficiency virus after administration of chewable, dispersible, buffered didanosine tablets. Pharmacotherapy. 2004 Nov;24(11):1539-45. | 15537559 |
| 585 | Deray G, Katlama C, Dohin E. Prevention of foscarnet nephrotoxicity [letter]. Annals of Internal Medicine 1990;113(4):332. | 2165372 |
| 1785 | Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 2002;30:608-12. | 11950795 |
| 396 | Desatnik HR, Foster RE, Lowder CY. Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. American Journal of Ophthalmology 1996;122(1):121-3. | 8659587 |
| 958 | Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Journal of the American Medical Association 2000;283:205-11. | 10634336 |
| 1140 | DeSilva KE, LeFlore DB, Marston BJ, et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001;15(10):1281-5. | 11426073 |
| 3072 | Desimone JA, Ojha A, Pathak R, Cohn J. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man. Clin Infect Dis 2004;39(10):110-2.
| 15546072 |
| 1909 | Desnoyer A, Al Kaied F, Descamps D, et al. Deleterious pharmacokinetic interaction between bexarotene and efavirenz AIDS 2010;24(14):2296-8. | 20736686 |
| 1675 | Di Baggio A, Rosso R, Siccardi M, et al. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. J Antimicrob Chemother 2009;64(4):874-5. | 19643773 |
| 1537 | Di Perri G, Madruga JV, Sathasivam K, et al. The impact of background regimen on virologic response to etravirine: pooled 48-week analysis to DUET-1 and DUET-2 [abstract TUPE0061]. XVIIth International AIDS Conference, August 3-8, 2008, Mexico City, Mexico. | |
| 2940 | Di Yacovo et al. CSF viral load and darunavir concentrations in patients receiving DRV/r 600/100 mg or 800/100 mg once daily plus 2 nucleosides [abstract P_46]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington DC, May 19-21, 2014. | http://www.natap.org/2014/Pharm/Pharm_27.htm |
| 3408 | Diamant M, van Agtmael M. Liraglutide Treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes. Diabetes Care 2012;35:e34. | 22517942 |
| 1615 | Diaz RAS, Sancho J, Serratosa J. Antiepileptic drug interactions. Neurologist 2008;14(6S):S55-S65. | 19225371 |
| 461 | Diaz-Llopis M, Chipont E, Sanchez S, et al. Intravitreal foscarnet for cytomegalovirus retinits in a patient with acquired immunodeficiency syndrome. American Journal of Opthalmology 1992;114:742-7. | 1334376 |
| 399 | Diaz-Llopis M, Espana E, Munoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. British Journal of Ophthalmology 1994;78(2):120-4. | 8123619 |
| 731 | Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes. Journal of the American Medical Association 1998;280(10):887-92. | 9739972 |
| 1367 | Dicenzo R, Forrest A, Squires KE, et al. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. antimicrobial Agents and Chemotherapy 2003;47(6):1929-35. | 12760869 |
| 1346 | Dicenzo R, Peterson D, Cruttenden K, et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrobial Agents and Chemotherapy 2004;48(11):4328-31. | 15504860 |
| 1596 | DiCenzo R, Peterson DR, Cruttenden K, et al. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. Antimicrob Agents Chemother 2008;52(9):3035-9. | 18573930 |
| 2939 | Dickinson L, Jackson A, Garvey L et al. Population pharmacokinetic modeling of plasma and intracellular once daily ritonavir-boosted darunavir in HIV-infected patients [abstract O_12]. 11th Int Workshop Clin Pharmacol HIV Ther: Miami, April 13-15, 2011. | http://regist2.virology-education.com/2011/12HIV_PK/docs/29_Dickinson.pdf |
| 745 | Dieleman JP, Gyssens IC, van der Ende MEM, et al. Urologic complaints in relation to indinavir plasma levels in HIV-infected patients. AIDS 1999;13:473-8. | 10197375 |
| 1197 | Dieleman JP, Jambroes M, Gyssens I, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA Cohort. AIDS 2002;16(5):737-45. | 11964530 |
| 573 | Dieterich DT, Poles MA, Lew EA, et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. Journal of Infectious Diseases 1993;167(5):1184-8. | 8387563 |
| 1340 | Ding R, Tayrouz Y, Riedel K-D, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clinical Pharmacology and Therapeutics 2004;76:73-84. | 15229466 |
| 2001 | Dingemanse J, van Giersbergen PL, Patat A, et al. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir Ther 2010;15(2):157-63. | 20386070 |
| 1064 | Dionisio D, Mininni S, Bartolozzi D, et al. Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS 2001;15:277-8. | 11216940 |
| 1637 | Dixit V, Hariparsad N, Li F, et al. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007;35(10):1853-9. | 17639026 |
| 2096 | Dooley K, Sayre P, Borland J, et al. Pharmacokinetics, safety and tolerability of the HIV integrase inhibitor dolutegravir coadministered with rifabutin in healthy subjects [abstract P_11]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 2076 | Dooley K, Sayre P, Purdy E, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acq Immune Def Syndr 2013;62(1):21-27. | 23075918 |
| 3181 | Dooley KE, Churchyard G, Savic RM, et al. Safety and pharmacokinetics of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir [abstract 80]. Conference on Retroviruses and Opportunistic Infections, March 4-7, 2019, Seattle, WA. | http://www.croiconference.org/sessions/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir |
| 2526 | Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. The Journal of infectious diseases 2008 Oct 1;198(7):948-61. | 18713054 |
| 3435 | Dooley KE, Park J-G, Swindells S, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. JAIDS 2012;59:455-62. | 22126739 |
| 3373 | Dooley KE, Savic R, Gupte A, et al. Once weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV 2020; Mar 30 | 32240629 |
| 3247 | Doose DR, Wang SS, Padmanabhan M et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 2003;44:540-9. | 12681003 |
| 241 | Doran CM. New approaches to using antiretroviral therapy for the management of HIV Infection. Annals of Pharmacotherapy 1997;31(2):228-36. | 9034425 |
| 283 | Dornsife RE, Averett DR. In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrobial Agents and Chemotherapy 1996;40(2):514-9. | 8834914 |
| 1969 | Dort K, Padia S, Wispelwey B, et al. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther 2009;6:10. | 19505306 |
| 3215 | Dougherty JA, Wynn RE, Maarsingh H. Unrecognized drug interaction: ranolazine adverse effects intensified by darunavir-cobicistat. Ann Pharmacother 2019;May 18 [epub ahead of print]. | 31106569 |
| 259 | Doweiko JP, Groopman JE. Hematological consequences of HIV infection. In: Broder S, Merigan TCJ, Bolognesi D, editors. Textbook of AIDS Medicine. Baltimore: Williams & Wilkins; 1994. p. 617-28. | |
| 1868 | Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44:590-8. | 15145966 |
| 2820 | Dowsett M, Cuzick J, Howell A, et al. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the \'Arimidex and tamoxifen alone or in combination\' (ATAC) trial. Br J Cancer 2001;85(3):317-24. | 11487258 |
| 2821 | Dowsett M, Pfister C, Johnston SR, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999;5(9):2338-43. | 10499602 |
| 867 | Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole [letter]. Clinical Infectious Diseases 1994;18(2):266. | 8161649 |
| 3514 | Drazilova S, Janicko M, Skladany L, et al. Glucose metabolism changes in patients with chronic hepatitis C treated with direct acting antivirals. Can J Gastroenterol Hepatol 2018;2018: 6095097. | 30402450 |
| 488 | Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. New England Journal of Medicine 1995;333(10):615-20. | 7637721 |
| 543 | Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. Journal of Infectious Diseases 1991;163(4):716-9. | 1849157 |
| 544 | Drew WL. Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance. JAIDS 1991;4(Suppl 1):S42-6. | 1848621 |
| 1284 | Droste JA, Verweij-van Wissen CP, Buffels R, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrobial Agents and Chemotherapy 2005;49(2):680-4. | 15673751 |
| 2216 | Drug Product Database Online Query [database on the Internet]2012 [cited September 1, 2012]. Available from: http://webprod3.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp. | |
| 582 | Drusano GL, Aweeka F, Gambertoglio J, et al. Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients. AIDS 1996;10:1113-9. | 8874628 |
| 966 | Dubé MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy. Recommendations of the Adult ACTG Cardiovascular Disease Focus Group. Clinical Infectious Diseases 2000;31:1216-24. | 11073755 |
| 2666 | DuBois BN, Atrio J, Stanczyk FZ, et al. Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. Contraception 2015 Jan;91(1):71-5. | |
| 2503 | Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clinical pharmacokinetics 1996 Oct;31(4):257-74. | 8896943 |
| 31 | Ducharme MP, Provenzano R, Dehoorne-Smith M, et al. Trough concentrations of cyclosporine following administration with grapefruit juice. British Journal of Clinical Pharmacology 1993;36:457-9. | 12959294 |
| 2306 | Dufty NE, Gilleran G, Hawkins D, et al. Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma. J Antimicrob Chemother 2013;68(4):972-4. | 23249840 |
| 305 | Dugel PU, Rao NA, Forster DJ, et al. Pneumocystis carinii choroiditis after long-term aerosolized pentamidine therapy [see comments]. American Journal of Ophthalmology 1990;110(2):113-7. | 2378374 |
| 2172 | Duggan J, Peterson WS, Schutz M, et al. Use of Complementary and Alternative Therapies in HIV-Infected Patients. AIDS Patient Care and STDs 2001;15(3):159-67. | 11313029 |
| 2858 | Duggan JM, Akpanudo B, Shukla V, Gutterson G, Eitniear L, Sahloff EG. Alternative antiretroviral therapy formulations for patients unable to swallow solid oral dosage forms. Am J Health Syst Pharm 2015;72(18):1555-65. | 26346211 |
| 409 | Duker JS, Robinson M, Anand R, et al. Initial experience with an eight-month sustained-release intravitreal ganciclovir implant for the treatment of CMV retinitis associated with AIDS. Ophthalmic Surgery and Lasers 1995;26(5):442-8. | 8963859 |
| 2375 | Duncan A, Mills J. An unusual case of HIV virologic failure during treatment with boosted atazanavir. Aids 2013 May 15;27(8):1361-2. | 23925384 |
| 650 | Dupont Merck. Data on file. 1998. | |
| 696 | Dupont Merck. Significant efavirenz-saquinavir interaction. May 12, 1998. | |
| 2546 | Durand R, Prendki V, Cailhol J, et al. Plasmodium falciparum malaria and atovaquone-proguanil treatment failure. Emerging infectious diseases 2008 Feb;14(2):320-2. | 18258131 |
| 959 | Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000 July 7;14(10):1333-8. | 10930147 |
| 1042 | Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999;353(9171):2195-9. | 10392984 |
| 1759 | Duthie SJ, Grant MH. The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived HepG2 hepatoma cells. Br J Cancer 1989;60:566-71. | 2553092 |
| 632 | Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. British Journal of Clinical Pharmacology 1997;44(2):190-4. | 9278209 |
| 2736 | East J, Blanton LS. Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy. Antimicrob Agents Chemother. 2012;56(2):1081-3. | |
| 3182 | Ebrahim I, Maartens G, Wiesner L et al. Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV. J Antimicrob Chemother 2020;75:1019-25. | 31942627 |
| 2241 | Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception 2010;82(4):314-23. | 20851224 |
| 17 | Edelstein H, Knight RT. Severe parkinsonism in two AIDS patients taking prochlorperazine [letter]. Lancet 1987;2:341-2. | 2886808 |
| 1343 | Edelstein HE, Cuadros Y. Failure of treatment of tuberculous adenitis due to an unexpected drug interaction with rifabutin and efavirenz. AIDS 2004;18(12):1748-9. | 15280794 |
| 2587 | Egan G, Hughes CA, Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother 2014:48(6):734-40. | 24615627 |
| 1756 | Ehninger G, Proksch B, Heinzel G, et al. Clinical pharmacology of mitoxantrone. Cancer Treat Rep 1986;70:1373-8. | 3791250 |
| 2185 | Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. British journal of clinical pharmacology. [Research Support, Non-U.S. Gov't] 1997 Nov;44(5):439-46. | 9384460 |
| 170 | Einarson TR. Drug-related hospital admissions. Annals of Pharmacotherapy 1993;27:832-40. | 8364259 |
| 3441 | Einolf HJ, Zhou J, Won C et al. A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A4 in cancer patients. Drug Metab Dispos 2017;45:361-74. | 28122787 |
| 1805 | Eisai Inc. Bexarotene (Taregretin) Capsules Package Insert. Woodcliff Lake, NJ January, 2007. | |
| 3273 | Eisai Inc. Halaven (eribulin) Package Insert. Woodcliff Lake, NJ. October 2016. | |
| 3245 | Eisai Inc. Lenvima (lenvatinib) Package Insert. Woodcliff Lake, NJ. December 2018. | |
| 3276 | Eisai Limited. Banzel (rufinamide) Product Monograph. Mississauga, ON. April 19, 2017. | |
| 3480 | Eisai Limited. Dayvigo (lemborexant) Product Monograph. Mississauga, ON. November 3, 2020. | https://pdf.hres.ca/dpd_pm/00058592.PDF |
| 3265 | Eisai Limited. Fycompa (perampanel) Product Monograph. Mississauga, ON. March 21, 2018. | https://pdf.hres.ca/dpd_pm/00044392.PDF |
| 3244 | Eisai Limited. Lenvima (lenvatinib) Product Monograph. Mississauga, ON. December 19, 2018. | https://pdf.hres.ca/dpd_pm/00048812.PDF |
| 3272 | Eisai Limited. Halaven (eribulin) Product Monograph. Mississauga, ON. August 4, 2017. | https://pdf.hres.ca/dpd_pm/00040614.PDF |
| 3114 | Ejsing TB, Pedersen AD, Linnet K. P‐glycoprotein interaction with risperidone and 9‐OH‐risperidone studied in vitro, in knock‐out mice and in drug–drug interaction experiments. Hum Psychopharmacol. 2005;20(7):493–500. | 16118767 |
| 3372 | Eke AC, Stek AM, Wang J, et al. Darunavir pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2020; 83(4):373-80. | 31923087 |
| 3650 | El Kamari V, Hileman CO, Kosco J, McComsey GA. Sleeve gastrectomy compared with Roux-en-Y gastric bypass in individuals living with HIV. J Acquir Immun Defic Syndr 2020; 84:e28-e31. | 32433253 |
| 1980 | El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008;13(2):123-32. | 18465473 |
| 313 | Eldred L, Wu A, Chaisson RE, et al. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. JAIDS 1998;18(2):117-25. | 9637576 |
| 2428 | Eley T, Gardiner D, Persson A, et al. Evaluation of drug interaction potential of the HCV protease inhibitor BMS-650032 at 200mg twice daily (bid) in metabolic cocktail and p-glycoprotein (p-gp) probe studies in healthy volunteers [abstract 381]. Hepatology 2011;54(S1). | |
| 2122 | Eley T, Han Y, Huang S, et al. In vivo and in vitro assessment of asunaprevir as an inhibitor and substrate of OATP transporters in healthy volunteers [abstract PK_04]. 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 27-28, 2012, Cambridge, MA. | |
| 2309 | Eley T, He B, Huang S, et al. Effect of multiple dose ketoconazole and the effect of multiple dose rifampin on pharmacokinetics of the HCV NS3 protease inhibitor asunaprevir [abstract O_13]. 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 26-27, 2013, Cambridge, MA. | |
| 2360 | Eley T, He B, Li J, et al. Effect of hepatic impairment on the pharmacokinetics of asunaprevir (BMS-650032, ASV) [abstract]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston, MA. | |
| 2313 | Eley T, Li W, Huang S, et al. Evaluation of pharmacokinetic drug drug interaction between BMS-791325, an NS5B non-nucleotide polymerase inhibitor, daclatasvir and asunaprevir in triple combination in HCV genotype 1 infected patients [abstract O_18]. 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 26-27, 2013, Cambridge, MA. | |
| 2310 | Eley T, You X, Huang S, et al. Evaluation of drug interaction potential between daclatasvir and sofosbuvir [abstract O_14]. 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 26-27, 2013, Cambridge, MA. | |
| 2564 | Eley T, You X, Wang R, et al. Daclatasvir: Overview of drug–drug interactions with antiretroviral agents and other common concomitant drugs [abstract]. HIV DART, December 9-12, 2014, Miami, FL. | |
| 1436 | Eley T, Zhu L, Yones C, et al. Effect of efavirenz on atazanavir 400 mg with ritonavir 100 mg in healthy subjects [abstract A-1416]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, IL. | |
| 3487 | Eli Lilly and Company. Bamlanivimab and Etesevimab Full Emergency Use Authorization (EUA) Prescribing information. Indianapolis, IN. February 9, 2021 | http://pi.lilly.com/eua/bam-and-ete-eua-factsheet-hcp.pdf |
| 3423 | Eli Lilly and Company. Bamlanivimab Full Emergency Use Authorization (EUA) Prescribing information. Indianapolis, IN. November 2020. | http://pi.lilly.com/eua/bamlanivimab-eua-factsheet-hcp.pdf |
| 3290 | Eli Lilly Canada Inc. Verzenio (abemaciclib) Product Monograph. Toronto, ON. September 23, 2019. | |
| 2060 | Eli Lilly Canada Inc. Cialis (tadalafil) Product Monograph. Toronto, ON. November 22, 2016. | http://www.lilly.ca/en/pdf/product-monograph/cialis-ca-pm-approved.pdf |
| 3674 | Eli Lilly Canada Inc. Humatrope (somatropin) Product Monograph, Toronto, ON. September 16, 2021. | https://pi.lilly.com/ca/humatrope-ca-pm.pdf |
| 2475 | Eli Lilly Canada Inc. Prasugrel (Effient) Product Monograph. Toronto. June 14, 2014. | http://www.lilly.ca/en/pdf/product-monograph/6_effient-pm_17jun2014.pdf |
| 688 | Eli Lilly Canada Inc. Zyprexa (olanzapine) Product Monograph. Toronto, ON. December 13, 2016. | http://www.lilly.ca/en/pdf/product-monograph/zyprexa-ca-pm-approved.pdf |
| 3335 | Eli Lilly Canada Incl. Olumiant (baricitinib) Product Monograph. Toronto, ON. August 14, 2018. | |
| 3306 | Eli Lilly Canada. Emgality (galcanezumab) Product Monograph. Toronto, ON. July 30, 2019 | http://pi.lilly.com/ca/emgality-ca-pm.pdf |
| 3585 | Eli Lily. Atomoxetine (Strattera) Prescribing Information. Indianapolis, IN. 2003. | |
| 989 | Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. American Journal of Cardiology 1998;81(4A):60B-65B. | 9526816 |
| 73 | Eller MG, Okerholm RA. Pharmacokinetic interaction between terfenadine and ketoconazole. Clinical Pharmacology and Therapeutics 1991;49:130 [abstract PI-29]. | |
| 3167 | Elliot ER, Cerrone M, Else L, et al. Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers. J Antimicrob Chemother 2019;74:149-56. | 30272231 |
| 1630 | Ello NF, Moutomé K, Tanon A, et al. A randomized clinical trial of efavirenz 600mg/day versus 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin in Abidjan (Côte d´Ivoire) [abstract TUPEB142]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Capetown, South Africa. | |
| 3503 | Elmekawy HA, Belal F, Abdelaziz AE et al. Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers. Eur J Clin Pharmacol 2021 Apr 1. doi: 10.1007/s00228-021-03130-z. Online ahead of print. | 33791829 |
| 2550 | Emmanuel A, Gillotin C, Farinotti R. Atovaquone suspension and indinavir have minimal pharmacokinetic interactions [abstract no. 12384]. International AIDS Conference, 1998. | |
| 2997 | Endo Pharmaceuticals Inc. Frova (frovatriptan) Product Monograph. Montreal, QC. December 17, 2012. | |
| 76 | Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampin and isoniazid. New England Journal of Medicine 1984;311:1681-3. | 6095080 |
| 2186 | English BA, Dortch M, Ereshefsky L, et al. Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting. Curr Psychiatry Rep 2012 Aug;14(4):376-90. | 22707017 |
| 391 | Engstrom RE, Jr., Holland GN. Local therapy for cytomegalovirus retinopathy [published erratum appears in Am J Ophthalmol 1996 Jan;121(1):104]. American Journal of Ophthalmology 1995;120(3):376-85. | 7661210 |
| 1492 | Ensom MHH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet 1998;34(4):265-79. | 9571300 |
| 162 | Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Annals of Internal Medicine 1984;100:258-68. | 6362512 |
| 1811 | Erickson TM, Koeppe JR, Miller YE, et al. Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making. J Thorac Oncol 2008;3(11):1353-5. | 18978572 |
| 854 | Eriksson BF, Schinazi RF. Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrobial Agents & Chemotherapy 1989;33(5):663-9. | 2546487 |
| 1671 | Eron J, Haubrich R, Reiss P, et al. Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials [abstract MOPEB043]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Capetown, South Africa. | |
| 269 | Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New England Journal of Medicine 1995;333(25):1662-9. | 7477218 |
| 1124 | Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004 Jan 15;189(2):265-72. | 14722892 |
| 3102 | Eron JJ, Lelievre JD, Kalayjian R, et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV 2018 Dec 13.pii: S2352-3018(18)30296-0. doi: 10.1016/S2352-3018(18)30296-0. [Epub ahead of print]. | 30555051 |
| 3421 | Eron JJ, Wilkin A, Ramgopal M et al. A daily single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults living with HIV and end-stage renal disease on chronic hemodialysis [abstract 1002]. IDWeek 2020, October 21-25. | https://academic.oup.com/ofid/article/7/Supplement_1/S529/6057179 |
| 860 | Ervine CM, Matthew DE, Brennan B, et al. Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. Drug Metabolism & Disposition 1996;24(2):211-5. | 8742233 |
| 725 | Esch LD, Shelton MJ, Adams JM, et al. HIV pharmaceutical care specialist (PCS): An alternative model of care for patients with HIV [abstract 42410]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 320 | Estabrook RW. The remarkable P450s: a historical overview of these versatile hemeprotein catalysts. FASEB Journal 1996;10(2):202-4. | 8641552 |
| 1963 | Estevez J, Molto J, Tuneu L, et al. No change in atazanavir exposure when boosted with 100 mg or 50 mg of ritonavir in healthy volunteers [abstract P_31]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13-15, 2011, Miami, USA. | |
| 1164 | Eugen-Olsen J, Benfield T, Axen TE, et al. Effect of the serotonin receptor agonist, buspirone, on immune function in HIV-infected individuals: a six-month randomized, double-blind, placebo-controlled trial. HIV Clinical Trials 2000;1(1):20-6. | 11590486 |
| 1851 | European AIDS Clinical Society (EACS). Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe (version 6.1). November, 2012. p. 1-82. | |
| 3120 | European Medicines Agency, Bictarvy: EPAR - Product Information (last updated 22/06/2018). | |
| 2880 | European Medicines Agency, Ziagen: EPAR - Product Information (last updated 24/07/2017). | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000252/WC500050343.pdf |
| 2791 | European Medicines Agency: Genvoya -EMEA/H/C/004042 -IB/0006 - Genvoya : EPAR - Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004042/WC500197861.pdf. May 2016 | |
| 2766 | European Medicines Agency: Sustiva : EPAR - Product Information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000249/WC500058311.pdf, May 2015. | |
| 602 | Evans LM, Grossman ME. Foscarnet-induced penile ulcer. Journal of the American Academy of Dermatology 1992;27(1):124-6. | 1320061 |
| 98 | Evans ME, Kortas KJ. Potential interaction between isoniazid and selective serotonin-reuptake inhibitors. American Journal of Health-System Pharmacy 1995;52:2135-6. | 8535949 |
| 1893 | Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010;50(10):1419-21. | 20380564 |
| 324 | Everson RE, Weidle PJ, Perdue BE, et al. Evaluation of drug interactions with indinavir. 4th National Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 3241 | Exelixis, Inc. Cabometyx (cabozantinib) Prescribing Information. Alameda, CA. January 2019. | |
| 2329 | Ezzat H, Cheung MC, Hicks LK, et al. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leuk Lymphoma 2012;53:2390-6. | 22642935 |
| 2535 | Ezzet F, van Vugt M, Nosten F, et al. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrobial agents and chemotherapy 2000 Mar;44(3):697-704. | 10681341 |
| 1858 | Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al. Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. Pharmacol Res 2011;63:249-53. | 21130167 |
| 1775 | Fabian C, Tilzer L, Sternson L. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos 1981;2:381-90. | 7317574 |
| 3196 | Fabrega F, Howarth A, D'Avolio A, et al. PBPK modelling and simulation of ritonavir-boosted atazanavir (ATV/r) dosing when coadministered with rifampicin [abstract 31]. 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, May 14-16, 2019, Noordwijk, the Netherlands. | |
| 3361 | Fact Sheet on Lopinavir and Ritonavir (LPV/R) Oral Pellets. The United Nations Children's Fund and The World Health Organization, Sept 28, 2015. | https://apps.who.int/iris/bitstream/handle/10665/193543/FactsheetIATT_WHO_UNICEF_lopinavir_eng.pdf?sequence=1 |
| 2243 | Faculty of Sexual & Reproductive Healthcare. Drug interactions with hormonal contraception. Royal College of Obstetricians and Gynecologists. January, 2012. p. 1-26 | http://www.fsrh.org/pdfs/CEUGuidanceDrugInteractionsHormonal.pdf |
| 1393 | Faivre L, Teicher H, Vincent I, et al. Potent drug interactions between tacrolimus and lopinavir/ritonavir therapy in HIV-infected liver transplant recipients [abstract 26]. 6th International Workshop on Clinical Pharmacology of HIV Therapy April 28-30, 2005, Quebec. | |
| 111 | Falloon J, Lavelle J, Ogata-Arakaki D, et al. Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia. Antimicrobial Agents and Chemotherapy 1994;38:1580-7. | 7979291 |
| 379 | Falloon J, Piscitelli S, Vogel S, et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clinical Infectious Diseases 2000;30:313-8. | 10671334 |
| 2656 | Fang A, Damle BD, Labadie R, et al. Omeprazole significantly decreases nelfinavir systemic exposure in healthy subjects [abstract A-0384]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27-30 2006, San Francisco, CA. | |
| 586 | Fanning MM, Read SE, Benson M, et al. Foscarnet therapy of cytomegalovirus retinitis in AIDS. Journal of the Acquired Immune Deficiency Syndrome 1990;3:472-9. | 2157835 |
| 591 | Farese Jr. RV, Schambelan M, Hollander H, et al. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Annals of Internal Medicine 1990;112(12):955-6. | 2160217 |
| 2476 | Farid NA, Jakubowski JA, Payne CD, et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Current medical research and opinion 2009 Aug;25(8):1821-9. | 19530977 |
| 2596 | Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007 May;81(5):735-41. | 17361128 |
| 308 | Farrell PL, Heinemann MH, Roberts CW, et al. Response of human immunodeficiency virus-associated uveitis to zidovudine. American Journal of Ophthalmology 1988;106(1):7-10. | 3164982 |
| 3223 | Farrow T, Deaton C, Nguyen N, et al. Cumulative safety review of elvitegravir and bictegravir use during pregnancy and risk of neural tube defects [abstract P030]. HIV Glascow 2018, Oct 28-31, 2018, Glaskow, UK. | http://hivglasgow.org/wp-content/uploads/2018/11/P030-4.pdf |
| 3481 | Fauchet F, Treluyer J, Valade E, et al. Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour? Br J Clin Pharmacol 2014;78(6):1387-96. | 25040510 |
| 60 | Faulds D, Heel RC. Ganciclovir- A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39:597-638. | 2161731 |
| 165 | Fawcett J. Compliance: definitions and key words. Journal of Clinical Psychiatry 1995;56 Suppl 1:4-8. | 7836349 |
| 596 | Fegueux S, Salmon D, Picard C, et al. Penile ulcerations with foscarnet [letter]. Lancet 1990;335:547. | |
| 2540 | Fehintola F, Huang L, Scarsi K, et al. Reduced artemether-lumefantrine exposure in HIV-infected Nigerian subjects on nevirapine-based antiretroviral therapy [abstract O_03]. . 15th International Workshop on Clinical Pharmacology of HIV Therapy, May 19-21, 2014, Washington, DC. | |
| 2501 | Fehintola FA, Scarsi KK, Ma Q, et al. Pharmacokinetics of amodiaquine and desethylamodiaqine in HIV-infected patients with and without nevirapine containing antiretroviral therapy [abstract P_19]. . 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona. | |
| 1241 | Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.[comment]. Lancet 2002;359(9300):30-6. | 11809184 |
| 498 | Felsenstein D, DJ DA, Hirsch MS, et al. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Annals of Internal Medicine 1985;103(3):377-80. | 2992334 |
| 2768 | Feng H-P, Auger P, Vaddady P, et al. No pharmacokinetic interaction between HCV inhibitors grazoprevir/elbasvir with famotidine and pantoprazole [abstract 731]. AASLD Liver Meeting, November 13-17, 2015, San Francisco, CA. | |
| 3186 | Feng HP, Caro L, Fandozzi C et al. Pharmacokinetic interactions between the hepatitis C virus inhibitors elbasvir and grazoprevir and HIV protease inhibitors ritonavir, atazanavir, lopinavir, and darunavir in healthy volunteers. Antimicrob Agents Chemother 2019;63:e02142-18. | 30745392 |
| 2804 | Feng HP, Caro L, Guo Z, et al. A clinically meaningful drug-drug interaction observed between Zepatier (grazoprevir/elbasvir) and Stribild HIV fixed-dose combination in health subjects [abstract O_22]. 17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, June 8-10, 2016, Washington, DC. | |
| 2454 | Ferry FR, Da Silva GA, Motta RN, et al. Use of lopinavir/ritonavir associated with ergotamine resulting in foot amputation: brief communication. Revista do Instituto de Medicina Tropical de Sao Paulo 2014 May-Jun;56(3):265-6. | 24879006 |
| 129 | Ferry J, Herman B, Cox S, et al. Delavirdine (DLV) and indinavir (IDV): a pharmacokinetic drug-drug interaction study in healthy adult volunteers. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 131 | Ferry J, Schneck D, Carlson G, et al. Evaluation of the pharmacokinetic interaction between ritonavir and delavirdine in healthy volunteers. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 928 | Fichtenbaum C, Gerber J, Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV-seronegative volunteers: ACTG Study A5047. AIDS 2002;16(4):569-77. | 11873000 |
| 2200 | Fichtenbaum C, Gerber J. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195-211. | 12405866 |
| 726 | Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sexually Transmitted Diseases 1997;24(8):481-6. | 9293612 |
| 3049 | Fillekes Q, Natukunda E, Balungi J, Kendall L, Bwakura-Dangarembizi M, Keishanyu R, Ferrier A, Lutakome J, Gibb DM, Burger DM, Walker AS; ARROW Trial Team. Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):392-8. | 21926634 |
| 417 | Fiscella RG, Aramwit P. Ganciclovir for intravitreal injection [letter]. American Journal of Health-System Pharmacy 1995;52(4):422. | 7757874 |
| 403 | Fiscella RG, Goldstein D, Labib S, et al. The formation of crystals in ganciclovir used for intraocular injection [letter]. Archives of Ophthalmology 1997;115(7):945-6. | 9230850 |
| 3159 | Fischetti B, Shah K, Taft DR, et al. Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment. Open Forum Infect Dis 2018;5:ofy225. eCollection 2018 Oct. | 30302352 |
| 266 | Fischl M, Parker C, Pettinelli C, et al. A randomized, controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 1990;323:1009-14. | 1977079 |
| 286 | Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New England Journal of Medicine 1987;317(4):185-91. | 3299089 |
| 3380 | Fisher DM, Chang P, Wada DR, et al. Pharmacokinetic properties of a sufentanil sublingual tablet intended to treat acute pain. Anesthesiology 2018;128:943-52. | 29498947 |
| 554 | Fisher M, Barton S. Oral ganciclovir: a new option for patients with CMV retinitis [editorial]. International Journal of STD & AIDS 1996;7(1):1-3. | 8652703 |
| 212 | Fisher RC. Patient education and compliance: a pharmacist's perspective. Patient Education and Counseling 1992;19:261-71. | 1300624 |
| 3038 | Fiske W, Benedek I, Brennan J, Davidson A, Gillette S, Joseph J, Kornhauser D. Pharmacokinetics of efavirenz in subjects with chronic liver disease. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4; 6th:137 (abstract no. 367). | |
| 704 | Fiske WD, Benedek IH, Joseph JL, et al. Pharmacokinetics of efavirenz and ritonavir after multiple oral doses in healthy volunteers [abstract 42269]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 351 | Fiske WD, Benedek IH, White SJ, et al. Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate in healthy volunteers [abstr. I-174]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 382 | Fiske WD, Benedek IH, White SJ, et al. Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in healthy volunteers [abstr. 349]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 678 | Fiske WD, Mayers D, Wagner K, et al. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals [abstract]. 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 607 | Flaherty J, Lalezari J, Petty B, et al. Pharmacokinetics and safety of oral lobucavir in cytomegalovirus-infected HIV patients [abstract 302]. 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 3002 | Fleishaker JC, Herman BC, Carel BJ, Azie NE. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol 2003;43:423-7. | 12723463 |
| 1243 | Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002;16(4):551-60. | 11872998 |
| 1364 | Fletcher CV, Henry WK, Noormohamed SE, et al. The effect of cimetidine and ranitidine administration with zidovudine. Pharmacotherapy 1995;15(6):701-8. | 8602376 |
| 981 | Fletcher CV. Pharmacologic considerations for therapeutic success with antiretroviral agents. Annals of Pharmacotherapy 1999;33(9):989-95. | 10492504 |
| 706 | Flexner C, Hsu A, Kerr B, et al. Steady-state pharmacokinetic interactions between ritonavir, nelfinavir, and the nelfinavir active metabolite M8 [abstract 42265]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 735 | Flexner C. HIV-protease inhibitors. New England Journal of Medicine 1998;338:1271-92. | 9562584 |
| 478 | Flores-Aguilar M, Besen G, Vuong C, et al. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. Journal of Infectious Diseases 1997;175(6):1308-16. | 9180168 |
| 491 | Flores-Aguilar M, Huang JS, Wiley CA, et al. Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. Journal of Infectious Diseases 1994;169(3):642-7. | 8158041 |
| 3475 | Foca E, Calcagno A, Bonito A, et al. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. J Antimicrob Chemother 2017;72(11):3163-3166. | 28961777 |
| 438 | Foisy M, Tseng A. Drug Interactions in HIV Patients. In: Fanning MM, editor. HIV Infection: A Clinical Approach. 2nd ed. Philadelphia: W. B. Saunders Company; 1997. p. 183-90. | |
| 2238 | Foisy M, Yakiwchuk E, Hughes C. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008;42:1048-59. | 18577765 |
| 2140 | Foisy MM, Ahmed R, Chiu I, et al. Managing complex anticonvulsant-antiretroviral drug interactions [abstract P098]. 21st Annual Conference on HIV/AIDS Research, April 19-22, 2012, Montreal, QC. Can J Infect Dis Med Microbiol 2012;23 (suppl A):72A. | |
| 814 | Foisy MM, Gough K, Quan C, et al. Hospitalization due to adverse drug reactions and drug interactions before and after HAART. Canadian Journal of Infectious Diseases 2000;11(4):193-201. | 18159290 |
| 199 | Foisy MM, Nix D, Middleton E, et al. The effects of single dose fluconazole versus multiple dose fluconazole (to steady state) on the pharmacokinetics of theophylline in young healthy volunteers [abstr]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995, San Francisco. | |
| 898 | Foisy MM, Slayter KL, Hewitt RG, et al. Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine. Annals of Pharmacotherapy 1994;28(9):1025-8. | 7803875 |
| 428 | Foisy MM, Tseng A, Blaikie N. Pharmacists' provision of continuity of care to patients with human immunodeficiency virus infection. American Journal of Health-System Pharmacy 1996;53(9):1013-7. | 8744462 |
| 1644 | Foisy MM, Yakiwchuk EMK, Chiu I, et al. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med 2008;9(6):389-96. | 18459946 |
| 282 | Fong IW. Hair loss associated with lamivudine [letter]. Lancet 1994;344(8938):1702. | 7996976 |
| 1263 | Ford J, Boffito M, Wildfire A, et al. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004 Jul;48(7):2388-93. | 15215085 |
| 3089 | Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. JAC. 2004 Dec;54(6):982-990. | https://academic.oup.com/jac/article/54/6/982/856189 |
| 3458 | Ford N, Mofenson L, Shubber Z et al. Safety of efavirenz in the first trimester of pregnancy: an updated systemic review and meta-analysis. AIDS 2014;28 Suppl 2:S123-31. | 24849471 |
| 1461 | Ford SL, Chen Y-C, Lou Y, et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother 2008;52(2):534-8. | 18056271 |
| 2203 | Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic interaction between rilpivirine and the integrase inhibitors dolutegravir and S/GSK1265744. Antimicrob Agents Chemother 2013;57:5472-7. | 23979733 |
| 3384 | Ford SL, Lou Y, Lewis N et al. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects. Antiv Ther 2019;24:301-8. | 30896438 |
| 1236 | Ford SL, Wire MB, Lou Y, et al. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrobial Agents and Chemotherapy 2005;49(1):467-9. | 15616339 |
| 1349 | Forest Laboratories I. Lexapro Product Monograph. St. Louis, MO 2004. | |
| 737 | Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents & Chemotherapy 1993;37(5):1073-81. | 8517694 |
| 888 | Foulds G, Hilligoss DM, Henry EB, et al. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. Journal of Clinical Pharmacology 1991;31(2):164-7. | 1849152 |
| 3140 | Fox E, Widemann BC, Pastakia D, et al. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol 2015;76:1273-83. | 26486517 |
| 3377 | Francis J, Denti P, Mcilleron H, et al. Antiretroviral & rifampicin cotreatment affects DMPA exposure: dosing implications [abstract 471]. 27th Conference on Retroviruses and Opportunistic Infections, March 8-11, 2020; Boston, USA | |
| 460 | Franco L, Malykh AG, Foli A, et al. Overcoming drug resistance to HIV-1 by the combination of cell and virus targeting. 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 3468 | Frange P, Tubiana R, Sibiude J, et al. Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch? J Antimicrob Chemother 2020;75(5)1324-1331. | 32157283 |
| 1979 | Frankel JK, Packer CD. Cushing’s syndrome due to antiretroviral-budesonide interaction. Ann Pharmacother 2011;45(6):823-4. | 21558486 |
| 2607 | Frascino RJ, Gaines Griffy K, Jung D, et al. Multiple dose crossover study of IV ganciclovir induction dose (5 mg/kg IV q12h) and didanosine (200 mg po q12h) in HIV-infected persons [abstract A-27]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco. | |
| 2426 | Fraser IP, Yeh W, Reitmann C, et al. Lack of PK interaction between the HCV protease inhibitor MK-5172 and methadone or buprenorphine/naloxone in subjects on opiate maintenance therapy [abstract O_16_PK]. 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June, 2013, Cambridge, USA. | |
| 642 | Fraunfelder FW, Rosenbaum JT. Drug-induced uveitis. Incidence, prevention and treatment. Drug Safety 1997;17(3):197-207. | 9306054 |
| 2112 | Fraunholz I, Rabeneck D, Gerstein J, et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol 2011;98(1):99-104. | 21168927 |
| 1829 | Fraunholz I, Weiss C, Eberlein K, et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. Int J Radiation Oncology Biol Phys 2010;76(5):1425-32. | 19744801 |
| 472 | Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. American Journal of Opthalmology 1993;116:713-20. | 8250074 |
| 522 | Freeman WR, Henderly DE, Wan WL, et al. Prevalence, pathophysiology, and treatment of rhegmatogenous retinal detachment in treated cytomegalovirus retinitis. American Journal of Ophthalmology 1987;103(4):527-36. | 3031984 |
| 648 | Freimuth W, Peaks S, Slater L, et al. An open-label randomized study of Rescriptor (delavirdine mesylate) plus nelfinavir, didanosine, and stavudine in quadruple treatment regimens in HIV-1 infected individuals [abstract 426]. 7th Annual Canadian Conference on HIV/AIDS Research, April 30-May 3, 1998, Quebec City, PQ. | |
| 1073 | Freitag V, Skifton RD, Lake K. Effect of short-term rifampin on stable cyclosporine concentrations. Annals of Pharmacotherapy 1999;33:871-2. | 10466920 |
| 59 | Freitas VR, Fraser-Smith EB, Matthews TR. Efficacy of ganciclovir in combination with other antimicrobial agents against cytomegalovirus in vitro and in vivo. Antiviral Research 1993;20:1-12. | 8384431 |
| 1136 | Freund YR, Dousman L, Riccio ES, et al. Immunohematotoxicity studies with combinations of dapsone and zidovudine. International Immunopharmacology 2001;1(12):2131-41. | 11710542 |
| 2928 | Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924-1935. | 21809362 |
| 413 | Friedberg DN. Treatment of cytomegalovirus retinitis with intraocular sustained-release ganciclovir implant [letter; comment]. Archives of Ophthalmology 1995;113(11):1354-5. | 7487584 |
| 2756 | Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction AIDS 2005;19:1635-41. | |
| 2453 | Frohlich G, Kaplan V, Amann-Vesti B. Holy fire in an HIV-positive man: a case of 21st-century ergotism. Cmaj 2010 Mar 9;182(4):378-80. | 20048008 |
| 1338 | Frohlich M, Burhenne J, Martin-Facklam M, et al. Oral contraception does not alter single dose saquinavir pharmacokinetics in women. British Journal of Clinical Pharmacology 2004;57(3):244-52. | 14998420 |
| 997 | Frye R, Bertz R, Granneman GR, et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam [abstract A59]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 900 | Frye RF, Bertz RJ, Granneman GR, et al. Effect of ritonavir on CYP1A2, 2C19, and 2E1 activities in vivo [abstract PI-44]. Clinical Pharmacology and Therapeutics 1998;62(2):148. | |
| 3068 | Fulco et al. Sustained virological response after taking crushed elvitegravir–cobicistat–emtricitabine–tenofovir tablets. AJHP. May 2014;71(10);784-6. | https://doi.org/10.2146/ajhp130737 |
| 3157 | Fulco PP, Bannister LH. Pharmacokinetic differences between cobicistat and ritonavir on warfarin. Ann Pharmacother 2018;52:1165-6. | 29909647 |
| 3158 | Fulco PP, Higginson RT. Enhanced HIV viral load suppression with crushed combination tablets containing tenofovir alafenamide and emtricitabine. Am J Health Syst Pharm 2018;15:594-5. | 29748295 |
| 1873 | Fulco PP, Hynicka L, Rackley D. Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. Ann Pharmacother 2010;44:377-82. | 20040700 |
| 3210 | Fulco PP, Sterling RK, Lavoie SR. Administration of crushed ledipasvir-sofosbuvir tablets via gastrostomy button in a patient coinfected with HIV and hepatitis C virus. Am J Health Syst Pharm 2017;74(21):1761-1762. | 29070496 |
| 1881 | Fulco PP, Zingone MM, Higginson RT. Possible antiretroviral therapy–warfarin drug interaction. Pharmacotherapy 2008;28:945-9. | 18576910 |
| 3366 | Fulco PP. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer. Am J Health Syst Pharm 2020;77(7):509-510. | https://pubmed.ncbi.nlm.nih.gov/32207818/ |
| 1744 | Fumagalli L, Zucchetti M, Parisi I, et al. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associate Kaposi’s sarcoma. Cancer Chemother Pharmacol 2000;45:495-501. | 10854138 |
| 1740 | Fumagalli LLF, Zucchetti M, Vigano MG, et al. Treatment of HIV-associated non-Hodgkin’s lymphoma with liposomal daunorubicin substituted CHOP and HAART: preliminary clinical results and CSF pharmacokinetic [abstract 136]. American Society of Clinical Oncology, 36th Annual Meeting, May 19-23, 2000, New Orleans, LA. | |
| 1542 | Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS 2009;23(3):434-5. | 19188762 |
| 635 | Furin JJ. "You have to be your own doctor": sociocultural influences on alternative therapy use among gay men with AIDS in west Hollywood. Medical Anthropology Quarterly 1997;11(4):498-504. | 9408903 |
| 2124 | Furosemide Drugdex® monograph. MICROMEDEX® 2.0 [database on the Internet]. Greenwood Village (COL): Thomson Healthcare. c.1974 - 2011. Available from: www.micromedex.com. 2011. | |
| 2578 | Fux, C. et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Abstract. 2008. 15th Conference on Retroviruses and Opportunistic Infections. | |
| 3394 | Fysekidis, M., Cohen, R., Bekheit, M. et al. Sleeve Gastrectomy Is a Safe and Efficient Procedure in HIV Patients with Morbid Obesity: a Case Series with Results in Weight Loss, Comorbidity Evolution, CD4 Count, and Viral Load. OBES SURG 25, 229–233 (2015) | 24968746 |
| 742 | Gaddis GM, Gaddis ML. Introduction to biostatistics: Part 2, Descriptive statistics. Annals of Emergency Medicine 1990;19(3):309-15. | 2310070 |
| 3189 | Gagliardini R, Fabbiani M, Fortuna S, et al. Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis. Infection 2014; 42: 775-778 | 24531907 |
| 135 | Gagnier P, Myers M, Lamson M, et al. Effect of nevirapine on pharmacokinetics of indinavir in HIV - 1 patients [abstract 374]. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 2139 | Gagnon A, Therrien R. Drug Interactions in AIDS, 4th ed.: Uhress du Chum, Quebec; 2002. | |
| 185 | Gaines K, Wong R, Jung D. Pharmacokinetic interactions with oral ganciclovir: zidovudine, didanosine, probenecid [abstract ]. X International Conference on AIDS, 1994, Yokohama Japan. | |
| 847 | Gallant JE, Moore RD, Keruly J, et al. Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group [see comments]. Journal of Infectious Diseases 1995;172(2):346-52. | 7622876 |
| 1309 | Gallant JE, Rodriguez A, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005 Dec 1;192(11):1921-30. | 16267763 |
| 813 | Gallicano K, Khaliq Y, Carignan G, et al. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clinical Pharmacology and Therapeutics 2001;70:149-58. | 11503009 |
| 179 | Gallicano K, Sahai J, Foster B, et al. Rifampin decreases zidovudine plasma concentrations in HIV-infected patients [abstr]. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 372 | Gallicano K, Sahai J, Kravcik S, et al. Nelfinavir increases plasma exposure of saquinavir in hard gel capsule in HIV+ patients [abstr. 353]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 43 | Gallicano K, Sahai J, Swick L, et al. Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 1995;21:1008-11. | 8645788 |
| 821 | Gallicano K, Sahai J, Zaror-Behrens G, et al. Effect of antacids in didanosine tablet on bioavailability of isoniazid. Antimicrobial Agents & Chemotherapy 1994;38(4):894-7. | 8031068 |
| 1134 | Gallicano KD, Sahai J, Shukla VK, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. British Journal of Clinical Pharmacology 1999;48(2):168-79. | 10417493 |
| 440 | Galpin JE, Lori F, Globe DR, et al. Improvement in CD4 cell diversity during 7-month trial of hydroxyurea in combination with ddI or ddI and d4T [abstr. 657]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 443 | Galpin JE, Lori F, Globe DR, et al. Safety, sheltering, & synergy of hydroxyurea with ddI or ddI plus d4T in HIV-infected patients [abstr. 654]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 3314 | Gantenbein M, Attolini L, Bruguerolle B et al. Oxidative metabolism of bupivacaine into pipecolyxlidine in humans is mainly catalyzed by CYP3A4. Drug Metab Dispos 2000;28:383-5. | 10725304 |
| 1344 | Garcia AB, Ibarra AL, Etessam JP, et al. Protease inhibitor-induced carbamazepine toxicity. Clinical Neuropharmacology 2000;23(4):216-8. | 11020127 |
| 922 | Garcia B, De Juana P, Bermejo T, et al. Sequential interaction of ritonavir and nelfinavir with acenocoumarol [abstract 1069]. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, October 23-27, 1999, Lisbon, Portugal. | |
| 3407 | García de Lucas MD, Olalla Sierra J, Piña Fernández J. Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome. Diabetes Metab 2015;41:102-3. | 25455831 |
| 495 | Garcia RF, Flores-Aguilar M, Quiceno JI, et al. Results of rhegmatogenous retinal detachment repair in cytomegalovirus retinitis with and without scleral buckling. Ophthalmology 1995;102(2):236-45. | 7862412 |
| 1133 | García-Benayas T, Blanco F, Barrios A, et al. Weight loss in HIV-infected patients receiving interferon plus ribavirin for chronic hepatitis C [abstract B10369]. XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain. | |
| 1792 | Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61. | 11895891 |
| 1252 | Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C.[see comment]. American Journal of Gastroenterology 2001;96(1):179-83. | 11197250 |
| 1116 | Garg V, Brill M, Rodriquiz A, et al. Clinical pharmacology of amprenavir in highly challenging, naive patients following a once-daily HAART regimen under direct observed therapy [abstract 2.5]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | |
| 2017 | Garg V, Chandorkar G, Farmer HF, et al. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 2012;52(10):1566-73. | 22162542 |
| 2018 | Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir [abstract PK_13]. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 22-23, 2011, Cambridge, MA. | |
| 1929 | Garg V, Luo X, McNair L, et al. Low-dose ritonavir and the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers [abstract 629]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA. | |
| 2020 | Garg V, Van Heeswijk RPG, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54(1):20-7. | 21618566 |
| 2021 | Garg V, Van Heeswijk RPG, Yang Y, et al. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol 2012;52(10):1574-83. | 22039291 |
| 2357 | Garimella T, Adamczyk R, Hu P, et al. No clinically-relevant interactions between asunaprevir and selective serotonin reuptake inhibitors (escitalopram and sertraline) in healthy subjects [abstract 493]. Hepatology 2013;58(4 suppl):445A. | |
| 2460 | Garimella T, Adamczyk R, Stonier M, et al. Effect of steady state daclatasvir plus asunaprevir on the single dose pharmacokinetics of the p-glycoprotein substrate digoxin in healthy adult subjects [abstract 822]. ID Week 2014, October 8-12, 2014, Philadelphia, PA. | |
| 2459 | Garimella T, Eley T, He B, et al. Evaluation of drug-drug interaction between asunaprevir and methadone or buprenorphine/naloxone [abstract 823]. ID Week 2014, October 8-12, 2014, Philadelphia, PA. | |
| 2349 | Garimella T, He B, Luo W-L, et al. Asunaprevir pharmacokinetics and safety in subjects with impaired renal function [abstract 463]. Hepatology 2013;58(4 (suppl)):430A. | |
| 2458 | Garimella T, Wang R, Luo W-L, et al. Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine/naloxone. Antimicrob Agents Chemother 2015;59:5503-10. | 26124175 |
| 2403 | Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, Marbury TC, Alcorn H, Bertz R, Bifano M. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther. 2015;20(5):535-43. | 25654812 |
| 1091 | Garraffo R, Demarles D, Durant J, et al. Amprenavir plasma and intracellular concentrations when coadministered with ritonavir in twice and once daily regimen in HIV-infected patients [abstract A-489]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 1419 | Garraffo R, Lavrut T, Ferrando S, et al. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol 2011;51(7):1071-8. | 21209236 |
| 2292 | Garraffo R, Lavrut T, Poisot-Martin I, et al. Pharmacokinetic interactions between boceprevir and atazanavir/ritonavir or raltegravir in HIV/HCV coinfected patients [abstract O_15]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | |
| 99 | Garrelts JC, Godley PJ, Peteried JD, et al. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrobial Agents and Chemotherapy 1990;34:931-3. | 2360833 |
| 2624 | Garrison K, Custodio J, Pang P, et al. Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens [abstract 71]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC. | |
| 3163 | Garrison K, Humeniuk R, West S, et al. Lack of clinically relevant drug interactions between bictegravir/emtricitabine/tenofovir alafenamide and ledipasvir/sofosbuvir or sofosbuvir/velpatasvir/voxilaprevir [abstract P264]. Glasgow HIV Drug Therapy Conference October 28-31, 2018, Glasgow, UK. | http://hivglasgow.org/wp-content/uploads/2018/11/P264.pdf |
| 2964 | Garrison KL, Ma G, Stamm LM et al. Lack of Pharmacokinetic Drug-Drug Interaction Between Norgestimate/Ethinyl Estradiol and Sofosbuvir/Velpatasvir/Voxilaprevir [abstract 37].18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL | |
| 1627 | Garvey L, Latch N, Erlwein O, et al. The effects of an integrase inhibitor containing and nucleoside analogue sparing antiretroviral regimen on the pharmacokinetic profile of darunavir/ritonavir 800/100 mg once daily, in HIV-1 infected subjects [abstract LBPEB08]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Capetown, South Africa. | |
| 2498 | Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008 Apr 1;46(7):985-91. | 18444813 |
| 2321 | Gatti DC, Cha A. Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection. . Am J Health Syst Pharm 2012;69(23):2062-5. | 23172264 |
| 807 | Gatti G, Alessandrini A, Camera M, et al. Influence of indinavir and ritonavir on warfarin anticoagulant activity [letter]. Aids 1998;12(7):825-6. | 9619821 |
| 763 | Gatti G, Biagio ADI, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS. 1999 Oct 22;13(15):2083-9. | 10546861 |
| 721 | Gatti G, Papa P, Torre D, et al. Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 1998;42(8):2017-23. | 9687400 |
| 3055 | Gaur A, Fourie J, Chokephaibulkit K et al. Pharmacokinetics, efficacy and safety of an integrase inhibitor-based single-tablet regimen in HIV-Infected treatment-naïve adolescents [abstract]. Conference on Retroviruses and Opportunistic Infections, Boston MA, March 3-6, 2014. | http://www.natap.org/2014/CROI/croi_176.htm |
| 3536 | Gaur AH, Cotton MF, Rodriquez CA, McGrath EJ, Helstrom E, Liberty A et al. Fixed-dose combination bictegravir, emtricitabine and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label multicentre, phase 2/3 trial. Lancet Child Adolesc Health 2021. https://doi.org/10.1016/S2352-4642(21)00165-6 | |
| 3127 | Gaur AH, Rodriguez C, McGrath EJ et al,. Bictegravir/FTC/TAF Single-tablet regimen in adolescents: week 24 results. [abstract 844]. CROI 2018, March 4-7, 2018. Boston, MA. | http://www.croiconference.org/sessions/bictegravirftctaf-single-tablet-regimen-adolescents-week-24-results |
| 3250 | Gausi K, Denti P, Weisner L, et al. Impact of isoniazid and pregnancy on efavirenz pharmacokinetics in women living with HIV [abstract WEPEB281]. 10th International AIDS Society Conference, July 21-24, 2019, Mexico City, Mexico. | http://programme.ias2019.org |
| 1502 | Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608. | 18826546 |
| 1852 | Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy: 2008. HIV Med 2008;9:563-608. | 18826546 |
| 592 | Gearhart MO, Sorg TB. Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. Annals of Pharmacotherapy 1993;27:285-9. | 8384030 |
| 1292 | Geel J, Pitt J, Orrell C, et al. The effect of fluconazole on nevirapine pharmacokinetics [abstract WeOrB1239]. XV International AIDS Conference, July 11-16, 2004, Bangkok, Thailand. | |
| 564 | Geier SA, Klauss V, Matuschke A, et al. 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis. German Journal of Ophthalmology 1992;1(2):110-3. | 1335812 |
| 422 | Geier SA, Sadri I, Bogner JR, et al. Ganciclovir intraocular device and patient survival [letter; comment]. Archives of Ophthalmology 1994;112(1):20; discussion 20-1. | 8285884 |
| 156 | Geletko SM, Ballard CR, Mathews WC. Health beliefs and discontinuation of zidovudine therapy. American Journal of Health-System Pharmacy 1995;52:505-7. | 7606554 |
| 979 | Geletko SM, Erickson AD. Decreased methadone effect after ritonavir initiation. Pharmacotherapy 2000;20(1):93-94. | 10641980 |
| 3351 | Genentech USA. Xofluza (baloxavir marboxil) Prescribing Information. San Francisco, CA. 2018. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210854s001lbl.pdf |
| 2401 | Generaux G, Song I, Bowers G, et al. A mechanistic SimCYP simulation evaluating dolutegravir and efavirenz pharmacokinetics following a switch from once-daily efavirenz to once-daily dolutegravir [abstract P_36]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 2413 | Generaux G. Use of mechanistic PBPK modeling to predict the potential for renal transporter DDIs between dolutegravir-tenofovir and dolutegravir-metformin. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 1703 | Gentile DM, Tomlinson ES, Maggs JL, et al. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996;277:105-12. | 8613906 |
| 402 | Gentile RC, Lewis JM, Puklin JE. Cyclodialysis complicating intravitreal ganciclovir implantation [letter]. Archives of Ophthalmology 1997;115(9):1204-5. | 9298069 |
| 1954 | Geraci MJ, McCoy SL, Crum PM, et al. Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction. Int J Emerg Med 2010;3(2):81-4. | 20606815 |
| 978 | Gerber JG, Rosenkranz S, Segal Y, et al. The effect of ritonavir/saquinavir on the stereoselective pharmacokinetics of methadone: results of AIDS clinical trials group (ACTG) 401. Journal of the Acquired Immune Deficiency Syndrome 2001 July 9-14;27:153-60. | 11404537 |
| 1264 | Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005;39:307-12. | 15980690 |
| 334 | Gerberding JL. Prophylaxis for occupational exposure to HIV. Annals of Internal Medicine 1996;125(6):497-501. | 8779463 |
| 3056 | German P et al. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir and the pharmacoenhancer GS-9350 as a fixed dose combination tablet [abstract A1-1300]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 12-15, 2009. | http://www.natap.org/2009/ICCAC/ICCAC_37.htm |
| 2575 | German P, Garrison K, Pang P, et al. Drug-drug interactions between anti-HCV regimen ledipasvir/sofosbuvir and antiretrovirals [abstract 82]. Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015, Seattle, WA. | |
| 2500 | German P, Greenhouse B, Coates C, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007 Mar 15;44(6):889-91. | 17304470 |
| 2299 | German P, Mathias A, Pang PS, et al. Lack of a clinically significant pharmacokinetic drug-drug interaction between sofosbuvir (GS-7977) and GS-5885 or GS-9669 in healthy volunteers [abstract 1888]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston. | |
| 1942 | German P, Mathias A, Wei L, et al. The effect of cobicistat on cytochrome P450 2D6, 2B6 and P-glycoprotein using phenotypic probes [abstract O_01]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13-15, 2011, Miami, USA. | |
| 1904 | German P, Mathias A, West S, et al. Evaluation of ritonavir-boosted elvitegravir PK upon coadministration with a second potent CYP3A inhibitor, ketoconazole [abstract 48]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7, 2010, Sorrento, Italy. | |
| 2350 | German P, Mathias A, Yang JC, et al. The pharmacokinetics of ledipasvir, an HCV specific NS5A inhibitor in HCV-uninfected subjects with moderate and severe hepatic impairment [abstract 467]. Hepatology 2013;58(4 (suppl)):432A. | http://www.natap.org/2013/AASLD/AASLD_52.htm |
| 2351 | German P, Moorehead L, Pang P, et al. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects. J Clin Pharmacol 2014 Nov;54(11):1290-8. | 24925712 |
| 2391 | German P, Pang P, West S, et al. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract O_06]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 1454 | German P, Parikh S, Lawrence J, et al. Drug interaction between antimalarial drugs and lopinavir/ritonavir [abstract 132]. 15th Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, MA. | |
| 2543 | German P, Parikh S, Lawrence J, et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. Journal of acquired immune deficiency syndromes (1999) 2009 Aug 1;51(4):424-9. | 19506482 |
| 1950 | German P, Wang M, Warren D, et al. Pharmacokinetic interaction between norgestimate/ethinyl estradiol and elvitegravir/cobicistat/emtricitabine/tenofovir single tablet regimen [abstract O_17]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13-15th, 2011, Miami, USA. | |
| 1854 | German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55:323-9. | 20683270 |
| 3057 | German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010 Nov;55(3):323-9. | 20683270 |
| 3058 | German P, Wei X, Mizuno V, Cheng A, Kearney B, Mathias A. Pharmacokinetics of elvitegravir and cobicistat in subjects with severe renal impairment [abstract P_38]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, Spain, April 16-18th, 2012. | http://www.natap.org/2012/pharm/Pharm_29.htm |
| 1467 | German P, West S, Hui J, et al. Pharmacokinetic interaction between elvitegravir/ritonavir and dose-adjusted rifabutin (abstract P19). 9th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9 2008, New Orleans, LA. | |
| 2395 | German P, Yang J, West S, et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir/sofosbuvir fixed dose combination tablet [abstract P_15]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | http://www.natap.org/2014/Pharm/Pharm_40.htm |
| 3655 | Gervasoni C, Cattaneo D, Di Cristo V, et al. Orlistat: weight lost at cost of HIV rebound. J Antimicrob Chemother 2016; 71(6): 1739–1741. | 26945709 |
| 3620 | Gervasoni C, Cattaneo D, Resnati C, et al. The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. Our J Clin Pharmacol 2017;73:789-790. | 28265690 |
| 2868 | Gervasoni C, Minisci D, Clementi E, Rizzardini G, Cattaneo D. How relevant is the interaction between dolutegravir and metformin in real life? J Acquir Immune Defic Syndr 2017;75:e24-e26. | 28114188 |
| 864 | Ghannoum MA, Fu Y, Ibrahim AS, et al. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrobial Agents & Chemotherapy 1995;39(11):2459-65. | 8585726 |
| 2038 | Ghany MG, Nelson DR, Strader DB, et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54(4):1433-44. | 21898493 |
| 1647 | Gheorghiade M, Adams KFJ, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004;109(24):2959-64. | 15210613 |
| 1933 | Ghosal A, Yuan Y, Tong W, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011;39(3):510-21. | 21123164 |
| 2504 | Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clinical pharmacokinetics 2001;40(5):343-73. | 11432537 |
| 1685 | Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 1996;56:3678-81. | 8706007 |
| 2031 | Gibson JN, Fulco PP. Concurrent atazanavir and voriconazole in a patient with multidrug-resistant HIV and a mycetoma AIDS 2011;25(16):2054-6. | 21997493 |
| 3266 | Gidal BE, Maganti R, Laurenza A et al. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters. Epilepsy Res. 2017 Aug;134:41-48. | 28535410 |
| 1899 | Giguere P, Burry J, Beique L, et al. The effect of food on the pharmacokinetics of atazanavir/ritonavir 300/100 mg daily in HIV-infected patients [abstract 30]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7, 2010, Sorrento, Italy. | http://www.natap.org/2010/PK/PK_06.htm |
| 1847 | Giguere P, La Porte CJL, Zhang G, et al. Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on hemodialysis. AIDS 2009;23(6):740-2. | 19279448 |
| 2557 | Gilbert DN, Moellering RC, Eliopoulos GM, et al. The Sanford guide to HIV/AIDS therapy 2009. 17th ed. Sperryville, VA: Antimicrobial Therapy, Inc.; 2009. | |
| 3226 | Gilead Sciences Canada Inc. Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Product monograph. Mississauga ON, April 14, 2023. | https://www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf |
| 2792 | Gilead Sciences Canada Inc. Descovy (emtricitabine, tenofovir alafenamide) Product Monograph. Mississauga, ON. August 5, 2022. | http://www.gilead.ca/application/files/5314/9704/5557/Descovy_pm_english.pdf |
| 1232 | Gilead Sciences Canada Inc. Emtriva (emtricitabine) Product Monograph. Mississauga, ON. September 5, 2013. | http://www.gilead.ca/application/files/9514/9754/8346/emtriva_pm_english.pdf |
| 2865 | Gilead Sciences Canada Inc. Epclusa (sofosbuvir/velpatasvir). Product Monograph. Mississauga, ON, August 8, 2022. | http://www.gilead.ca/application/files/3415/0695/6820/Epclusa_English_PM_e186388_GS-002.pdf |
| 2774 | Gilead Sciences Canada Inc. Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) Product Monograph. Mississauga, ON. August 6, 2021. | http://www.gilead.ca/pdf/ca/genvoya_pm_english.pdf |
| 2462 | Gilead Sciences Canada Inc. Harvoni (ledipasvir/sofosbuvir) Product Monograph. Missisauga, ON, June 21, 2021. | http://www.gilead.ca/application/files/3214/9754/4243/harvoni_pm_english.pdf |
| 2193 | Gilead Sciences Canada Inc. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) Product Monograph. Mississauga, ON. July 26, 2021. | http://www.gilead.ca/application/files/2114/9823/1411/stribild_pm_english.pdf |
| 2477 | Gilead Sciences Canada Inc. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) Product Monograph. Mississauga, ON. July 26, 2021. | http://www.gilead.ca/application/files/2114/9823/1411/stribild_pm_english.pdf |
| 1233 | Gilead Sciences Canada Inc. Viread (tenofovir disoproxil fumarate) Product Monograph. Mississauga, ON. June 13, 2018. | http://www.gilead.ca/application/files/8914/9704/5557/viread_pm_english.pdf |
| 2854 | Gilead Sciences Canada Inc. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Product Monograph. Mississauga, ON, May 19, 2021. | http://www.gilead.ca/application/files/2415/0298/1957/Vosevi_pm_english.pdf |
| 3233 | Gilead Sciences Canada Inc. Zydelig (idelalisib) Product monograph. Mississauga ON, August 18, 2020. | |
| 3129 | Gilead Sciences Canada, Inc. Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) Product Monograph. Mississauga, ON. April 14, 2023. | http://www.gilead.ca/application/files/7215/3134/3186/Biktarvy_English_PM_e203718-GS-000.pdf |
| 2378 | Gilead Sciences Canada. Sovaldi (sofosbuvir) Product Monograph Mississauga, ON, June 21, 2021. | http://www.gilead.ca/application/files/9714/9704/5557/sovaldi_pm_english.pdf |
| 194 | Gilead Sciences Inc. Data on file. Foster City, CA October, 1996. | |
| 2802 | Gilead Sciences Inc. Epclusa (sofosbuvir/velpatasvir) Prescribing Information. Foster City, CA. April 2022. | https://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf?la=en |
| 2461 | Gilead Sciences Inc. Harvoni (ledipasvir/sofosbuvir) Prescribing Information. Foster City, CA. March 2020. | http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf |
| 3214 | Gilead Sciences Inc. Ranexa (ranolazine) Prescribing Information. Foster City, CA. January 2016. | https://www.gilead.com/-/media/files/pdfs/medicines/cardiovascular/ranexa/ranexa_pi.pdf |
| 697 | Gilead Sciences Inc. Vistide (cidofovir) Product Monograph. Foster City, CA, September 2010. | http://www.gilead.com/~/media/files/pdfs/medicines/other/vistide/vistide.pdf |
| 3238 | Gilead Sciences, Inc. Biktarvy (bictegravir, emtricitabine, tenofovir alafanamide) Product Monograph. Foster City, CA. May 2023. | https://www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf |
| 3616 | Gilead Sciences, Inc. Biktarvy (bictegravir, emtricitabine, tenofovir alafanamide) Product Monograph. Foster City, CA. May 2023. | https://www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf |
| 2966 | Gilead Sciences, Inc. Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) Product Monograph. Foster City, CA. May 2023. | http://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf |
| 2721 | Gilead Sciences, Inc. HEPSERA (adefovir dipivoxil) Product Monograph. Foster City, CA. November 2012. | http://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/hepsera/hepsera_pi.pdf?la=en |
| 2726 | Gilead Sciences, Inc. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) Product Monograph. Foster City, CA. September 2021. | http://www.gilead.com/~/media/files/pdfs/medicines/hiv/stribild/stribild_pi.pdf?la=en |
| 3131 | Gilead Sciences, Inc. Tybost (cobicistat) Prescribing Information. Foster City, CA. September 2021. | |
| 3095 | Gilead Sciences. Descovy (tenofovir alafenamide and emtricitabine) Product Monograph. Foster City, CA. January 2022. | http://www.gilead.com/~/media/files/pdfs/medicines/hiv/descovy/descovy_pi.pdf |
| 3096 | Gilead Sciences. Tenofovir disoproxil fumarate and emtricitabine (Truvada). Mississauga, ON. 5 July 2018. | http://www.gilead.ca/application/files/9814/9797/8029/truvada_pm_english.pdf |
| 2855 | Gilead Sciences. Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Summary of Product Characteristics. European Union 2017. | http://ec.europa.eu/health/documents/community-register/2017/20170726138516/anx_138516_en.pdf |
| 3039 | Gill MJ, Ostrop NJ, Fiske WD, Brennan JM. Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis. AIDS. 2000 May 26;14(8):1062-4. | 10853991 |
| 1742 | Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1996;14:2353-64. | 8708728 |
| 3375 | Gillies H, Wang X, Staehr P, Zack J. PAH therapy in HIV: lack of drug-drug interaction between ambrisentan and ritonavir. American Thoracic Society International Conference, Denver, CO, USA [abstract]. Am J Respir Crit Care Med. 2011;183:A5913. | https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A5913 |
| 1734 | Gillies HC, Herriot D, Liang R, et al. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 1987;23:303-10. | 3471265 |
| 885 | Gillum JG, Bruzzese VL, Israel DS, et al. Effect of clarithromycin on the pharmacokinetics of 2',3'-dideoxyinosine in patients who are seropositive for human immunodeficiency virus. Clinical Infectious Diseases 1996;22(4):716-8. | 8729217 |
| 594 | Gilquin J, Weiss L, Kazatchkine MD. Genital and oral erosions induced by foscarnet [letter]. Lancet 1990;335:287. | 1967737 |
| 644 | Gilroy N, Gottlieb T, Spring P, et al. Trimethoprim-induced aseptic meningitis and uveitis [letter]. Lancet 1997;350(9071):112. | 9228966 |
| 3433 | Gingrich D, Deitchman AN, Kantor A, et al. Methotrexate decreases tenofovir exposure in antiretroviral-suppressed individuals living with HIV. JAIDS 2020;85:651-8. | 33177476 |
| 1741 | Girard PM, Bouchaud O, Goetschel A, et al. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi’s sarcoma. AIDS 1996;10:753-7. | 8805866 |
| 2113 | Giunta G. Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters: a review of the literature starting from a case report. Case Report Med 2010;2010(426804):1-4. | 20671989 |
| 183 | Glaxo Wellcome Inc. Data on file, RM1996/00090/00. 1996. | |
| 3448 | GlaxoSmithKline (Ireland) Ltd. Zejula (niraparib) Summary of Product Characteristics. Dublin, Ireland. November 6, 2020. | https://www.ema.europa.eu/en/documents/product-information/zejula-epar-product-information_en.pdf |
| 3542 | GlaxoSmithKline Inc. Sotrovimab for injection Product Monograph. Mississauga, ON. September 14, 2021 | https://pdf.hres.ca/dpd_pm/00062881.PDF |
| 2999 | GlaxoSmithKline Inc. Amerge (naratriptan) Product Monograph. Mississauga, ON. November 2, 2016. | |
| 3000 | GlaxoSmithKline Inc. Imitrex (sumatriptan) Product Monograph. Mississauga, ON. July 24, 2014. | |
| 2735 | GlaxoSmithKline, Inc. Mepron (atovaquone) Prescribing Information.Mississauga, ON. July 26, 2016. | http://pdf.hres.ca/dpd_pm/00035998.PDF |
| 3447 | GlaxoSmithKline. Zejula (niraparib) Product Monograph. Mississauga, ON. December 10, 2019. | |
| 995 | GlaxoSmithKline. Agenerase (amprenavir) Agenerase Capsules & Oral Solution Product Monograph. Mississauga, ON. June 27. 2005. | http://pdf.hres.ca/dpd_pm/00001494.PDF |
| 3395 | GlaxoSmithKline. Anoro Ellipta (umeclidinium and vilanterol) Product Monograph. Mississauga, ON. August 9, 2017. | |
| 210 | GlaxoSmithKline. Daraprim (pyrimethamine) Prescribing Information. Research Triangle Park, NC. March, 2003. | http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/08578slr016_daraprim_lbl.pdf |
| 1839 | GlaxoSmithKline. Lanvis (thioguanine) Product Monograph. Mississauga, ON. Sept 21, 2017. | http://pdf.hres.ca/dpd_pm/00041379.PDF |
| 1636 | GlaxoSmithKline. Lexiva (fosamprenavir) Product Monograph. Research Triangle Park, NC. September 2009. | http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021548s021,022116s005lbl.pdf |
| 2549 | GlaxoSmithKline. Malarone (atovaquone/proguanil) Product Monograph. Mississauga, ON. August 7, 2015. | http://ca.gsk.com/media/591413/malarone.pdf |
| 3662 | GlaxoSmithKline. Serevent Diskus (salmeterol) Prescribing Information. Durham, NC. October 2022. | |
| 1815 | GlaxoSmithKline. Tykerb (lapatinib) Product Monograph. Mississauga, ON. February 16, 2017. | http://pdf.hres.ca/dpd_pm/00038157.PDF |
| 1598 | Glesby MJ, Aberg JA, Kendall MA, et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005;78(2):143-53. | 16084849 |
| 1693 | Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-22. | 10458260 |
| 3201 | Godinho R, Bugnon S, Gracin T, Tataw J. Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya (EVG/COBI/FTC/TAF) and simvastatin: a case report. BMC Nephrol 2019;20(1):69. doi: 10.1186/s12882-019-1257-6. | 30808332 |
| 1554 | Goebel F, Yakovlev A, Pozniak A, et al. TMC278: potent anti-HIV activity in antiretroviral therapy-naive patients [abstract 160]. 12th Conference on Retroviruses and Opportunistic Infections, February 22-25, 2005, Boston, MA. | |
| 2303 | Goelzer P, Morcos PN, Tran JQ, et al. Coadministration of ritonavir with the HCV protease inhibitor danoprevir substantially reduces reactive metabolite formation both in vitro and in vivo [abstract 796]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston. | |
| 1720 | Goeptar AR, Groot EF, Scheerens H, et al. Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450. Cancer Res 1994;54:2411-8. | 8162589 |
| 1719 | Goeptar AR, Te Koppele JM, Lamme EK, et al. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol Pharmacol 1993;44:1267-77. | 8264564 |
| 2180 | Goicoechea M, Best B, Capparelli E, et al. Concurrent use of efavirenz and oxcarbazepine may not affect efavirenz plasma concentrations [correspondence]. Clin Infec Dis 2006;43:116-7. | 16758435 |
| 1889 | Goicoechea M, Jain S, Bi L, et al. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. AIDS 2010;24:707-16. | 20087154 |
| 2341 | Golden PL, Mathis A, Chu H-M, et al. Population pharmacokinetic analysis demonstrates no drug-drug interactions between crofelemer, a novel treatment for noninfectious diarrhea in HIV+ individuals, and antiretroviral therapy [abstract A-1577]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 10-13, 2013, Denver, CO. | |
| 2840 | Goldwirt L, Barrail-Tran A, Laforest C, et al. Exposure to sofosbuvir and daclatasvir is unchanged in liver transplant patients on cyclosporine or tacrolimus based immunosuppression [abstract P_34]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL. | http://regist2.virology-education.com/Abstractbook/2017_5.pdf |
| 1570 | Goldwirt L, Braun J, de Castro N, et al. Tipranavir and darunavir pharmacokinetics in patients switching from enfuvirtide to raltegravir: a substudy of the ANRS 138 EASIER trial [abstract O_12]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 2942 | Gonzalez de Requena D et al. Variability of darunavir and ritonavir trough concentrations in the clinical setting [abstract P33]. 9th Int Workshop Clin Pharmacol HIV Ther: New Orleans, April 7-9, 2008. | |
| 2895 | Gonzalez de Requena D, Bonora S, D'Avolio A, Tettoni C, Calcagno A, Siccardi M, et al. Bilirubin levels in HIV+ patients switching from atazanavir 400 mg QD to atazanavir 200 mg BID [abstract P42]. 11th International Workshop on Clinical Pharmacology of HIV Therapy. Sorrento, Italy, April 7-9, 2010. | |
| 2692 | Gonzalez de Requena D, Calcagno A, Bonora S, et al. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS 2006;20(15):1977-9 | |
| 2594 | Good BL, Gomes DC, Fulco PP. An unexpected interaction between warfarin and cobicistat-boosted elvitegravir. AIDS 2015;29(8):985-6. | 25909832 |
| 1812 | Goodin S. Oral chemotherapeutic agents: understanding mechanism of action and drug interactions. Am J Health-Syst Pharm 2007;64(Suppl 5):S15-24. | 17468152 |
| 2519 | Gordi T, Huong DX, Hai TN, et al. Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrobial agents and chemotherapy 2002 Apr;46(4):1026-31. | 11897585 |
| 430 | Gordin FM, Simon GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 1984;100(4):495-9. | 6230976 |
| 140 | Gordis L. Methodological issues in the measurement of patient compliance. In: Sackett DL, Haynes RB, editors. Compliance with Therapeutic Regimens. Baltimore: Johns Hopkins University Press; 1976. p. 51-66. | |
| 2782 | Gordon LA, Kumar P, Brooks KM, Kellogg A, McManus M, Alfaro RM et al. Antiretroviral boosting agent cobicistat increases the pharmacokinetic exposure and anticoagulant effect of dabigatran in HIV-negative healthy volunteers. Circulation 2016;134(23):1909-11. | 27920076 |
| 2339 | Gordon LA, Malati CY, Hadigan C, et al. Influence of lopinavir/ritonavir and ritonavir alone on the pharmacokinetics of fenofibric acid in healthy volunteers [abstract A-1575]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 10-13, 2013, Denver, CO. | |
| 1770 | Goria-Gatti L, Iannone A, Tomasi A, et al. In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin trapping study. Carcinogenesis 1992;13:799-805. | 1316811 |
| 982 | Gotzkowsky SK, Kim J, Tonkin J, et al. Altered drug metabolizing enzyme activity and genotype-phenotype discordance in HIV-infected subjects [abstract 1169]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. | |
| 986 | Goujard C, Vincent I, Meynard JL, et al. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2003 Jan;47(1):118-23. | 12499178 |
| 714 | Gournay K, Sandford T, Hohnson S, et al. Dual diagnosis of severe mental health problems and substance abuse/dependence: a major priority for mental health nursing. J Psychiatr Ment Health Nurs 1997;4(2):89-95. | 9224004 |
| 2191 | Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet 2012;51(7):411-27. | 22568694 |
| 723 | Graham K, Beeler LH, Renae S, et al. Interventions and patient outcome from a pharmacist-based HIV medication adherence referral clinic [abstract 390/32323]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 319 | Graham-Lorence S, Peterson JA. P450s: structural similarities and functional differences. FASEB Journal 1996;10(2):206-14. | 8641554 |
| 684 | Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clinical Pharmacology & Therapeutics 1995;57(6):670-7. | 7781267 |
| 365 | Grant DM, Mauskopf JA, Bell L, et al. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Pharmacotherapy 1997;17(2):333-41. | 9085325 |
| 69 | Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamics and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877-916. | 2196167 |
| 1736 | Granvil CP, Madan A, Sharkawi M, et al. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 1999;27:533-41. | 10101149 |
| 1973 | Gray D, Roux P, Carrihill M, et al. Adrenal suppression and Cushing's syndrome secondary to ritonavir and budesonide. S Afr Med J 2010;100(5):296-7. | 20460021 |
| 996 | Greenblatt D, Motlke L, Harmatz J, et al. Alprazolam-ritonavir interaction: Implications for product labeling. Clinical Pharmacology and Therapeutics 2000;67:335-41. | 10801241 |
| 1001 | Greenblatt DJ, von Moltke LL, Daily JP, et al. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. Journal of Clinical Psychopharmacology 1999;19:293-6. | 10440454 |
| 1165 | Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. Journal of the Acquired Immune Deficiency Syndrome 2000;24(2):129-36. | 10935688 |
| 1351 | Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. Journal of Clinical Pharmacology 2003;43(4):414-22. | 12723462 |
| 224 | Greenblatt RM, Hollander H, McMaster JR, et al. Polypharmacy among patients attending an AIDS clinic: utilization of prescribed, unorthodox, and investigational treatments. Journal of the Acquired Immune Deficiency Syndrome 1991;4:136-43. | 1987351 |
| 2388 | Greene M, Steinman MA, McNicholl IR, et al. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. Journal of the American Geriatrics Society 2014 Mar;62(3):447-53. | 24576251 |
| 2979 | Greener BN, Patterson KB, Prince H, Sykes C, et al. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV negative men after single and multiple dosing. J Acquir Immune Defic Syndr 2013;64:39-44. | 23945251 |
| 7 | Greenson JK, Belitsos PC, Yardley JH, et al. AIDS enteropathy: occult enteric infections and duodenal mucosal alterations in chronic diarrhea. Annals of Internal Medicine 1991;114:366-72. | 1992878 |
| 3282 | Greenwich Biosciences, Inc. Epidiolex (cannabidiol) Prescribing Information. Carlsbad, CA. December 2018. | |
| 3700 | Griesel R, Banda CG, Zhao Y et al. Pharmacokinetics of single-dose versus double-dose dolutegravir after switching from a failing efavirenz-based regimen. JAIDS 2024;96:85-91. | 38372621 |
| 3639 | Griesel R, Zhao Y, Simmons B, et al. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2 non-comparative randomized controlled trial. Lancet HIV 2023;10:e433-41. | 37230101 |
| 2509 | Griffith KS, Lewis LS, Mali S, et al. Treatment of malaria in the United States: a systematic review. Jama 2007 May 23;297(20):2264-77. | 17519416 |
| 1721 | Grill HJ, Pollow K. Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. Am J Clin Oncol 1991;14(Suppl 2):S21-9. | 1962593 |
| 2965 | Grimm SW, Richtand NM, Winter HR, et al. Effects of cytochrome P450 3A4 modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006;61:58-69. | 16390352 |
| 2412 | Grinsztejn B, De Castro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. The Lancet infectious diseases 2014 Jun;14(6):459-67. | 24726095 |
| 338 | Griswold MW, Preston SL, Purdy BD, et al. Prospective minimization of protease inhibitor drug interactions due to pharmacist intervention [abstr]. American College of Clinical Pharmacy 1997 Annual Meeting, November 9-12, 1997, Phoenix, Arizona. | |
| 339 | Griswold MW, Purdy BD, Briceland LL, et al. Evaluation of drug-related problems in an outpatient HIV clinic [abstr]. Pharmacotherapy 1997;17(5):1122. | |
| 601 | Gross AS, Dretler RH. Foscarnet-induced penile ulcer in an uncircumcised patient with AIDS [letter]. Clinical Infectious Diseases 1993;17:1076-7. | 8110943 |
| 2728 | Grub S, Bryson H, Goggin T, Ludin E, Jorga K. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol. 2001;57(2):115-21. | |
| 2065 | Gruber VA, Rainey PM, Moody DE, et al. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Clin Infect Dis 2011;Nov 18 [Epub ahead of print]. | 22100576 |
| 625 | Grzywacz M, Deayton JR, Bowen EF, et al. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients. J Med Virol. 1999 Nov;59(3):323-8. | 10502264 |
| 3032 | GTx, Inc. Fareston (toremifene) Prescribing Information. Memphis, TN. March 2011. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020497s006lbl.pdf |
| 2068 | Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011;53(11):1120-6. | 21998278 |
| 2704 | Guay DR. Extended-Release Alfuzosin Hydrochloride: A New Alpha-Adrenergic Receptor Antagonist for Symptomatic Benign Prostatic Hyperplasia. Am J Geriatr Pharmacother. 2004;2(1):14-23. | |
| 477 | Guembel HOCRCMKFUSOEEvGOCUECFaMHG. Improved surgical technique for implantation of the intraocular sustaine-release ganciclovir implant reduce postoperative complications in patients with AIDS and CMV retinitis [abstr. Mo.B.1221]. XI International Conference on AIDS, July 7-12, 1996, Vancouver. | |
| 1283 | Guffanti M, Villani P, Seminari E, et al. Atazanavir pharmacokinetics when combined with amprenavir in highly experienced HIV-positive patients [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 1495 | Guiard-Schmid J, Poirier J, Meynard J, et al. High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother 2003;47(3):986-90. | 12604531 |
| 2903 | Guillemi S, Hull M, Kanters S, Harris M, Milan D, Dias Lima V et al. Does smoking tobacco affect atazanavir exposure in HIV-infected individuals? [abstract WEPE0095]. XVIII International AIDS Conference, Vienna, Austria, July 18-23rd, 2010. (page 23) | http://i-base.info/htb/files/2010/08/HTB-Vol11-No7-8-JulAug2010e.pdf |
| 733 | Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 1997;337:734-39. | 9287228 |
| 2114 | Gunes A, Coskun U, Boruban C, et al. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol 2006;98(2):197-200. | 16445595 |
| 1371 | Guo Y, Fung HB. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. Pharmacotherapy 2004;24(8):1089-94. | 15338857 |
| 1910 | Gupta S, Lataillade M, Farber S, et al. Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants. JIAPAC 2009;8(2):87-92. | 19270153 |
| 3040 | Gupta S, Rosenkranz S, Cramer Y, Koletar S, et al. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS 2008;22:1919– 1927. | 18784455 |
| 1350 | Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and cytochrome P450 3A4 inhibitor ritonavir. Clinical Therapeutics 2003;25(4):1200-10. | 12809966 |
| 2449 | Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, et al. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir. Clin Infect Dis 2014 Jan;58(2):268-73. | 24145880 |
| 3283 | GW Pharma Ltd. Sativex (delta-9-tetrahydrocannabidiol and cannabidiol) Product Monograph. Salisbury, UK. March 31, 2015. | https://pdf.hres.ca/dpd_pm/00016162.PDF |
| 3284 | GW Pharma Ltd. Sativex (delta-9-tetrahydrocannabidiol and cannabidiol) Summary of Product Characteristics. Cambridge, UK. April 27, 2019. | https://www.medicines.org.uk/emc/product/602/smpc |
| 2577 | Gyllensten, K. et al. Severe Vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59ºN. AIDS. 2006. 20(14): 1906-1907. | 16954738 |
| 3651 | H2-Pharma, LLC. Xenical (orlistat) Prescribing Information. Montgomery, AL. August, 2017. | https://xenical.com/pdf/PI_Xenical-brand_FINAL.PDF |
| 1226 | Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003;17(9):1339-49. | 12799555 |
| 2187 | Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Therapeutic drug monitoring. [Review] 2002 Feb;24(1):91-103. | 11805729 |
| 887 | Hafner R, Bethel J, Power M, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrobial Agents & Chemotherapy 1998;42(3):631-9. | 9517944 |
| 3020 | Hall JJ, Bolina M, Chatterley T, Jamali F. Interaction between low-dose methotrexate and nonsteroidal anti-inflammatory drugs, penicillins, and proton-pump inhibitors. Ann Pharmacother 2017;51:163-78. | 27701081 |
| 2380 | Hall JJ, Hughes CA, Foisy MM, et al. Iatrogenic Cushing syndrome after intra-articular triamcinolone in a patient receiving ritonavir-boosted darunavir. Int J STD AIDS 2013 Sep;24(9):748-52. | 23970582 |
| 1837 | Hall JR, Short SC. Management of glioblastoma multiforme in HIV patients: a case series and review of published studies. Clin Oncol (R Coll Radiol) 2009;21(8):591-7. | 19589665 |
| 2798 | Hallberg P, Marten L, Wadelius M. Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol 2006;62(6):491-492 | 16758267 |
| 2551 | Hamer DH, Mwanakasale V, Macleod WB, et al. Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. The Journal of infectious diseases 2007 Dec 1;196(11):1585-94. | 18008241 |
| 2819 | Hamilton M, Wolf JL, Drolet DW, et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemother Pharmacol 2014;73(3):613-621. | 24474302 |
| 219 | Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. New England Journal of Medicine 1996;335:1081-90. | 8813038 |
| 254 | Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine 1997 Sep 11;337(11):725-33. | 9287227 |
| 2293 | Hammond K, Jimmerson L, MacBrayne CE, et al. Increased plasma intracellular ribavirin concentrations associated with telaprevir use [abstract PP_02]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | |
| 2397 | Hammond K, Wempe MF, Ray M, et al. Enzyme induction not alterations in protein binding contribute to reduced etravirine exposures with boceprevir [abstract P_21]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 2082 | Hammond K, Wolfe P, Burton J, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acq Immune Def Syndr 2013;62(1):67-73. | 23075915 |
| 994 | Hamzeh FM, Benson CA, Gerber JG, et al. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clinical Pharmacology and Therapeutics 2003;73(3):159-69. | 12621381 |
| 3635 | Han K, Shaik JS, Crauwels H, et al. Pharmacokinetics (PK) and tolerability of cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) intramuscular (IM) injections to the vastus lateralis (lateral thigh) muscles of health adult participants [abstract EPB176]. 24th International AIDS Conference, July 29 - August 2, 2022; Virtual and Montreal, Canada. | https://programme.aids2022.org/Abstract/Abstract/?abstractid=9906 |
| 2789 | Han Z, Kane BM, Petty LA, et al. Cobicistat significantly increases tacrolimus serum concentrations in a renal transplant recipient with human immunodeficiency virus infection. Pharmacotherapy 2016 Apr 3 [Epub ahead of print] | 27041642 |
| 1568 | Hanley WD, Wenning L, Moreau AR, et al. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009 July;53:2752-5. | 19398643 |
| 115 | Hansen JM, Kampmann JP, Siersbaek-Nielsen K, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Medica Scandinavia 1979;624 (suppl):106-10. | 284708 |
| 177 | Hansten PD, Horn JR. Pharmacokinetic drug interaction mechanisms and clinical characteristics. In: Hansten PD, Horn JR, editors. Drug Interactions. Washington, SA: Applied Therapeutics; 1993. | |
| 1955 | Hantson P, Di Fazio V, Wallemacq P. Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose. Drug Metab Lett 2010;4(1):7-8. | 20201782 |
| 9 | Harb GE, Jacobson MA. Human immunodeficiency virus infection: does it increase susceptibility to adverse drug reactions? Drug Safety 1993;9:1-8. | 8347288 |
| 184 | Hardin TC, Sharkey-Mathis PK, Rinaldi MG, et al. Evaluation of the pharmacokinetic interaction between itraconazole and didanosine in HIV-infected subjects [abstr]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco. | |
| 546 | Hardy D, Spector S, Polsky B, et al. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. European Journal of Clinical Microbiology & Infectious Diseases 1994;13(Suppl 2):S34-40. | 7875151 |
| 2005 | Hardy H, Backman ES, Farber HW. Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. Pharmacotherapy 2010;30(4):139e-44e. | 20334465 |
| 2190 | Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24(1):62-9. | 14709949 |
| 1201 | Harrington M, Carpenter CJC. Hit HIV-1 hard, but only when necessary. Lancet 2000;355(9221):2147. | 10902643 |
| 2582 | Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Archives of Internal Medicine 1999;159:2221-4. | 10527300 |
| 1114 | Harris M, Alexander C, Ting L, et al. Pharmacokinetic profile of indinavir 600 mg twice daily with lopinavir/ritonavir [abstract 2.3]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | |
| 133 | Harris M, Durakovic C, Conway B, et al. A pilot study of indinavir, nevirapine, and 3TC in patients with advanced HIV disease. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 348 | Harris M, Durakovic C, Rae S, et al. Virologic response to indinavir/nevirapine/3TC correlates with indinavir trough concentrations [abst. I-173.]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 2731 | Harris M, Ramirez S, Joy R, et al. Effect of lopinavir and ritonavir dose adjustments on the pharmacokinetic interaction between LPV/RTV and tipranavir [abstract 584]. 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006, Denver, CO. | |
| 2685 | Harris M, Zala C, Ramirez S, et al. Pharmacokinetics and safety of adding TMC125 to stable regimens of saquinavir, lopinavir, ritonavir and NRTI in HIV+ adults [abstract 575b]. 13th Conference on Retroviruses and Opportunistic Infections February 5-8, 2006, Denver, CO | |
| 505 | Harris ML, Mathalone MB. Intravitreal ganciclovir in CMV retinitis: case report. British Journal of Ophthalmology 1989;73(5):382-4. | 2543438 |
| 1767 | Harris RZ, Tsunoda SM, Mroczkowski P, et al. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 1996;59:429-35. | 8612388 |
| 2609 | Harrison B, Magee MH, Mandagere A, et al. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study. Clin Drug Investig 2010;30(12):875-85. | 20923245 |
| 682 | Hartter S, Dingemanse J, Baier D, et al. Inhibition of dextromethorphan metabolism by moclobemide. Psychopharmacology 1998;135(1):22-6. | 9489930 |
| 683 | Hartter S, Dingemanse J, Baier D, et al. The role of cytochrome P450 2D6 in the metabolism of moclobemide. European Neuropsychopharmacology 1996;6(3):225-30. | 8880082 |
| 893 | Harvey WD, Holzman RS, Avramis V, et al. Clinical and pharmacokinetic interactions of combined zidovudine therapy and sulfadoxine-pyrimethamine (Fansidar) prophylaxis in post-PCP AIDS patients (ACTG 021) [abstract TBP46]. 5th International Conference on AIDS, June, 1989, Montreal. | |
| 3013 | Hassan M, Oberg G, Bjorkholm M et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993;33:181-6. | 8269597 |
| 2536 | Hatz C, Soto J, Nothdurft HD, et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. The American journal of tropical medicine and hygiene 2008 Feb;78(2):241-7. | 18256423 |
| 1541 | Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients [abstract 791]. 15th Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, MA. | |
| 1538 | Haubrich R, Eron J, Thompson M, et al. Reduction in AIDS-defining events/death with etravirine compared to placebo: pooled DUET 48-week results [abstract H-1239]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington, DC. | |
| 666 | Havlir DV, Riddler S, Squires K, et al. Co-administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity results [abstract 393]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 1273 | Hawkins T, Veikley W, St.Claire R, et al. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):406-11. | 16010161 |
| 1579 | Hawkins T, Weikley W, Durand-Gasselin L, et al. Evaluation of potential intracellular drug interaction between tenofovir and didanosine in HIV-infected patients [abstract P_26]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 138 | Haynes RB. Introduction. In: Haynes RB, Taylor DW, Sackett DL, editors. Compliance in Health Care. Baltimore: Johns Hopkins University Press; 1979. p. 1-7. | |
| 1959 | He Z, Chen L, You J, et al. In vitro interactions between antiretroviral protease inhibitors and artemisinin endoperoxides against Plasmodium falciparum. Int J Antimicrob Agents 2010;35(2):191-3. | 19896339 |
| 2523 | He Z, Chen L, You J, et al. In vitro interactions between antiretroviral protease inhibitors and artemisinin endoperoxides against Plasmodium falciparum. International journal of antimicrobial agents 2010 Feb;35(2):191-3. | 19896339 |
| 1975 | Health Canada. Health Canada Public Safety Information. Available from: www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/fluticasone_ritonavir_pa-ap_e.pdf, accessed May, 2011. | |
| 1646 | Heart Failure Society of North America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006;12(1):10-38. | 16500578 |
| 2048 | Heelon M, Skiest D, Tereso G, et al. Effect of a clinical pharmacist's interventions on duration of antiretroviral-related errors in hospitalized patients. Am J Health Syst Pharm 2007;64(19):2064-8. | 17893418 |
| 1005 | Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 1999;19:471-2. | 10212021 |
| 2468 | Heffron R, Mugo N, Were E, et al. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception AIDS 2014;28:2771–76. | 25493602 |
| 2227 | Heikinheimo O, Lehtovirta P, Aho I, et al. The levonorgestrel-releasing intrauterine system in human immunodeficiency virus infected women: a 5-year follow-up study. Am J Obstet Gynecol 2011;204(2):126.e1-4. | 21035781 |
| 2137 | Heikinheimo O, Lehtovirta P, Suni J, et al. The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women-effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 2006;21(11):2857-61. | 16880227 |
| 464 | Heinemann MH, Bloom AF, Horowitz J. Candida albicans endophthalmitis in a patient with AIDS. Case report. Archives of Ophthalmology 1987;105(9):1172-3. | 3498472 |
| 502 | Heinemann MH. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Archives of Ophthalmology 1989;107(12):1767-72. | 2556990 |
| 299 | Heinemann MH. Long-term intravitreal ganciclovir treatment of cytomegalovirus retinopathy. Archives of Ophthalmology 1989;107:1767-72. | 2556990 |
| 2723 | Heiskanen T, Backman JT, Neuvonen M, et al. Itraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphine. Acta anaesthesiologica Scandinavica 2008 Nov;52(10):1319-26. | |
| 1913 | Heller MK, Laks J, Kovesi TA, et al. Reversal of adrenal suppression with ciclesonide. J Asthma 2010;47(3):337-9. | 20394520 |
| 454 | Hellinger JA, Iwane MK, Smith JJ, et al. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network. J Infect Dis. 2000 Feb;181(2):540-7. | 10669337 |
| 521 | Henderly DE, Freeman WR, Causey DM, et al. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987;94(4):425-34. | 3035453 |
| 296 | Henderly DE, Genstler AJ, Smith RE, et al. Changing patterns of uveitis. American Journal of Ophthalmology 1987;103(2):131-6. | 3812615 |
| 501 | Henderson JR. Use of ganciclovir in the treatment of cytomegalovirus infections. British Journal of Clinical Practice 1989;43(7):233-7. | 2557071 |
| 2044 | Henderson KC, Hindman J, Johnson SC, et al. Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV. AIDS Patient Care Stds 2011;25(4):221-8. | 21323566 |
| 215 | Henderson T, Hall J, Lipton T. Changing self-destructive behaviors. In: Stone G, editor. Health Psychology: A Handbook. San Francisco: Jossey-Bass Publishers; 1979. | |
| 926 | Hendrix CW, Fiske WD, Fuchs EJ, et al. Pharmacokinetics of the triple combination of saquinavir, ritonavir, and efavirenz in HIV-positive patients [abstract 79]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco. | |
| 975 | Hendrix CW, Wakeford J, Wire MB, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy 2004;24:1110-21. | 15460171 |
| 2583 | Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998;352:1751-2. | 9848354 |
| 524 | Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. American Journal of Ophthalmology 1987;103(1):17-23. | 3026186 |
| 468 | Henry K, Cantrill H, Fletcher C, et al. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. American Journal of Opthalmology 1987;103(1):17-23. | 3026186 |
| 523 | Henry K, Thurn JR, Johnson S. Experience with central venous catheters in patients with AIDS [letter]. New England Journal of Medicine 1989:1496. | 2716803 |
| 616 | Henry K. Reports of DHPG treatment of cytomegalovirus retinitis [letter]. Annals of Internal Medicine 1986;105(1):144-5. | 3013061 |
| 2119 | Henshaw J, Adiwijaya B, Adda N, et al. The pharmacokinetics of telaprevir and selected ART medications in HCV/HIV co-infected patients [abstract PK_08]. 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 27-28, 2012, Cambridge, MA. | |
| 1793 | Herben VMM, Schoemaker NE, Rosing H, et al. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemother Pharmacol 2002;50:59-64. | 12111113 |
| 891 | Hermans P, Rozenbaum W, Jou A, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group. Aids 1996;10(14):1627-33. | 8970682 |
| 2970 | Hernandez-Novoa et al. Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study. HIV Med 2008;9:187-191. | 18298579 |
| 718 | Hertogs K, Mellors JW, Schel P, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates [abstract 395]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 1361 | Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003;17(7):513-32. | 12751920 |
| 1068 | Hesse LM, von Moltke LL, Shader RI, et al. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metabolism & Disposition 2001;29:100-02. | 11159797 |
| 1019 | Hester EK, Peacock JE. Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection. AIDS 1998;12:439-40. | 9520175 |
| 2247 | Higgins N, Tseng A, Sheehan N, et al. Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice. Can J Hosp Pharm 2009;62(6):500-9. | 22478939 |
| 3168 | Hikasa S, Sawada A, Seino H, et al. A potential drug interaction between phenobarbital and dolutegravir: A case report. J Infect Chemother 2018 Jun; 24(6):476-478 | 29415844 |
| 3339 | Hill L, Momper J, Abulhosn K et al. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in combination with boosted darunavir in treatment experienced patients with HIV [abstract PE2/56]. 17th European AIDS Conference, Basel, Switzerland. November 6-9, 2019. | |
| 1610 | Hills-Nieminen C, Hughes C, Houston S, et al. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir. Ann Pharmacother 2009;43:2117-20. | 19934385 |
| 803 | Hilts AE, Fish DN. Dosage adjustment of antiretroviral agents in patients with organ dysfunction. American Journal of Health-System Pharmacy 1998;55:2528-33. | 9853641 |
| 2327 | Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004;18(suppl):S19-S25. | 15075494 |
| 3691 | Hiransuthikul A, Thammajaruk N, Kerr S, et al. Drug-drug interaction between emtricitabine/tenofovir alafenamide (FTC/TAF)-based PrEP and feminizing hormones in transgender women: peripheral blood mononuclear cells and urine analysis from the iFACT3 study. IAS 2023 Conference, Brisbane, Australia. July 23-26, 2023. | https://programme.ias2023.org/Abstract/Abstract/?abstractid=373 |
| 1525 | Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infec Dis 2008;47(2):266-85. | 18549313 |
| 3467 | Hirt D, Urien S, Ekouevi DK, et al. Population pharmacokinetics of tenofovir in HIV-1 infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther 2009;85(2):182-9. | 18987623 |
| 1713 | Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000;6:1255-8. | 10778948 |
| 1131 | Hittinger G. Mitochondrial toxicity in HIV/HVC coinfected patients treated with ribavirin, interferon alpha and antiretroviral therapy [abstract TuPeB4516]. XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain. | |
| 2580 | HIV Insite. Antiretroviral management charts and tables [online]. Available from URL: http://arv.ucsf.edu/insite?page=ar-00-02&post=10¶m=21 [Accessed 2015 April 8] | |
| 3589 | HLS Therapeutics. Clozaril (clozapine) Prescribing Information. Rosemont, PA. February 2020. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/019758s095lbl.pdf |
| 1202 | Ho DD. Time to hit HIV, early and hard. New England Journal of Medicine 1995;333(7):450-1. | 7616996 |
| 534 | Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Annals of Internal Medicine 1990;113(2):111-7. | 2163228 |
| 3539 | Hocqueloux L, Lefeuvre S, Bois J, et al. Bioavailability of solid vs. dissolved vs. crushed single-tablet of bictegravir/emtricitabine/tenofovir alafenamide in HIV negative volunteers: the SOLUBIC study [abstract PE2/76]. 18th European AIDS Conference, virtual/London, UK. October 27-30, 2021. | https://eacs2021.abstractserver.com/program/#/details/presentations/695 |
| 1674 | Hodder S, Jayaweera D, Mrus J, et al. GRACE (Gender, Race And Clinical Experience): etravirine subgroup analysis at week 48 [abstract H-919]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco. | |
| 412 | Hodge WG, Lalonde RG, Sampalis J, et al. Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome. Journal of Infectious Diseases 1996;174(2):393-6. | 8699072 |
| 1036 | Hoechst Marion Roussel. Allegra Product Monograph. 2000. | |
| 1551 | Hoetelmans R, Van Heeswijk R, Kestens D, et al. Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation [abstract TuPe3.1B10]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, July 24-27, 2005, Rio de Janeiro, Brazil. | |
| 2730 | Hoetelmans RM, al. E. Pharmacokinetic interaction between TMC 278, an investigational non-nucleoside reverse transcriptase inhibitor, and lopinavir/ritonavir in healthy volunteers [abstract 4.3/1]. 10th European AIDS Conference, November 17-20, 2005, Dublin, Ireland. | |
| 1391 | Hoetelmans RM, Kestens D, Stevens M, et al. Pharmacokinetic interaction between the novel non-nucleoside reverse transcriptase inhibitor TMC278 and tenofovir disoproxil fumarate in healthy volunteers [abstract 18]. 6th International Workshop on Clinical Pharmacology of HIV Therapy, April 28-30, 2005, Quebec. | |
| 751 | Hoetelmans RMW, Reijers MHE, Weberling GF, et al. The rate of decline of HIV-1 RNA in plasma correlates with nelfinavir concentrations in plasma [abstract 510/42259]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 752 | Hoetelmans RMW, Van Heeswijk RPG, Meenhorst PL, et al. Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period [abstract 511/42261]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 3262 | Hoffman La Roche Ltd. Alecensaro (alectinib) Product Monograph. Mississauga,ON. September, 2018. | |
| 1034 | Hoffmann-La Roche Inc. Hivid (zalcitabine) Prescribing Information. Nutley, NJ September, 2002. | http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/daclhof072902LB.pdf |
| 3312 | Hoffmann-La Roche limited. Actemra (tocilizumab) Product Monograph. Mississauga, ON. September 16, 2019. | |
| 3270 | Hoffmann-La Roche Limited. Avastin (bevacizumab) Product Monograph. Mississauga, ON. June 6, 2018. | https://pdf.hres.ca/dpd_pm/00045825.PDF |
| 3073 | Hoffmann-La Roche Limited. Fuzeon® Product monograph. Mississauga, Ont. March 7, 2016. | https://pdf.hres.ca/dpd_pm/00033971.PDF |
| 1827 | Hoffmann-La Roche Limited. Rituxan (rituximab) Product Monograph. Mississauga, ON. October 13, 2016. | http://pdf.hres.ca/dpd_pm/00036665.PDF |
| 1809 | Hoffmann-La Roche Limited. Tarceva (erlotinib) Product Monograph. Mississauga, ON. March 27, 2017. | http://pdf.hres.ca/dpd_pm/00038669.PDF |
| 795 | Hoffmann-La Roche Ltd. Fortovase (saquinavir) Prescribing Information. Mississauga, ON. June 14, 2005. | http://pdf.hres.ca/dpd_pm/00001461.PDF |
| 176 | Hoffmann-La Roche Ltd. Invirase (saquinavir) Product Monograph. Mississauga, ON. December 9, 2015. | http://pdf.hres.ca/dpd_pm/00032946.PDF |
| 3092 | Hoffmann-La Roche. Pegasys (peginterferon alfa-2a) Product Monograph. Mississauga, ON. March 11, 2016. | |
| 1192 | Hoffmann-LaRoche Laboratories Inc. Valcyte (valganciclovir) Prescribing Information. Nutley, New Jersey. August 2009. | http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021304s007,022257s000lbl.pdf |
| 195 | Hoffmann-LaRoche Limited. Cytovene (ganciclovir) Prescribing Information. Nutley, NJ. July 2017. | http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019661s036lbl.pdf |
| 2568 | Hogeland GW, Swindells S, McNabb JC, et al. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clinical Pharmacology and Therapeutics 2007;81(1):69-75. | 17186001 |
| 773 | Hogg RS, MV OS, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997;349(9061):1294. | 9142067 |
| 2052 | Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(7):1911-30. | 21646368 |
| 537 | Holland GN, Buhles WC, Jr., Mastre B, et al. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Archives of Ophthalmology 1989;107(12):1759-66. | 2556989 |
| 307 | Holland GN, Engstrom RE, Jr., Glasgow BJ, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. American Journal of Ophthalmology 1988;106(6):653-67. | 3195645 |
| 527 | Holland GN, Sakamoto MJ, Hardy D, et al. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Archives of Ophthalmology 1986;104(12):1794-800. | 3024606 |
| 535 | Holland GN, Shuler JD. Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients. Archives of Ophthalmology 1992;110(10):1435-42. | 1329703 |
| 528 | Holland GN, Sidikaro Y, Kreiger AE, et al. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 1987;94(7):815-23. | 2821464 |
| 536 | Holland GN, Sison RF, Jatulis DE, et al. Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. UCLA CMV Retinopathy Study Group. Ophthalmology 1990;97(2):204-11. | 2158029 |
| 1765 | Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995;57:318-24. | 7697949 |
| 18 | Hollander H, Golden J, Mendelson T, et al. Extrapyramidal symptoms in AIDS patients taking low-dose metoclopramide or chlorpromazine [letter]. Lancet 1985;2:1186-7. | 2865637 |
| 1362 | Hollander H, Lifson AR, Maha M, et al. Phase I study of low-dose zidovudine and acyclovir in asymptomatic human immunodeficiency virus seropositive individuals. American Journal of Medicine 1989;87(6):628-32. | 2574006 |
| 2194 | Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol 2009;5:225-41. | 19331589 |
| 816 | Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-1997 [letter]. AIDS 1998;12(14):1931-3. | 9792398 |
| 2171 | Holtzman C, Armon C, Tedaldi EM, et al. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-positive population: findings from the HIV Outpatient Study (HOPS). XIX International AIDS Conference, July 22-27, 2012, Washington, DC. | |
| 905 | Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. Aids Patient Care & STDS 1999;13(3):185-97. | 10375267 |
| 1010 | Honda M, Yasuoka A, Aoki M, et al. A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin. Internal Medicine 1999;38(3):302-3. | 10337948 |
| 88 | Honig P, Wortham DC, Zamani K, et al. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady state and electrocardiographic parameters. Drug Investigation 1994;7:148-56. | |
| 62 | Honig PK, Worham DC, Zamani K, et al. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clinical Pharmacology and Therapeutics 1993;53:630-6. | 8513654 |
| 74 | Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Journal of the American Medical Association 1993;269:1513-8. | 8445813 |
| 2700 | Hoogewerf M, Regez RM, Schouten WE, et al. Change to abacavir–lamivudine–tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003 December 13;362(9400):1979-80. | 14683659 |
| 3413 | Hoover K, Welming Z, Ya-Lin H, Clark EA, Wiener J, Lampe MA, Kourtis AP. Neural tube defects and adverse pregnancy outcomes after maternal exposure to dolutegravir and other antiretroviral medications during pregnancy, United States, 2013-2017. [abstract PEB0356]. 23rd International AIDS Conference Virtual. July 6-10, 2020. | https://cattendee.abstractsonline.com/meeting/9289/Presentation/1368 |
| 2209 | Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41(4):674-80. | 17389673 |
| 817 | Horowitz HW, Telzak EE, Sepkowitz KA, et al. Human immunodeficiency virus infection, Part II. Disease-A-Month 1998;44(12):677-716. | 9883269 |
| 2799 | Horton R, Barber C. Opioid-induced respiratory depression resulting from transdermal fentanyl-clarithromycin drug interaction in a patient with advanced COPD. J Pain Symptom Manage 2009 Jun;37(6):e2-5 | 19500718 |
| 944 | Hsu A, Bertz R, Ashbrenner E, et al. Interaction of ABT-378/ritonavir with protease inhibitors in healthy volunteers [abstract 2.4]. First International Workshop on Clinical Pharmacology of HIV Therapy, March 30-31, 2000, Noordwijk, the Netherlands. | |
| 1062 | Hsu A, Bertz R, Granneman GR. Assessing ritonavir dose effect on the pharmacokinetic parameters of protease inhibitors [abstract 3.3]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4, 2001, Noordwijk, the Netherlands. | |
| 785 | Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrobial Agents and Chemotherapy 1998;42(11):2784-91. | 9797204 |
| 376 | Hsu A, Granneman GR, Carothers L, et al. Ritonavir does not increase methadone exposure in healthy volunteers [abstr. 342]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 699 | Hsu A, Granneman GR, Heath-Chiozzi M, et al. Indinavir can be taken with regular meals when administered with ritonavir [abstract 22361]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 675 | Hsu A, Granneman GR, Japour A, et al. ***Evaluation of potential ritonavir and indinavir combination BID regimens [abstract A-57]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 192 | Hsu A, Granneman GR, Sun E, et al. Assessment of single- and multiple-dose interactions between ritonavir and saquinavir [abstr]. XI International Conference on AIDS, 1996, Vancouver. | |
| 720 | Hsu A, Granneman R, Molla A, et al. Ritonavir-containing dual protease inhibitor regimens may have synergistic antiviral effects in patients - based on in vitro model [abstract 22350]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 2146 | Hsu AJ, Carson KA, Yung R, et al. Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy. Pharmacother 2012;32(6):538-45. | 22488554 |
| 929 | Hsyu PH, Lillibridge JH, Maroldo L, et al. Pharmacokinetic and pharmacodynamic interactions between nelfinavir and methadone [abstract 87]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco. | |
| 964 | Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrobial Agents and Chemotherapy 2001;45:3445-50. | 11709322 |
| 2479 | Htun WW, Steinhubl SR. Ticagrelor: the first novel reversible P2Y(12) inhibitor. Expert opinion on pharmacotherapy 2013 Feb;14(2):237-45. | 23268703 |
| 14 | Huang E, Hewitt RG, Shelton M, et al. Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy 1996;16:222-9. | 8820465 |
| 2348 | Huang F, Moschetti V, Lang B, et al. Pharmacokinetics, safety and tolerability of faldaprevir in patients with different levels of renal impairment [abstract 466]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC. | |
| 2541 | Huang L, Parikh S, Rosenthal PJ, et al. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. Journal of acquired immune deficiency syndromes (1999) 2012 Nov 1;61(3):310-6. | 22918158 |
| 1696 | Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000;59:961-72. | 10692561 |
| 3211 | Huesgen E, DeSear KE, Egelund EF, et al. A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios. Pharmacotherapy 2016;36(11):1145-1165. | 27636237 |
| 3091 | Hugen PW, Burger DM, et al. Development of an indinavir oral liquid for children. AJHP. 2000; 57(14):1332-9. | http://www.ajhp.org/content/57/14/1332 |
| 946 | Hugen PWH, Burger DM, Brinkman K, et al. Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Annals of Pharmacotherapy 2000;34:465-70. | 10772431 |
| 1151 | Hugen PWH, Burger DM. Author's reply on Comment: potential risk of valproic acid therapy in patients who are HIV-positive. Annals of Pharmacotherapy 2000;34(11):1349. | 11098354 |
| 1976 | Hughes CA, Foisy M, Tseng A. Interactions between antifungal and antiretroviral agents. Expert Opin Drug Saf 2010;9(5):723-42. | 20345324 |
| 1428 | Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. Canadian Medical Association Journal 2007;177(4):357-9. | 17698824 |
| 35 | Hughes WT, Gray VL, Gutteridge WE, et al. Efficacy of hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrobial Agents and Chemotherapy 1990;34:225-8. | 2327770 |
| 34 | Hughes WT, Kennedy W, Shenep JL, et al. Safety and pharmacokinetics of 566C80, a hydroxynapthoquinone with anti-pneumocystis activity: a phase I study in human immunodeficiency virus (HIV) infected men. Journal of Infectious Diseases 1991;163:843-8. | 2010637 |
| 939 | Hughes WT. Postulates for the evaluation of adverse reactions to drugs. Clinical Infectious Diseases 1995;20:179-82. | 7727649 |
| 2828 | Huhn GD, Tebas P, Gallant J, et al. A randomized, open-label trial to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1 infected adults. J Acquir Immune Defic Syndr 2017;74(2);193-200. | 27753684 |
| 2120 | Hulskotte EGJ, Feng H-P, Bruce RD, et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy [abstract PK_09]. 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 27-28, 2012, Cambridge, MA. | |
| 2055 | Hulskotte EGJ, Feng H-P, Xuan F, et al. Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother 2013;57:2582-8. | 23529734 |
| 2073 | Hulskotte EGJ, Feng H-P, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infec Dis 2013;56(5):718-26. | 23155151 |
| 2307 | Hulskotte EGJ, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the HCV protease inhibitor boceprevir and sirolimus in healthy subjects [abstract 463]. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), April 24-28th, 2013, Amsterdam. | |
| 2057 | Hulskotte EGJ, Gupta S, Xuan F, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers [abstract]. HEP DART, December 4-8, 2011, Koloa, Hawaii. | |
| 2058 | Hulskotte EGJ, Gupta S, Xuan F, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers [abstract]. HEP DART, December 4-8, 2011, Koloa, Hawaii. | |
| 2056 | Hulskotte EGJ, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012;56:1622-30. | 22576324 |
| 1640 | Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28:648-53. | 3004323 |
| 636 | Hung OL, Shih RD, Chiang WK, et al. Herbal preparation use among urban emergency department patients. Academic Emergency Medicine 1997;4(3):209-13. | 9063549 |
| 92 | Hurwitz A, Scholzman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. American Review of Respiratory Disease 1974;109:41-7. | 4588090 |
| 3378 | Hurwitz S, Tao S, Jiang Y, et al. Pharmacokinetics of ruxolitinib with ART in HIV-suppressed individuals (ACTG #A5336) [abstract 452]. 27th Conference on Retroviruses and Opportunistic Infections, March 8-11, 2020; Boston, USA. | |
| 361 | Huse DM, Schainbaum S, Kirsch AJ, et al. Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. American Journal of Health-System Pharmacy 1997;54(10):1180-4. | 9161626 |
| 482 | Hutcherson SL, Palestine AG, Cantrill HL, et al. Antisense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients [abstract H-136]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco. | |
| 2556 | Hutchinson DB, Whiteman PD, Farquhar JA. Agranulocytosis associated with maloprim: review of cases. Human toxicology 1986 Jul;5(4):221-7. | 3733111 |
| 936 | Hutchinson TA, Lane DA. Assessing methods for causality assessment of suspected adverse drug reactions. Journal of Clinical Epidemiology 1989;42(1):5-16. | 2913186 |
| 2320 | Hyle EP, Wood BR, Backman ES, et al. High frequency of hypothalamic-pituitary-adrenal axis dysfunction after local corticosteroid injection in HIV-infected patients on protease inhibitor therapy. J Acq Immune Def Syndr 2013;May 24 [Epub ahead of print]. | 23714741 |
| 3658 | Ibarra-Barrueta O, Palacios-Zabalza I, Mora-Atorrasagasti O, et al. Effect of concomitant use of montelukast and Efavirenz on neuropsychiatric adverse events. Ann Pharmacotherapy 2014; 48: 145-148. | 24259633 |
| 686 | ICN Canada Ltd. Tryptan Product Monograph. Montreal, Quebec 1997. | |
| 3682 | Idorsia Pharmaceuticals Ltd. Quviviq (daridorexant) Product Monograph. Oakville, ON, April 26, 2023. | |
| 2925 | Imaz A, Niubó J, Amara A, et al. Drug concentrations and HIV-1 RNA in CSF in patients switching to ritonavir-boosted atazanavir (ATV/r) plus lamivudine (3TC) dual therapy. [abstract MOPEB0337]. 9th IAS Conference on HIV Science, July 23-26, 2017, Paris, France. | http://www.ias2017.org/Portals/1/Files/IAS2017_LO.compressed.pdf?ver=2017-07-27-211231-197 |
| 1841 | Imaz A, Villar del Saz S, Ribas MA, et al. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2009;52:382-6. | 19654552 |
| 3177 | Inaba T, Fischer NE, Riddick DS, et al. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol Lett 1997;93:215-9. | 9486958 |
| 3345 | Incyte Corporation. Jakafi (ruxolitinib) Package Insert. Wilmington, DE. January 2020. | |
| 1727 | Innocenti F, Iyer L, Ramirez J, et al. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 2001;29:686-92. | 11302935 |
| 3443 | Innomar Strategies Inc. Givlaari (givosiran) Product Monograph. Oakville, ON. October 8, 2020. | https://pdf.hres.ca/dpd_pm/00058274.PDF |
| 2800 | Institute for Safe Medication Practices Canada. Drug interaction incident with HIV post-exposure prophylaxis. ISMP Canada Safety Bulletin. 2008;8(3):1-2. | http://www.ismp-canada.org/download/safetyBulletins/ISMPCSB2008-03HIVPEP.pdf |
| 3602 | Intra-Cellular Therapies, Inc. Caplyta (lumateperone) Prescribing Information. New York, NY. December, 2019. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf |
| 3341 | Ippolito MM, Jacobson JM, Lederman MM et al. Effect of antiretroviral therapy on plasma concentrations of chlorquine and desethyl-chloroquine. Clin Infect Dis 2018;67:1617-20. | 29771277 |
| 3240 | Ipsen Biopharmaceuticals Canada Inc. Cabometyx (cabozantinib) Product Monograph. Mississauga, ON. September 13, 2018. | https://pdf.hres.ca/dpd_pm/00047356.PDF |
| 1335 | Isaac A, Taylor S, Cane P, et al. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. Antimicrobial Agents and Chemotherapy 2004;54(2):498-502. | 15254024 |
| 3627 | Israel S, Elinav H, Elazary R, et al. Case report of increased exposure to antiretrovirals following sleeve gastrectomy. Antimicrob Agents Chemother. 2020;64:e02453-19. | 32015045 |
| 44 | Israelski DM, Tom C, Remington JS. Zidovudine antagonizes the action of pyrimethamine in experimental infection with Toxoplasma gondii. Antimicrobial Agents and Chemotherapy 1989;33:30-4. | 2712547 |
| 3193 | Itkonen MK, Tornio A, Lapatto-Reiniluoto O, et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. Clin Pharmacol Ther, 2019; 105(1):219-228. | 29696643 |
| 2943 | Ivanovic J, Bellagamba R, Nicastri E, Signore F, Vallone C, Tempestilli M et al. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS 2010;24:1083-4. | 20386380 |
| 2912 | Ivanovic J, Nicastri E, Viscione M, Bellagamba R, Signore F, Pisani G et al. Cord blood and amniotic fluid exposures of protease inhibitors and viral load quantification in HIV-infected pregnant women [abstract WEPE0100]. XVIII International AIDS Conference, Vienna, Austria, July 18-23rd, 2010. | |
| 368 | Ives DV. Cytomegalovirus disease in AIDS. AIDS 1997;11:1791-7. | 9412696 |
| 2725 | Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008;48(2):209-14. | 18077730 |
| 1474 | Iwamoto M, Wenning L, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clinical Infectious Diseases 2008;47(1):137-40. | 18513146 |
| 1516 | Iwamoto M, Wenning L, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infec Dis 2009;48(4):489-92. | 19143531 |
| 1587 | Iwamoto M, Wenning L, Petry A, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2008;52(12):4338-43. | 18838589 |
| 2554 | Iyer JK, Milhous WK, Cortese JF, et al. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 2001 Sep 29;358(9287):1066-7. | 11589941 |
| 3079 | Izurieta P, Kakuda TN, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med. 2011 Apr;12(4):257-8. | 21371239 |
| 3041 | Izzedine H, Aymard G, Launay-Vacher V, Hamani A, Deray G. Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis. AIDS 2000;14(5):618-9. | 10780727 |
| 1342 | Izzedine H, Launay-Vacher V, Deray G, et al. Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction. Clinical Pharmacology and Therapeutics 2004;75(4):362-3. | 15060514 |
| 3109 | Izzedine H, Launay-Vacher V, Deray G. Dosage of lamivudine in a haemodialysis patient. Nephron. 2000 Dec;86(4):553. | 11124630 |
| 2917 | Izzedine H, Launay-Vacher V, Peytavin G, Valantin MA, Deray G.Atazanavir: a novel inhibitor of HIV-protease in haemodialysis. Nephrol Dial Transplant. 2005 Apr;20(4):852-3. | 15772278 |
| 507 | Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Archives of Ophthalmology 1989;107(1):75-80. | 2535932 |
| 471 | Jabs DA, Enger C, Haller J, et al. Retinal detachments in patients with cytomegalovirus retinitis. Archives of Ophthalmology 1991;109:794-9. | 1645952 |
| 518 | Jabs DA, Newman C, De Bustros S, et al. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987;94(7):824-30. | 2821465 |
| 557 | Jabs DA. Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Infectious Agents & Disease 1995;4(3):131-42. | 8548191 |
| 572 | Jabs DA. Design of clinical trials for drug combinations: cytomegalovirus retinitis--foscarnet and ganciclovir. The CMV retinitis retreatment trial. Antiviral Research 1996;29(1):69-71. | 8721550 |
| 2783 | Jackson A, Else L, Higgs C et al. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals. HIV Clin Trials. 2018 Feb;19(1):31-37. | 29189101 |
| 1563 | Jackson A, Moyle G, Watson V, et al. Variability in steady state raltegravir pharmacokinetics, impact of ezetimibe? [abstract P25]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam, The Netherlands. | |
| 1924 | Jackson A, Watson V, Back D, et al. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr 2011;58:450-7. | 21926632 |
| 1691 | Jacobs C, Kalman SM, Tretton M, et al. Renal handling of cis-diamminedichloroplatinum(II). Cancer Treat Rep 1980;64:1223-6. | 7193518 |
| 3631 | Jacobs TG, Marzolini C, Back DJ, Burger DM. Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV. J Antimicrob Chemother 2022; 77:568-573. | 34791318 |
| 3640 | Jacobs TG, Mumbiro V, Moraleda C, et al. Suboptimal lopinavir exposure in infants 1-12 months on rifampicin treatment receiving double-dosed or semi-superboosted lopinavir/ritonavir; results from the EMPIRICAL trial [abstract 12648]. 24th International AIDS Conference, July 29 - August 2, 2022; Virtual and Montreal, Canada. | https://programme.aids2022.org/Abstract/Abstract/?abstractid=12648 |
| 892 | Jacobson JM, Davidian M, Rainey PM, et al. Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. Antimicrobial Agents & Chemotherapy 1996;40(6):1360-5. | 8726001 |
| 589 | Jacobson MA, Causey D, Polsky B, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. Journal of Infectious Diseases 1993;168:444-8. | 8393058 |
| 519 | Jacobson MA, de Miranda P, Cederberg DM, et al. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrobial Agents & Chemotherapy 1987;31(8):1251-4. | 2820301 |
| 542 | Jacobson MA, Drew WL, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. Journal of Infectious Diseases 1991;163(6):1348-51. | 1645385 |
| 593 | Jacobson MA, Gambertoglio JG, Aweeka FT, et al. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. Journal of Clinical Endocrinology and Metabolism 1991;72:1130-5. | 1827127 |
| 513 | Jacobson MA, JJ OD, Brodie HR, et al. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. Journal of Medical Virology 1988;25(3):339-49. | 2844981 |
| 503 | Jacobson MA, JJ OD, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrobial Agents & Chemotherapy 1989;33(5):736-41. | 2546490 |
| 508 | Jacobson MA, JJ OD, Porteous D, et al. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Quarterly Journal of Medicine 1988;67(254):473-86. | 2854894 |
| 561 | Jacobson MA, Kramer F, Bassiakos Y, et al. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. Journal of Infectious Diseases 1994;170(1):189-93. | 8014496 |
| 583 | Jacobson MA, Wulfsohn M, Feinberg JE, et al. Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093). AIDS 1994;8:451-9. | 8011248 |
| 608 | Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5. | 9164318 |
| 247 | Jacobson MA. Current management of cytomegalovirus disease in patients with AIDS. AIDS Research and Human Retroviruses 1994;10:917-23. | 7811543 |
| 248 | Jacobson MA. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 1997;337(2):105-14. | 9211681 |
| 1789 | Jacobson PA, Green K, Birnbaum A, et al. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002;49:461-7. | 12107550 |
| 1773 | Jacolot F, Simon I, Dreano I, et al. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991;41:1911-9. | 2039544 |
| 110 | Jain A, Mehta VL, Kulshrestha S. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tubercle and Lung Disease 1993;74:87-90. | 8324212 |
| 1167 | Jain AK, Venkataramanan R, Shapiro R, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transplantation 2002;8(9):841-5. | 12200788 |
| 2159 | Jamois C, Smith P, Morrison R, et al. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. Addict Biol 2009;14(3):321-7. | 19523046 |
| 1804 | Janney LM, Waterbury NV. Capecitabine-warfarin interaction. Ann Pharmacother 2005;39:1546-51. | 16014372 |
| 1922 | Jansen A, Colbers A, van der Ven A, et al. Pharmacokinetics of once-daily raltegravir/atazanavir in HIV-1 infected patients [abstract 634]. 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011, Boston, USA. | |
| 3152 | Janssen Inc. Ditropan XL (oxybutynin) Product Monograph. Toronto, ON. April 17, 2018. | |
| 3175 | Janssen Inc. Erleada (apalutamide) Product Monograph. Toronto, ON. July 3, 2018 | |
| 3490 | Janssen Inc. Uptravi (selexipag) Product Monograph. Toronto, ON. June 19, 2020. | |
| 2801 | Janssen Inc. Duragesic(fentanyl) Product Monograph. Toronto, ON. April 21, 2017. | http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/duragesic_cpm.pdf |
| 2030 | Janssen Inc. Edurant (rilpivirine) Product Monograph. Toronto, ON. July 26, 2017. | http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/edurant_cpm.pdf |
| 2366 | Janssen Inc. Galexos (simeprevir) Product Monograph. Toronto, ON. July 19, 2017. | http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/galexos_cpm.pdf |
| 3243 | Janssen Inc. Imbruvica (ibrutinib) Product Monograph. Toronto, ON. March 19, 2019. | https://pdf.hres.ca/dpd_pm/00050262.PDF |
| 1453 | Janssen Inc. Intelence (etravirine) Product Monograph. Toronto, ON. May 17, 2017. | http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/intelence_cpm.pdf |
| 2784 | Janssen Inc. Invokana (canagliflozin) Product Monograph. Toronto, ON. November 7, 2017. | http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/invokana_cpm.pdf |
| 3493 | Janssen Inc. Janssen COVID-19 Vaccine (SARS-CoV-2 Vaccine [Ad26.COV2.S, recombinant]) Product Monograph. Toronto, ON. March 5, 2021 | https://covid-vaccine.canada.ca/info/pdf/janssen-covid-19-vaccine-pm-en.pdf |
| 2443 | Janssen Inc. Olysio (simeprevir) Prescribing Information. Titusville, NJ May, 2017. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf |
| 2993 | Janssen Inc. Prezcobix (darunavir/cobicistat) Prescribing Information. Titusville, NJ, March 2023. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205395S6S7lbl.pdf |
| 2565 | Janssen Inc. Prezcobix (darunavir/cobicistat) Product Monograph. Toronto, ON, March 3, 2023. | http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/prezcobix_cpm.pdf |
| 1590 | Janssen Inc. Prezista (darunavir) Product Monograph. Toronto, Ontario. March 3, 2023. | http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/prezista_cpm.pdf |
| 1039 | Janssen Inc. Sporanox (itraconazole) Product Monograph. Toronto, ON. March 20, 2015. | http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/sporanox_caps_cpm.pdf |
| 3417 | Janssen Inc. Zytiga (abiraterone) Product Monograph. Toronto, ON. March 9, 2018. | |
| 3590 | Janssen Pharmaceutica. Haldol (haloperidol) Prescribing Information. Raritan, NJ. June 2009. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018701s059lbl.pdf |
| 3489 | Janssen Pharmaceutical Companies. Janssen COVID-19 Vaccine Full Emergency Use Authorization (EUA) Prescribing Information. Horsham PA. February 27, 2021. | https://www.fda.gov/media/146304/download |
| 3003 | Janssen Pharmaceuticals Inc. Axert (almotriptan) Prescribing Information. Titusville, NJ, May 2017. | |
| 3401 | Janssen Pharmaceuticals, Inc. Prezcobix (darunavir/cobicistat) Product Monograph. Titusville, NJ. March 2023. | http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/PREZCOBIX-pi.pdf |
| 3619 | Janssen Pharmaceuticals. Razadyne (galantamine) Prescribing Information. Titusville, NJ. February 2015. | |
| 3434 | Janssen Products, LP. Sirturo (bedaquiline) Package Insert. Titusville, NJ, December 2012. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf |
| 197 | Janssen-Ortho Inc. Prepulsid Product Monograph. 1995. | |
| 1818 | Janssen-Ortho Inc. Velcade (bortezomib) Product Monograph. Toronto, ON. March 16, 2016. | http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/velcade_cpm.pdf |
| 1613 | Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol 2007;63(5):451-6. | 17342480 |
| 3101 | Jassen Inc. Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) Product Monograph. Toronto, ON. March 3, 2023. | http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/symtuza_cpm.pdf |
| 612 | Jayaweera DT, White G, Moreno J. Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy. Genitourinary Medicine 1995;71:414-5. | 8566991 |
| 2663 | JB Dumond, M Vourvahis, NL Rezk, et al. A Phenotype–Genotype Approach to Predicting CYP450 and PGlycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir. Clin Pharmacol Ther. 2010 June;87(6):735–742. | |
| 903 | Jefferson JW. Possible risks associated with valproate treatment of AIDS-related mania [letter]. Journal of Clinical Psychiatry 1998;59(6):317. | 9671345 |
| 1224 | Jemsek J, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006 Jan 15;42(2):273-80. | 16355341 |
| 1308 | Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF [abstract 51]. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco CA. | |
| 1150 | Jennings HR, Romanelli F. Comment: potential risk of valproic acid therapy in patients who are HIV-positive. Annals of Pharmacotherapy 2000;34(11):1348-9. | 11098354 |
| 1149 | Jennings HR, Romanelli F. The use of valproic acid in HIV-positive patients. Annals of Pharmacotherapy 1999;33(10):1113-6. | 10534224 |
| 1618 | Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infec Dis 2009;48:1471-4. | 19368504 |
| 1300 | Jeu L, Cheng JWM. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clinical Therapeutics 2003;25:2352-87. | 14604738 |
| 2502 | Jewell H, Maggs JL, Harrison AC, et al. Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica; the fate of foreign compounds in biological systems 1995 Feb;25(2):199-217. | 7618347 |
| 2672 | Ji HY, Lee H, Lim SR, et al. Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. Molecules. 2012 Jan 17;17(1):851-60. | |
| 1616 | Ji P, Damle B, Xie J, et al. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in health subjects. J Clin Pharmacol 2008;48(8):948-56. | 18519918 |
| 2598 | Jiang F, Desta Z, Shon JH, et al. Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. Br J Clin Pharmacol 2013 Jan;75(1):244-53. | 22554354 |
| 3209 | Jindracek L, Stark J. Treatment of Chronic Hepatitis C Virus Infection With Crushed Ledipasvir/Sofosbuvir Administered via a Percutaneous Endoscopic Gastrostomy Tube. J Pharm Pract 2018;31(5):522-524. | https://www.ncbi.nlm.nih.gov/pubmed/28925327 |
| 1723 | John BA, Brodie RR, Baldock GA, et al. Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects. Xenobiotica 2002;32:699-713. | 12296990 |
| 2379 | John G, Ollo D, Meyer P, et al. Pulmonary embolism and iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavir. AIDS 2013 Nov 13;27(17):2827-8. | 24384635 |
| 117 | Johnson JA, Kappel JE, Sharif MN. Hypoglycemia secondary to trimethoprim/sulfamethoxazole drug interaction. DICP 1990;24:250-1. | 2316232 |
| 2291 | Johnson M, Borland J, Chen S, et al. The effect of boceprevir and telaprevir on dolutegravir pharmacokinetics, in healthy adult subjects [abstract O_16]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | |
| 759 | Johnson M, Nelson M, Peters B, et al. A comparison of BID and TID dosing of nelfinavir mesylate when given in combination with stavudine (d4T) and lamivudine (3TC) for up to 48 weeks [abstract I-216.]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24-27, 1998, San Diego. | |
| 3400 | Johnson SW, Teachey AL, Valanejad SM, Griffin SM, Weber SF. Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass. J Clin Pharm Ther. 2017;42(5):624-626. | 28474386 |
| 2944 | Johnson VA. Brun-Vezinet F. Clotet B et al. Update of the drug resistance mutations in HIV-1: 2007. Topics in HIV Medicine. 15(4):119-125 August/September. | https://pdfs.semanticscholar.org/cdbd/4986ac39df742b34e6195d0863f957479482.pdf |
| 2254 | Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update. Geneva, Switzerland 2009 Available from: http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2009/jc1700_epi_update_2009_en.pdf. | |
| 2262 | Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). Global HIV/AIDS response. Epidemic update and health sector progress towards universal access. Progress report 2011. Geneva, Switzerland 2011 Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_ua_report_en.pdf. | |
| 2263 | Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic. Geneva, Switzerland 2012 Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf. | |
| 3565 | Jonas MM, Rhee S, Kelly DA et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology 2020;71(2):456-62. | 31254392 |
| 3563 | Jonas MM, Rhee S, Kelly DA et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic HCV: part 2 of the DORA study. Hepatology 2021;74(1):19-27. | 33811356 |
| 3564 | Jones MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology 2020;71(2):456-62. | 31254392 |
| 3067 | Jongbloed-de Hoon M, Colbers A, Velthoven-Graafland K, Duisenberg-van Essenberg M, Kruijssen M, Abbink E, van Crevel R, Burger D. Brief Report: Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given With or Without Enteral Nutrition. J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):571-574. | 28166190 |
| 1778 | Jordan VC, Collins MM, Rowsby L, et al. A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J Endocrinol 1977;75:305-16. | 591813 |
| 910 | Jorga K, Buss NE. Pharmacokinetic drug interaction with saquinavir soft gelatin capsule [abstract 339]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-28, 1999, San Francisco, CA. | |
| 2369 | Joseph D, Rose P, Strelkowa N, et al. Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers [abstract 501]. Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014, Boston, MA. | |
| 2355 | Joseph D, Schobelock M, Riesenberg RA, et al. Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy. Antimicrob Agents Chemother. 2015 Jan;59(1):498-504. | 25385094 |
| 381 | Joshi AS, Fiske WD, Benedek IH, et al. Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers [abstr 348]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 3547 | Joshi S, Cohen M, Katz R et al. A case series of safety and efficacy of crushed sofosbuvir/velpatasvir in hepatitic C infected patients [abstract 950]. AASLD: The Liver Meeting, Digital Experience, 12-15 November, 2021. | |
| 1354 | Jover F, Cuadrado JM, Andreu L, et al. Reversible coma caused by risperidone-ritonavir interaction. Clinical Neuropharmacology 2002;25(5):251-3. | 12410055 |
| 2142 | Juba KM, Weiland D. Seizure management in a complex hospice patient. J Pain Palliat Care Pharmacother 2010;24(1):27-32. | 20345197 |
| 222 | Juergens JP, Basara LR. Patient information: community pharmacy needs and perspectives. Topics in Hospital Pharmacy Management 1994;14(3):47-57. | 10138928 |
| 2261 | Jumes P, Feng H-P, Chatterjee M, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and prednisone in healthy volunteers [abstract 1896]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9-13, 2012, Boston, MA. | |
| 2117 | Jumes P, Feng H-P, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and digoxin in healthy adult volunteers [abstract PK_05]. 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 27-28, 2012, Cambridge, MA. | |
| 2336 | Juneja M, Euliano R, Satoskar R, et al. Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis. Dig Dis Sci 2013;epub ahead of print. | 23925819 |
| 1027 | Jung D, Griffy K, Dorr A, et al. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients. Journal of Clinical Pharmacology 1998;38(11):1057-62. | 9824788 |
| 278 | Jung H, Medina R, Castro N, et al. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrobial Agents and Chemotherapy 1997;41:1256-9. | 9174180 |
| 3392 | Jungmann NA, Lang D, Saleh S, et al. In vitro-in vivo correlation of the drug-drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat. Expert Opin Drug Metab Toxicol 2019;15:975-84. | 31619082 |
| 2208 | Jurgens C, Groth Hoegberg LC, Graudal NA. The effect of activated charcoal on drug exposure in healthy volunteers: a metaanalysis. Clin Pharmacol Ther 2009;85(5):501-5. | 19194372 |
| 3675 | Jurgens G, Lange KHW, Reuther LE, et al. Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. Clin Pharmacol Ther 2002;71:162-8. | 11907490 |
| 1336 | Justesen U, Andersen AB, Klitgaard NA, et al. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clinical Infectious Diseases 2004;38(3):426-9. | 14727216 |
| 1103 | Justesen U, Klitgaard N, Brosen K, et al. Amprenavir is an effective inducer of delavirdine metabolism: a steady-state pharmacokinetic interaction study between amprenavir and delavirdine in healthy volunteers [abstract 442-W]. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA. | |
| 1442 | Kaeser B, Zandt H, Bour F, et al. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. Antimicrob Agents Chemother 2009;53(2):609-14. | 19015329 |
| 775 | Kahn J, Lagakos S, Weng D, et al. A Multicenter, Randomized, Double-Blind Placebo Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil (Adv) When Added to Standard Antiretroviral Therapy (Art) [abstract I-108.]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24-27, 1998, San Diego. | |
| 1799 | Kajita J, Kuwabara T, Kobayashi H, et al. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000;28:1121-7. | 10950859 |
| 2867 | Kakadiya PP, Higginson RT, Fulco PP. Ritonavir-boosted protease inhibitors but not cobicistat appear safe in HIV-positive patients ingesting dabigatran. Antimicrob Agents Chemother 2019;62(2). pii: e02275-17. doi: 10.1128/AAC.02275-17. | 29133562 |
| 3080 | Kakuda T et al. Pharmacokinetics of etravirine according to CYP2C9 and CYP2C19 metabolizer status: a meta-analysis of Phase I Trials [abstract 515]. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, March 3-6, 2013. | |
| 2947 | Kakuda T, Brochot A, van de Casteele T, Opsomer M, Tomaka F. Establishing darunavir dosing recommendations in treatment-naïve and treatment-experienced pediatric patients [abstract O_13]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | http://www.natap.org/2013/Pharm/Pharm_19.htm |
| 2945 | Kakuda T, Sekar VJ, Vis P, Coate B, Ryan R, De La Rosa G et al. Intrinsic/extrinsic covariates and darunavir pharmacokinetics in treatment-experienced patients in GRACE (Gender, Race and Clinical Experience) [abstract 16]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7th, 2010, Sorrento, Italy. [page 17] | http://regist2.virology-education.com/abstractbook/2010_2.pdf |
| 2948 | Kakuda T, van de Casteele T, Petrovic, R, Opsomer M, Tomaka F, Hoetelmans RMW. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents in healthy volunteers [abstract P_10]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | http://www.natap.org/2013/Pharm/Pharm_17.htm |
| 1951 | Kakuda TN, Abel S, Davis J, et al. Pharmacokinetic interactions of maraviroc with darunavir/ritonavir, maraviroc with etravirine, and maraviroc with etravirine/darunavir/ritonavir in healthy volunteers: results of two drug interaction trials. Antimicrob Agents Chemother 2011;55(5):2290-6. | 21383098 |
| 3082 | Kakuda TN, Berckmans C, De Smedt G, et al. Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies. Int J Clin Pharmacol Ther 2013;51(9):725-37. | 23924679 |
| 1256 | Kakuda TN, Brinkman K. Mitochondrial toxic effects and ribavirin.[comment]. Lancet 2001;357(9270):1802-3. | 11407388 |
| 3081 | Kakuda TN, Brochot A, Green B, Nijs S, Vis P, Opsomer M, Tomaka FL, Hoetelmans RM. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO. J Clin Pharmacol. 2016 Nov;56(11):1395-1405. | 27060341 |
| 1957 | Kakuda TN, de Smedt G, Peeters M, et al. No effect of ritonavir or timing of food intake on etravirine pharmacokinetics in HIV-negative volunteers [abstract P_11]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13-15th, 2011, Miami, USA. | |
| 3100 | Kakuda TN, DeMasi R, van Delft Y, et al. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. HIV Med 2013;14(7):421-429. | 23441978 |
| 2542 | Kakuda TN, Jarus-Dziedzic K, Demasi R, et al. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemeter/lumefantrine in healthy volunteers: a randomised study [abstract O_05]. . 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona. | |
| 2083 | Kakuda TN, Leopold L, Nijs S, et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir: a randomised, two-way crossover trial [abstract O_18]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 2946 | Kakuda TN, Leopold L, Timmers M, Van De Casteele T, Hillewaert V, Tomaka FL, Hoetelmans RM. Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation. Int J Clin Pharmacol Ther. 2014 Sep;52(9):805-16. | 25109510 |
| 2092 | Kakuda TN, Nijs S, Latham J, et al. Pharmacokinetics of atazanavir/ritonavir 300/100 mg or 400/100 mg QD when coadministered with etravirine 200 mg BID in HIV-infected patients [abstract O_24]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 2098 | Kakuda TN, Opsomer M, Timmers M, et al. Bioavailability of two FDC formulations of darunavir/cobicistat 800/150 mg compared with darunavir/ritonavir 800/100 mg co-administered as single agents [abstract O_20]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 789 | Kakuda TN, Page LM, Anderson PL, et al. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrobial Agents and Chemotherapy 2001;45:236-42. | 11120972 |
| 1676 | Kakuda TN, Peeters M, Corbett C, et al. Pharmacokinetics and pharmacodynamics of etravirine in treatment-experienced HIV-1-infected patients: pooled 48-week results of DUET-1 and DUET-2 [abstract H-4056]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington, DC. | |
| 1845 | Kakuda TN, Scholler-Gyure M, De Smedt G, et al. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med 2009;10(3):173-81. | 19207601 |
| 2010 | Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet 2011;50(1):25-39. | 21142266 |
| 2480 | Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clinical pharmacokinetics 2011;50(1):25-39. | 21142266 |
| 2683 | Kakuda TN, Scholler-Gyure M, Peeters M, et al. Pharmacokinetic interaction study with TMC125 and TMC114/rtv in HIV-negative volunteers [abstract TUPE0086]. XVI International AIDS Conference, August 13-18 2006, Toronto, Canada. | |
| 1485 | Kakuda TN, Scholler-Gyure M, Peeters M, et al. Pharmacokinetics of etravirine are not affected by sex, age, race, use of enfuvirtide or treatment duration in HIV-1 infected patients [abstract P34]. 9th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9 2008, New Orleans, LA. | http://medadvocates.org/resources/conferences/international_aids_conferences/17/etravirine/aa17KakudaPoster_FINAL.pdf |
| 2110 | Kakuda TN, Scholler-Gyure M, Woodfall B, et al. TMC125 in combination with other medications: summary of drug-drug interaction studies [abstract PL5.2]. 8th International Congress on Drug Therapy in HIV Infection, November 12-16, 2006, Glasgow. | |
| 435 | Kakuda TN, Struble KA, Piscitelli SC. Protease inhibitors for the treatment of human immunodeficiency virus infection. American Journal of Health-System Pharmacy 1998;55:233-54. | 9492254 |
| 2390 | Kakuda TN, Van Solingen-Ristea RM, Onkelinx J, et al. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. J Clin Pharmacol 2014 Apr;54(4):422-31. | 24165884 |
| 2362 | Kakuda TN, Woodfall B, De Marez T, et al. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. J Antimicrob Chemother 2013;Oct 23 [epub ahead of print]. | 24155058 |
| 105 | Kamada AK. Possible interaction between ciprofloxacin and warfarin. DICP 1990;24:27-8. | 2301186 |
| 1797 | Kamaluddin M, McNally P, Breatnach F, et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001;90:1204-7. | 11697438 |
| 3029 | Kamdem LK, Liu Y, Stearns V, et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 2010;70:854-69. | 21175441 |
| 3398 | Kamimura M, Watanabe K, Kobayakawa M, et al. Successful absorption of antiretroviral drugs after gastrojejunal bypass surgery following failure of therapy through a jejunal tube. Intern Med. 2009;48(12):1103‐1104. | 19525608 |
| 3255 | Kandil MM, Badowski ME, Schriever CA. Sustained viral suppression with co-administration of oxcarbazepine and dolutegravir. Int J STD AIDS 2018; 29(8): 831-833. | 29350111 |
| 3551 | Kang J, Kim Y. Use of dolutegravir and rilpivirine in treatment of HIV in PLWH with CKD and ESRD [abstract 899]. IDWeek 2021, September 29 - October 3, 2021, virutal. | |
| 3538 | Kant R, Cromer MD, Chandra R, Munir K, Verma V. Avascular necrosis of both hips from Iatrogenic Cushing's syndrome due to coadministration of fluticasone and ritonavir in an HIV-infected patient. Cureus 2020;12:e9644. | 32923244 |
| 2760 | Kapil RP, Friedman K, Cipriano A, et al. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended release hydrocodone tablet. Clin Ther 2015;37(10):2286-96. | 26350273 |
| 1652 | Kaplan JE, Benson C, Holmes KK, et al. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009;58:1-207. | 19357635 |
| 3251 | Kaplun O, Psevdos G.Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. Am J Health Syst Pharm 2019;76(16):1180-1181. | 31287497 |
| 1990 | Kappelhoff BS, Huitema AD, Mairuhu AT, et al. No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. Anticancer Drugs 2005;16:627-30. | 15930890 |
| 1768 | Karunanayake EH, Hearse DJ, Mellows G. The metabolic fate and elimination of streptozocin. Biochem Soc Trans 1975;3:410-4. | 124280 |
| 3681 | Karyopharm Therapeutics Inc. Xpovio (selinexor) Prescribing Information, Newton MA, July 2022. | https://pdf.hres.ca/dpd_pm/00066090.PDF |
| 1771 | Kasel D, Baumhakel M, Fuhr U. Biodegradation of procarbazine by human liver microsomes. Int J Clin Pharmacol Ther 2000;38:153-5. | |
| 1153 | Kashuba ADM, Lim ML. Interactions between heroin and antiretrovirals. Medscape Portals, Inc, Medscape HIV/AIDS 2002;8(1). | |
| 1931 | Kasserra C, Hughes E, Treitel M, et al. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA. | |
| 1666 | Kasserra C, O’Mara EM, Lisbon E. Assessment of pharmacokinetic and safety interactions between vicriviroc and CYP3A4 substrates, inhibitors, and inducers [abstract H-230]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco. | |
| 1471 | Kasserra C, Sansone-Parsons A, Keung A, et al. Vicriviroc pharmacokinetic parameters are unchanged when co-administered with darunavir in a ritonavir-containing regimen (abstract P35). 9th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9 2008, New Orleans, LA. | |
| 2175 | Kassler W, Blanc P, Greenblatt R. The use of medicinal herbs by human immunodeficiency virus-infected patients. Arch Int Med 1991;151(11):2281-8. | 1953234 |
| 218 | Kastrissios H, Suarez JR, Katzenstein D, et al. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 1998;12(17):2295-303. | 9863872 |
| 1540 | Katlama C, Campbell T, Schechter M, et al. Incidence and severity of nervous system and psychiatric events are similar with etravirine versus placebo: pooled 48 week data from the Phase III DUET studies [abstract TUPE0056]. XVIIth International AIDS Conference, August 3-8, 2008, Mexico City, Mexico. | |
| 587 | Katlama C, Dohin E, Caumes E, et al. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times daily regimens. Journal of the Acquired Immune Deficiency Syndrome 1992;5(Suppl 1):S18-S24. | 1318363 |
| 1535 | Katlama C, Gatell JM, Molina JM, et al. Pooled 24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients [abstract P7.13/18]. 11th European AIDS Conference, October 24-27, 2007, Madrid, Spain. | |
| 1534 | Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009;23(17):2289-300. | 19710593 |
| 270 | Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Jama 1996;276(2):118-25. | 8656503 |
| 963 | Kato Y, Fujii T, Mizoguchi N, et al. Potential interaction between ritonavir and carbamazepine. Pharmacotherapy 2000;20(7):851-4. | 10907977 |
| 894 | Kaufman MB, Simionatto C. A review of protease inhibitor-induced hyperglycemia. Pharmacotherapy 1999;19:114-7. | 9917085 |
| 3491 | Kaufmann P, Niglis S, Bruderer S et al. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol 2015:80:670-7. | 25851691 |
| 1174 | Kaul S, Agarwala S, Hess H, et al. The effect of coadministration of indinavir and ritonavir on the pharmacokinetics of stavudine [abstract A1825]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. | |
| 2690 | Kaul S, Bassi K, Damle BD, et al. Lack of interaction between stavudine extended-release formulation and tenofovir disoproxil fumarate [abstract 534]. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston. | |
| 1258 | Kaul S, Bassi K, Damle BD, et al. Pharmacokinetic evaluation of the combination of atazanavir, enteric coated didanosine, and tenofovir disoproxil fumarate for a once-daily antiretroviral regimen [abstract A-1616]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003, Chicago, IL. | |
| 3048 | Kaul S, Ji P, Lu M, Nguyen KL, Shangguan T, Grasela D. Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. Am J Health Syst Pharm. 2010 Feb 1;67(3):217-22. | 20101064 |
| 1731 | Kawashiro T, Yamashita K, Zhao XJ, et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 1998;286:1294-300. | 9732391 |
| 3697 | Kawuma AN, Wasmann RE, Dooley KE, et al. Population pharmacokinetic model and alternative dosing regimens for dolutegravir coadministered with rifampicin. Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0021522 | 35604212 |
| 108 | Kay L, Kampmann JP, Svendsen TL, et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. British Journal of Clinical Pharmacology 1985;20:323-6. | 4074601 |
| 1262 | Kearney BP, Benhamou Y, Flaherty J, et al. Tenofovir pharmacokinetics in hepatic impairment and drug interaction potential with agents used to treat viral hepatitis [abstract 600]. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco CA. | |
| 1182 | Kearney BP, Damle BD, Plummer A, et al. Pharmacokinetics evaluation of tenofovir DF and enteric-coated didanosine [abstract P186]. 6th International Congress on Drug Therapy in HIV Infection, November 17-21, 2002, Glasgow. | |
| 1097 | Kearney BP, Flaherty J, Wolf J, et al. Coadministration of tenofovir DF and didanosine: pharmacokinetic drug-drug interaction and safety evaluation [abstract P172]. 8th European Conference on Clinical Aspects and Treatment of HIV Infection, October 28-31, 2001, Athens. | |
| 1096 | Kearney BP, Flaherty J, Wolf J, et al. Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine, and lopinavir/ritonavir in healthy subjects [abstract P171]. 8th European Conference on Clinical Aspects and Treatment of HIV Infection, October 28-31, 2001, Athens. | |
| 1328 | Kearney BP, Isaacson E, Sayre J, et al. Tenofovir DF and oral contraceptives: lack of a pharmacokinetic drug interaction [abstract A-1618]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003, Chicago, IL. | |
| 1326 | Kearney BP, Isaacson E, Sayre J, et al. The pharmacokinetics of abacavir, a purine nucleotide analog, are not affected by tenofovir DF [abstract A-1615]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003, Chicago, IL. | |
| 1238 | Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):278-83. | 17079992 |
| 2132 | Kearney BP, Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacother 2009;29(8):924-9. | 19637945 |
| 2697 | Kearney BP, Mittan A, Sayre J, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir [abstract A-1617]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003, Chicago, IL. | |
| 1370 | Kearney BP, Sayre J, Shah J, et al. Lack of systemic or renal drug interactions of tenofovir DF with adefovir dipivoxil or ribavirin [abstract TuPeB4628]. XV International AIDS Conference, July 11-16 2004 Bangkok, Thailand, 2004. | |
| 1972 | Kedem E, Shahar E, Hassoun G, et al. Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma 2010;47(7):830-1. | 20653496 |
| 354 | Keiser P, Turner D, Ramilo O, et al. An open-label pilot study of the efficacy and tolerability of once-daily didanosine versus twice-daily didanosine. Clin Infect Dis. 1998 Aug;27(2):400-1. | 9709897 |
| 1352 | Kelly DV, Beique LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Annals of Pharmacotherapy 2002;36(5):827-30. | 11978161 |
| 191 | Kempf D, Marsh K, Denissen J, et al. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450 [abstr]. 3rd National Conference on Human Retroviruses and Related Infections, 1996, Washington DC. | |
| 1940 | Kempf DJ, Klein C, Chen HJ, et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007;18(3):163-7. | 17626600 |
| 3653 | Kent SJ. Loss of control of HIV viremia associated with the fat malabsorption drug orlistat. AIDS Res Hum Retrov 2012; 28: 961– 962. | 22280308 |
| 1074 | Keown PA, Laupacis A, Carruthers G, et al. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 1984;38:304-6. | 6474556 |
| 1751 | Kerpel-Fronius S, Verwey J, Stuurman M, et al. Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism. Cancer Chemother Pharmacol 1988;22:104-8. | 3136940 |
| 700 | Kerr B, Lee C, Yuen G, et al. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate, a new HIV-1 protease inhibitor [abstract 373]. 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 753 | Kerr B, Pithavala Y, Zhang M, et al. Virologic response-plasma drug concentration relationship in Phase III study of nelfinavir mesylate (VIRACEPT(r)) [abstract 12304]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 127 | Kerr B, Yuen G, Daniels R, et al. Strategic approach to nelfinavir mesylate (NFV) drug interactions involving CYP3A metabolism. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 812 | Kerr BM, Daniels R, Clendeninn N. Pharmacokinetic interaction of nelfinavir with half-dose rifabutin [abstract B203]. 8th Annual Canadian Conference on HIV/AIDS Research, May 1-4, 1999, Victoria, BC. | |
| 1546 | Kerrigan H, Towner W, Klein D, et al. Treatment response among HIV patients co-enrolled in the etravirine and raltegravir expanded access programs at Kaiser Permanente [abstract H-1263]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington, DC. | |
| 2767 | Keubler A1, Weiss J, Haefeli WE, Mikus G, Burhenne J.Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro. Drug Metab Dispos. 2012 Jun;40(6):1178-82. | 22415932 |
| 2555 | Khalil I, Ronn AM, Alifrangis M, et al. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. The American journal of tropical medicine and hygiene 2003 May;68(5):586-9. | 12812351 |
| 3404 | Khalilieh S, Sanchez RI, Yee KL, et al. Dose adjustment of doravirine mitigates the pharmacokinetic interaction with the moderate CYP3A inducer, rifabutin [abstract PEA0083]. 23rd International AIDS Conference Virtual, July 6-10, 2020. | https://cattendee.abstractsonline.com/meeting/9289/Presentation/1073 |
| 3142 | Khalilieh S, Yee KL, Liu R, et al. Moderate hepatic impairment does not affect doravirine pharmacokinetics. J Clin Pharmacol 2016;57(6):777–83. | 28026013 |
| 3149 | Khalilieh S, Yee KL, Sanchez RI, et al. Results of a doravirine-atorvastatin drug-drug interaction study. Antimicrob Agents Chemother 2017;61: pii: e01364-16. | 27872071 |
| 2851 | Khalilieh S, Yee KL, Sanchez RI, et al. A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents. J Clin Pharmacol. 2019; 59(8):1093-1098. | 30817001 |
| 2861 | Khalilieh S, Yee KL, Sanchez RI, et al. Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone. Clin Pharmacol Drug Dev 2020;9:151-161. | 31120195 |
| 3144 | Khalilieh SG, Yee KL, Sanchez RI, et al. Multiple doses of rifabutin reduce exposure of doravirine in healthy subjects. J Clin Pharmacol 2018 May 3 [epub ahead of print]. | 29723418 |
| 1089 | Khaliq Y, Gallicano K, Cameron DW, et al. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. British Journal of Clinical Pharmacology 2001;51:591-600. | 11422019 |
| 804 | Khaliq Y, Gallicano K, Seguin I, et al. Therapeutic drug monitoring of nelfinavir in HIV-infected patients with liver disease [abstract 369]. 6th Conference on Retroviruses and Opportunistic Infections, January 31-February 4, 1999, Chicago IL. | |
| 1657 | Khaliq Y, Gallicano K, Venance S, et al. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2000;68(6):637-46. | 11180024 |
| 836 | Khaliq Y, Gallicano K, Venance S, et al. Effect of the p-glycoprotein and cytochrome P450 3A4 inhibitor ketoconazole, on ritonavir and saquinavir plasma and cerebrospinal fluid concentrations [abstract B205]. 8th Annual Canadian Conference on HIV/AIDS Research, May 1-4, 1999, Victoria, BC. | |
| 2616 | Khanlou H, Bhatti L, Farthing C. Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients. JAIDS 2006;41(1):124-5. | 16340485 |
| 1594 | Kharasch ED, Mitchell D, Coles R, et al. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008;52(5):1663-9. | 18285471 |
| 2435 | Khatri A, Dutta S, Dunbar M et al. Evaluation of drug-drug interactions between direct-acting anti-hepatitis C virus combination regimens and the HIV-1 antiretroviral agents raltegravir, tenofovir, emtricitabine, efavirenz, and rilpivirine. Antimicrob Agents Chemother 2016;60(5):2965-71. | 26953200 |
| 2467 | Khatri A, Dutta S, Marbury TC, et al. Pharmacokinetics and tolerability of anti-hepatitis C virus treatment with ombitasvir, paritaprevir, ritonavir, with or without dasabuvir, in subjects with renal impairment. Clin Pharmacokinet 2016 Jul 7. [Epub ahead of print] | 27389403 |
| 2432 | Khatri A, Dutta S, Wang H, et al. Evaluation of drug-drug interactions between hepatitis C antiviral agents ombitasvir, paritaprevir/ritonavir, and dasabuvir and HIV-1 protease inhibitors. Clin Infec Dis 2016;Jan 5 [Epub ahead of print]. | 26740513 |
| 2333 | Khatri A, Menon R, Marbury TC, Podsadecki TJ, Mullally VM, Ding B, et al. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. J Hepatol 2015;63(4):805-12. | 26070406 |
| 2623 | Khatri A, Trinh R, Zhao W, Podsadecki T, Menon R. Drug-drug interaction between the directly-acting antiviral regimen of ombitasvir/paritaprevir/ritonavir plus dasabuvir and the HIV antiretroviral agents dolutegravir or abacavir plus lamivudine. Antimicrob Agents Chemother 2016;60(10):6244-51. | 27503645 |
| 2507 | Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS (London, England) 2005 Jul 1;19(10):995-1005. | 15958830 |
| 2399 | Khoo S, Hill A, Back D, et al. The induction effect of rifampicin of efavirenz is time-dependent: systemic review of 12 drug interaction studies [abstract P_29]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 1494 | Khoo S, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN): a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 2006;41(4):461-7. | 16652054 |
| 917 | Kilby JM, Sfakianos G, Gizzi NA, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative patients. Antimicrobial Agents and Chemotherapy 2000;44(10):2672-8. | 10991842 |
| 831 | Kim AE, Dintaman JM, Waddell DS, et al. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. Journal of Pharmacology & Experimental Therapeutics 1998;286(3):1439-45. | 9732409 |
| 2941 | Kim C, Muzevich K, Fulco P. Orogastric Administration of Crushed Darunavir Tablets for a Critically Ill Patient. The Canadian Journal of Hospital Pharmacy 2014;67(1):39-42. | 24634526 |
| 835 | Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation 1998;101(2):289-94. | 9435299 |
| 1242 | Kim RB. Drug transporters in HIV Therapy. Topics in HIV Medicine 2003;11(4):136-9. | 12876331 |
| 3042 | King J, McCall M, Cannella A, Markiewicz MA, James A, Hood CB, Acosta EP. A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet. J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):e130-2. | 22046602 |
| 2706 | King J, Paul Lundy S, Kakuda TN, et al. Pharmacokinetics of saquinavir with low-dose ritonavir or atazanavir twice daily in seronegative volunteers: ASPIRE II [abstract 586]. 13th Conference on Retroviruses and Opportunistic Infections February 5-8, 2006, Denver, CO. | |
| 2777 | King JR, Dutta S, Cohen D, Podsadecki TJ, Ding B, Awni WM, Menon RM.Drug-drug interactions between sofosbuvir and ombitasvir-paritaprevir-ritonavir with or without dasabuvir. Antimicrob Agents Chemother 2016;60(2):855-61. | 26596948 |
| 3309 | Kinvig H, Stader F, Bunglawala FS, et al. High-dose rifampicin for the treatment of leprosy in HIV patients taking dolutegravir [abstract 450]. Conference on Retroviruses and Opportunistic Infections (CROI), March 8-11, 2020, Boston, MA. | http://www.croiconference.org/sessions/high-dose-rifampicin-treatment-leprosy-hiv-patients-taking-dolutegravir |
| 2359 | Kirby B, Gordi T, Symonds W, et al. Population pharmacokinetics of sofosbuvir and Its major metabolite (GS-331007) in healthy and HCV-Infected adult subjects [abstract]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-4, 2013, Washington, DC. | |
| 2400 | Kirby B, Li H, Kearney BP, et al. Population pharmacokinetic analysis of ledipasvir (GS-5885) in healthy and hepatitis C virus infected subjects [abstract P_33]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 2222 | Kirby B, Mathias A, Rossi S, et al. No clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals Atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers [abstract 1877]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston, MA. | |
| 2312 | Kirby B, Mathias A, Yang C, et al. Metabolism and excretion of ledipasvir (GS-5885) in humans [abstract O_20]. 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 26-27, 2013, Cambridge, MA. | http://regist2.virology-education.com/2013/8hepcam/docs/25_Kirby.pdf |
| 2856 | Kirby B, Taylor J, Stamm L et al. Evaluation of transporter and cytochrome P450-mediated Drud-Drug Interactions with Pan Genotypic HCV NS3/4A Protease Inhibitor Voxilaprevir (GS-9857) or Sofosbuvir/Velpatasvir/Voxilaprevir and Phenotypic Probe Drugs. 17th International Workshop of HIV & Hepatitis Therapy. June 8-10 2016, Washington DC. | http://regist2.virology-education.com/2016/17HIVHEPPK/40_Kirby.pdf |
| 2651 | Kirby BJ, Collier AC, Kharasch ED, et al. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos. 2012 Mar;40(3):610-6. | |
| 1374 | Kirian MA, Higginson RTH, Fulco PP. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. Annals of Pharmacotherapy 2004;38(10):1660-3. | 15340130 |
| 292 | Kirsch LS, Arevalo JF, De Clercq E, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. American Journal of Ophthalmology 1995;119(4):466-76. | 7709971 |
| 2716 | Kis O, Robillard K, Chan GNY, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends in Pharmacological Sciences 2009;31(1):22-35. | |
| 2084 | Kiser J, Burton J, Anderson P, et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012;55(5):1620-8. | 22331658 |
| 2396 | Kiser J, Lu D, Rosenkranz S, et al. Boceprevir and antiretroviral pharmacokinetic interactions in HIV/HCV coinfected persons - AIDS clinical trials group study A5309S [abstract P_18]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 1917 | Kiser JJ, Bumpass JB, Meditz A, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother 2010;54(12):4999-5003. | 20921313 |
| 1462 | Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes 2008;47(5):570-8. | 18176327 |
| 2891 | Kiser JJ, Rutstein RM, Samson P, Graham B, Mofenson L, Smith E, Fenton T, Brundage RC, Fletcher CV*. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents; Infant Maternal Pediatric Adolescent AIDS Clinical Trials Group P1020A. AIDS 2011;25(12):1489-96. | 21610486 |
| 626 | Kitano K, Abboud CN, Ryan DH, et al. Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells. Blood 1991;77(8):1699-705. | 1707694 |
| 2822 | Kivisto KT, Billikka K, Nyman L, et al. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998, 64:648-54. | 9871429 |
| 1783 | Kivisto KT, Villikka K, Nyman L, et al. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998;64:648-54. | 9871429 |
| 2649 | Klein C, Bertz R, Ashbrenner E, et al. Assessment of the multiple-dose pharmacokinetic interaction of lopinavir/ritonavir with nelfinavir [abstract 536]. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston, MA | |
| 2650 | Klein C, Chiu Y-L, Cai Y, et al. Lack of effect of acid reducing agents on the pharmacokinetics of lopinavir/ritonavir tablet [abstract 578]. 13th Conference on Retroviruses and Opportunistic Infections February 5-8, 2006, Denver, CO. | |
| 2681 | Klein C, Zhu T, Chiu Y-L, et al. Effect of efavirenz on lopinavir/ritonavir pharmacokinetics from a new tablet formulation [abstract 4.3/2]. 10th European AIDS Conference, November 17-20, 2005, Dublin, Ireland. | |
| 3199 | Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007 Apr 1;44(4):401-10. | 17224848 |
| 1417 | Klibanov OM, Gaughan JP, Tedaldi EM, et al. The effect of ezetimibe on the steady-state trough levels of lopinavir/ritonavir [abstract 64]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2007, Budapest, Hungary. | |
| 3462 | Knapp KM, Brogly SB, Muenz DG, et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 2012;31(2):164-70. | 21983213 |
| 722 | Knobel H, Carmona A, Lopez JL, et al. Adherencia al tratamiento antirretroviral de gran actividad: impacto de una intervencion De asesoramiento individualizado. [Adherence to very active antiretroviral treatment: impact of individualized assessment]. Enferm Infecc Microbiol Clin. 1999 Feb;17(2):78-81. | 10193067 |
| 808 | Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Annals of Pharmacotherapy 1998;32:1299-302. | 9876810 |
| 48 | Knupp CA, Brater C, Relue J, et al. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. Journal of Clinical Pharmacology 1993;33:912-7. | 8227460 |
| 3524 | Kobayashi M, Chinen M, Hirano A, et al. Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis. J Antimicrob Chemother 2021;76:1370-2. | 33491079 |
| 802 | Koda RT, Dube MP, Li WY, et al. Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia. Journal of Clinical Pharmacology 1999;39(3):268-74. | 10073326 |
| 3327 | Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011;91:852-8. | 21403643 |
| 1108 | Koks CH, van Heeswijk RP, Veldkamp AI, et al. Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir. AIDS 2000;14(1):89-90. | 10714572 |
| 768 | Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nature Medicine 1998;4(8):953-6. | 9701250 |
| 3679 | Konishi H, Takenaka A, Minouchi T, Yamaji A. Impairment of CYP3A4 capacity in patients receiving danazol therapy: examination on oxidative cortisol metabolism. Horm Metab Res 2001;33:628-30. | 11607885 |
| 1443 | Koo HL, Hamill RJ, Andrade RA. Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis Clinical Infectious Diseases 2007;45:e77-79. | 17712747 |
| 10 | Koopmans PP, van der Ven A, Vree TB, et al. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? AIDS 1995;9:217-22. | 7755908 |
| 433 | Koopmans PP, van der Ven AJ, Vree TB, et al. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? [editorial]. Aids 1995;9(3):217-22. | 7755908 |
| 845 | Kornhauser DM, Petty BG, Hendrix CW, et al. Probenecid and zidovudine metabolism. Lancet 1989;2(8661):473-5. | 2570186 |
| 2634 | Kosel B, Storey SS, Collier AC. Lack of interaction between atazanavir and lansoprazole. AIDS 2005;19(6):637-8. | 15802988 |
| 2722 | Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002;16:543-50. | |
| 853 | Koshida R, Vrang L, Gilljam G, et al. Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet. Antimicrobial Agents & Chemotherapy 1989;33(5):778-80. | 2526616 |
| 2849 | Kosloski M, Zhao W, Li H, et al. Drug-drug interactions of glecaprevir and pibrentasvir with pravastatin, rosuvastatin, or dabigatran etexilate [abstract O_18]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy. June 14-16, 2017, Chicago, IL. | |
| 3424 | Kosloski MP, Oberoi R, Wang S, et al. Drug-drug Interactions of glecaprevir and pibrentasvir coadministered with human immunodeficiency virus antiretrovirals. J Infect Dis 2020; 221: 223-31. | 31504702 |
| 756 | Kosmyna JM, MacArthur RD. The incidence and severity of diarrhea in HIV+ patients from a large, urban medical center who have taken nelfinavir in the past twelve months [abstract 12392]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 1304 | Koss Pharmaceuticals Inc. Niaspan (niacin extended release tablets) Prescribing Information. Miami, FL 2003. | |
| 1801 | Koth R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman’s disease. Eur J Haematol 2006;76(3):269-71. | 16451402 |
| 2971 | Kovari H et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009;49: 626-35. | 19589079 |
| 1912 | Kozal MJ, Lupo S, DeJesus E, et al. The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300mg BID plus raltegravir (RAL) 400mg BID (ATV+RAL) in treatment-naive HIV-infected subjects [abstract THLBB204]. 18th International AIDS Conference, July 18-23, 2010, Vienna, Austria. | |
| 2304 | Kraft K, Martin D, Streepey D, et al. Telaprevir interferes with levothyroxine treatment of hypothyroidism [abstract 1845]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston. | |
| 2003 | Krakower D, Kwan CK, Yassa DS, et al. iAIDS: HIV-related internet resources for the practicing clinician. Clin Infect Dis 2010;51(7):813–22. | 20738185 |
| 2225 | Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomized, double-blind, placebo-controlled study. Gut 2008;57(4):531-6. | 18079286 |
| 124 | Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV+ patients. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 2544 | Kredo T, et al. The interaction between lopinavir/ritonavir and artemether-lumefantrine in HIV+ patients [abstract 613]. 19th Conference on Retroviruses and Opportunistic Infections, 2012, Seattle, WA. | |
| 2539 | Kredo T, Mauff K, Van der Walt JS, et al. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrobial agents and chemotherapy 2011 Dec;55(12):5616-23. | 21947399 |
| 3478 | Kreitchman R, Best B, Wang J, et al. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquir Immune Defic Syndr 2013;63(1):59-66. | 23392467 |
| 2908 | Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts D et al. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. JAIDS 2013;63:59-66. | 23392467 |
| 2229 | Kreitchmann R, Innocente AP, Preussler GM. Safety and efficacy of contraceptive implants for HIV-infected women in Porto Alegre, Brazil. Int J Gynaecol Obstet 2012;117(1):81-2. | 22249127 |
| 2926 | Kreitchmann R, Stek A, Best B, et al. INTERACTION BETWEEN ETONOGESTREL-RELEASING IMPLANT AND 3 ANTIRETROVIRAL REGIMENS [abstract 938]. Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle, WA. | http://www.croiconference.org/sites/default/files/posters-2017/938_Kreitchmann.pdf |
| 1626 | Krishna G, Moton a, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009;51:437-44. | 19623694 |
| 2780 | Krishna R, Bergman A, Larson P, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol. 2007 Feb;47(2):165-74. | 17244767 |
| 3121 | Krishna R, East L, Larson P, et al. Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir. Biopharm Drug Dispos 2016;37:542-9. | 27704562 |
| 2834 | Krishna R, East L, Larson P, et al. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. J Pharm Pharmacol 2016;68(11):1359-65. | 27671833 |
| 3322 | Krogstad P, Samson P, Acosta E, et al. Pharmacokinetics of raltegravir in HIV/TB cotreated infants and young children [abstract 846]. Conference on Retroviruses and Opportunistic Infections (CROI), March 8-11, 2020. Boston, MA. | http://www.croiconference.org/sessions/pharmacokinetics-raltegravir-hivtb-cotreated-infants-and-young-children |
| 3023 | Kruijtzer CMF, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein Inhibitor GF120918. J Clin Oncol 2002;20:2943-50. | 12089223 |
| 1307 | Kruse G, Esser S, Stocker H, et al. Tenofovir does not Impair the pharmacokinetics of nelfinavir in HIV-infected patients [A-446]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC. | |
| 1291 | Kruse G, Stocker H, Breske A, et al. Trough levels of six different atazanavir regimens in HIV-infected patients [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 206 | Kucers A, McBennett N. The use of antibiotics: a comprehensive review with clinical emphasis. 4th ed. Philadelphia: J B Lippincott; 1987. | |
| 2242 | Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51(2):188-215. | 8808163 |
| 2478 | Kumar P, Gordon LA, Brooks KM, et al. Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport and the pharmacokinetic/pharmacodynamic disposition of dabigatran. Antimicrob Agents Chemother 2017;61:e01201-17. | 28848011 |
| 799 | Kumar PN, Sweet DE, McDowell JA, et al. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults [In Process Citation]. Antimicrob Agents Chemother 1999;43(3):603-8. | 10049274 |
| 624 | Kumar PN, Tamari M, Rich W, et al. A prospective, randomized, parallel-group, single-center, phase II study comparing the safety and efficacy of 10/5, 10/10, and 15/15 mg/kg/day ganciclovir induction/maintenance therapy with filgrastim support in delaying or preventing the progression of CMV retinitis in patients with AIDS [abstract H-59b]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 2286 | Kunze A, Huwyler J, Camenisch G, et al. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochemical Pharmacology 2012;84:1096-102. | 22902721 |
| 634 | Kupferschmidt HHT, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. British Journal of Clinical Pharmacology 1998;45(4):355-9. | 9578182 |
| 494 | Kuppermann BD, Assil KK, Vuong C, et al. Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for long-acting therapy of viral retinitis. Journal of Infectious Diseases 1996;173(1):18-23. | 8537656 |
| 563 | Kuppermann BD, Flores-Aguilar M, Quiceno JI, et al. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Archives of Ophthalmology 1993;111(10):1359-66. | 8216016 |
| 424 | Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. Journal of Infectious Diseases 1993;168(6):1506-9. | 8245536 |
| 1061 | Kurowski M, Arslan A, Arasteh K, et al. Comparative pharmacokinetics of twice daily Fortovase/ritonavir and Invirase/ritonavir [abstract 3.2]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4, 2001, Noordwijk, the Netherlands. | |
| 972 | Kurowski M, Kaeser B, Sawyer A, et al. Low-dose ritonavir moderately enhances nelfinavir exposure. Clinical Pharmacology and Therapeutics 2002;72:123-32. | 12189359 |
| 1098 | Kurowski M, Sternfeld T, Sawyer A, et al. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med. 2003 Apr;4(2):94-100. | 12702129 |
| 1383 | Kurowski M, Walli R, Breske A, et al. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. AIDS 2007;21(10):1368-70. | 17545717 |
| 2407 | Kurz M, Stoeckle M, Krasniqi F, et al. Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma. Int J STD AIDS 2014 May 8. | 24810214 |
| 2103 | Kwo PJ, Ghabril M, Lacerda M, et al. Use of telaprevir plus peg interferon/ribavirin for null responders post OLT with advanced fibrosis/cholestatic hepatitis C [abstract 202]. 47th Annual Meeting of the European Association for the Study of the Liver, April 18-22nd, 2012, Barcelona. | |
| 2429 | Kwo PJ, Mantry PS, Coakley E, et al. Results of the phase 2 study M12-999: interferon-free regimen of ABT-450/r/ABT-267 + ABT-333 + ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection [abstract O114]. 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, England. | |
| 2143 | L'homme RF, Dijkema T, van der Ven AJ, et al. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. J Acq Immune Def Syndr Hum Retr 2006;43(2):193-6. | 16940857 |
| 1489 | La Porte CJL, Back DJ, Blaschke T, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006;3:4-14. | |
| 1414 | La Porte CJL, Cameron DW, Sabo J, et al. The effect of omeprazole, food and formulation on the pharmacokinetics of tipranavir administered with ritonavir [abstract 59]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2007, Budapest, Hungary. | |
| 1168 | La Porte CJL, Colbers EPH, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrobial Agents and Chemotherapy 2004;48:1553-60. | 15105105 |
| 1439 | La Porte CJL, Sabo J, Beique LC, et al. Lack of effect of efavirenz on the pharmacokinetics of tipranavir/ritonavir in healthy volunteers. Antimicrob Agents Chemother 2009;53(11):4840-44. | 19721063 |
| 1562 | La Porte CJL, Sabo JP, Elgadi M, et al. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. Antimicrob Agents Chemother 2009;53(1):162-73. | 19015362 |
| 600 | Lacey HB, Ness A, Mandal BK. Vulval ulceration associated with foscarnet. Genitourinary Medicine 1992;68:182. | 1535062 |
| 1251 | Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.[see comment]. Lancet 2001;357(9252):280-1. | 11214134 |
| 3673 | Lagoutte-Renosi J, Karsenty J, Martha B et al. Management of a drug–drug interaction between BRAF inhibitors and combined antiretroviral therapy in a HIV-infected patient with craniopharyngioma. AIDS 2023;37:1181-3. | 37139656 |
| 2481 | Lakatos B, Stoeckle M, Elzi L, et al. Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. Swiss medical weekly 2014;144:w13906. | 24452338 |
| 1070 | Lake KD. Management of drug interactions with cyclosporine. Pharmacotherapy 1991;11:110S-18S. | 1745616 |
| 11 | Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 1988;109:471-3. | 3415107 |
| 1982 | Lakhi N, Govind A. Implanon® failure in patients on antiretroviral medication: the importance of disclosure. J Fam Plann Reprod Health Care 2010;36(3):181. | 20659385 |
| 947 | Lal R, Hsu A, Bertz R, et al. Evaluation of the pharmacokinetics of the concurrent administration of ABT-378/ritonavir and nevirapine [abstract 782]. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, October 23-27, 1999, Lisbon, Portugal. | |
| 3303 | Lalanne S, Jézéquel C, Tron C, et al. Therapeutic drug monitoring-guided crushed sofosbuvir-velpatasvir treatment: a case study. Ther Drug Monit 2020;42:163-4. | 31809407 |
| 630 | Lalezari J, Drew W, Jordan C, et al. In vivo anti-CMV activity and safety of oral lobucavir in HIV-infected patients [abstr. 301]. 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 631 | Lalezari J, Friedberg D, Bisset J, et al. A comparison of the safety and efficacy of 3g, 4.5g, and 6g doses of oral ganciclovir versus IV ganciclovir for maintenance treatment of CMV retinitis [abstr. Th.B.305]. XI International Conference on AIDS, July 7-12, 1996, Vancouver. | |
| 252 | Lalezari J, Haubrich R, Burger HU, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase) plus HIVID (zalcitabine, ddC) [abst. LB.B.6033]. XI International Conference on AIDS, July 7-12, 1996, Vancouver. | |
| 2365 | Lalezari J, Sullivan J, Rustgi V, et al. Abbvie IFN-free 3 DAA regimen in HCV genotype 1-infected patients on methadone or buprenorphine [abstract 662LB]. 21st Annual Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014, Boston, MA. | http://www.croiconference.org/sessions/ifn-free-3-daa-regimen-hcv-genotype-1-infected-patients-methadone-or-buprenorphine |
| 628 | Lalezari JP, Aberg JA, Wang LH, et al. In vivo anti-CMV activity, safety and pharmacokinetics of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding [abstract 762]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 490 | Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. Journal of Infectious Diseases 1995;171(4):788-96. | 7706804 |
| 493 | Lalezari JP, Kuppermann BD. Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1997;14(Suppl 1):S27-31. | 9058615 |
| 484 | Lalezari JP, Stagg RJ, Jaffe HS, et al. A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC). Advances in Experimental Medicine & Biology 1996;394:105-15. | 8815677 |
| 389 | Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Annals of Internal Medicine 1997;126(4):257-63. | 9036797 |
| 1888 | Lalezeri J, DeJesus E, Osiyemi O, et al. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV-1 infected adults [abstract 0413]. 9th International Congress on Drug Therapy in HIV Infection (HIV9), November 9-13, 2008, Glasgow, UK. | |
| 3299 | Lalley-Chareczko L, Clark D, Zuppa AF, et al. A case study of chewed Truvada® for PrEP maintaining protective drug levels as measured by a novel urine tenofovir assay. Antivir Ther 2017;22(7):639-641. | 28260694 |
| 3418 | Lam E, Schaefer J, Zheng R, et al. Twice-daily doravirine overcomes the interaction effect from once-weekly rifapentine and isoniazid in healthy volunteers. Clin Transl Sci 2020; May 14 n | 32407548 |
| 1739 | Lamb HM, Adkins JC. Letrozole: a review of its use in postmenopausal women with advanced breast cancer. Drugs 1998;56:1125-40. | 9878997 |
| 2909 | Lambert J, Jackson V, Lawless M, Ferguson W, Eogan M, Brennan M, et al. Transplacental passage of atazanavir and neonatal hyperbilirubinemia [abstract P_16]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | http://www.thebodypro.com/content/71686/transplacental-transfer-of-atazanavir-and-neonatal.html |
| 991 | Lamotte C, Peytavin G, Perre P, et al. Increasing adverse events with indinavir dosages and plasma concentrations in four different ritonavir-indinavir containing regimens in HIV-infected patients [abstract 738]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago IL. | |
| 136 | Lamson M, Gagnier P, Greguski R, et al. Effect of nevirapine (NVP) on pharmacokinetics (PK) of ritonavir (RTV) in HIV-1 patients. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 709 | Lamson M, Robinson P, Gigliotti M, et al. The pharmacokinetic interactions of nevirapine and ketoconazole [abstract 12218]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 1130 | Landau A, Batisse D, Piketty C, et al. Lack of interference between ribavirin and nucleoside analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS 2000;14(12):1857-8. | 10985327 |
| 330 | Landers MB, 3rd, Fraser VJ. Antiviral chemoprophylaxis after occupational exposure to human immunodeficiency virus: why, when, where, and what [see comments]. American Journal of Ophthalmology 1997;124(2):234-9. | 9262549 |
| 2270 | Landolt NK, Phanuphak N, Ubolyam S, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when co-administered with combined oral contraceptives. J Acquir Immune Defic Syndr 2013;62:534–39. | 23187949 |
| 2405 | Landolt NK, Phanuphak N, Ubolyam S, et al. Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women. J Acquir Immune Defic Syndr 2014 Jun 1;66(2):e50-2. | 24608892 |
| 122 | Lange D, Hardin J, Heykants J, et al. The effect of co-administration of a cola beverage on the bioavailability of itraconazole in AIDS patients [abstr]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco. | |
| 2552 | Langmann P, Schirmer D, Zilly M, et al. Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. Medical science monitor : international medical journal of experimental and clinical research 2004 May;10(5):Pi65-9. | 15114280 |
| 2331 | Langness JA, Johnson S, Everson G, et al. Identification and management of potential drug-drug interactions with boceprevir and telaprevir [abstract O_17_PK]. 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 26-27, 2013, Cambridge, MA. | |
| 2734 | Lanzafame M, Trevenzoli M, Faggian F, et al. Interaction between levothyroxine and indinavir in a patient with HIV infection. Infection 2002;30:54-5. | 11876520 |
| 274 | Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269(5224):696-9. | 7542804 |
| 3256 | Larkin JG, McKee PJ, Forrest G, et al. Lack of enzyme induction with oxcarbazepine (600mg daily) in healthy subjects. Br J Clin Pharmacol 1991;31:65-71. | 2015172 |
| 529 | Laskin OL, Cederberg DM, Mills J, et al. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. American Journal of Medicine 1987;83(2):201-7. | 3039841 |
| 895 | Laskin OL, de Miranda P, King DH, et al. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrobial Agents & Chemotherapy 1982;21(5):804-7. | 7103460 |
| 530 | Laskin OL, Stahl-Bayliss CM, Kalman CM, et al. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. Journal of Infectious Diseases 1987;155(2):323-7. | 3027195 |
| 3350 | Lau E, Brophy J, Samson L et al. Nevirapine pharmacokinetics and safety in neonates receiving combination antiretroviral therapy for prevention of vertical transmission. JAIDS 2017; 74(5):493-98. | 28114187 |
| 1938 | Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008;13(7):953-7. | 19043930 |
| 200 | Lavrijsen K, van't Klooster G, Heykants J. The role of CYP3A4 in the in-vitro metabolism of cisapride in human liver microsomes and in-vitro and in-vivo interactions of cisapride with co-administered drugs. Pharmacogenetics Conference, May 4-5, 1995, Bethesda MD. | |
| 1595 | Lavrut T, Garraffo R, Ferrando S, et al. Effect of tipranavir/ritonavir treatment on the steady-state pharmacokinetics of bupropion in healthy volunteers [abstract P4.3/03]. 11th European AIDS Conference/EACS, October 24-27, 2007, Madrid, Spain. | |
| 2301 | Lawitz E, Rodriguez-Torres M, Cornpropst M, et al. The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days [abstract 1130]. 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22, 2012, Barcelona, Spain. | |
| 3132 | Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 57: 24-31. | 22314425 |
| 2438 | Lawson EB, Martin H, McCallister S, et al. Drug interactions between tenofovir alafenamide and HIV antiretroviral agents [abstract H-1012]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, 2014, Washington, DC. | |
| 63 | Lazar JD, Wilner KD. Drug interactions with fluconazole. Reviews of Infectious Diseases 1990;12(suppl 3):S327-33. | 2330488 |
| 1533 | Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24 week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48. | 17617271 |
| 3141 | Le LH, Moore MJ, Siu LL, et al. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 2005;56:154-60. | 15809877 |
| 2275 | Le MP, Gervais A, Le Beller C, et al. Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir. J Antimicrob Chemother 2013;[epub ahead of print, January 13]. | 23335198 |
| 3477 | Le MP, Mandelbrot L, Descamps D, et al. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1 infected pregnant women. Antivir Ther 2015;20(5):507-13. | 25599649 |
| 740 | Leader WG, Chandler MH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clinical Pharmacokinetics 1995;28(4):327-42. | 7648760 |
| 724 | Leake H, Fisher M, Eipe SA, et al. Maximising the benefits of HAART in the real world: The role of a pharmacist-led antiRetroviral clinic [abstract 60621]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 1707 | Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001;51:443-50. | 11422002 |
| 1427 | Lechelt M, Hull E, Leake-Date H, et al. Analysis of plasma lopinavir levels when Kaletra (lopinavir 400 mg/ritonavir 100 mg) tablets are administered with and without a non-nucleoside reverse transcriptase inhibitor [abstract 71]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2007, Budapest, Hungary. | |
| 3343 | Leden I. Digoxin-hydroxychloroquine interaction? Acta Med Scand 1982;211:411-2. | 7113754 |
| 113 | Lee BL, Medina I, Benowitz NL, et al. Dapsone, trimethoprim and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with acquired immunodeficiency syndrome: evidence of drug interactions. Annals of Internal Medicine 1989;110:606-11. | 2784648 |
| 1015 | Lee BL, Safrin S, Makrides V, et al. Zidovudine, trimethoprim and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 1996;40:1231-6. | 8723472 |
| 46 | Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clinical Infectious Diseases 1992;14:773-9. | 1314104 |
| 879 | Lee BL, Tauber MG, Chambers HF, et al. The effect of zalcitabine on the pharmacokinetics of isoniazid in HIV-infected patients [abstract A4]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 4-7, 1994, New Orleans. | |
| 40 | Lee BL, Tauber MG, Sadler B, et al. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clinical Pharmacology and Therapeutics 1996;59:14-21. | 8549029 |
| 181 | Lee BL, Tuber MG, Chambers HR, et al. The effect of trimethoprim on the pharmacokinetics of zalcitabine in HIV-infected patients [abstr]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco. | |
| 128 | Lee CA, Liang BH, Wu EY, et al. Prediction of nelfinavir mesylate (VIRACEPT) clinical drug interactions based on in vitro human P450 metabolism studies. 4th National Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 834 | Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37(11):3594-601. | 9530286 |
| 1747 | Lee FY, Workman P, Roberts JT, et al. Clinical pharmacokinetics of oral CCNU (lomustine). Cancer Chemother Pharmacol 1985;14:125-31. | 3971475 |
| 2019 | Lee JE, Van Heeswijk RPG, Alves K, et al. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011;55(10):4569-74. | 21825288 |
| 2144 | Lee K, Vivithanaporn P, Siemieniuk RA, et al. Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS. BMC Neurol 2010;10:44. | 20565780 |
| 1896 | Lee L, Soon GH, Shen P, et al. Effect of efavirenz and darunavir/ritonavir on bilirubin levels in healthy adult volunteers: role of induction of UGT1A1 and bile efflux transporters [abstract 27]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7, 2010, Sorrento, Italy. | |
| 2094 | Lee LS, Hee KH, Yao Z, et al. Induction and inhibition of raltegravir metabolism in healthy volunteers [abstract P_07]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 2671 | Lee LS, Pham P, Flexner C. Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz. Ann Acad Med Singapore. 2012 Dec;41(12):559-62. | |
| 1353 | Lee SI, Klesmer J, Hirsch BE. Neuroleptic malignant syndrome associated with the use or risperidone, ritonavir and indinavir: a case report. Psychosomatics 2000;41:453-4. | 11015640 |
| 3642 | Leegwater E, Strik A, Wilms EB et al. Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors. Clin Infect Dis . 2021 Apr 8;72(7):1256-1258. | 32594120 |
| 2344 | Lefebevre E, Enejosa J, Chang W, et al. Pharmacokinetic interactions between cenicriviroc and darunavir/ritonavir [abstract PE10/9]. 14th European AIDS Conference (EACS), October 16-19, 2013, Brussels, Belgium. | |
| 2345 | Lefebevre E, Enejosa J, Chang W, et al. Pharmacokinetic interactions between cenicriviroc and dolutegravir [abstract PE10/8]. 14th European AIDS Conference (EACS), October 16-19, 2013, Brussels, Belgium. | |
| 2296 | Lefebevre E, Enejosa J, Chang W, et al. Pharmacokinetic interactions between cenicriviroc and efavirenz [abstract O_09B]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | |
| 2297 | Lefebevre E, Enejosa J, Chang W, et al. Pharmacokinetics of cenicriviroc when administered with and without ritonavir, darunavir/ritonavir or atazanavir/ritonavir [abstract O_09A]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | |
| 1396 | Lefebvre T, Foster BC, Drouin CE, et al. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 2004;7(2):265-73. | 15367385 |
| 260 | Lefort A, Launay O, Carbon C. Uveitis associated with rifabutin prophylaxis and itraconazole therapy [letter]. Annals of Internal Medicine 1996;125(11):939-40. | 8967681 |
| 504 | Lehoang P, Girard B, Robinet M, et al. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1989;96(6):865-73; discussion 73-4. | 2544840 |
| 1368 | Leitz G, Lamson M, Lionetti D, et al. Nevirapine/lamivudine drug-drug interaction study in HIV infected patients [abstract 12217]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 45 | LeLacheur SF, Simon GL. Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine. Journal of the Acquired Immune Deficiency Syndrome 1991;4:538-9. | 1849990 |
| 72 | Lelawongs P, Barone JA, Colaizzi JL, et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988;7:228-35. | 3356120 |
| 2949 | Lentendre S et al. Darunavir concentrations in CSF exceed the median inhibitory concentration [abstract A1-1312]. 49th ICAAC, September 12-15, 2009, San Francisco. | |
| 598 | Lernestedt JO, Chanas AC. Penile ulcerations with foscarnet [letter]. Lancet 1990;335:548. | |
| 1692 | LeRoy AF, Lutz RJ, Dedrick RL, et al. Pharmacokinetic study of cis-diamminedichloroplatinum (II) (DDP) in the beagle dog: thermodynamic and kinetic behaviour of DDP in a biologic milieu. Cancer Treat Rep 1979;63:59-71. | 421234 |
| 1024 | Lertora JJ, Rege AB, Greenspan DL, et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clinical Pharmacology and Therapeutics 1994;56:272-8. | 7924122 |
| 2883 | Letendre S, Best B, Rossi S, Way L, Grant I, Ellis R, et al. Therapeutic amprenavir and abacavir concentrations in CSF from the same individuals [abstract P_18]. 10 International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, the Netherlands, April 15-17, 2009. | |
| 2884 | Letendre SL, Ellis RJ, Ances BM, et al. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010;18(2):45–55. | 20516524 |
| 2135 | Leticee N, Viard JP, Yamgnane A, et al. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception 2012;85(4):425-7. | 22036046 |
| 217 | Leventhal H, Cameron L. Behavioral theories and the problem of compliance. Patient Education and Counseling 1987;10:117-38. | |
| 216 | Leventhal H, Safer MA, Panagis DM. The impact of communications on the self-regulation of health beliefs, decisions and behavior. Health Education Quarterly 1983;10:3-29. | 6629788 |
| 1832 | Levêque D, Santucci R, Pavillet J, et al. Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine. Pharm World Sci 2009;31(6):619-21. | 19757141 |
| 2214 | Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70. | 10075613 |
| 907 | Levin GM, Nelson LA, DeVane CL, et al. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull 2001;35(2):62-71. | 12397887 |
| 2464 | Lewis J, Turtle L, Khoo S, et al. A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops. AIDS 2014;28(17):2636-7. | 25574967 |
| 863 | Lewis RE, Lund BC, Klepser ME, et al. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrobial Agents & Chemotherapy 1998;42(6):1382-6. | 9624480 |
| 1031 | Li RC, Narang' PK, Sahai J, et al. Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients. Antimicrobial Agents and Chemotherapy 1997;41(7):1566-70. | 9210686 |
| 1154 | Li Y, Wang X, Tian S, et al. Methadone enhances human immunodeficiency virus infection of human immune cells. Journal of Infectious Diseases 2002;185(1):118-22. | 11756991 |
| 906 | Liang D, Breaux K, Nornoo A, et al. Pharmacokinetic interaction between didanosine (ddI) and allopurinol in healthy volunteers [abstract 662]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-28, 1999, San Francisco, CA. | |
| 1083 | Liang D, Breaux K, Rodriguez-Barradas M, et al. Allopurinol increases didanosine absorption in HIV-infected patients [abstract A498]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 1228 | Lichtenstein K, Clumeck N, Bellos N, et al. Improvement in lipid levels in antiretroviral-experienced 119 HIV-infected patients who are failing therapy and are switched to an atazanavir-containing regimen [abstract 119]. Antiviral Therapy 2003;8(4):L79-80. | |
| 3676 | Liddle C, Goodwin BJ, George J et al. Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab 1998;83:2411-6. | 9661620 |
| 400 | Lieberman RM, Orellana J, Melton RC. Efficacy of intravitreal foscarnet in a patient with AIDS [letter]. New England Journal of Medicine 1994;330(12):868-9. | 8114855 |
| 480 | Lieberman RM, Orellana J. Safety and efficacy of fomivirsen sodium (ISIS 2922) for CMV retinitis in AIDS patients [abstract 308]. 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 1993 | Liedtke MD, Rathbun RC. Drug interactions with antiretrovirals and warfarin. Expert Opin Drug Saf 2010;9(2):215-23. | 20095918 |
| 2219 | Liedtke MD, Vanguri A, Rathbun RC. A probable interaction between warfarin and the antiretroviral TRIO study regimen. Ann Pharmacother 2012;epub October 31. | 23115227 |
| 1347 | Lietke MD, Lockhart SM, Rathbun RC. Anticonvulsant and antiretroviral interactions. Annals of Pharmacotherapy 2004;38:482-9. | 14970370 |
| 2129 | Lilly. Prasugrel (Effient) Product Monograph. Toronto, ON. September 20, 2011. | |
| 3010 | Lilly. Trulicity (dulaglutide) Product Monograph. Toronto, ON. June 15, 2017. | |
| 811 | Lim JI, Wolitz RA, Dowling AH, et al. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. American Journal of Opthalmology 1999;127(3):288-93. | 10088738 |
| 2160 | Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acq Immune Def Syndr 2004;36(5):1034-40. | 15247556 |
| 1890 | Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009;50:529-36. | 19223785 |
| 3692 | Lin KY, Sun HY, Yang CJ, et al. Short-course rifapentine-based regimens for latent tuberculosis injection among people living with HIV who received integrase inhibitor-based antiretroviral therapy. IAS 2023 Conference, Brisbane, Australia. July 23-26, 2023. | https://programme.ias2023.org/Abstract/Abstract/?abstractid=3454 |
| 3550 | Lin KY, Yang CJ, Sun HY, et al. Screening and short-course treatment for latent tuberculosis infection among people living with HIV who received integrase inhibitor-based antiretroviral therapy [abstract PE3/58]. 18th European AIDS Conference, October 27-30, 2021, online and London, UK. | https://eacs2021.abstractserver.com/program/#/details/presentations/335 |
| 2260 | Lin WH, Feng H-P, Chatterjee M, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and ethinyl estradiol/norethindrone [abstract 1901]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases, November 9-13, 2012, Boston, MA. | |
| 3301 | Lindholm DA, Calvano TP, Minidis NM, et al.Treatment challenges for inflammatory demyelinating polyneuropathy in the setting of acute retroviral syndrome: Case report and review of the literature. J AIDS Clin Res 2013;4(12):1-7. | https://pdfs.semanticscholar.org/530f/6095c63ddf7c99f879192418cddd2a8fef3b.pdf |
| 106 | Linville T, Matanin D. Norfloxacin and warfarin [letter]. Annals of Internal Medicine 1989;110:751-2. | 2930115 |
| 3636 | Liou BH, Cheng CN, Lin YT, et al. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. J Int AIDS Soc 2021; Nov 24(11):e25844 | 34822220 |
| 2168 | Littlewood RA, Vanable PA. Complementary and alternative medicine use among HIV-positive people: research synthesis and implications for HIV care. AIDS Care 2008;20(8):1002 - 18. | 18608078 |
| 1480 | Liu P, Foster G, Gandelman K, et al. Steady state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrobial Agents and Chemotherapy 2007;51(10):3617-26. | 17646413 |
| 1862 | Liu P, Foster G, LaBadie RR, et al. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008;48(1):73-84. | 18025525 |
| 2217 | Liverpool HIV Pharmacology Group. HIV drug interactions database [database on the Internet]2012 [cited September 1, 2012]. Available from: http://www.hiv-druginteractions.org/Interactions.aspx. | |
| 1983 | Llibre JM, Romeu J, Lopez E, et al. Severe interaction between ritonavir and acenocoumarol. Ann Pharmacother 2002;36:621-3. | 11918509 |
| 1505 | Loebstein R, Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monitor 2002;24:15-22. | 11805716 |
| 755 | Lohmeyer J, Selhorst J, Friese G, et al. Combined nelfinavir/saquinavir protease inhibitor treatment in a BID regimen as salvage therapy in advanced HIV disease [abstract 12303]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 839 | Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Annals of Pharmacotherapy 1998;32:915-28. | 9762380 |
| 1733 | Lonning PE, Geisler J, Johannessen DC, et al. Pharmacokinetics and metabolism of formestane in breast cancer patients. J Steroid Biochem Mol Biol 2001;77:39-47. | 11358673 |
| 2245 | Lopez LM, Grimes DA, Schulz KF, et al. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev 2011;6(7). | 21735401 |
| 1102 | López-Cortés LF, Viciana P, Ruiz-Valderas R, et al. Pharmacokinetics, efficacy, and safety of once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz in HIV-pretreated patients [abstract 441-W]. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA. | |
| 741 | Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study. Aids 1997;11(12):F95-9. | 9342060 |
| 441 | Lori F, Jessen H, Clerici M, et al. Consistent, sustained HIV suppression without rebound by hydroxyurea, ddI and a protease inhibitor prevents loss of immunologic functions [abstr. 655]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 444 | Lori F, Jessen H, Clerici M, et al. Drugs suppressing HIV replication and cell proliferation decrease proviral DNA to undetectable levels [abstr. LB-11]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 2696 | Louie M, al. E. Factors increasing the risk of renal dysfunction with tenofovir difumarate [abstract TePe3.5B01]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, July 24-27, 2005, Rio de Janeiro | |
| 2695 | Louie M, al. E. Multidrug resistance protein 2 (MRP2) inhibition by ritonavir increases tenofovir-associated renal epithelial cell cytotoxicity [abstract WePe3.3C09]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment July 24-27, 2005, Rio de Janeiro. | |
| 2011 | Loulergue P, Gaillard R, Mir O. Interaction involving tadalafil and CYP3A4 inhibition by ritonavir. Scand J Infect Dis 2011;43(3):239-40. | 20942777 |
| 3024 | Loulergue P, Merad M, Coriat R, et al. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. Invest New Drugs 2017;35:247-9. | 27838867 |
| 1475 | Loulergue P, Mir O, Allali J, et al. Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma. AIDS 2008;22(10):1237-8. | 18525276 |
| 2235 | Loutfy M, Margolese S, Money DM, et al. Canadian HIV pregnancy planning guidelines. J Obstet Gynaecol Can 2012;34(6):575-90. | 22673174 |
| 1848 | Loutfy M, Ribera E, Florence E, et al. Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. J Antimicrob Chemother 2009;64(6):1341-4. | 19828488 |
| 1700 | Loveless H, Arena E, Felsted RL, et al. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 1978;38:593-8. | 626965 |
| 728 | Loveless M, Harris W, Sacks S. Treatment of first episode genital herpes with famciclovir [abst]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco. | |
| 1702 | Lown JW, Chen HH. Electron paramagnetic resonance characterization and conformation of daunorubicin semiquinone intermediate implicated in anthracycline metabolism, cardiotoxicity, and anticancer action. Can J Chem 1981;59:3212-7. | |
| 3363 | Lozano AB, Chueca N, de Salazar A, et al. Failure to Biktarvy® and development of resistance mutations in an antiretroviral-experienced patient. Antiviral Res 2020 Jul;179:104717. | https://pubmed.ncbi.nlm.nih.gov/31982483/ |
| 1819 | Lu C, Gallegos R, Li P, et al. Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos 2006;34:702-8. | 16443666 |
| 1447 | Luber A, Brower R, Kim D, et al. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Medicine 2007;8(7):457-64. | 17760738 |
| 1567 | Luber A, Condoluci D, Slowinski PD, et al. Steady-state pharmacokinetics of maraviroc and amprenavir alone and in combination after maraviroc is given BID with unboosted or ritonavir-boosted fosamprenavir once- or twice-daily in fasted healthy volunteers [abstract P_31]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam, the Netherlands. | |
| 1665 | Luber A, Slowinski D, Acosta E, et al. Steady-state pharmacokinetics of fosamprenavir and raltegravir alone and combined with unboosted and ritonavir-boosted fosamprenavir [abstract A1-1297]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco. | |
| 1884 | Luber AD, Condoluci DV, Slowinski PD, et al. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. HIV Med 2010;11(3):193-9. | 19863619 |
| 358 | Luber AD, Flaherty JF, Jr. Famciclovir for treatment of herpesvirus infections. Annals of Pharmacotherapy 1996;30(9):978-85. | 8876860 |
| 416 | Luckie A, Ai E. Sustained-release intravitreal ganciclovir pellets in the treatment of cytomegalovirus retinitis in the acquired immunodeficiency syndrome [letter]. Australian & New Zealand Journal of Ophthalmology 1995;23(2):157-8. | 7546694 |
| 2732 | Luder PJ, Siffert B, Witassek F, Meister F, Bircher J. Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions. Eur J Clin Pharmacol. 1986;31(4):443-8. | 3816925 |
| 1621 | Lundbeck Canada I. Celexa (citalopram) Product Monograph. Montreal, QC. July 8, 2016. | http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Celexa.pdf |
| 1622 | Lundbeck Canada I. Cipralex (escitalopram) Product Monograph. Montreal, QC. July 8, 2016. | http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Cipralex.pdf |
| 3117 | Lundbeck Canada Inc. Trintellix (vortioxetine) Product Monograph. St-Laurent, QC. July 8, 2016. | |
| 1750 | Lundbeck Inc. Product monograph. Mustargen (mechlorethamine). Deerfield, IL September 11, 2009. | http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/06695slr031_mustargen_lbl.pdf |
| 3597 | Lundbeck. Clopixol (zuclopenthixol) Prescribing Information. St-Laurent, QC. October 2020. | https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/clopixol_product_monograph_english.pdf |
| 2059 | Luo X, Trevejo J, Van Heeswijk RPG, et al. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob Agents Chemother 2012;56(7):3641-7. | 22564847 |
| 2016 | Luo X, Van Heeswijk RPG, Alves K, et al. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers [abstract PK_11]. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 22-23, 2011, Cambridge, MA. | |
| 3346 | Lupin Pharma Canada Ltd. Zaxine (rifaximin) Product Monograph. Montreal, QC. February 11, 2019. | |
| 2371 | Luque AE, Cohn SE, Park J-G, et al. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. Antimicrob Agents Chemother. 2015 Apr;59(4):2094-101. | 25624326 |
| 2845 | Lutz J, Kirby B, Massetto B, et al. CYP3A induction data can predict other P450 and drug transporter DDI liability: An example of carbamazepine and rifabutin with sofosbuvir and P-gp [abstract O_13]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL. | http://regist2.virology-education.com/Abstractbook/2017_5.pdf |
| 451 | Luzzati R, Di Perri G, Fendt D, et al. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine. J Antimicrob Chemother. 1998 Oct;42(4):565-6. | 9818769 |
| 715 | Lyketsos CG, Hutton H, Fishman M, et al. Psychiatric morbidity on entry to an HIV primary care clinic. AIDS 1996;10(9):1033-9. | 8853738 |
| 2045 | Ma A, Chen DM, Chau FM, et al. Improving adherence and clinical outcomes through an HIV pharmacist's interventions. AIDS Care 2010;22(10):1189-94. | 20640958 |
| 1667 | Ma Q, Fehintola F, Zingman B, et al. Tobacco and marijuana uses significantly decrease atazanavir trough concentrations in HIV-infected individuals [H-231]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco. | |
| 2913 | Ma Q, Forrest A, Brazeau D, Zingman B, Reichman RC, Fischl MA, et al. Association between ABCB1 polymorphisms, atazanavir pharmacokinetics and immunological responses [abstract A-1413]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicaco, IL, September 17-20, 2007. | |
| 1678 | MacArthur RD, Huppler Hullsiek K, Peng G, et al. Failing therapy with efavirenz results in significantly fewer mutations limiting to etravirine than failing therapy with nevirapine: on-treatment analyses from the CPCRA FIRST Study. Antiviral Ther 2008;13(Suppl 3):A141. | |
| 2839 | Macbrayne C, Castillo-Mancilla J, Burton J, et al. Small increased in dolutegravir trough, but equivalent total exposure with simeprevir [abstract P_48]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL. | http://regist2.virology-education.com/Abstractbook/2017_5.pdf |
| 3396 | MacBrayne CE, Blum JD, Kiser JJ. Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery. Ann Pharmacother. 2014;48(6):816-819. | 24615629 |
| 769 | Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. Journal of Infectious Diseases 1998;177(5):1182-7. | 9593001 |
| 3569 | MacKenzie M, Gorman SK, Doucette S, et al. Incidence of and factors associated with manipulation of nimodipine dosage in patients with aneurysmal subarachnoid hemorrhage. Can J Hosp Pharm. 2014;67(5):368-365. | 25364018 |
| 962 | MacKenzie-Wood AR, Whitfeld MJ, Ray JE. Itraconazole and HIV protease inhibitors: an important interaction (letter). Medical Journal of Australia 1999;170:46-47. | 10026677 |
| 3515 | Mada PK, Malus ME, Parvathaneni A, et al. Impact of treatment with direct acting antiviral drugs on glycemic control in patients with hepatitis C and diabetes mellitus. Int J Hepatol 2020 Jan 13;2020:6438753. | 32395351 |
| 2761 | Madadi P, Hildebrandt D, Gong IY, et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics 2010;126(4):e986-9. | 20837591 |
| 1532 | Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38. | 17617270 |
| 2853 | Magee M, Sevinsky H, Ackerman P, et al. The effect of fostemsavir on the pharmacokinetics of a combined oral contraceptive (OC) containing ethinyl estradiol (EE) and norethindrone (NE) in healthy female subjects [abstract MOPEB0339]. 9th IAS Conference on HIV Science (IAS 2017). July 23-26th, 2017, Paris, France. | http://programme.ias2017.org/Abstract/Abstract/3312 |
| 1152 | Maggi JD, Halman MH. The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes. Canadian Journal of Psychiatry 2001;46(4):359-62. | 11387794 |
| 2972 | Maida I et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006;42:177-182. | 16688096 |
| 1312 | Maitland D, Moyle GJ, Hand J, et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS. 2005 Jul 22;19(11):1183-8. | 15990571 |
| 2872 | Majeed S, West S, Jiang S, et al. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives [abstract O_05]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, Chicago, IL. June 14-16, 2017. | http://www.infectiousdiseasesonline.com/18antiviralpk-presentation/ |
| 3324 | Majeed SR, German P, West SK, et al. B/F/TAF low-dose tablet relative bioavailability in HVs and PK in children with HIV [abstract 841]. Conference on Retroviruses and Opportunistic Infections (CROI), March 8-11, 2020. Boston, MA. | |
| 1986 | Makinson A, Pujol J-L, Le Moing V, et al. Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. J Thorac Oncol 2010;5(4):562-71. | 20195169 |
| 3173 | Malagnino V, Cerva C, Teti E, et al. Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report. AIDS. 2019;33:360-361. | 30489284 |
| 909 | Maldonaldo S, Lamson M, Gigliotti M, et al. Pharmacokinetic interaction between nevirapine and rifabutin [abstract 341]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-28, 1999, San Francisco, CA. | |
| 394 | Malley DS, Barone R, Heinemann MH. Treatment of bilateral cytomegalovirus retinitis with sustained-release ganciclovir implants in a child. American Journal of Ophthalmology 1996;122(5):731-2. | 8909217 |
| 3438 | Mallikaarjun S, Wells C, Petersen C, et al. Delamanid coadministered with antiretroviral drugs or antitubercular drugs shows no clinically relevant drug-drug interactions in healthy subjects. Antimicrob Agents Chemother 2016;60:5976-85. | 27458223 |
| 3086 | Mallolas J et al. Fosamprenavir/ritonavir dose adjustment for patients with mild and moderate hepatic impairment (APV10017) [abstract 1]. 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary, April 16-18, 2007. | http://i-base.info/htb/2436 |
| 2641 | Mallolas J, Nomdedeu M, Soriano A, et al. Pharmacokinetic interaction between rifampin and the combination of atazanavir and low dose ritonavir in HIV-infected patients [abstract A-1202]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy December 16-19, 2005, Washington, DC. | |
| 3409 | Malm-Erjefalt M, Ekblom M, Vouis J, et al. Effect on the gastrointestinal absorption of drugs from different classes in the biopharmaceutics classification system, when treating with liraglutide. Mol Pharm 2015 12:4166-73. | 26426736 |
| 2442 | Malvestutto CD, Ma Q, Morse GD, et al. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr 2014;67(4):390-6. | 25202920 |
| 2340 | Malvestutto CD, Ma Q, Morse GD, et al. Pharmacokinetic study assessing drug interactions of pitavastatin with darunavir/ritonavir and pitavastatin with efavirenz in healthy volunteers [abstract A-1577c]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 10-13, 2013, Denver, CO. | |
| 1777 | Mandlekar S, Hebbar V, Christov K, et al. Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res 2000;60:6601-6. | 11118041 |
| 132 | Manion D, Merrill DP, Hirsch MS. Combination drug regimens against multidrug resistant Hiv-1 in vitro. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 611 | Manischewitz JF, Quinnan GVJ, Lane HC, et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrobial Agents and Chemotherapy 1990;34:373-5. | 2158278 |
| 1210 | Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases 2002;34(8):1115-21. | 11915001 |
| 779 | Mannheimer S, Hirsch Y, El-Sadr W. The impact of the ALR(tm) alarm device on antiRetroviral adherence among HIV-infected outpatients in Harlem [abstract 32325]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 1655 | Manosuthi W, Athichathanabadi C, Uttayamakul S, et al. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007;7:14-21. | 17352798 |
| 2741 | Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006 January 2;20(1):131-2. | 16327334 |
| 2740 | Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS 2005;19:1481-6. | |
| 2743 | Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin Clin Infec Dis 2006;43:253-5. | 16779754 |
| 2070 | Mantry PS, Hassett MS, Weinstein J, et al. Triple therapy using telaprevir in the treatment of hepatitic C recurrence after liver transplantation: an early single center experience [abstract 90]. HEP DART, December 4-8, 2011, Koloa, Hawaii. | |
| 3296 | Manzardo C, Castelli A, Brunet M, et al. Drug-drug interactions between dolutegravir and immunosuppressant drugs in HIV-infected patients with solid organ transplantation: a single-arm clinical trial [abstract PE27/7]. 17th European AIDS Conference. November 6-9, 2019, Basel, Switzerland. | |
| 3305 | Manzardo C, Castelli A, Brunet M, et al. Drug-drug interactions between dolutegravir and immunosuppressant drugs in HIV-infected patients with solid organ transplantation: a single-arm trial [abstract PE27/7]. 17th European AIDS Conference. November 6-9, 2019, Basel, Switzerland. | |
| 824 | March F, Garriga X, Rodriguez P, et al. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clinical Infectious Diseases 1997;25(5):1044-7. | 9402354 |
| 2046 | March K, Mak M, Louie SG. Effects of pharmacists' interventions on patient outcomes in an HIV primary care clinic. Am J Health Syst Pharm 2007;64(24):2574-8. | 18056946 |
| 1687 | Marchand DH, Remmel RP, Abdel-Monem MM. Biliary excretion of a glutathione conjugate of busulfan and 1,4-diiodobutane in the rat. Drug Metab Dispos 1993;16:85-92. | 2894960 |
| 2013 | Marfo K, Greenstein S. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus–infected liver and kidney transplant recipients. Transplantation Proceedings 2009;41:3796-9. | 19917390 |
| 2842 | Marinaro L, Barco A, Merli M, et al. Daclatasvir pharmacokinetics and appropriate dosing in HCV/HIV patients coadministered with antiretroviral drugs [abstract P_43]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL. | http://regist2.virology-education.com/Abstractbook/2017_5.pdf |
| 160 | Marinker M. Personal paper: writing prescriptions is easy. British Medical Journal 1997;314:747-8. | 9116558 |
| 496 | Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994;48(3):455-84. | 7527763 |
| 1223 | Markowitz M, Simon V, Vasan S, et al. 48-week results of an atazanavir based QD regimen in patients switching from BID PI-based HAART [abstract 543]. Antiviral Therapy 2003;8(S1):S329-30. | |
| 2653 | Maroldo L, Manocchio S, Artenstein A, et al. Lack of effect of nelfinavir mesylate on maintenance methadone dose requirement (abstract WePeB4120). XIII International AIDS Conference, July 9-14, 2000, Durban, South Africa. | |
| 1712 | Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56:1296-302. | 8640817 |
| 2384 | Marshall W, Jumes P, Yeh W, et al. Lack of PK interaction between the hepatitis c virus non-structural protein 5a inhibitor MK-8742 and methadone in subjects on stable opiate maintenance therapy [abstract]. HEP DART, December 8-12, 2013, Hawaii. | |
| 2385 | Marshall W, Yeh W, Caro L, et al. No pharmacokinetic interaction between the hepatitis c virus non-structural protein 5a inhibitor MK-8742 and ethinyl estradiol and levonorgestrel [abstract]. HEPDART, Dec 8-12, 2013, Hawaii. | |
| 2770 | Marshall WL, Feng HP, Dupuis M, et al. Co-administration of digoxin with the HCV NS5A protease inhibitor elbasvir has no effect on digoxin exposure in healthy subjects [abstract 64]. HEPDART 2015, December 6-10, 2015, Maui, Hawaii. | |
| 2402 | Marshall WL, Garrett G, Yeh W, et al. Pharmacokinetics and safety of hepatitis C virus non-structural protein 5a inhibitor MK-8742 in cirrhotic patients with mild and moderate hepatic insufficiency [abstract P_41]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | http://www.natap.org/2014/Pharm/Pharm_44.htm |
| 2769 | Marshall WL, Marenco T, Feng HP, et al. No pharmacokinetic interaction between HCV NS5A inhibitor elbasvir and buprenorphine/naloxone in healthy volunteers [abstract]. AASLD Liver Meeting, November 13-17, 2015, San Francisco, CA. | |
| 2393 | Marshall WL, Yeh W, Caro L, et al. Age and gender effects on the pharmacokinetics of HCV NS5A inhibitor MK-8742 [abstract PP_03]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | http://www.natap.org/2014/Pharm/Pharm_42.htm |
| 3191 | Marsousi N, Daali Y, Fontana P, et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin Pharmacokinet, 2018, 57(10):1347-1354 | 29453687 |
| 2919 | Marsousi N, Samer CF, Fontana P, et al. Coadministration of ticagrelor and ritonavir: toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin Pharmacol Ther 2016;100:295-304. | 27264793 |
| 2290 | Martel D, Sheehan NL, Tremblay CL, et al. Pharmacokinetic interaction of the directly acting antiviral agent boceprevir and maraviroc in healthy volunteers [abstract P_04]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | |
| 3090 | Martin C, Soennerborg A, Svensson JO, Stahle L. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. AIDS. 1999;13(10):1227-32. | 10416527 |
| 810 | Martin DF, Dunn JP, Davis JL, et al. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: Recommendations of the International AIDS Society - USA panel. American Journal of Opthalmology 1999;127(3):329-39. | 10088745 |
| 620 | Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. New England Journal of Medicine 1999;340:1063-70. | 10194235 |
| 418 | Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Archives of Ophthalmology 1994;112(12):1531-9. | 7993207 |
| 3548 | Martin TCS, Hill LA, Tang, ME, Balcombe SM. Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: a retrospective observational study. Int J Infect Dis 2020; 100:470-472. | 32979587 |
| 6 | Martin Z, Ullrich R, Heise W, et al. Malabsorption is found in early stages of HIV infection and independent of secondary infections [abstr]. Seventh International Conference on AIDS, June 16-21, 1991, Florence, Italy. | |
| 1962 | Martinez-Rebollar M, Munoz A, Perez I, et al. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients. Ther Drug Monit 2013;35:552-6. | 23851911 |
| 310 | Martins JC, Wilensky JT, Asseff CF, et al. Corticosteroid-induced uveitis. American Journal of Ophthalmology 1974;77(4):433-7. | 4819444 |
| 2035 | Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011;66(9):2107-11. | 21680580 |
| 1138 | Marzolini C, Chave JP, Telenti A, et al. Impaired absorption of rifabutin by concomitant administration of didanosine. AIDS 2001;15(16):2203-4. | 11684946 |
| 1891 | Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010;15(3):413-23. | 20516560 |
| 3136 | Marzolini C, Rajoli R, Battegay M, et al. Physiologically based pharmacokinetic modeling to predict drug-drug interactions with efavirenz involving simultaneous inducing and inhibitory effects on cytochromes. Clin Pharmacokinet 2017;56:409-20. | 27599706 |
| 1496 | Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-5. | 11192870 |
| 1160 | Marzolini C, Troillet N, Telenti A, et al. Efavirenz decreases methadone blood concentrations. AIDS 2000;14(9):1291-2. | 10894303 |
| 876 | Maserati R, Villani P, Seminari E, et al. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS 1999;13(7):870-7. | 10357395 |
| 2667 | Mason, J., Reynolds, R. and Rao, N. The systemic safety of fexofenadine HCl. Clinical & Experimental Allergy 1999;29:163–170. | |
| 896 | Massarella JW, Nazareno LA, Passe S, et al. The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients. Pharmaceutical Research 1996;13(3):449-52. | 8692740 |
| 526 | Masur H, Lane HC, Palestine A, et al. Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Annals of Internal Medicine 1986;104(1):41-4. | 3000248 |
| 548 | Masur H, Whitcup SM, Cartwright C, et al. Advances in the management of AIDS-related cytomegalovirus retinitis [see comments]. Annals of Internal Medicine 1996;125(2):126-36. | 8678367 |
| 3507 | Maswabi K, Ajibola G, Bennett K, et al. Safety and efficacy of starting antiretroviral therapy in the first week of life. Clin Infect Dis 2020;72(3):388-93. | 31927562 |
| 990 | Mateu de Antonio J, Grau S, Gimeno-Bayon J-L, et al. Ritonavir-induced carbamazepine toxicity [letter]. Annals of Pharmacotherapy 2001;35:125-6. | 11197575 |
| 2298 | Mathias A, Cornpropst M, Clemons D, et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers [abstract 1869]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston. | |
| 1403 | Mathias A, Hinkle J, Shen G, et al. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. J Acquir Immune Defic Syndr 2008;49(2):156-62. | 18769354 |
| 1953 | Mathias A, Koziara J, Wei L, et al. Effect of acid reducing agents on the relative bioavailability and pharmacokinetics of cobicistat-boosted elvitegravir [abstract P_13]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13-15, 2011, Miami, USA. | |
| 1897 | Mathias A, Liu H, Warren D, et al. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir [abstract 28]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7, 2010, Sorrento, Italy. | |
| 3162 | Mathias A, Lutz J, West S, et al. Pharmacokinetics (PK) of bictegravir (BIC) in combination with polyvalent cation containing (PVCC) antacids and supplements [abstract P260]. Glasgow HIV Drug Therapy Conference October 28-31, 2018, Glasgow, UK. | http://hivglasgow.org/wp-content/uploads/2018/11/P260.pdf |
| 1941 | Mathias A, Murray B, Iwata Q, et al. Metabolism and excretion in humans of the pharmacoenhancer GS-9350 [abstract 18]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7, 2010, Sorrento, Italy. | |
| 1437 | Mathias A, Ramanathan S, Hinkle J, et al. Effect of atazanavir/r on the steady-state pharmacokinetics of elvitegravir [abstract A-1417]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, IL | |
| 1402 | Mathias A, Shen G, Enejosa J, et al. Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and darunavir/ritonavir [abstract TUPDB03]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention July 22-25, 2007, Sydney, Australia. | |
| 1438 | Mathias A, West S, Enejosa J, et al. A pharmacokinetic interaction between lopinavir/r and elvitegravir [abstract A-1418]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, IL. | |
| 1407 | Mathias A, West S, Hui J, et al. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther. 2009 Jan;85(1):64-70. | 18815591 |
| 2319 | Mathias A. Clinical pharmacology of DAAs for hepatitis C: what's new and what's in the pipeline. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | |
| 1738 | Mathijssen RHJ, van Alpen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94. | 11489791 |
| 2228 | Matiluko AA, Soundararjan L, Hogston P. Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Health Care 2007;33(4):277-8. | 17925115 |
| 3406 | Matovu FK. Depo-Provera worsens bone loss with TDF-containing ART initiation in young women [abstract OAB0105]. 23rd International AIDS Conference Virtual, July 6-10, 2020. | https://cattendee.abstractsonline.com/meeting/9289/Presentation/65 |
| 91 | Mattila MJ, Linnoila M ST, Koskinen R. Effect of aluminium hydroxide and glycopyrrhonium on the absorption of ethambutol and alcohol in man. British Journal of Clinical Pharmacology 1978;5:161-6. | 619949 |
| 520 | Maurice DM. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS [letter]. American Journal of Ophthalmology 1987;103(6):842-3. | 3035928 |
| 840 | May DB, Drew RH, Yedinak KC, et al. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994;14:509-13. | 7997384 |
| 2064 | May MT, Ingle SM. Life expectancy of HIV-positive adults: a review. Sex Health 2011;8(4):526-33. | 22127039 |
| 2248 | Mayer K, Poblete R, Hathaway B, et al. Efficacy, effect of oral contraceptive, and adherence in HIV-infected women receiving Fortovase (saquinavir) soft gel capsule thrice daily and twice daily regimens [abstract TuPeB3226]. 13th International AIDS Conference, July, 2000, Durban, South Africa. | |
| 405 | McAuliffe PF, Hall MJ, Castro-Malaspina H, et al. Use of the ganciclovir implant for treating cytomegalovirus retinitis secondary to immunosuppression after bone marrow transplantation. American Journal of Ophthalmology 1997;123(5):702-3. | 9152083 |
| 1100 | McCallister S, Sabo J, Galitz L, et al. An open-label steady state investigation of the pharmacokinetics of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal healthy volunteers (BI 1182.5) [abstract 434-W]. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA. | |
| 2655 | McCance-Katz EF, Farber S, Selwyn PA, et al. Decrease in methadone levels with nelfinavir mesylate [letter]. Am J Psychiatry 2000;157:481. | |
| 2753 | McCance-Katz EF, Moody D, Morse G, et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine Clin Infec Dis 2006;43(Suppl 4):S224-34. | |
| 2752 | McCance-Katz EF, Moody D, Smith P, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infec Dis 2006;43(Suppl 4):S235-46. | |
| 1448 | McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007;91(2-3):269-78. | 17643869 |
| 1965 | McCance-Katz EF, Moody DE, Morse GD, et al. Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict 2010;19(1):30-7. | 20132119 |
| 1333 | McCance-Katz EF, Rainey PM, Friedland G, et al. Effect of opioid dependence pharmacotherapies on zidovudine disposition. American Journal of Addictions 2001;10(4):296-307. | 11783744 |
| 1298 | McCance-Katz EF, Rainey PM, Friedland G, et al. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clinical Infectious Diseases 2003;37(4):476-82. | 12905130 |
| 1020 | McCance-Katz EF, Rainey PM, P PJ, et al. Methadone effects on zidovudine disposition (AIDS clinical trials group 262). Journal of the Acquired Immune Deficiency Syndrome 1998;18:435-43. | 9715839 |
| 2157 | McCance-Katz EF, Rainey PM, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict 2006;15:23-34. | 16449090 |
| 1358 | McCance-Katz EF, Rainey PM, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. American Journal of Addictions 2004;13(2):163-80. | 15204667 |
| 2131 | McCarty EJ, Keane H, Quinn K, et al. Implanon® failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies. Int J Std AIDS 2011;22(7):413-4. | 21729965 |
| 2250 | McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infec Dis 2010;51(8):937-46. | 20839968 |
| 189 | McCrea J, Buss N, Stone J, et al. Indinavir-saquinavir single dose pharmacokinetic study [abstr]. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 3316 | McCreary EK, Pogue JM, on behalf of the Society of Infectious Diseases Pharmacists, COVID-19 Treatment: A Review of Early and Emerging Options, Open Forum Infectious Diseases, ofaa105 | https://doi.org/10.1093/ofid/ofaa105 |
| 3633 | McCune JS, Hawke RL, LeCluyse EL et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000; 68:356-66 | 11061575 |
| 1711 | McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68:356-66. | 11061575 |
| 3671 | McDaniel K, Utz AE, Akbashev M, et al. Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: an international multicenter retrospective cohort study. J Viral Hepat 2022;29:1073-8. | |
| 153 | McDonald CK, Gerber JG. Drug Prescription Practices in a University Hospital HIV Clinic [abstract 190]. 4th National Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 783 | McDowell JA, Chittick GE, Pilati-Stevens C, et al. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrobial Agents and Chemotherapy 2000;44:1686-90. | |
| 1504 | McFayden L, Jacqmin P, Wade J, et al. Maraviroc exposure response analysis: phase 3 antiviral efficacy in treatment-experienced HIV+ patients [abstract P4-13]. 16th PAGE Population Approach Group in Europe Meeting, June, 2007, Kobenhavn, Denmark. | |
| 142 | McKenney JM, Harrison WL. Drug-related hospital admissions. American Journal of Health-System Pharmacy 1976;33:792-5. | 949062 |
| 1689 | McLean A, Newell D, Baker G, et al. The metabolism of chlorambucil. Biochem Pharmacol 1980;29:2039-47. | 7406916 |
| 2455 | McMorran M. Tenofovir (Viread) and NSAIDS: acute renal failure. Can Adverse Reaction Newsletter 2006 April;16(2):1-2. | |
| 2995 | McNeil Consumer Healthcare. Axert (almotriptan) Product Monograph. Markham, ON. April 13, 2016. | |
| 2226 | McNutt MD, Liu S, Manatunga A, et al. Neurobehavioral effects of interferon-alpha in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology 2012;37(6):1444-54. | 22353759 |
| 2835 | MEDA Pharmaceuticals. Cesamet (nabilone) Product Monograph. Somerset, NJ. September, 2013 | http://www.cesamet.com/pdf/Cesamet_PI_50_count.pdf |
| 467 | Melchior WR, Bindlsih V, Rybak MJ. Intravitreal ganciclovir for cytomegalovirus retinitis in AIDS patients. Annals of Pharmacotherapy 1992;26:36-7. | 1318760 |
| 1743 | Melosky B, Gelmon K. Phase II trial of liposomal daunorubicin with concurrent protease inhibitors in AIDS-related Kaposi’s sarcoma (abstract 34). J Acquir Immune Defic Syndr 2000;23:A23. | |
| 3508 | Melvin AJ, Best B, Muresan P, et al. IMPAACT 2014 24-week PK and safety of doravirine/3TC/TDF in adolescents with HIV-1 [abstract 604]. Conference on Retroviruses and Opportunistic Infections (CROI). 2021.Virtual. | https://www.croiconference.org/abstract/impaact-2014-24-week-pk-and-safety-of-doravirine-3tc-tdf-in-adolescents-with-hiv-1/ |
| 2434 | Menon R, Badri P, Das U, et al. Drug-drug interactions with direct acting antiviral combination therapy of ABT-450/r, ombitasvir and dasabuvir [abstract A-007]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, 2014, Washington, DC. | |
| 2414 | Menon R, Badri P, Khatri A, et al. ABT-450/ritonavir +ombitasvir + dasabuvir: drug interactions mediated by transporters. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 2688 | Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 2015;63(2):20-9 | 25646891 |
| 2797 | Mercadante S, Villari P, Ferrera P. Itraconazole-fentanyl interaction in a cancer patient. J Pain Symptom Manage 2002;24(3):284-286 | 12458106 |
| 2047 | Merchen BA, Gerzenshtein L, Scarsi KK, et al. HIV-specialized pharmacists’ impact on prescribing errors in hospitalized patients on antiretroviral therapy [abstract H2-794]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2011, Chicago, IL. | |
| 3553 | Merck & Co, Inc. Emergency use authorization for molnupiravir, Fact Sheet for Healthcare Providers. Kenilworth, NJ. December 2021. | https://www.merck.com/eua/molnupiravir-hcp-fact-sheet.pdf |
| 3618 | Merck & Co Inc. DELSTRIGO™ (doravirine, lamivudine, and tenofovir disoproxil fumarate) Prescribing information. NJ. June 2022 | https://www.merck.com/product/usa/pi_circulars/d/delstrigo/delstrigo_pi.pdf |
| 3156 | Merck & Co, Inc. Pifeltro (doravirine) Prescribing Information. Whitehouse Station, NJ, June 2022. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf |
| 3419 | Merck Canada Inc. Prevymis (letermovir) Product Monograph. Kirkland, QC. May 8, 2020. | https://pdf.hres.ca/dpd_pm/00056375.PDF |
| 1817 | Merck Canada Inc. Zolinza (vorinostat) Product Monograph. Kirkland, QC. October 18, 2013. | http://pdf.hres.ca/dpd_pm/00022508.PDF |
| 3504 | Merck Canada Inc. Belsomra (suvorexant) Product Monograph. Kirkland, QC. March 4, 2021. | |
| 3485 | Merck Canada Inc. Emend (aprepitant) Product Monograph. Kirkland, QC. October 17, 2018. | https://pdf.hres.ca/dpd_pm/00023565.PDF |
| 2674 | Merck Canada Inc. Januvia (sitagliptin) Product Monograph. Kirkland, QC. July 27, 2021. | http://pdf.hres.ca/dpd_pm/00038450.PDF |
| 2998 | Merck Canada Inc. Maxalt (rizatriptan) Product Monograph. Kirkland, QC. May 8, 2013. | |
| 3160 | Merck Canada Inc. Pifeltro (doravirine) Product Monograph. Kirkland, QC Canada. December 5, 2019. | http://www.merck.ca/static/pdf/PIFELTRO-PM_E.pdf |
| 186 | Merck Canada Inc. Posanol (posaconazole) Product Monograph. Kirkland, QC. August 22, 2019. | http://pdf.hres.ca/dpd_pm/00040130.PDF |
| 1643 | Merck Canada Inc. Posanol (posaconazole) Product Monograph. Kirkland, QC. August 22, 2019. | http://pdf.hres.ca/dpd_pm/00040130.PDF |
| 3334 | Merck Canada Inc. Stromectol (ivermectin) Product Monograph. Kirkland, QC. September 5, 2018. | |
| 1836 | Merck Canada Inc. Temodol (temozolomide) Product Monograph. Kirkland, QC. June 23, 2017. | http://pdf.hres.ca/dpd_pm/00039947.PDF |
| 2053 | Merck Canada Inc. Victrelis (boceprevir) Product Monograph. Kirkland, QC. May 27, 2015. | http://pdf.hres.ca/dpd_pm/00030648.PDF |
| 2773 | Merck Canada Inc. Zepatier (elbasvir/grazoprevir) Product Monograph. Kirkland, QC. March 17, 2021. | https://pdf.hres.ca/dpd_pm/00039964.PDF |
| 178 | Merck Frosst Canada Ltd. Crixivan (indinavir) Product Monograph. Kirkland, QC. June 9, 2014. | http://pdf.hres.ca/dpd_pm/00025439.PDF |
| 2482 | Merck Frosst Canada Ltd. Isentress & Isentress HD (raltegravir) Prescribing Information. June 10, 2022. | https://pdf.hres.ca/dpd_pm/00039853.PDF |
| 1459 | Merck Frosst Canada Ltd. Isentress & Isentress HD (raltegravir) Prescribing Information. Kirkland, QC, June 10, 2022. | https://pdf.hres.ca/dpd_pm/00039853.PDF |
| 3688 | Merck Sharp & Dohme LLC. Belsomra (suvorexant) Prescribing Information. Rahway, NJ. February 2023. | https://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf |
| 2833 | Merck Sharp & Dohme Corp. Isentress & Isentress HD (raltegravir) Prescribing Information. Whitehouse Station, NJ, May 2022. | https://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.pdf |
| 2315 | Merck Sharp & Dohme Corp. Victrelis (boceprevir) Product Monograph. Whitehouse Station, NJ. January 2017. | http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202258s016lbl.pdf |
| 1244 | Merck Canada Inc. Cancidas (caspofungin) Product Monograph. Kirkland, QC. April 28, 2017. | http://pdf.hres.ca/dpd_pm/00039081.PDF |
| 3657 | Merck. Singulair (montelukast) Prescribing Information. Whitehouse Station, NJ. April, 2020. | |
| 1303 | Merck/Schering-Plough Pharmaceuticals. Ezetimibe (Zetia) Prescribing Information. Whitehouse Station, NJ. July 2005. | http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021445s014lbl.pdf |
| 169 | Meredith PA. Therapeutic implications of drug "holidays". European Heart Journal 1996;17 Suppl A(21-4). | 8737197 |
| 190 | Merrill DP, Manion DJ, Chou TC, et al. Protease inhibitor combination regimens against HIV-1 in vitro [abstr]. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 367 | Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997;11:F117-F20. | 9412695 |
| 633 | Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997;11(4):F29-33. | 9084785 |
| 371 | Merry C, Barry MG, Mulcahy FM, et al. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV infected patients. AIDS. 1997 Dec;11(15):F117-20. | 9412695 |
| 370 | Merry C, Barry MG, Mulcahy FN, et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 1998;12(10):1163-7. | 9677165 |
| 921 | Merry C, Barry MG, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 1999;13(15):101-07. | 10546851 |
| 998 | Merry C, Mulcahy F, Barry M, et al. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease [letter]. AIDS 1997;11(2):268-9. | 9030388 |
| 1565 | Mertz D, Battegay M, Marzolini C, et al. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. Am J Kidney Dis 2009;54(1):e1-4. | 19346040 |
| 357 | Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Archives of Internal Medicine 1997;157(3):343-9. | 9040303 |
| 3150 | Merus Labs Luxco S.a.R.L. Enablex (darifenacin) Product Monograph. Steichen, Luxumbourg, November 17, 2017. | |
| 36 | Metroka CE, McMechan MR, Andrada R, et al. Failure of prophylaxis with dapsone in patients taking dideoxyinosine [letter]. New England Journal of Medicine 1991;325:737. | 1908060 |
| 2597 | Metzger NL, Momary KM. A patient with HIV and tuberculosis with diminished clopidogrel response. Int J STD AIDS 2013 Dec 18;25(7):532-34. | 24352136 |
| 1758 | Mewes K, Blanz J, Ehninger G, et al. Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. Cancer Res 1993;53:5135-42. | 8221649 |
| 935 | Meyboom RHB, Hekster YA, Egberts ACG, et al. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Safety 1997;17(6):374-89. | 9429837 |
| 315 | Meyer UA. Overview of enzymes of drug metabolism. Journal of Pharmacokinetics & Biopharmaceutics 1996;24(5):449-59. | 9131484 |
| 436 | Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18(1):84-112. | 9469685 |
| 3630 | Michalik DE, Jackson-Alvarez JT, Flores R et al. Low third-trimester serum levels of lamivudine/zidovudine and lopinavir/ritonavir in an HIV-infected pregnant woman with gastric bypass. J Int Assoc Provid AIDS Care 2015;14(2):116-119. | 25361558 |
| 818 | Michelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. Aids 1998;12(14):1815-22. | 9792382 |
| 3367 | Michienzi SM, Schriever CA, Badowski ME. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int J STD AIDS 2019;30:181-7. | 30381029 |
| 1599 | Micromedex 2.0 [database on the Internet]. Thomson Reuters (Healthcare) Inc. 2012 [cited June 10]. | |
| 316 | Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Safety 1997;16(4):267-78. | 9113494 |
| 3018 | Mikkelsen TS, Thorn CF, Yang JJ, et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 2011;21:679-86. | 21317831 |
| 1606 | Mikus G, Schmidt L, Burhenne J, et al. Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. Clin Pharmacokinet 2004;43(14):1015-24. | 15530130 |
| 1864 | Mikus G, Schowel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126-35. | 16890574 |
| 934 | Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. Journal of the Acquired Immune Deficiency Syndrome 2002;29:471-77. | 11981363 |
| 42 | Millar AB, Miller RF, Patou G, et al. Treatment of cytomegalovirus retinitis with zidovudine and ganciclovir in patients with AIDS: outcome and toxicity. Genitourinary Medicine 1990;66:156-8. | 2164492 |
| 2162 | Miller CD, El-Kholi R, Faragon JJ, et al. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacother 2007;27(10):1379-86. | 17896893 |
| 2675 | Miller J, Migoya E, Talaty J,et al. The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects: results of a multiple-dose, double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther 2006;79:24. | |
| 5 | Miller TL, Orav EJ, Martin SR, et al. Malnutrition and carbohydrate malabsorption in children with vertically transmitted human immunodeficiency virus 1 infection. Gastroenterology 1991;100:1296-302. | 2013374 |
| 1670 | Mills A, Cahn P, Molina JM, et al. Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results [abstract MOPEB036]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Capetown, South Africa. | |
| 1539 | Mills A, Grinsztejn B, Katlama C, et al. The incidence of rash observed with the NNRTI etravirine in the Phase III DUET trials using pooled 48-week data [abstract TUPE0059]. XVIIth International AIDS Conference, August 3-8, 2008, Mexico City, Mexico. | |
| 1907 | Mills A, Mildvan D, Podzamczer D, et al. Safety and immunological activity of once daily maraviroc in combination with ritonavir-boosted atazanavir compared to emtricitabine 200 mg/tenofovir 300 mg QD plus ATVr in treatment-naive patients infected with CCR5-tropic HIV-1 (Study A4001078): a week 24 planned interim analysis [abstract THLBB203]. XVIII International AIDS Conference, July 18-23, 2010, Vienna, Austria. | |
| 509 | Mills J, Jacobson MA, JJ OD, et al. Treatment of cytomegalovirus retinitis in patients with AIDS. Reviews of Infectious Diseases 1988;10(Suppl 3):S522-31. | 2847289 |
| 3074 | Mink M, Greenberg ML, Moshier S, Janumpalli S, Davison D, Jin L, Sista P, Melby T, Lambert D, Cammack N, Salgo M, Matthews TJ. Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3. Antivir Ther. Vol. 7, 2002:S17. | |
| 3075 | Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol. 2005 Oct;79(19):12447-54. | 16160172 |
| 326 | Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. American Journal of Obstetrics & Gynecology 1997;176(2):478-89. | 9065202 |
| 1887 | Mir O, Dessard-Diana B, Louet AL, et al. Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients. Br J Clin Pharmacol 2010;69(1):99-101. | 20078618 |
| 1939 | Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008;62(6):1365-73. | 18854330 |
| 1925 | Miro J, Manzardo C, Brunet M, et al. Combination of RAL + 3TC or FTC + ABV or TDF is safe, effective, and prevents pharmacokinetic interactions with immunosuppressive drugs in HIV-1-infected solid organ transplant recipients [abstract 644]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA. | |
| 2907 | Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS; IMPAACT 1026s Study Team. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9. | 21283017 |
| 1506 | Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004;43:1071-87. | 15568888 |
| 2863 | Mittelstadt M, Stewart K.Treatment emergent resistance and virologic failure of a dolutegravir based regimen due to complex drug-drug interactions in HIV treatment naive patient [abstract PE10/4]. 16th European AIDS Conference, October 25-27, 2017, Milan, Italy. | http://www.professionalabstracts.com/eacs2017/iplanner/#/grid |
| 832 | Miyama T, Takanaga H, Matsuo H, et al. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrobial Agents & Chemotherapy 1998;42(7):1738-44. | 9661014 |
| 3451 | Moderna Therapeutics Inc. Moderna COIVD-19 Vaccine (mRNA-1273 SARS-CoV-2 vaccine) Product Monograph. Cambridge, USA. December 23, 2020. | https://covid-vaccine.canada.ca/info/pdf/moderna-covid-19-vaccine-pm1.pdf |
| 3482 | Mofenson LM, Watts DH. Safety of pediatric HIV elimination: the growing population of HIV- and antiretroviral exposed but uninfected infants. PLos Med 2014;11(4):e.1001636. | 24781352 |
| 2352 | Mogalian E, German P, Brainard DM, et al. Lack of a clinically significant pharmacokinetic drug-drug interaction between sofosbuvir and GS-5816 in healthy volunteers [abstract 465]. Hepatology 2013;58(4 (suppl)):431A. | |
| 3050 | Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. Clin Pharmacokinet 2016;55:605-13. | 26519191 |
| 2787 | Mogalian E, German P, Yang C, et al. Evaluation of transporter and cytochrome P450-mediated drug-drug interactions between pan-genotypic HCV NS5A inhibitor GS-5816 and phenotypic probe drugs [abstract O_07]. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 3349 | Mogalian E, Kirby B, Liyun N et al. Evaluation of drug-drug interaction between sofosbuvir/velpatasvir and rifaximin in HCV-infected subjects with moderate hepatic impairment [abstract O_08]. 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. Washington, DC. June 8-10, 2016. | http://regist2.virology-education.com/2016/17HIVHEPPK/11_Mogalian.pdf |
| 3133 | Mogalian E, Mathias A, Yang J et al. The pharmacokinetics of ledipasvir, an HIV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment [abstract]. 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, Nov 13-17 2015. | http://www.natap.org/2015/AASLD/AASLD_131.htm |
| 2793 | Mogalian E, McNally J, Shen G, et al. Drug-drug interaction profile of sofosbuvir/velpatasvir fixed-dose combination [abstract FRI-168]. The International Liver Congress, April 13-17, 2016, Barcelona, Spain | |
| 2785 | Mogalian E, Stamm L, Osinusi A, et al. Drug-drug interaction studies between HCV antivirals sofosbuvir/velpatasvir and boosted and unboosted HIV antiretroviral regimens in healthy volunteers. Clin Infect Dis 2018 Mar 7 [epub ahead of print]. | 29522076 |
| 2786 | Mogalian E, Stamm L, Osinusi A, et al. Drug-drug interaction studies between HCV antivirals sofosbuvir/velpatasvir and boosted and unboosted HIV antiretroviral regimens in healthy volunteers. Clin Infect Dis 2018 Mar 7 [epub ahead of print]. | 29522076 |
| 3304 | Mogul A, Teixeira E, McAuliffe L, et al. Effectiveness of crushed sofosbuvir-velpatasvir in a patient with dysphagia. Am J Health Syst Pharm 2020;77:417-8. | 31930300 |
| 3661 | Mohammed H, Hicks A, Viramgama P, Boffito M. Managing drug-drug interactions between antiretrovirals and tacrolimus in liver transplantation [abstract 21]. International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Drugs. Sep 19-20, 2022, Barcelona, Spain. | |
| 2008 | Molloy A, Matheson NJ, Meyer PAR, et al. Cushing’s syndrome and adrenal axis suppression in a patient treated with ritonavir and corticosteroid eye drops. AIDS 2011;25:1337-9. | 21659797 |
| 3670 | Moltó J, Bailón L, Pérez-Mañá C, et al. Absence of drug-drug interactions between ɣ-hydroxybutyric acid (GHB) and cobicistat. J Antimicrob chemother 2022;77:181-184. | 34561695 |
| 1497 | Molto J, Blanco A, Miranda C, et al. Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol 2007;63(715-21). | 17223856 |
| 2829 | Molto J, Curran A, Miranda C et al. Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients. J Antimicrob Chemother 2017 Dec 11. doi: 10.1093/jac/dkx459. [Epub ahead of print] | 29237008 |
| 1468 | Molto J, Deig E, Valle M, et al. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir. Ther Drug Monitor 2010;32(1):93-6. | 20040897 |
| 3574 | Molto J, Graterol F, Curran A et al. Removal of doravirine by hemodialysis in HIV-infected patients [abstract 435]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, February 12-16, 2022. | |
| 2980 | Molto J, Graterol F, Miranda C et al. Removal of dolutegravir by hemodialysis in HIV-Infected patients wiht end-stage renal disease. Antimicrob Agents Chemother 2016;60:2564-6. | 26856824 |
| 2617 | Molto J, Rajoli R, Back D, et al. Use of a physiologically based pharmacokinetic model to simulate drug-drug interaction between antineoplastic and antiretroviral drugs. J Antimicrob Chemother 2017;72:805-11. | 27999009 |
| 2392 | Molto J, Rajoli R, Cirauqui B, et al. Simulation of the interaction between erlotinib and ritonavir using a physiologically based pharmacokinetic model [abstract PP_01]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 1503 | Molto J, Santos JR, Perez-Alvarez N, et al. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in HIV-infected protease inhibitor-experienced patients. Antimicrob Agents Chemother 2008:[epub ahead of print]. | 18725446 |
| 2951 | Molto J, Valle M, Cedeno S, Miranda C, Jou A, Negredo E, Clotet B. Exposure to darunavir among HIV+ patients with chronic viral hepatitis without liver function impairment [abstract P_55]. 10th Int Workshop Clin Pharmacol HIV Ther: Amsterdam, April 15-17, 2009. | |
| 2950 | Molto J, Valle M, Ferrer E, et al. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients [abstract O_03]. 15th International Workshop on Clinical Pharmacology of HIV Therapy, May 19-21, 2014, Washington, DC. | http://www.natap.org/2014/Pharm/Pharm_10.htm |
| 2644 | Molto J, Valle M, Miranda C et al. Effect of Milk Thistle on the Pharmacokinetics of Darunavir-Ritonavir in HIV-Infected Patients. Antimicrob. Agents Chemother. June 2012;56(6):2837-2841 | 22430963 |
| 1999 | Molto J, Valle M, Miranda C, et al. Herb-drug Interaction between echinacea purpurea and darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother 2011;55:326-30. | 21078942 |
| 1571 | Molto J, Valle M, Mothe B, et al. Pharmacokinetics and safety of once-daily raltegravir 800 mg plus atazanavir 400 mg in HIV-infected patients [abstract O_13]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 3166 | Moltó, José Graterol, Fredzzia Miranda, Cristina et al. Antimicrobial Agents and Chemotherapy 2016;60(4):2564-66 | 26856824 |
| 3479 | Momper J, Stek A, Wang J, et al. Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum [abstract 10]. Presented at: Workshop on Clinical Pharmacology of HIV, Hepatitis, and other Antiviral Drugs 2019. Noordwijk, Netherlands. | https://www.natap.org/2019/Pharm/Pharm_18.htm |
| 3220 | Momper JD, Best B, Wang J, et al. Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy. [Abstract THAB0302]. 22nd International AIDS Conference. July 23-27, 2018, Amsterdam, The Netherlands | https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25148 |
| 3368 | Momper JD, Best Brookie M, Wang J, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS 2018;32(17):2507-16. | 30134297 |
| 3431 | Monbaliu J, Gonzalez M, Bernard A et al. In vitro and in vivo drug-drug interaction studies to assess the effect of abiraterone acetate, abiraterone, and metabolites of abiraterone on CYP2C8 activity. Drug Metab Disp 2016;44:1682-91. | 27504016 |
| 3455 | Money D, Lee T, O'Brien C, et al. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study. BJOG 2019;126(11):1338-45. | 31188522 |
| 3249 | Money D, Lee T, O’Brien C, Brophy J, Bitnun A, Kakkar F , Boucoiran I, Alimenti A, Vaudry W, Singer J, Sauve LJ., for the Canadian Perinatal HIV Surveillance Program. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study. BJOG. 2019 Jun 12. doi: 10.1111/1471-0528.15838 | 31188522 |
| 1198 | Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000;14(5):499-507. | 10780712 |
| 1763 | Monsarrat B, Royer I, Wright M, et al. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Bull Cancer 1997;84:125-33. | 9180834 |
| 780 | Montaner JSG, Raboud JM, Rae S. Adherence to treatment increases duration of virologic suppression regardless of pVL nadir [abstract LB-10]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24-27, 1998, San Diego. | |
| 950 | Montaner JSG, Schechter MT, Rachlis A, et al. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group. Annals of Internal Medicine 1995;123(8):561-71. | 7677296 |
| 410 | Montero MC, Pastor M, Buenestado C, et al. Intravitreal ganciclovir for cytomegalovirus retinitis in patients with AIDS. Annals of Pharmacotherapy 1996;30(7-8):717-23. | 8826547 |
| 1683 | Montgomery MR, Furry J, Fernandez S. Bleomycin inhibits hepatic mixed function oxidation. Res Commun Chem Pathol Pharmacol 1981;34:287-93. | 6175013 |
| 157 | Montgomery SB, Joseph JG, Becker MH, et al. The Health Belief Model in understanding compliance with preventive recommendations for AIDS: how useful? AIDS Education and Prevention 1989;1(303-23). | 2701353 |
| 2283 | Montrucchio C, Calcagno A, Lanzafame M, et al. Pharmacokinetics of the dual NRTI- and protease inhibitor-sparing regimen raltegravir plus nevirapine in HIV-1+ patients [abstract 536]. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA. | |
| 1359 | Moody DE, Walsh SL, Rollins DE, et al. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naïve individuals. Clinical Pharmacology and Therapeutics 2004;76(2):154-66. | 15289792 |
| 3512 | Moore C, Kekitiinwa A, Kaudha E, et al. ODYSSEY: A randomized trial evaluating the efficacy and toxicity of dolutegravir-based antiiretroviral therapy compared to standard of care in HIV-infected children starting first-line or second-line therapy: design, current status and baseline characteristics. Presented at: 10th International Workshop on HIV Pediatrics. Amsterdam, Netherlands 2019 | |
| 3608 | Moore CB, Capparelli E, Calabrese E, et al. Safety and PK of long-acting cabotegravir and rilpivirine in adolescents. CROI 2022, Feb 12-24, 2022, hybrid virtual/Denver CO. | https://www.natap.org/2022/CROI/croi_23.htm |
| 614 | Moore DAJ, Gazzard GB, Nelson MR. Central venous line infections in AIDS. Journal of Infection 1997;34:35-40. | 9120322 |
| 3164 | Moore K, Magee M, Gunshenan M, et al. Impact of mild, moderate and severe renal impairment and haemodialysis on temsavir pharmacokinetics following oral administration of fostemsavir, an attachment inhibitor for heavily treatment-experienced, HIV-1-infected patients [abstract P261]. Glasgow HIV Drug Therapy Conference October 28-31, 2018, Glasgow, UK. | http://hivglasgow.org/wp-content/uploads/2018/11/P261.pdf |
| 52 | Moore KHP, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clinical Pharmacology and Therapeutics 1996;59:550-8. | 8646826 |
| 3277 | Moore KP, Mageau AS, Magee M, et al. Fostemsavir drug-drug interaction profile, an attachment inhibitor and oral prodrug of temsavir, for heavily treatment experienced HIV-1 infected patients. IDWeek, October 2-6, 2019, Washington, DC. Abstract 2500. | |
| 550 | Moore RD, Chaisson RE. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1997;16(1):15-21. | 9377120 |
| 765 | Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic disease with combination antiretroviral therapy [abstract 184]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 736 | Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. Journal of Infectious Diseases 1987;155(1):93-9. | 3540140 |
| 3364 | Moore SE, Huesgen E, Howe Z. Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis. Int J STD AIDS 2020;31(3):285-287. | https://pubmed.ncbi.nlm.nih.gov/32036755/ |
| 2118 | Morcos PN, Moreira SA, Navarro MT, et al. Ritonavir-boosted danoprevir may be coadministered without regard to meals or in combination with ranitidine or omeprazole: a healthy volunteer study [abstract PK_06]. 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 27-28, 2012, Cambridge, MA. | |
| 2121 | Moreira SA, Morcos PN, Navarro MT, et al. No change in the steady-state pharmacokinetics of methadone after co-administration with danoprevir/ritonavir [abstract PK_10]. 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 27-28, 2012, Cambridge, MA. | |
| 1936 | Morello J, Soriano V, Barreiro P, et al. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother 2010;54(4):1647-9. | 20100874 |
| 1478 | Moreno A, Barcena R, Querada C, et al. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplant. AIDS 2008;22(4):547-8. | 18301075 |
| 2215 | Moreno A, Quereda C, Montes M, et al. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir. J Acq Immune Def Syndr 2012;61(3):e47-9. | 23095936 |
| 49 | Moreno F, Hardin TC, Rinaldi MG, et al. Itraconazole-didanosine excipient interaction [letter]. Journal of the American Medical Association 1993;269:1508. | 8383255 |
| 1908 | Moreno-Zamora A, Pérez-Elías MJ, Casado JL, et al. Safety (specially renal) and antiretroviral activity or raltegravir-based HAART in HIV-subjects after solid organ transplantation [abstract]. XVIII International AIDS Conference, July 18-23, 2010, Vienna, Austria. | |
| 2027 | Morgan R, Campbell S, Suehira K, et al. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes 2012;60(2):158-64. | 22627182 |
| 415 | Morlet N, Young S, Naidoo D, et al. High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study. British Journal of Ophthalmology 1995;79(8):753-5. | 7547787 |
| 411 | Morlet N, Young S, Naidoo D, et al. High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. British Journal of Ophthalmology 1996;80(3):214-6. | 8703858 |
| 419 | Morlet N, Young SH, Coroneo MT. Ganciclovir intraocular device and patient survival [letter]. Archives of Ophthalmology 1994;112(11):1404. | 7980124 |
| 425 | Morlet N, Young SH. Prevention of intraocular pressure rise following intravitreal injection. British Journal of Ophthalmology 1993;77(9):572-3. | 8218055 |
| 406 | Morley MG, Duker JS, Reichel E. Ganciclovir intraocular implant [letter; comment]. Ophthalmology 1996;103(10):1517. | 8874416 |
| 2524 | Morris CA, Lopez-Lazaro L, Jung D, et al. Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers. The American journal of tropical medicine and hygiene 2012 Mar;86(3):489-95. | 22403324 |
| 238 | Morris DJ. Adverse effects and drug interactions of clinical importance with antiretrovirals. Drug Safety 1994;10:281-91. | 8018300 |
| 51 | Morse GD, Fischl MA, Shelton MJ, et al. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 1997;41:169-74. | 8980774 |
| 1270 | Morse GD, Rosenkranz S, Para MF, et al. 3-way pharmacokinetic interaction among amprenavir, efavirenz, and a second protease inhibitor [abstract 614]. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco CA. | |
| 606 | Moses A, Mortimer C, Salit I, et al. Cytomegalovirus (CMV) retinitis in an HIV clinical setting: tolerance and responses to systematic and local antiviral therapies [abstract Th.B.4195]. XI International Conference on AIDS, July 7-12, 1996, Vancouver. | |
| 605 | Moses A, Mortimer C, Salit I, et al. Efficacy of therapy for cytomegalovirus (CMV) in AIDS [abstract 165]. 3rd National Conference on Human Retroviruses and Related Infections, January 28-February 1, 1996, Washington. | |
| 1988 | Mounier N, Katlama C, Costagliola D, et al. Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice. Critical Rev Oncol/Hematol 2009;72:10-20. | 19070506 |
| 3405 | Mounzer K, Brunet L, Wyatt CM, et al. To dose-adjust of not to dose-adjust: lamivudine dose in renal impairment. AIDS: July 1, 2021 - Volume 35 - Issue 8 - p 1201-1208. | https://cattendee.abstractsonline.com/meeting/9289/Presentation/1278 |
| 772 | Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. Aids 1997;11(12):F101-5. | 9342061 |
| 599 | Moyle G, Barton S, Gazzard BG. Penile ulceration with foscarnet therapy. AIDS 1993;7:140-1. | 8382924 |
| 743 | Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996;51(5):701-12. | 8861542 |
| 597 | Moyle G, Nelson M, Barton SE, et al. Penile ulcerations with foscarnet [letter]. Lancet 1990;335:547-8. | 1968562 |
| 2710 | Moyle G, Rajicic N, Valdez H, et al. Concurrent use of statins does not influence efficacy of maraviroc in MOTIVATE studies [abstract MOPEB039]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Capetown, South Africa. | |
| 1107 | Moyle GJ, Buss NE, Gazzard B. Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy. J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):460-2. | 12138355 |
| 1209 | Moyle GJ. The Assessing Patients' Preferred Treatments (APPT-1) study. Int J STD AIDS. 2003 Oct;14 Suppl 1:34-6. | 14617402 |
| 3600 | Mozo Ruiz M, Rosado Barrasa N, Tena Gomez D, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy in a patient with human immunodeficiency virus infection. Enferm Infecc Micriobiol Clin (Engl Ed) 2020;38:396-7. | 32005559 |
| 1724 | Mross K, Maessen P, van der Vijgh WJ, et al. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 1988;6:517-26. | 3162516 |
| 481 | Muccioli C, Goldstein DA, Johnson DW, et al. Fomivirsen safety and efficacy in the treatment of CMV retinitis: a phase 3, controlled, multicenter study comparing immediate versus delayed treatment [abstract LB-6]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 2483 | Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. British journal of clinical pharmacology 2013 Sep;76(3):455-66. | 23305158 |
| 27 | Mueller BA, Abel SR, Brierton DG. Fluoroquinolone bioavailability in patients receiving nutritional supplements. American Journal of Health-System Pharmacy 1995;52:892-3. | 7634121 |
| 2579 | Mueller, C. et al. High prevalence of severe vitamin D deficiency in cART-naïve and successfully treated Swiss HIV patients. Abstract. 2010. 17th Conference on Retroviruses and Opportunistic Infections. | |
| 3465 | Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA 2014;312(4):362-71. | 25038355 |
| 2678 | Muirhead G, Russell D, Pozniak A, et al. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the PK of a single oral dose of Maraviroc in HIV+ve subjects [abstract 31]. 6th International Workshop on Clinical Pharmacology of HIV Therapy April 28-30, 2005, Quebec. | |
| 911 | Muirhead GJ, Wulff MB, Fielding A, et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. British Journal of Clinical Pharmacology 2000;50:99-107. | 10930961 |
| 3571 | Mukherjee D, Zha J, Menon RM, et al. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. J Pharmacokinet Pharmacodyn. 2018;45(3):443-456. | 29427135 |
| 2585 | Mukwaya G, MacGregor TR, Hoelscher D, et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 2005 December;49(12):4903-10. | 16304151 |
| 159 | Mullen PD. Compliance becomes concordance: making a change in terminology produce a change in behaviour. British Medical Journal 1997;314:691-2. | 9116538 |
| 2981 | Mulligan N, Best B, Capparelli EV et al. Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women [abstract 438]. Conference on Retroviruses and Opportunistic Infections, Boston MA, Feb 22-25,2016. | http://www.croiconference.org/sessions/dolutegravir-pharmacokinetics-hiv-infected-pregnant-and-postpartum-women-0 |
| 148 | Muma RD, Ross MW, Parcel GS, et al. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995;7(4):439-47. | 8547359 |
| 2604 | Mummaneni V, Kaul S, Knupp CA. Single oral dose pharmacokinetic interaction study of didanosine and indinavir sulfate in healthy subjects. Abstracts 26th Annual ACCP [abstract 34]. J Clin Pharmacol 1997;37(9):865. | |
| 1178 | Mummaneni V, Randall D, Chabuel D, et al. Steady-state pharmacokinetic interaction study of atazanavir with clarithromycin in healthy subjects [abstract H1717]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. | |
| 1175 | Mummaneni V, Randall D, Geraldes M, et al. Steady-state pharmacokinetic interaction study of atazanavir with lamivudine and zidovudine in healthy subjects [abstract H1713]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. | |
| 3459 | Mumpe-Mwanje D, Barlow-Mosha LB, Williamson D, et al. A hospital-based birth defects surveillance system in Kampala, Uganda. BMC Pregnancy Childbirth 2019;19(1):372. | 31640605 |
| 2758 | Munsiff AV, Patel J. Regimens with once daily ritonavir + Fortovase are highly effective in PI-experienced HIV-HCV co-infected patients on methadone [abstract 684]. 39th Annual meeting of the Infectious Diseases Society of America, October 25-28, 2001, San Francisco, CA. | |
| 1246 | Mur Lalaguna MA, Cobo Campos R, Hurtado Gomez MF, et al. [Study of interactions between anti-retroviral agents and concomitant drugs]. Farmacia Hospitalaria 2003;27(2):84-92. | 12717563 |
| 3561 | Murdoch IG, Jacobs TG, Nieuwenhuize RM et al. Ritonavir-boosted antiretroviral therapy with paclitaxel: will it lead to boosted toxicity? AIDS 2022;36:322-3. | 34934024 |
| 1420 | Muret P, Montange D, Bettinger D, et al. Assessment of amprenavir plasma C levels in patients receiving once-daily fosamprenavir in combination with either 100 or 200 mg ritonavir [abstract 26]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2007, Budapest, Hungary. | |
| 2141 | Muro EP, Fillekes Q, Kisanga ER, et al. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention. J Acq Immune Def Syndr Hum Retr 2012;59(3):266-73. | 22134145 |
| 1372 | Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clinical Infectious Diseases 2003;36(8):1082-5. | 12684925 |
| 701 | Murphy R, Gagnier P, Lamson M, et al. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-1 patients [abstract 374]. 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 1205 | Murphy R, Pokrovsky V, Rozenbaum W, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir: 108-week results of BMS study 008/044 [abstract 555]. 10th Conference on Retroviruses and Opportunistic Infections,, February 10-14, 2003, Boston. | |
| 747 | Murphy R, Sommadossi JP, Lamson M, et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis. 1999 May;179(5):1116-23. | 10191212 |
| 1029 | Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Expert Opinion on Investigational Drugs 1996;5:1183-99. | |
| 872 | Murray JF. Tuberculosis and HIV infection: a global perspective. Respiration 1998;65(5):335-42. | 9782213 |
| 404 | Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. New England Journal of Medicine 1997;337(2):83-90. | 9211677 |
| 225 | Nabors KL, Sauer BL, Soehn MS, et al. Drug information monographs for AIDS patients. American Journal of Health-System Pharmacy 1989;46:1546-7. | 2773953 |
| 3558 | Naccarato M, Kwee F, Zaltzman J, Fong IW. Ritonavir-boosted antiretroviral therapy precipitating tacrolimus toxicity in a renal transplant patient: is it time for a priori tacrolimus dosage reduction? AIDS 2021;35:2065-8. | 34471078 |
| 2750 | Naccarato M, Yoong D, Gough K. A potential drug-herbal interaction between Ginkgo biloba and efavirenz. J Int Assoc Physicians AIDS Care (Chic) 2012 Mar-Apr;11(2):98-100. | 22323244 |
| 2111 | Naccarato M, Yoong D, Kovacs C, et al. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antiviral Ther 2012;17:589-92. | 22293514 |
| 1466 | Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1–Infected Children Aged 2 Through 18 Years. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2014;58(3):413-422. doi:10.1093/cid/cit696. | 24145879 |
| 578 | Naesens L, Snoeck R, Andrei G, et al. HPMPC (cidofovir), PMEA (adefovir) and related acyclic-nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chemistry and Chemotherapy 1997;8:1-23. | |
| 3581 | Naghani SM, Jansen MM, Jaspers T et al. Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19. Eur J Hosp Pharm 2021 May 14;ejhpharm-2020-002596. doi: 10.1136/ejhpharm-2020-002596. Online ahead of print. | 33990390 |
| 284 | Naides SJ, Howard EJ, Swack NS, et al. Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy [see comments]. Journal of Infectious Diseases 1993;168(1):101-5. | 8515096 |
| 3699 | Naidoo A, Naidoo K, Letsaolo MP et al. Efficacy, safety and PK of BIC/FTC/TAF in adults with HIV and tuberculosis on rifampicin at week 24 [abstract 211]. Conference on Retroviruses and Opportunistic Infections (CROI), Mar 3-6, 2024, Denver, CO. | |
| 1926 | Naiker S, Conolly C, Weisner L, et al. Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on lopinavir/ritonavir-based ART [abstract 650]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA. | |
| 3498 | Nakalema S, Chappell CA, Pham M, et al. Pharmacokinetics of 2 contraceptive implants among women on rilpivirine-based ART [abstract 368]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, March 6-10, 2021. | |
| 2929 | Nakamoto S, Kanda T, Wu S, et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014;20:2902-12. | 24659881 |
| 3667 | Nakatsuka A, Nagai M, Yabe H, et al. Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease. J Pharmacol Sci 2006;100:59-64. | 16410677 |
| 2602 | Nallani S, Glauser T, Hariparsad N, et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 2003;44(12):1521-8. | 14636322 |
| 3342 | Nampoory MR, Nessim J, Gupta RK, Johny KV. Drug interaction of chloroquine with ciclosporin. Nephron 1992;62:108-9. | 1436274 |
| 1885 | Nanda K, Amaral E, Hays M, et al. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril 2008;90(4):965-71. | 17880953 |
| 2409 | Nanda K, Delany-Moretlwe S, Dube K, et al. Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness. Aids 2013 Oct;27 Suppl 1:S17-25. | 24088680 |
| 2269 | Nanda K, Delany-Moretlwe S, Dube K, et al. Nevirapine-containing ART does not reduce combined oral contraceptive effectiveness: results from South Africa and Uganda [abstract O_03]. 3rd International Workshop on HIV & Women, January 14-15, 2013, Toronto, Canada. | |
| 904 | Nandwani R, Gourlay Y. Possible interaction between sildenafil and HIV combination therapy [letter]. Lancet 1999;353:840. | 10459981 |
| 2244 | Nappi C, Bifulco G, Tommaselli GA, et al. Hormonal contraception and bone metabolism: a systematic review. Contraception 2012;86:606-21. | 22717184 |
| 3672 | NATAP. New PrEP studies: long-acting HIV-1 capsid inhibitor lenacapavir every 6 months. 2021. https://www.natap.org/2021/HIV/021021_01.htm | |
| 172 | National Pharmaceutical Council. Emerging issues in pharmaceutical cost containment. Reston VA: National Pharmaceutical Council1992. Report No.: 2(2):1-16. | |
| 145 | National Pharmaceutical Council. Improving medication compliance, 1985, Washington DC. | |
| 3617 | Natukunda E, Rodriquez C, McGrath EJ, et al. B/F/TAF In Virologically Suppressed Adolescents and Children: Two-year Outcomes in 6 to <18 Year Olds and Six-month Outcomes in Toddlers. International Workshop on HIV & Pediatrics 2021, 16-17 July (virtual). | https://www.natap.org/2021/IAS/IAS_80.htm |
| 2885 | Navarro J, Curran A, Burgos J, et al. Acute leg ischaemia in an HIV-infected patient receiving antiretroviral treatment. Antivi Ther 2017;22:89-90. | 27546463 |
| 1628 | Neely M, Decosterd LA, Fayet A, et al. Pharmacokinetics of once daily raltegravir and atazanavir in healthy volunteers [abstract WEPEB254]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Capetown, South Africa. | |
| 2911 | Neely M, Spencer L, Mordwinkin N, Leon T, Louie S, Jelliffe R, et al. Atazanavir concentrations in plasma, breast milk and vaginal secretions of HIV-infected women [abstract P_51]. 10thInternational Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam. April 15-17, 2009. | |
| 1187 | Neff G, Tzakes A, Safdar K, et al. Liver transplantation in HIV, complex pharmacokinetic interactions between tacrolimus and highly active antiretroviral therapy [abstract 8.4]. 4th International Workshop on Clinical Pharmacology of HIV Therapy, March 27-29, 2003, Cannes, France. | |
| 1325 | Negredo E, Molto J, Burger D, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004;18:459–63. | 15090798 |
| 1322 | Negredo E, Puig J, Masmitja E, et al. CD4 cell count changes after reduction of didanosine dosage in patients receiving standard doses of didanosine and tenofovir [abstract H561]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC. | |
| 3076 | Neijzen RW, Van Maarseveen EM, Hoepelman AI, Wensing AM, Bonora S, D'Avolio A, Mudrikova T. Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain. Int J Clin Pharm. 2016 Aug;38(4):749-51. | 27180258 |
| 2367 | Nelson M, Arasteh K, Jain MK, et al. Effect of faldaprevir on atazanavir pharmacokinetics in patients with HIV/HCV coinfection [abstract 499]. Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014, Boston, MA. | |
| 2049 | Nelson M, Dockrell DH, Edwards S, et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med 2011;12(Suppl 2):1-144. | 21851517 |
| 567 | Nelson MR, Barter G, Hawkins D, et al. Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet [letter] [see comments]. Lancet 1991;338(8761):250. | 1676798 |
| 1493 | Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infec Dis 2006;42:1189-96. | 16575741 |
| 2163 | Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse 2006;41(10-12):1395-463. | 17002989 |
| 25 | Neuvonen PJ, Kivisto KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clinical Pharmacology and Therapeutics 1991;50:498-502. | 1934862 |
| 276 | Newberry DL, Bass SN, Mbanefo CO. A fluconazole/amitriptyline drug interaction in three male adults. Clinical Infectious Diseases 1997;24(2):270-1. | 9114163 |
| 3388 | Newman T, Cafardi JM, Warshak CR. Human immunodeficiency virus-associated pulmonary arterial hypertension diagnosed postpartum. Obstet Gynecol 2015;125:193-5. | 25560124 |
| 1984 | Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS 1999;13:1788-9. | 10509586 |
| 902 | Newshan G. HIV neuropathy treated with gabapentin. AIDS 1998;12:219-21. | 9468374 |
| 1456 | Ng J, Klein C, Xiong J, et al. Lopinavir/ritonavir 500/125 mg twice-daily + efavirenz approximate the pharmacokinetic exposure of LPV/r 400/100 mg twice-daily administered alone in healthy adult subjects [abstract 765]. 15th Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, MA. | |
| 1575 | Ng J, Nada A, Freeman S, et al. Pharmacokinetics of rifabutin 150 mg three times weekly plus lopinavir/ritonavir 400/100 mg BID administered in healthy subjects [abstract O_21]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 3430 | Nguyen D, Miao X, Magee M et al. No dose adjustment of metformin with fostemsavir coadministration based on mechanistic static and physiologically based pharmacokinetic models [abstract 1315]. IDWeek 2020, October 21-25. | |
| 3174 | Nhean S, Bravo J, Sheehan NL, Walmsley S, Tilley D, Tseng AL. Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer. AIDS 2018;32:2640-4. | 30379691 |
| 2288 | Nichols A, Liang Y, Matschke K, et al. An evaluation of the potential of cytochrome P450 3A4-mediated drug-drug interactions with desvenlafaxine use. J Bioequiv Availab 2013;5:53-9. | |
| 1918 | Nieminen TH, Hagelberg NM, Saari TI, et al. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharmacol 2010;66(10):977-85. | 20697700 |
| 1217 | Nieto-Cisneros L, Zala C, Fessel WJ, et al. Antiviral efficacy, metabolic changes and safety of atazanavir versus lopinavir/ritonavir in combination with two NRTIs in patients who have experienced virological failure with prior PI-containing regimen(s): 24-week results from BMS AI424-043 [abstract 117]. Antiviral Therapy 2003;8(S1):S212. | |
| 3537 | Nieuwenstein T, Jacobs T, van der Heijden J, de Wildt S, Burger D, Freriksen J, Colbers A. Using PBPK modelling to estimate lamivudine exposure in children with abnormal renal function [abstract 14]. 22nd International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, Sept 20-22, 2021. Virtual Meeting. | |
| 1200 | Nieuwkerk P, Gisolf E, Sprangers M, et al. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response. Antiviral Therapy 2001;6(2):97-103. | 11491422 |
| 1422 | Nijland H, L'homme R, Rongen G, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008;22(8):931-5. | 18453852 |
| 3190 | Nisly SA, Stevens BN. Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: a case for apixaban. Int J STD AIDS 2019;30:718-22. | 30975070 |
| 100 | Nix DE, Watson WA, Handy L, et al. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin. Pharmacotherapy 1989;9:377-80. | 2616352 |
| 101 | Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clinical Pharmacology and Therapeutics 1989;46:700-5. | 2598571 |
| 640 | Nokes KM, Kendrew J, Longo M. Alternative/complementary therapies used by persons with HIV disease. Journal of the Association of Nurses in AIDS Care 1995;6(4):19-24. | 7495988 |
| 455 | Nokta M, Rossero R, Loesch K, et al. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea. AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1633-8. | 9430255 |
| 452 | Nokta MA, Rossero R, Nichols J, et al. Partial immune restoration of HIV-infected patients on aggressive antiretroviral therapy (ddI, d4T and hydroxyurea) [abstr. I-77]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 646 | Northrop CV, Shepherd SM, Abbuhl S. Sulfonamide-induced iritis. American Journal of Emergency Medicine 1996;14(6):577-9. | 8857810 |
| 2528 | Nosten F, McGready R, d'Alessandro U, et al. Antimalarial drugs in pregnancy: a review. Current drug safety 2006 Jan;1(1):1-15. | 18690910 |
| 2510 | Nosten F, Vincenti M, Simpson J, et al. The effects of mefloquine treatment in pregnancy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999 Apr;28(4):808-15. | 10825043 |
| 3292 | Novartis Pharmaceuticals Canada Inc. Kisqali (ribociclib) Product Monograph. Dorval, QC. September 5, 2019. | |
| 3288 | Novartis Pharmaceuticals Canada Inc. Tafinlar (dabrafenib) Product Monograph. Dorval, QC. July 31, 2015. | |
| 3264 | Novartis Pharmaceuticals Canada Inc. Zykadia (ceritinib) Product Monograph. Dorval, Quebec. December, 2018. | |
| 3229 | Novartis Pharmaceuticals Canada Inc. Afinitor (everolimus) Product Monograph. Dorval, QC. November 16, 2017. | |
| 3344 | Novartis Pharmaceuticals Canada Inc. Jakavi (ruxolitinib) Product Monograph. Dorval, QC. September 28, 2018. | |
| 3218 | Novartis Pharmaceuticals Canada Inc. Lamisil (terbinafine) Product Monograph. Dorval, QC. May 17, 2016. | https://pdf.hres.ca/dpd_pm/00035035.PDF |
| 3289 | Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) Product Monograph. Dorval, QC. July 31, 2015. | |
| 1816 | Novartis Pharmaceuticals Canada Inc. Tasigna (nilotinib) Product Monograph. Dorval, QC. December 5, 2018. | http://pdf.hres.ca/dpd_pm/00036197.PDF |
| 2188 | Novartis Pharmaceuticals Canada Inc. Tegretol (Carbamazepine) Product Monograph. Dorval, Que. May 4, 2018. | http://pdf.hres.ca/dpd_pm/00042061.PDF |
| 3530 | Novartis Pharmaceuticals Canada. Zofran (ondansetron), Zofran ODT (ondansetron oral disintegrating tablets) Product Monograph. Dorval, QC. October 21, 2020. | https://pdf.hres.ca/dpd_pm/00058412.PDF |
| 3022 | Novartis Pharmaceuticals Corp. Hycamtin (topotecan) capsules Prescribing Information. East Hanover, NJ, June 2015. | https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/hycamtin_caps.pdf |
| 3450 | Novartis Pharmaceuticals. Votrient (pazopanib) Product Monograph. Dorval, QC. July 31, 2019. | |
| 2531 | Novartis Pharmaceuticals. Coartem (artemether/lumefantrine) Product Monograph. New Jersey March 2015 | http://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/coartem.pdf |
| 1069 | Novartis Pharmaceuticals. Neoral Product Monograph. March 2015. | http://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/neoral.pdf |
| 3118 | Novartis Pharmaceuticals. Onbrez (Indacaterol) Product Monograph. Dorval, QC. Jan 2, 2015. | |
| 2717 | Novartis Pharmaceuticals. Revolade (eltrombopag) Product Monograph. Dorval, QC. May 15, 2019. | http://pdf.hres.ca/dpd_pm/00039266.PDF |
| 3298 | Novo Nordisk. Ozempic (semaglutide) Product Monograph. Mississauga, ON. November 5, 2018. | |
| 1838 | Novopharm Limited. Purinethol (mercaptopurine) Product Monograph. Toronto, ON. July 16, 2014. | http://pdf.hres.ca/dpd_pm/00025910.PDF |
| 1905 | Nozza S, Galli L, Visco F, et al. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 2010;24(6):924-7. | 20154578 |
| 3425 | Nwokolo N, Post E, Magee M et al. Fostemsavir and ethinyl estradiol drug interaction: clinical application for co-administration. HIV Glasgow, October 5-8, 2020, abstract P102. | |
| 2515 | Nyunt MM, Lu Y, El-Gasim M, et al. Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine. Clinical pharmacology and therapeutics 2012 May;91(5):889-95. | 22472986 |
| 303 | O' Hara MA, Raphael SA, Nelson LB. Isolated anterior uveitis in a child with acquired immunodeficiency syndrome. Annals of Ophthalmology 1991;23(2):71-3. | 2029118 |
| 919 | O'Brien WA, Atkinson TA, Han X, et al. Combination therapy with indinavir and ritonavir in antiretroviral-experienced patients [abstract 2209]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-28, 1999, San Francisco, CA. | |
| 2308 | O'Leary JG, McKenna GJ, Klintmalm GB, et al. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transplantation 2013;19(4):463-5. | 23408534 |
| 1105 | O'Mara E, Agarwala S, Randall D, et al. Steady-state pharmacokinetic interaction study of atazanavir with efavirenz and ritonavir in healthy subjects [abstract 444-W]. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA. | |
| 993 | O'Mara E, Mummaneni V, Bifano M, et al. Steady-state pharmacokinetic interaction study between BMS-232632 and ritonavir in healthy subjects [abstract 740]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago IL. | |
| 1051 | O'Mara E, Mummaneni V, Randall D, et al. BMS-232632: a summary of multiple-dose pharmacokinetic, food effect, and drug interaction studies in healthy subjects [abstract 504]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco. | |
| 1110 | O'Mara E, Randall D, Uderman H, et al. Steady-state pharmacokinetic interaction study between BMS-232632 and ketoconazole in healthy subjects [abstract 1646]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. | |
| 118 | O'Reilly RA, Motley CH. Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. Annals of Internal Medicine 1979;91:34-6. | 464451 |
| 1624 | Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in humans: an in vitro study. Drug Metab Dispos 2005;33:262-70. | 15547048 |
| 3016 | Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol. 2005;72(3):255-260. | 15937649 |
| 3165 | Oberoi RK, Zhao W, Sidhu DS et al. A phase 1 study to evaluate the effect of crushing, cutting in half, or grinding of glecaprevir/pibrentasvir tablets on exposures in healthy subjects. J Pharm Sci 2018;107:1724-30. | 29476763 |
| 2952 | Ocadiz A, Le MP, Charpentier C, Soulie C, Landman R, Calvez V, Descamps D et al. Circadian variation of darunavir plasma concentrations in HIV-infected patients receiving darunavir/r once-daily containing regimen [abstract P_31]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18th, 2012, Barcelona, Spain. | |
| 2558 | Occhipinti DJ, Choi A, Deyo K, et al. Influence of rifampin and clarithromycin on dapsone disposition and methemoglobin concentrations. Clinical pharmacology and therapeutics 1995;57:163. | |
| 749 | Ochoa de Echaguen A, Juanola DD, Xercauins M, et al. Correlation between plasmatic levels of indinavir and inmunologic and virologic parameters in HIV-patients [abstract 12286]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 2201 | Oette M, Kurowski M, Feldt T, et al. Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients. J Antimicrob Chemother 2005;56:416-9. | 15983027 |
| 1406 | Ofotokun I, Acosta E, Lennox J, et al. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. Pharmacotherapy. 2008 Jan;28(1):74-81. | 18154477 |
| 3445 | Ogasawara K, LoRusso PM, Olszanski AJ, et al. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. Cancer Chemother Pharmacol 2020;86:87-95. | 32537715 |
| 1710 | Ogg MS, Williams JM, Tarbit M, et al. A receptor gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro. Xenobiotica 1999;29:269-79. | 10219967 |
| 940 | Oh PI, Lanctot KL, Naranjo CA, et al. Fatal aplastic anemia associated with ticlopidine therapy - approaches to an adverse drug reaction. Canadian Journal of Clinical Pharmacology 1995;2(1):19-22. | |
| 3643 | Okochi H, Benet L, Gandhi M. Drug-drug interactions between antiretrovirals and remdesivir [abstract 7484]. 24th International AIDS Conference, July 29 - August 2, 2022; Virtual and Montreal, Canada | https://programme.aids2022.org/Abstract/Abstract/?abstractid=7484 |
| 1923 | Okoli C, Siccardi M, Thomas-William S, et al. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. J Antimicrob Chemother 2012;67(3):671-4. | 22174038 |
| 3025 | Okuma Y, Hosomi Y, Imamura A. Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus. Onco Targets Ther 2014;8:111-5. | 2567898 |
| 2234 | Oladapo OT, Daniel OJ, Odusoga OL, et al. Fertility desires and intentions of HIV-positive patients at a suburban specialist center. J Natl Med Assoc 2005;97:1672-81. | 16396059 |
| 3043 | Olagunju A, Bolaji O, Amara A, Waitt C, Else L, Adejuyigbe E, Siccardi M, Back D, Khoo S, Owen A. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother infant pairs: an observational study. Clin Infect Dis. 2015 Aug 1;61(3):453-63. | 25882300 |
| 2742 | Oliva J, Moreno S, Sanz J, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis [letter]. AIDS 2003;17(4):637-8. | |
| 1002 | Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999;91:681-85. | 10485779 |
| 2207 | Olson K. Activated charcoal for acute poisoning: one toxicologist's journey. J Med Toxicol 2010;6(2):190-8. | 20490748 |
| 2324 | Onen NF, Overton ET, Seyfried W, et al. Aging and HIV Infection: A comparison between older HIV-infected persons and the general population. HIV Clinical Trials 2010;11:100-9. | 20542846 |
| 3137 | Oostendorp RL, Buckle T, Veijnen JH et al. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitiors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 2009;27:31-40. | 18449471 |
| 1840 | Oostendorp RL, Huitema A, Rosing H, et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res 2009;15(12):4228-33. | 19509162 |
| 517 | Orellana J, Teich SA, Friedman AH, et al. Combined short- and long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U). Ophthalmology 1987;94(7):831-8. | 2821466 |
| 514 | Orellana J, Teich SA, Winterkorn JS, et al. Treatment of cytomegalovirus retinitis with ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine (BW B759U). British Journal of Ophthalmology 1988;72(7):525-9. | 2843219 |
| 483 | Orellana JH, Lieberman R, Velez W, et al. Intravitreal foscarnet therapy for patients with recurrent progressive cytomegalovirus (CMV) retinitis [We.B.3216]. XI International Conference on AIDS, July 7-12, 1996, Vancouver. | |
| 1141 | Organon Canada LTD. Remeron Product Monograph. Scarborough, ON 2001. | |
| 2164 | Orlando G, Meraviglia P, Valsecchi L, et al. cART durability and causes for treatment switching or discontinuation in HIV positive patients older than 50 years of age. J Acq Immune Def Syndr 2010;55:e12-4. | 20859084 |
| 2066 | Orrell C, Cohen K, Conradie F, et al. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther 2011;16(4):527-34. | 21685540 |
| 1360 | Ortho-McNeil Pharmaceuticals I. Ultram Product Monograph. Raritan, NJ 1998. | |
| 323 | Ortiz de Montellano PR. The 1994 Bernard B. Brodie Award Lecture. Structure, mechanism, and inhibition of cytochrome P450. Drug Metabolism & Disposition 1995;23(11):1181-7. | 8591716 |
| 3028 | OSI Pharmaceuticals Inc. Tarceva (erlotinib) Prescribing Information. Melville, NY. April 2010. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf |
| 3470 | Osiyemi O, Yasin S, Zorrilla C, et al. Pharmacokinetics, antiviral activity, and safety of rilpivirine in pregnant women with HIV-1 infection: results of a phase 3b, multicentre, open-label study. Infect Dis Ther 2018;7(1):147-59. | 29335895 |
| 637 | Ostrow MJ, Cornelisse PG, Heath KV, et al. Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1997;15(2):115-20. | 9241109 |
| 1004 | Otero MJ, Fuertes A, Sanchez R, et al. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS 1999;13(8):1004-5. | 10371190 |
| 2593 | Otsuka Canada Pharmaceutical Inc. Abilify (aripiprazole) Product Monograph. Montreal, QC. November 30, 2017. | http://www.bmscanada.ca/static/products/en/pm_pdf/ABILIFY_EN_PM.pdf |
| 3115 | Otsuka Canada Pharmaceutical Inc. Rexulti (brexpiprazole) Product Monograph. Saint-Laurent, QC. February 16, 2017. | |
| 3439 | Otsuka Novel Products GmbH. Deltyba (delamanid) Summary of Product Characteristics, EMA, May 2020. | https://www.ema.europa.eu/en/documents/product-information/deltyba-epar-product-information_en.pdf |
| 3015 | Otsuka Pharmaceutical Co., Ltd. Busulfex (busulfan) Product Monograph. Saint-Laurent, QC. March 10, 2017. | |
| 1006 | Ouellet D, AHsu, Qian J. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrobial Agents and Chemotherapy 1998;42:3107-12. | 9835499 |
| 679 | Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. British Journal of Clinical Pharmacology 1998;46(2):111-6. | 9723818 |
| 55 | Ouellet D, Hsu H, Mukherjee D, et al. Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin. Clinical Pharmacology and Therapeutics 1996;59:143 [abstr. PI-58]. | |
| 2278 | Ouwerkerk-Mahadevan S, Beaumont-Mauviel M, Peeters M, et al. The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and escitalopram [abstract 1354]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston, MA. | |
| 2279 | Ouwerkerk-Mahadevan S, Beaumont-Mauviel M, Peeters M, et al. The pharmacokinetic interaction between the investigational NS3/4A HCV protease inhibitor TMC435 and methadone [abstract 1353]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston, MA. | |
| 2074 | Ouwerkerk-Mahadevan S, Sekar V, Peeters M, et al. The pharmacokinetic interactions of HCV protease inhibitor TMC435 with rilpivirine, tenofovir, efavirenz or raltegravir in healthy volunteers [abstract 49]. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA. | |
| 2212 | Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers. Infectious Diseases Society of America (IDSA) Annual Meeting [abstract 1618], October 17-21, 2012, San Diego. | |
| 2272 | Ouwerkerk-Mahadevan S, Simion A, Mortier S, et al. No clinically significant interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and the immunosuppressive agents cyclosporine and tacrolimus [abstract 80]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 913, 2012, Boston, MA. | |
| 2338 | Ouwerkerk-Mahadevan S, Simion A, Peeters M, et al. Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus NS3/4A protease inhibitor [abstract PE 10/7]. 14th European AIDS Conference (EACS), October 16-19, 2013, Brussels, Belgium. | |
| 2271 | Ouwerkerk-Mahadevan S, Simion A, Spittaels K, et al. No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive containing ethinylestradiol and norethindrone [abstract 773]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston, MA. | |
| 2314 | Ouwerkerk-Mahadevan S, Simion A, Spittaels K, et al. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment [abstract O_04]. 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 26-27, 2013, Cambridge, MA. | |
| 1413 | Overton ET, Tschampa JM, Klebert M, et al. The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy. J Clin Pharmacol. 2010 Sep;50(9):1050-5. | 20147613 |
| 2505 | Owen A, Janneh O, Bray PG, et al. In vitro interaction between mefloquine and saquinavir: the role of breast cancer resistance protein [abstract TuPeB 4588]. XV International Conference on AIDS, July, 2004, Bangkok. | |
| 999 | Paklama VJ, Ahonen J, Neuvonen PJ, et al. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clinical Pharmacology and Therapeutics 1999;66:33-9. | 10430107 |
| 3528 | Paladin Labs Inc. Monurol (fosfomycin tromethamine) Product Monograph. St-Laurent, QC. August 10, 2017. | https://pdf.hres.ca/dpd_pm/00040638.PDF |
| 3452 | Paladin Labs Inc. Iclusig (ponatinib) Product Monograph. Saint-Laurent, QC. December 11, 2018 | |
| 492 | Palau LA, Tufty GT, Pankey GA. Recurrent iritis after intravenous administration of cidofovir. Clinical Infectious Diseases 1997;25(2):337-8. | 9332544 |
| 2967 | Palazzo A, Trunfio M, Pirriatore V, et al. Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. J Antimicrob Chemother 2018;73:826-7. | 29244118 |
| 734 | Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998;338(13):853-60. | 9516219 |
| 499 | Palestine AG, Stevens G, Jr., Lane HC, et al. Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. American Journal of Ophthalmology 1986;101(1):95-101. | 3002177 |
| 3358 | Palkama VJ, Neuvonen PJ, Olkkola KT. Effect of itraconazole on the pharmacokinetics of bupivacaine in healthy volunteers. Br J Anaesth 1999:83:659-61. | 10673888 |
| 2918 | Pancanowski J, Poirier J-M, Petit I, et al. Atazanavir urinary stones in an HIV-infected patient. AIDS 2006 24 Oct;20(16):2131. | 17053366 |
| 3437 | Pandie M, Wiesner L, McIlleron H et al. Drug–drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother 2016;71:1037-40. | 26747099 |
| 689 | Panel of Clinical Practices for Treatment of HIV Infection- Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. Federal Register November 5, 1997. (Updated April 8, 2015) | |
| 1204 | Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. Federal register May 30, 2018. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0 | https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0 |
| 3110 | Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. | https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/0 |
| 2236 | Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. . Federal register. July 31, 2012. p. 1-235 Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. | |
| 3646 | Panko N, Dunford G, Lutfi R. HIV infection is not a contraindication to laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2018;28:464-468. | 28842820 |
| 2924 | Panter Faber K, Wu HF, Yago MR, et al. Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption. Pharml Res 2017;34(3):619–628. | https://doi.org/10.1007/s11095-016-2090-2 |
| 2817 | Parikh S, Fehintola F, Huang L, et al. Artemether-lumefantrine exposure in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. Antimicrob Agents Chemother 2015;59(12):7852-56. | 26392500 |
| 2812 | Parikh S, Kajubi R, Huang L, Ssebuliba J, et al. Antiretroviral choice for HIV impacts antimalarial exposure and treatment outcomes in Ugandan children. Clin Inf Dis 2016;63(3):414-22. | |
| 2499 | Parikh S, Ouedraogo JB, Goldstein JA, et al. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clinical pharmacology and therapeutics 2007 Aug;82(2):197-203. | 17361129 |
| 2151 | Park J, Vousden M, Brittain C, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol 2010;50(10):1180-7. | 20484617 |
| 1196 | Park-Wyllie LY, Antoniou A. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003;17(4):638-40. | 12598790 |
| 1195 | Park-Wyllie LY, Scalera A, Tseng A, et al. High rate of discontinuations of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: missed opportunities for adherence support? AIDS 2002;16:1084-6. | 11953481 |
| 685 | Parke-Davis. Nardil Product Monograph. Scarborough, Ontario 1998. | |
| 1215 | Parker RA, Wang S, Mulvey R, et al. Proteasome and glucose transport inhibition: a unifying hypothesis for the mechanism of protease inhibitor induced metabolic disturbances and for the superior lipid profile of atazanavir [abstract 708]. Antiviral Therapy 2003;8(S1):S380. | |
| 647 | Parkkali T, Volin L, Siren MK, et al. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplantation 1996;17(3):433-4. | 8704701 |
| 1421 | Parks D, Jennings HR, Taylor C, et al. Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. AIDS 2007;21(10):1373-5. | 17545719 |
| 295 | Passo MS, Rosenbaum JT. Ocular syphilis in patients with human immunodeficiency virus infection. American Journal of Ophthalmology 1988;106(1):1-6. | 3394758 |
| 182 | Pastore A, Van Cleef G, Risher EJ, et al. Dideoxycytidine pharmacokinetics and interaction with clarithromycin in patients seropositive for HIV [abstr]. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 3008 | Patel CG, Li L, Girgis S, et al. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clin Pharmacol 2011;13:13-25. | 22287853 |
| 825 | Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients [letter]. New England Journal of Medicine 1995;332(5):336-7. | 7816080 |
| 2034 | Patel N, Abdelsayed S, Veve M, et al. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor–, protease inhibitor–, and raltegravir-based antiretroviral regimens. Ann Pharmacother 2011;45:317-24. | 21386025 |
| 3544 | Patel P, Ford SL, Baker M, et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long acting cabotegravir and rilpivirine in clinical trials [abstract 885]. IDWeek 2021, September 29-October 3, 2021, Virtual. | |
| 2988 | Patel P, Song I, Borland J, Chen S, Peppercorn A, Wajima T, Funaki T, Fujita N, Hughes J, Piscitelli S. Relative bioavailability of a paediatric granule formulation of the HIV integrase inhibitor dolutegravir in healthy adult subjects. Antivir Ther. 2014;19(3):229-33. | 24275098 |
| 1944 | Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 2011;66(7):1567-72. | 21493648 |
| 3320 | Patel P, Thiagarajah S, Ford SL et al. Cabotegravir pharmacokinetic tail in pregnancy and neonatal outcomes [abstract 775]. Conference on Retroviruses and Opportunistic Infections, March 8-11, 2020. Boston MA. | |
| 363 | Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group [see comments]. Genitourinary Medicine 1997;73(2):105-9. | 9215091 |
| 3308 | Patel R, Stalter R, Onono M, et al. Dolutegravir-containing ART does not reduce etonogestrel implant concentrations [abstract 129]. Conference on Retroviruses and Opportunistic Infections (CROI), March 8-11, 2020, Boston, MA. | http://www.croiconference.org/sessions/dolutegravir-containing-art-does-not-reduce-etonogestrel-implant-concentrations |
| 918 | Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000;133(1):21-30. | 10877736 |
| 345 | Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of HIV-1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrobial Agents and Chemotherapy 1998;42(10):2637-44. | 9756769 |
| 344 | Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrobial Agents & Chemotherapy 1996;40(2):292-7. | 8834868 |
| 243 | Patrick DM, Strathdee SA, Currie S, et al. Incidence of HIV in the Vancouver IDU Study Cohort. 6th Annual Canadian Conference on HIV/AIDS Research, May 22-26, 1997, 1997, Ottawa. | |
| 96 | Patsalos PN, Duncan JS. Antiepileptic drugs. A review of clinically significant drug interactions. Drug Safety 1993;9:156-84. | 8240723 |
| 2165 | Pau AK, Boyd SD. Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy. Clin Pharmacol Ther 2010;88(5):712-9. | 20668439 |
| 2729 | Pawlotsky JM, Aghemo A, Back D et al. EASL Recommendations on Treatment of Hepatitis C 2015.J Hepatol. 2015 Jul;63(1):199-236. | 25911336 |
| 3134 | Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013;59:375-382. | 23567084 |
| 1876 | Pea F, Tavio M, Pavan F, et al. Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. Antivir Ther 2008;13(5):739-42. | 18771060 |
| 401 | Pearson PA, Jaffe GJ, Ashton P. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome [letter]. American Journal of Ophthalmology 1993;115(5):686-8. | 8387726 |
| 3205 | Pecora Fulco P, Gatesman TL. Administration of crushed maraviroc via percutaneous gastrostomy tube in a patient with human immunodeficiency virus and progressive multifocal leukoencephalopathy. Am J Health Syst Pharm 2019;76(5):265-267. | 30753286 |
| 3280 | Pecora Fulco P, Patel B. Sildenafil use for pulmonary artery hypertension with a cobicistat-boosted antiretroviral regimen. Ann Pharmacother 2020;54:84-5. | 31364387 |
| 3669 | Pecora Fulco P, Winthrop E. Tecovirimat use in combination with fixed-dose bictegravir in a person with HIV and concurrent Monkeypox. Ann Pharmacother 2022; Dec 28 | 36575972 |
| 1137 | Pecora Fulco PPF, Higginson RTH, Orenstein RO. Acute pancreatitis associated with the concurrent use of valganciclovir and didanosine [abstract B10396]. XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain. | |
| 850 | Pedersen C, Cooper DA, Brun-Vezinet F, et al. The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex. Aids 1992;6(8):821-5. | 1418778 |
| 125 | Pedneault L, Elion R, Adler M, et al. Stavudine (d4T), Didanosine (ddI), and Nelfinavir Combination Therapy in HIV-Infected Subjects: Antiviral Effect and Safety in an Ongoing Pilot Study. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 798 | Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999;43(3):568-72. | 10049268 |
| 877 | Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy. 1998 Nov-Dec;18(6):1205-11. | 9855317 |
| 12 | Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Annals of Pharmacotherapy 1996;30:919-25. | 8876848 |
| 3171 | Pena MJ, Chueca N, D'Avolio A, et al. Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: rare but possible. Open Forum Infect Dis. 2018 Dec 10;6(1):ofy332. | 30631792 |
| 2739 | PENDOPHARM, Division of Pharmascience, Inc. Ibavyr (ribavirin) Product Monograph. Montreal, QC March 26, 2015. | http://pdf.hres.ca/dpd_pm/00029996.PDF |
| 3686 | Pendopharm. Myinfla (colchicine) Product Monograph. Montreal, QC, August 20, 2021. | |
| 1585 | Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44(9):879-94. | 16122278 |
| 1387 | Penzak S, Formentini E, Alfaro R, et al. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. J Acquir Immune Defic Syndr 2005;40(5):573-80. | 16284534 |
| 2746 | Penzak SR, Acosta EP, Turner M, et al. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol 2002 Oct;42(10):1165-70. | 12362932 |
| 965 | Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000;20(9):1066-71. | 10999499 |
| 1086 | Penzak SR, Hon YY, Lawhorn WD, et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. Journal of Clinical Psychopharmacology 2002;22(4):366-70. | 12172335 |
| 1661 | Penzak SR, Robertson SM, Hunt JD, et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010;30(8):797-805. | 20653355 |
| 309 | Pepose JS, Hilborne LH, Cancilla PA, et al. Concurrent herpes simplex and cytomegalovirus retinitis and encephalitis in the acquired immune deficiency syndrome (AIDS). Ophthalmology 1984;91(12):1669-77. | 6097855 |
| 2128 | Perboni G, Costa P, Fibbia GC, et al. Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. Oncologist 2010;15(2):142-5. | 20142333 |
| 3044 | Pereira SA, Caixas U, Branco T, Germano I, Lampreia F, Papoila AL, Monteiro EC. Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. Br J Clin Pharmacol. 2008 Oct;66(4):551-5. | 18662298 |
| 748 | Perello L, Goujard C, Delfraissy JF, et al. Therapeutic drug monitoring in HIV-infected patients receiving indinavir [abstract 42272]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 255 | Perez R, Suarez E, Morales JO. Epidemiologic profile of AIDS in the standard metropolitan statistical area of San Juan, Puerto Rico [abstr. Mo.C.1454]. XI International Conference on AIDS, July 7-12, 1996, Vancouver. | |
| 3583 | Perez-Alvarez R, Perez-Lopez R, Lombrana JLS, et al. Sarcoidosis in two patients with chronic hepatitis C treated with interferon, ribavirin and amantadine. Journal of Viral Hepatitis 2002;9:75-79. | 11851906 |
| 3087 | Pérez-Elías M et al. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. Antimicrob Agents Chemother 2009;53:5185-96. | 19667283 |
| 89 | Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics 1992;23:106-31. | 1511528 |
| 333 | Perlmutter BL, Harris BR. New recommendations for prophylaxis after HIV exposure. American Family Physician 1997;55(2):507-12, 15-7. | 9054220 |
| 2866 | Perram J, Joseph J, Holloway C. Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals. BMJ Case Reports 2015 Nov 20. pii: bcr2015211651. doi: 10.1136/bcr-2015-211651. | 26590187 |
| 2410 | Perry SH, Swamy P, Preidis GA, et al. Implementing the Jadelle implant for women living with HIV in a resource-limited setting in sub-Saharan Africa: concerns for drug interactions leading to unintended pregnancies. AIDS 2014 Mar 13;28(5):791-3. | 24401645 |
| 3139 | Persico M, Aglitti A, Caruso R, et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. Hepatology 2018;67:48-55. | 28714143 |
| 609 | Pertel P, Hirschtick R, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. Journal of the Acquired Immune Deficiency Syndrome 1992;5:1069-74. | 1357151 |
| 1301 | Petersen C, Pun E, Strada R, et al. Pharmacokinetics of nelfinavir (Viracept 250 mg tablet): effect of food intake on single-dose pharmacokinetic parameters [abstract 543]. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston. | |
| 2922 | Peterson D, Van Ermen A. Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and warfarin. Am J Health Syst Pharm 2017;15:888-92. | 28596225 |
| 532 | Peterson P, Stahl-Bayliss CM. Cytomegalovirus thrombophlebitis after successful DHPG therapy [letter]. Annals of Internal Medicine 1987;106(4):632-3. | 3030175 |
| 353 | Petrak RM, Boyer N, Hines D, et al. A study to evaluate the clinical and virologic efficacy of a Crixivan, ddI, and d4T combination [abstr]. 35th Annual Meeting of the Infectious Diseases Society of America, September 13-16, 1997, San Francisco. | |
| 843 | Petty BG, Kornhauser DM, Lietman PS. Zidovudine with probenecid: a warning [letter]. Lancet 1990;335(8696):1044-5. | 1970102 |
| 2116 | Peyriere H, Eiden C, Macia J-C, et al. Antihypertensive drugs in patients treated with antiretrovirals. Ann Pharmacother 2012;46:703-9. | 22550277 |
| 2809 | Peyrin-Biroulet L, Cadranel JF, Nousbaum JB, et al. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Ther. 2008;28(8):984-993. | 18657132 |
| 1063 | Peytavin G, Lamotte C, Ait-Mohand H, et al. Ritonavir-indinavir 100/400 mg BID: pharmacokinetic, efficacy and tolerance of a simple regimen in a prospective study in HIV-infected patients [abstract 3.15]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4, 2001, Noordwijk, the Netherlands. | |
| 1384 | Peytavin G, Marcelin AG, Rouault a, et al. Plasma concentrations of amprenavir, ritonavir and tenofovir in HIV-infected patients treated with fosamprenavir/ritonavir (700/100 mg BID) and tenofovir 300 mg QD containing regimens [abstract 32]. 6th International Workshop on Clinical Pharmacology of HIV Therapy April 28-30, 2005, Quebec. | |
| 2702 | Peytavin G, Marcelin AG, Rouault a, et al. Therapeutic drug monitoring of boosted tipranavir with and without combination to lopinavir or fosamprenavir [abstract 591]. 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006, Denver, CO | |
| 2976 | Peytavin G,Gautran C, Otoul C, Cremieux AC, Moulaert B, Delatour F, Melac M, Strolin-Benedetti M, Farinotti R. Evaluation of pharmacokinetic interaction between cetirizine andritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. Eur J Clin Pharmacol (2005) 61, 267–73. | 15889300 |
| 3505 | Pfizer Canada Inc. Aricept (donepezil) Product Monograph. Kirkland, QC. December 18, 2014. | |
| 3030 | Pfizer Canada Inc. Aromasin (exemestane) Product Monograph. Kirkland, QC. February 24, 2014. | https://pdf.hres.ca/dpd_pm/00024107.PDF |
| 3154 | Pfizer Canada Inc. Detrol (tolterodine) Product Monograph. Kirkland, QC. February 12, 2015. | |
| 3151 | Pfizer Canada Inc. Toviaz (fesoterodine) Product Monograph. Kirkland, QC. December 13, 2017. | |
| 2708 | Pfizer Canada Inc. Cardura (doxazosin) product monograph. Kirkland, QC; August 26, 2016. | http://www.pfizer.ca/sites/g/files/g10028126/f/201609/CARDURA_PM_E_195152_26Aug2016.pdf |
| 2718 | Pfizer Canada Inc. Champix (varenicline) Product Monograph. Kirkland, QC. February 20, 2017. | https://www.pfizer.ca/sites/g/files/g10037206/f/201711/CHAMPIX_PM_193081_20Feb2017_E.pdf |
| 2253 | Pfizer Canada Inc. Depo-Provera (medroxyprogesterone acetate injectable suspension) Product Monograph. Kirkland, QC. December 23, 2013. | http://www.pfizer.ca/sites/g/files/g10017036/f/201410/DEPO-PROVERA.pdf |
| 1654 | Pfizer Canada Inc. Diflucan (fluconazole) Prescribing Information. Kirkland, QC. August 22, 2014. | http://www.pfizer.ca/sites/g/files/g10017036/f/201410/Diflucan.pdf |
| 2485 | Pfizer Canada Inc. Eliquis (apixaban) Product Monograph. Kirkland, QC. June 16, 2016. | http://www.pfizer.ca/sites/g/files/g10037206/f/201710/ELIQUIS_PM_184464_16June2016_E_marketed.pdf |
| 1835 | Pfizer Canada Inc. EMCYT (estramustine) Product Monograph. Kirkland, QC July 14, 2008. | https://www.pfizer.ca/sites/g/files/g10017036/f/201410/EMCYT_.pdf |
| 1966 | Pfizer Canada Inc. Lyrica (pregabalin) Product Monograph. Kirkland, QC. October 23, 2014. | http://www.pfizer.ca/sites/g/files/g10023216/f/201505/LYRICA_DC_PM_E_176683_23Oct2014.pdf |
| 3019 | Pfizer Canada Inc. Methotrexate Injection (methotrexate) Product Monograph. Kirkland, QC. October 13, 2017. | |
| 3325 | Pfizer Canada Inc. Precedex (dexmedetomidine) Product Monograph. Kirkland, QC. January 8, 2020. | |
| 2996 | Pfizer Canada Inc. Relpax (eletriptan) Product Monograph. Kirkland, QC. November 26, 2013. | |
| 1814 | Pfizer Canada Inc. Sutent (sunitinib) Product Monograph. Kirkland, QC. December 3, 2014. | http://www.pfizer.ca/sites/g/files/g10017036/f/201505/Sutent_PM_E_DC_3_December_2014.pdf |
| 1863 | Pfizer Canada Inc. Vfend (voriconazole) Product Monograph. Kirkland, Quebec. October 30, 2014. | http://www.pfizer.ca/sites/g/files/g10023216/f/201505/VFEND_PM_E_177182_30Oct2014.pdf |
| 355 | Pfizer Canada Inc. Viracept (nelfinavir) Product Monograph. Montreal, QC. October 28, 2016. | http://www.pfizer.ca/sites/g/files/g10017036/f/201410/VIRACEPT_PM_E_155130_21Dec2012.pdf |
| 1040 | Pfizer Canada Inc. Zithromax (azithromycin) Product Monograph. Kirkland, QC. July 2, 2014. | http://www.pfizer.ca/sites/g/files/g10017036/f/201411/Zithromax.pdf |
| 1038 | Pfizer Canada Inc. Mycobutin (rifabutin) Product Monograph. Kirkland, QC. January 23, 2015. | http://www.pfizer.ca/sites/g/files/g10017036/f/201505/MYCOBUTIN_PM_23_Jan_2015_E.pdf |
| 3567 | Pfizer Canada ULC. Paxlovid (nirmatrelvir and ritonavir tablets) Product Monograph. Kirland, QC. January 17, 2022 | https://covid-vaccine.canada.ca/info/pdf/paxlovid-pm-en.pdf |
| 3329 | Pfizer Canada ULC. Xeljanz (tofacitinib) Product Monograph. Kirkland, QC. October 24, 2019. | https://pdf.hres.ca/dpd_pm/00053735.PDF |
| 3319 | Pfizer Canada ULC. Rocuronium Bromide Injection Product Monograph. Kirkland, QC. May 31, 2019. | |
| 3291 | Pfizer Canada. Ibrance (palbociclib) Product Monograph. Kirkland, QC. June 5, 2018. | |
| 3432 | Pfizer Canada. Pfizer-BioNTech COVID-19 Vaccine (tozinameran) Product Monograph. Kirkland, QC. December 9, 2020. | https://pdf.hres.ca/dpd_pm/00059112.PDF |
| 3285 | Pfizer Canada. Xalkori (crizotinib) Product Monograph. Kirkland, QC. March 27, 2019. | |
| 3554 | Pfizer Labs. Emergency use authorization for Paxlovid (nirmatrelvir and ritonavir) Fact Sheet for Healthcare Providers. New York, NY. December 22, 2021. | https://www.fda.gov/media/155050/download |
| 1425 | Pfizer Labs. SELZENTRY (maraviroc) Prescribing Information. New York, NY August, 2007. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022128lbl.pdf |
| 3239 | Pfizer Products Inc. Inlyta (axitinib) Product Monograph. Kirkland, QC. March 13, 2019. | https://pdf.hres.ca/dpd_pm/00050265.PDF |
| 1145 | Pfizer USA Pharmaceuticals. Geodon Product Monograph. New York, NY. February 2017. | http://labeling.pfizer.com/ShowLabeling.aspx?id=584 |
| 3031 | Pfizer. Aromasin (exemestane) Prescribing Information, New York, NY. March 2011. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020753s009s011s012lbl.pdf |
| 3449 | Pfizer. Bosulif (bosutinib) Product Monograph. Kirkland, QC. July 27, 2017. | |
| 2658 | Pfizer. Pristiq® (desvenlafaxine) Product Monograph. Canada. December 3, 2014. | http://www.pfizer.ca/sites/g/files/g10017036/f/201505/Pristiq_DC_PM_E_170902_3Dec2014.pdf |
| 3596 | Pfizer. Geodon (ziprasidone) Prescribing Information. New York, NY. January 2020. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020825s058,020919s045lbl.pdf |
| 3594 | Pfizer. Zoloft (sertraline) Prescribing Information. New York, NY. December 2016. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019839S74S86S87_20990S35S44S45lbl.pdf |
| 337 | Pflomm JM, Ho M, Gray DR, et al. Indinavir adherence and efficacy in a veteran AIDS population [abstr]. Pharmacotherapy 1997;17(5):1091-2. | |
| 2701 | Pham P, Barditch-Crovo P, Parish M, et al. Amprenavir and lopinavir pharmacokinetics in HIV-infected patients switched from APV 750 mg BID plus LPV/r 533 mg/133 mg BID to fosamprenavir 1400 mg BID plus LPV/r 533 mg/133 mg BID or vice versa [abstract A-0381]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30 2006, San Francisco, CA. | |
| 1446 | Pham PA, Flexner C, Parsons T, et al. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir. JAIDS 2007;45(2):201-5. | 17414932 |
| 1455 | Pham PA, La Porte CJL, Lee LS, et al. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 2009;53(10):4385-92. | 19667285 |
| 1199 | Phillips EJ, Rachlis AR, Ito S. Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein? AIDS 2003;17(10):1577-8. | 12824804 |
| 1111 | Phillips L, Borin MT, Hopkins NK, et al. The pharmacokinetics of nucleoside reverse transcriptase inhibitors when coadministered with the HIV protease inhibitor tipranavir in HIV-1 infected patients [abstract 81]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco. | |
| 641 | Phillips LG, Nichols MH, King WD. Herbs and HIV: the health food industry's answer. Southern Medical Journal 1995;88(9):911-3. | 7660206 |
| 2595 | Picard N, Cresteil T, Djebli N, et al. IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS Drug Metab Dispos May 2005 33:689-695. | 15743975 |
| 1964 | Piedoux S, Piroth L, Solas C, et al. Lack of relevant pharmacokinetic interaction between raltegravir and ribavirin in HIV/HCV coinfected patients [abstract P_38]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13-15, 2011, Miami, USA. | |
| 75 | Pilheu JA, Galati MR, Yunis AS, et al. Interaccion farmacocinetica entre ketconazol, isoniacida y rifampicina (Pharmacokinetic interaction of ketoconazole, isoniazid, and rifampicin). Medicina 1989;49:43-7. | 2698437 |
| 873 | Pilheu JA. Tuberculosis 2000: problems and solutions. International Journal of Tuberculosis & Lung Disease 1998;2(9):696-703. | 9755922 |
| 1206 | Piliero P, Cahn P, Pantaleo G, et al. Atazanavir: a once-daily protease inhibitor with a superior lipid profile: results of clinical trials beyond week 48 [abstract 706-T]. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA. | |
| 1084 | Piliero PJ, Preston SL, Japour A, et al. Pharmacokinetics of the combination of ritonavir plus saquinavir, with and without efavirenz, in healthy volunteers [abstract A495]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 21 | Pinching AJ, Helbert M, Peddle B, et al. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. J Infect 1989;18 (suppl. 1):33-40. | 2521663 |
| 1003 | Pinzani V, Faucherre V, Peyriere H. Methadone withdrawal symptoms with nevirapine and efavirenz. Annals of Pharmacotherapy 2000;34:405-7. | 10917395 |
| 1171 | Piscitelli S, Baede P, Van't Klooster G, et al. TMC125 does not alter lopinavir/ritonavir pharmacokinetics in healthy volunteers [abstract A1824]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. | |
| 925 | Piscitelli S, Bechtel C, Sadler B, et al. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations [abstract 78]. 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, 2000, San Francisco. | |
| 1127 | Piscitelli S, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002;22(5):551-6. | 12013352 |
| 793 | Piscitelli S, Rock-Kress D, Bertz R, et al. The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy 2000;20(5):549-53. | 10809341 |
| 942 | Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St. John's wort. Lancet 2000;355:547-8. | 10683007 |
| 1048 | Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clinical Infectious Diseases 2002;34(2):234-38. | 11740713 |
| 236 | Piscitelli SC, Flexner C, Minor JR, et al. Drug interactions in patients infected with HIV. Clinical Infectious Diseases 1996;23:685-93. | 8909827 |
| 71 | Piscitelli SC, Goss TF, Wilton JH, et al. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrobial Agents and Chemotherapy 1991;35:1765-71. | 1952845 |
| 800 | Piscitelli SC, Kelly G, Walker RE, et al. A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999;43(3):647-50. | 10049281 |
| 1148 | Piscitelli SC. Dosing phenytoin with PIs or NNRTIs? Medscape Portals Inc, 2000(6):2. | |
| 3169 | Piso RJ, Battegay M, Marzolini C. Dolutegravir plasma levels after gastric bypass surgery. AIDS 2017;31:1052-4. | 28350583 |
| 393 | Pivetti-Pezzi P, Accorinti M, Ciapparoni V, et al. Treatment of clinically resistant cytomegalovirus retinitis in AIDS patients: combination of intravenous ganciclovir and intravitreal foscarnet. European Journal of Ophthalmology 1995;5(4):199-203. | 8963154 |
| 545 | Plotkin SA, Drew WL, Felsenstein D, et al. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Journal of Infectious Diseases 1985;152(4):833-4. | 2995505 |
| 257 | Pluda JM, Mitsuya H, Yarchoan R. Hematologic effects of AIDS therapies. Hematology and Oncology Clinics of North America 1991;5:229-48. | 1708759 |
| 627 | Pluda JM, Yarchoan R, Smith PD, et al. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood 1990;76(3):463-72. | 2198957 |
| 3194 | Podany A, Sizemore E, Samaneka W, et al. Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine [abstract 1]. 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, May 14-16, 2019, Noordwijk, the Netherlands. | |
| 2781 | Podany AT, Bao Y, Swindells S et al. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis 2015;61:1322-7. | 26082504 |
| 3579 | Podany AT, Cramer Y, Imperial M et al. Twice-daily dolutegravir based antiretroviral therpay with one month of daily rifapentine and isoniazid (1HP) for TB prevention. Clin Infect Dis 2024 Apr 3:ciae183. doi: 10.1093/cid/ciae183. Online ahead of print. | 38568956 |
| 1323 | Podzamczer D, Ferrer E, Gatell JM, et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther. 2005;10(1):171-7. | 15751775 |
| 2807 | Podzamczer D, Tashima K, Daar E et al. Utilizing Phase 3 Clinical Trial Data to Assess Adverse Event (AE) Frequency of a Potentially Interacting Medication (PIM) Amlodipine with Elvitegravir/Cobicistat [abstract P314]. HIV Drug Therapy, Oct 22-26, 2016, Glasgow, UK. | |
| 83 | Pohjola-Sintonen S, Viitasalo M, Toivonen L, et al. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. European Journal of Clinical Pharmacology 1993;45:191-3. | 8223844 |
| 2635 | Poirier J, Guiard-Schmid J, Bonnard P, et al. Proton pump inhibitors do not decrease atazanavir trough plasma concentrations in HIV-infected patients treated with ritonavir boosted atazanavir regimen (300/100 mg qd) [abstract H-1895]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy December 16-19, 2005, Washington, DC | |
| 1176 | Poirier J, Meynard J, Guiard-Schmid J, et al. Lack of alteration of lopinavir and ritonavir trough plasma concentrations in HIV-experienced patients treated with Kaletra and tenofovir DF [abstract H1715]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego, CA. | |
| 1288 | Poirier J, Meynard J, Zouai O, et al. Lack of alteration of lopinavir and indinavir trough plasma concentrations in HIV-experienced patients treated with Kaletra and Crixivan [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 1191 | Poirier J, Zouai O, Meynard J, et al. Lack of drug-drug interaction between lopinavir and saquinavir based on their trough plasma concentrations in highly HIV-experienced patients treated with Kaletra and Invirase [abstract 8.12]. 4th International Workshop on Clinical Pharmacology of HIV Therapy, March 27-29, 2003, Cannes, France. | |
| 1054 | Poirier JM, Meynard JL, Guiard-Schmid JB, et al. Lopinavir and ritonavir trough plasma concentrations in HIV-experienced patients treated with Kaletra [abstract 1.7]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4, 2001, Noordwijk, the Netherlands. | |
| 1055 | Poirier JM, Meynard JL, Guiard-Schmid JB, et al. Unexpected drug-drug interaction between amprenavir and ritonavir [abstract 1.6]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4, 2001, Noordwijk, the Netherlands. | |
| 2015 | Poland B, Kastrissios H, Gupta S, et al. Population pharmacokinetic analysis finds no clinically important effects of demographic and health covariates on boceprevir exposure [abstract PK_6]. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 22-23, 2011, Cambridge, MA. | |
| 2618 | Polepally A, King J, Ding S, et al. Drug-drug interactions between the anti-hepatitis c virus 3D regimen of ombitasvir, paritaprevir/ritonavir, and dasabuvir and eight commonly used medications in healthy volunteers. Clin Pharmacokinet 2016;Feb 19 [Epub ahead of print] | 26895022 |
| 2778 | Polepally A, King J, Ding S, et al. Drug-drug interactions between the anti-hepatitis c virus 3D regimen of ombitasvir, paritaprevir/ritonavir, and dasabuvir and eight commonly used medications in healthy volunteers. Clin Pharmacokinet 2016;Feb 19 [Epub ahead of print] | 26895022 |
| 584 | Polis MA, Desmet MD, Baird BF, et al. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (Foscarnet). American Journal of Medicine 1993;94:175-80. | 8381583 |
| 549 | Polis MA, Masur H. Promising new treatments for cytomegalovirus retinitis. Jama 1995;273(18):1457-9. | 7723160 |
| 856 | Polis MA, Piscitelli SC, Vogel S, et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrobial Agents & Chemotherapy 1997;41(8):1709-14. | 9257746 |
| 680 | Polk HE, Israel DS, Pastor A, et al. Effects of ketoconazole and amprenavir (14 lW94) on P450 (CYP)3A4 activity measured by the erythromycin breath test (ERMBT) [abstract 341]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 369 | Polk RE, Brophy DF, Israel DS, et al. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrobial Agents and Chemotherapy 2001;45(2):502-8. | 11158747 |
| 698 | Polk RE, Crouch M, Israel DS, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 1999;19(12):1378-84. | 10600086 |
| 26 | Polk RE, Healy DP, Sahai J, et al. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989;33:1841-4. | 2610494 |
| 1870 | Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy 2009;29(11):1386-91. | 19857154 |
| 1686 | Poonkuzhali B, Chandy M, Srivastava A, et al. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos 2001;29:264-7. | 11181493 |
| 3187 | Portola Pharmaceuticals, Inc. Bevyxxa (betrixaban) Prescribing Information. San Francisco, CA. June 2017. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf |
| 3059 | Post FA, Winston J, Andrade-Villanueva JF, Fisher M, Liu Y, Beraud C, Abram ME, Graham H, Rhee MS, Cheng AK, Szwarcberg J; Study 118 Team. Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment. J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):310-3. | 25469527 |
| 3170 | Pourcher G, Peytavin G, Schneider L et al. Bariatric surgery in HIV patients: experience of an Obesity Reference Center in France. Surg Obes Relat Dis 2017;13:1990-6. | 29079381 |
| 3389 | Pousada G, Baloira A, Castro-Anon O, Valverde D. Pulmonary arterial hypertension associated with human immunodeficiency virus infection: study of 4 cases. Med Clin (Barc) 2016;146:350-3. | 26897508 |
| 1557 | Pozniak A, Steyn D, Grinsztejn B, et al. Less frequent reporting of central nervous system and psychiatric adverse events with TMC278 than with efavirenz [abstract WEPEA105]. 4th IAS Conference on HIV Pathogensis, Treatment and Prevention, July 22-25, 2007, Sydney, Australia. | |
| 1558 | Pozniak A, Yazdanpanah Y, Shalit P, et al. Lower lipid levels in antiretroviral-naive patients receiving the investigational NNRTI TMC278 versus efavirenz [abstract P9.2/05]. 11th European AIDS Conference, October 24-27, 2007, Madrid, Spain. | |
| 3595 | Pragma Pharmaceuticals. Desyrel (trazodone) Prescribing Information. Locust Valley, NY. June 2017. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf |
| 1895 | Pratt G, Gascoyne K, Cunningham K, et al. Human immunodeficiency virus (HIV) in older people. Age Ageing 2010;39(3):289-94. | 20190230 |
| 1190 | Prelutsky D, Salvato P, Falcon R. Pharmacokinetics of saquinavir hard gel (Invirase) when combined with atazanavir [abstract 8.11]. 4th International Workshop on Clinical Pharmacology of HIV Therapy, March 27-29, 2003, Cannes, France. | |
| 3611 | Premgamone A, Anugulruengkitt S, Wacharachaisurapol C et al. Pharmacokinetics/safety of DTG, ABC/3TC dispersible tablets in Thai children <20 kg. [abstract 736] CROI 2022, Feb 12-24, 2022. Hybrid virtual/Denver CO. | |
| 317 | Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clinical Pharmacokinetics 1997;32(Suppl 1):1-21. | 9068931 |
| 1104 | Preston S, Piliero P, O'Mara E, et al. Evaluation of steady-state interaction between atazanavir and efavirenz [abstract 443-W]. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA. | |
| 325 | Preston SL, Postelnick M, Purdy BD, et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy [letter]. AIDS 1998 January 22;12(2):228-30. | 9468380 |
| 16 | Prevention. CfDCa. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Morbid Mortal Wkly Rep July 1995;14:44(R-8). | 7565547 |
| 3624 | Prevymis. European Union Summary of Product Characteristics, January 10, 2022 | https://www.ema.europa.eu/en/documents/product-information/prevymis-epar-product-information_en.pdf |
| 643 | Price T, Stallman J, Dretler RH. Anterior uveitis in a patient with AIDS who was treated with terbinafine for oral candidiasis: a potential drug-induced reaction. Clinical Infectious Diseases 1997;25(3):752-3. | 9314484 |
| 618 | Prichard JG, Nelson MJ, Burns L, et al. Infections caused by central venous catheters in patients with acquired immunodeficiency syndrome. Southern Medical Journal 1988;81:1496-8. | 3201296 |
| 3294 | Prins HA, Bollen P, Velthoven K et al. Total dolutegravir levels decreased but free fraction increased by valproic acid [ abstract 451]. 27th Conference on Retroviruses and Opportunistic Infections, March 8-11, 2020; Boston, USA. | |
| 3393 | Proietti I, Skroza N, Michelini S et al. Efficacy of nivolumab in HIV patient with melanoma brain metastases. AIDS 2020;34:1433-5. | 32590440 |
| 1397 | Pruvost A, Negredo E, Benech H, et al. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 2005;49(5):1907-14. | 15855513 |
| 1426 | Pruvost A, Negredo E, Theodoro F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009 May;53(5):1937-43. | 19273671 |
| 3328 | Psevdos G Jr, Gonzalez E, Sharp V. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. AIDS Read 2009;19:245-8. | 19642243 |
| 2232 | Public Health Agency of Canada. At a Glance - HIV and AIDS in Canada: Surveillance Report to December 31st, 2010. Available from: http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/2010/dec/index-eng.php. . | |
| 1978 | Puech R, Gagnieu M-C, Planus C, et al. Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir. Br J Clin Pharmacol 2011;71(4):621-3. | 21395657 |
| 2516 | Pukrittayakamee S, Prakongpan S, Wanwimolruk S, et al. Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. Antimicrobial agents and chemotherapy 2003 May;47(5):1509-13. | 12709315 |
| 732 | Purdy BD, Raymond AM, Lesar T. Antiretroviral prescribing errors in hospitalized patients. Ann Pharmacother. 2000 Jul-Aug;34(7-8):833-8. | 10928390 |
| 1339 | Purkins L, Wood N, Kleinermans D, et al. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. British Journal of Clinical Pharmacology 2003;56(Suppl 1):62-8. | 14616416 |
| 2408 | Quinn DI, Nemunaitis J, Fuloria J, et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet 2009;48(3):199-209. | 19385713 |
| 1821 | Quinn DI, Nemunaitis J, Fuloria J, et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet 2009;48:199-209. | 19385713 |
| 1293 | Raber S, Amantea M, Zhou J, et al. Addition of saquinavir (SQV) to a regimen of capravirine (CPV) plus lopinavir/ritonavir (LPV/r) does not alter systemic exposure of the antiretrovirals in healthy volunteers [abstract TuPeB4631]. XV International AIDS Conference, July 11-16, 2004, Bangkok, Thailand. | |
| 1186 | Raber S, Reynolds R, Hee B, et al. Evaluation of the pharmacokinetic drug interaction between capravirine and nelfinavir in healthy volunteers and HIV-infected patients [abstract 8.8]. 4th International Workshop on Clinical Pharmacology of HIV Therapy, March 27-29, 2003, Cannes, France. | |
| 2323 | Raboud J, Blitz S, Antoniou T, et al. Recent immigrants show improved clinical outcomes at a tertiary care HIV clinic. Can J Infect Dis Med Microbiol 2012;23:9-14. | 23449134 |
| 2326 | Raboud J, Li M, Walmsley S, et al. Once daily dosing improves adherence to antiretroviral therapy. AIDS Behav 2011;15:1397-409. | 20878227 |
| 335 | Raboud JM, Montaner JSG, Rae S, et al. Predictors of duration of plasma viral load suppression [abstr. A-14]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 901 | RachBeisel JA, Weintraub E. Valproic acid treatment of AIDS-related mania [letter]. Journal of Clinical Psychiatry 1997;58(9):406-7. | 9378697 |
| 264 | Rachlis A, Fanning M. Zidovudine toxicity: clinical features and management. Drug Safety 1993;8:312-20. | 8481217 |
| 1790 | Rae JM, Soukhova NV, Flockhart DA, et al. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 2002;30:525-30. | 11950782 |
| 1444 | Raffi F, Battegay M, Rusconi S, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007;21(14):1977-80. | 17721109 |
| 970 | Raffi F, Benhamou Y, Sereni D, et al. Pharmacokinetics of, and tolerability to, a single oral 600 mg dose of abacavir in HIV-positive subjects with or without liver disease [abstract 1630]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. | |
| 2486 | Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug metabolism and disposition: the biological fate of chemicals 2009 Jan;37(1):74-81. | 18832478 |
| 293 | Rahhal FM, Arevalo JF, Chavez de la Paz E, et al. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report. Annals of Internal Medicine 1996;125(2):98-103. | 8678386 |
| 290 | Rahhal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 1996;103(7):1078-83. | 8684797 |
| 1761 | Rahman A, Korzekwa KR, Grogan J, et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. cancer Res 1994;54:5543-6. | 7923194 |
| 790 | Rainey PM, Friedland G, McCance-Katz EF, et al. Interaction of methadone with didanosine and stavudine. Journal of the Acquired Immune Deficiency Syndrome 2000;24(3):241-8. | 10969348 |
| 429 | Raman-Wilms L, Tseng AL, Wighardt S, et al. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstetrics & Gynecology 1995;85(1):141-9. | 7800312 |
| 1508 | Ramanathan R, Pau AK, Busse KH, et al. Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1–infected patient receiving therapy with ritonavir-lopinavir. Clin Infec Dis 2008;47(12):e97-99. | 18991509 |
| 2091 | Ramanathan S, Custodio JM, Wei X,et al. Pharmacokinetics of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate after switch from efavirenz/emtricitabine/tenofovir disoproxil fumarate in healthy subjects. J Acquir Immune Defic Syndr 2016;72(3):281-8. | 26885802 |
| 1431 | Ramanathan S, Abel S, Tweedy S, et al. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. JAIDS 2010;53(2):209-14. | 19851115 |
| 2439 | Ramanathan S, Custodio J, Fordyce M, et al. Tenofovir alafenamide pharmacokinetics in renal impairment: Potential for administration without dose adjustment [abstract 529]. 20th Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2013, Atlanta, GA. | |
| 3060 | Ramanathan S, Kakuda T, Mack R, West S, Kearney B. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antiviral Therapy. 2008; 13:1011-1107. | https://www.intmedpress.com/serveFile.cfm?sUID=9110602e-ad24-4982-94d4-79f686b5c226 |
| 1432 | Ramanathan S, Kakuda TN, Mack R, et al. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antiviral Ther 2008;13:1011-7. | 19195326 |
| 1404 | Ramanathan S, Mathias A, Shen G, et al. Lack of clinically relevant drug-drug interaction between ritonavir-boosted GS-9137 (elvitegravir) and fosamprenavir/ritonavir [abstract WEPEB014]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention July 22-25, 2007, Sydney, Australia. | |
| 1411 | Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted-elvitegravir when administered in combination with acid reducing agents. J Acq Immune Def Syndr 2013;Jun 14. [Epub ahead of print]. | 23774876 |
| 1412 | Ramanathan S, Shen G, Cheng A, et al. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. JAIDS 2007;45:274-9. | 17414929 |
| 1597 | Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. J Acquir Immune Defic Syndr 2007;46(2):160-66. | 17693892 |
| 3217 | Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat boosted-elvitegravir with atazanavir, rosuvastatin or rifabutin, 13th International Workshop of Pharmacology of HIV Therapy. April 16-18, 2012. Barcelona, Spain. Abstract O_03 | |
| 2095 | Ramanathan S, Wang H, Szwarcberg J, et al. Safety/tolerability, pharmacokinetics and boosting of twice-daily cobicistat administered alone or in combination with darunavir or tipranavir [abstract P_08]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 1668 | Ramanathan S, Warren D, Wei L, et al. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir [abstract A1-1301]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco. | |
| 2588 | Ramanathan S, Wei X,Custodio J, et al. Pharmacokinetics of a Novel EVG/COBI/FTC/GS-7340 Single Tablet Regimen [abstract O_13]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 1464 | Ramanathan S, West S, Hui J, et al. Clinical pharmacokinetics of once-daily elvitegravir boosted by atazanavir versus ritonavir (abstract O18). 9th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9 2008, New Orleans, LA. | |
| 3061 | Ramanathan S, West, S, Hui J, Chuck SL, Kearney BP. Clinical pharmacokinetics of once-daily elvitegravir boosted by atazanavir versus ritonavir [abstract O18]. 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, USA, April 7-9, 2008. | http://www.natap.org/2008/Pharm/Pharm_25.htm |
| 1607 | Ramirez J, Innocenti F, Schuetz, et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 2004;32:930-6. | 15319333 |
| 3036 | Ramos JC, Sparano JA, Rudek MA, et al. Safety and preliminary efficacy of vorinostat with R-EPOCH in high-risk HIV-associated non-Hodgkin's lymphoma (AMC-075). Clin Lymphoma Myeloma Leuk 2018;18:180-90. | 29426719 |
| 857 | Rana KZ, Darnowski JW, Strayer AH, et al. Clarithromycin does not affect phosphorylation of zidovudine in vitro. Antimicrobial Agents & Chemotherapy 1996;40(8):1945-7. | 8843311 |
| 453 | Rana KZ, Simmons KA, Dudley MN. Hydroxyurea reduces the 50% inhibitory concentration of didanosine in HIV-infected cells. AIDS. 1999 Oct 22;13(15):2186-8. | 10546884 |
| 233 | Rance LB, Tseng AL, Bayoumi A. Megestrol for appetite stimulation and as a progestin in hormone replacement therapy [letter]. Archives of Internal Medicine 1996;156:2498. | 8944744 |
| 1547 | Raoof A, Lachau-Durand S, Verbeeck J, et al. Etravirine has no effect on fetal development in rats and rabbits [abstract TUPE0013]. XVIIth International AIDS Conference, August 3-8, 2008, Mexico City, Mexico. | |
| 2328 | Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001;19(8):2171-8. | 11304769 |
| 2751 | Rattanapunya S, Cressey TR, Rueangweerayut R, Tawon Y, Kongjam P, Na-Bangchang K. Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults. Malar J. 2015 Oct 9;14(1):400. | |
| 251 | Rau SE, Bend JR, ARnold MO, et al. Grapefruit juice-terfandine single-dose interaction: magnitude, mechanism, and relevance. Clinical Pharmacology and Therapeutics 1997;61:401-9. | 9129557 |
| 617 | Raviglione MC, Battan R, Pablos-Mendez A, et al. Infections associated with Hickman catheters in patients with acquired immunodeficiency syndrome. American Journal of Medicine 1989;86:780-6. | 2729339 |
| 375 | Ravitch JR, Bryant BJ, Reese MJ, et al. In vivo and in vitro studies of the potential for drug interactions involving the anti-retroviral 1592 in humans [abstr. 634]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 1271 | Ray A, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir or tenofovir. Antimicrob Agents Chemother 2004;48:1089-95. | 15047506 |
| 1272 | Ray A, Vela JE, Olson L, et al. Lack of negative interaction between tenofovir and abacavir in human cells [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 806 | Razzeca K, Frye J, Odenheimerz S, et al. The treatment of nelfinavir induced diarrhea [abstract 12383]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 2876 | Reau N, Robertson MN, Feng HP et al. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection. Hepatology Communications 2017;1:757-764 | 29404492 |
| 1356 | Reckitt Benckiser Pharmaceuticals Inc. Subutex & Suboxone Product Monograph. Richmond, VA 2002. | |
| 2904 | Regazzi M, Villani P, Gulminetti R, Cusato M, Brandolini M, Tinelli C, Barassi A, Maserati R, Sighinolfi L, D'Arminio Monforte A, Melzi D'Eril GV. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens. Ther Drug Monit. 2011 Jun;33(3):303-8. | 21544015 |
| 3429 | Regeneron Pharmaceuticals Inc. Casirivimab and Imdevimab Full Emergency Use Authorization Prescribing Information. Tarrytown, New York. November 2020 | https://www.fda.gov/media/143892/download?utm_medium=email&utm_source=govdelivery |
| 1698 | Reid JM, Kuffel MJ, Miller JK, et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999;5:2192-7. | 10473105 |
| 58 | Reines ED, Gross PA. Antiviral agents. Med Clin NA 1988;72:691-715. | 3280914 |
| 754 | Reiser M, Salzberger B, Stiepel A, et al. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy. Eur J Med Res. 1999 Feb 25;4(2):54-8. | 10066640 |
| 1729 | Relling MV, Evans R, Dass C, et al. Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 1992;261:491-6. | 1578365 |
| 1730 | Relling MV, Nemec J, Schuetz EG, et al. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994;45:352-8. | 8114683 |
| 2258 | Remis RS, Swantee C, Liu J. HIV/AIDS in Ontario: preliminary report, 2010. Toronto: Ontario Ministry of Health and Long Term Care,. 2012 Available from: http://www.ohemu.utoronto.ca/doc/PHERO2010_report_preliminary.pdf. | |
| 1487 | Rendon AL, Nunez M, Jiminez-Nacher I, et al. Clinical benefit of interventions driven by therapeutic drug monitoring. HIV Med 2005;6:360-5. | 16156885 |
| 3613 | Revollo B, Vinuela L, de la Mora L, et al. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. J Antimicrob Chemother 2022 Mar 11;dkac082. doi: 10.1093/jac/dkac082. Online ahead of print. | 35274144 |
| 81 | Rex J. Itraconazole-digoxin interaction [letter]. Ann Intern Med 1992;116:525. | 1310840 |
| 1559 | Rey D, Hoen B, Chavanet P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009 February;63(2):380-8. | 19036752 |
| 352 | Reynes J, Denisi R, Massip P et al. Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group. J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):103-5. | 10534154 |
| 2411 | Reynolds H, Chrdle A, Egan D, et al. Pharmacokinetics of raltegravir 400 vs 800 mg bid with intermittent rifampicin thrice weekly [abstract 496]. 21st Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014, Boston, MA. | |
| 3051 | Reynolds H, Lewis J, Egan D , et al.The effect of antacids and multivitamins on raltegravir [abstract 470]. 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018), Boston, March 4-7, 2018. | |
| 1857 | Rhame F, Matson M, Wood D, et al. Effects of famotidine and omeprazole on raltegravir pharmacokinetics in HIV-infected individuals [abstract PE4.1/1]. 12th European AIDS Conference, November 11-14, 2009, Cologne, Germany. | |
| 1465 | Rhame FS, Long M, Acosta E. RAL-KAL: pharmacokinetics of coadministered raltegravir and lopinavir-ritonavir in healthy adults (abstract O19). 9th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9 2008, New Orleans, LA. | |
| 2276 | Rhee E, Feng H-P, Xuan F, et al. Absence of a significant pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and HIV-1 NNRTI rilpivirine [abstract 537]. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA. | |
| 208 | Rhone-Poulenc Rorer. Flagyl Product Monograph. Canada. | |
| 209 | Rhone-Poulenc Rorer. Pentacarinat Product Monograph. Canada October 13, 1993. | |
| 3356 | Ribeiro RMP, Moreira FL, Moises ECD et al. Lopinavir/ritonavir increases the placental transfer of bupivicaine enantiomers in human immunodeficiency virus-infected pregnant women. Br J Clin Pharmacol 2018;84:2415-21. | 29959798 |
| 2648 | Ribera E, Azuaje C, Lopez RM, et al. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 2006;20:1131-9. | |
| 1181 | Ribera E, Azuaje C, Lopez RM, et al. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):317-23. | 16249706 |
| 1095 | Ribera E, Pou L, Fernandez-Sola A, et al. Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 2001;45:3238-41. | 11600390 |
| 1094 | Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. Journal of the Acquired Immune Deficiency Syndrome 2001;28:450-3. | 11744833 |
| 332 | Rich JD, Ramratnam B, Flanigan TP. Triple combination antiretroviral prophylaxis for needlestick exposure to HIV [letter]. Infection Control & Hospital Epidemiology 1997;18(3):161. | 9090541 |
| 2608 | Richards DB, Walker GA, Mandagere A, et al. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol 2009 Jun;49(6):719-24. | 19389876 |
| 951 | Richardson D, Liou S, Kahn JO. Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS clinical trials group protocols 116a and 116b/117. Journal of the Acquired Immune Deficiency Syndrome 1993;6(11):1212-23. | 8229656 |
| 285 | Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New England Journal of Medicine 1987;317(4):192-7. | 3299090 |
| 794 | Riddler S, Havlir D, Squires KE, et al. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity. Antimicrobial Agents and Chemotherapy 2002;46(12):3877-82. | 12435691 |
| 705 | Riddler S, Squires K, Havlir D, et al. ***Co-administration of indinavir 1000 mg and escalating nelfinavir dose in a twice-daily regimen: preliminary safety, pharmacokinetic and antiviral activity [abstract 22352]***see Squires, 1999 #794 for update. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 2033 | Ridtitid W, Wongnawa M, Mahatthanatrakul W, et al. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol 2000;52:1265-8. | 11092571 |
| 321 | Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995;15(6 Pt 2):84S-99S. | 8587855 |
| 1718 | Riggs CE, Benjamin RS, Serpick AA, et al. Biliary disposition of adriamycin. Clin Pharmacol Ther 1977;22:234-41. | 884924 |
| 2923 | Rindone JP, Mellen CK. Reduction in warfarin effect associated with sofosbuvir-velpatasvir. Am J Health Syst Pharm 2017;74:1308-11. | 28842460 |
| 1911 | Ripamonti D, Cattaneo D, Baldelli S, et al. Steady-state pharmacokinetics, efficacy, safety and tolerability of dual regimen with atazanavir (300mg bid) plus raltegravir (400mg bid) in HIV-1 infected patients: 24-week results (CARDS study) [abstract LBPE4.3/5]. 12th European AIDS Conference, November 11-14, 2009, Cologne, Germany. | |
| 1859 | Ripamonti D, Cattaneo D, Baldelli S, et al. Steady-state pharmacokinetics, efficacy, safety and tolerability of dual regimen with atazanavir (300mg bid) plus raltegravir (400mg bid) in HIV-1-infected patients: 24-week results (CARDS study) [abstract LBPE4.3/5]. 12th European AIDS Conference, November 11-14, 2009, Cologne, Germany. | |
| 1572 | Ripamonti D, Maggiolo F, D'Avolio A, et al. Steady-state pharmacokinetics of atazanavir 200 mg BID when combined with raltegravir 400 mg BID in HIV-1 infected adults [abstract O_14]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 3588 | Roa P-AE, Bazzi R. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer. Int J STD AIDS 2022;33:97-8. | 34787026 |
| 2994 | Roberts RL, Wallace MC, Phipps-Green AJ et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2017 Mar;17(2):201-203 | 26810134 |
| 1460 | Robertson S, Davey RT, Voell J, et al. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008 Feb;24(2):591-9. | 18205997 |
| 1457 | Robertson S, Maldarelli F, Natarajan V, et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):513-9. | 18989234 |
| 2709 | Robertson S, Penzak S, Lane J, et al. A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature. Clin Infec Dis 2005 Jul 15;41:e15-8. | |
| 1593 | Robertson SM, Maldarelli F, Natarajan V, et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008;49(5):513-9. | 18989234 |
| 1052 | Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrobial Agents and Chemotherapy 2000;44(8):2093-9. | 10898681 |
| 791 | Robinson P, Gigliotti M, Lamson M, et al. Effect of the reverse transcriptase inhibitor, nevirapine, on the steady-state pharmacokinetics of clarithromycin in HIV-positive patients [abstract 374]. 6th Conference on Retroviruses and Opportunistic Infections, January 31-February 4, 1999, Chicago IL. | |
| 708 | Robinson P, Lamson M, Gigliotti M, et al. Pharmacokinetic interaction between nevirapine and rifampin [abstract 60623]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 1803 | Roche. Capecitabine (Xeloda) Prescribing Information. Mississauga, Ontario. August 03, 2016 | https://pdf.hres.ca/dpd_pm/00035936.PDF |
| 3415 | Rock AE, DeMarai PL, Vergara-Rodriguez PT, Max BE. HIV-1 Virologic Rebound Due to Coadministration of Divalent Cations and Bictegravir. Infect Dis Ther 2020;9:691-6. | 32623580 |
| 1934 | Rockstroh J, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008 Feb;9(2):82-8. | 18257771 |
| 2368 | Rockstroh JK, Valantin M-A, Mallolas J, et al. Pharmacokinetics of faldaprevir and antiretrovirals in patients with hiv/hcv coinfection [abstract 497]. Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014, Boston, MA. | |
| 1249 | Rockstroh JK. Management of hepatitis B and C in HIV co-infected patients. Journal of Acquired Immune Deficiency Syndromes: JAIDS 2003;34(Suppl 1):S59-65. | 14562859 |
| 3323 | Rodriguez C, Chokephaibulkit K, Liberty A, et al. Safety, PK, and efficacy of low dose B/F/TAF in children at least 2 years old living with HIV [abstract 840]. Conference on Retroviruses and Opportunistic Infections (CROI), March 8-11, 2020. Boston, MA. | http://www.croiconference.org/sessions/safety-pk-and-efficacy-low-dose-bftaf-children-%E2%89%A52-years-old-living-hiv |
| 2220 | Rodríguez-Nóvoa S, Morello J, González M, et al. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008;22(18):2535-7. | 19005277 |
| 1260 | Rodriguez-Torres M, Torriani FJ, Soriano V, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother. 2005 Oct;49(10):3997-4008. | 16189072 |
| 3195 | Roelofsen E, Wildenbeest S, Mollema F, Burger D. Pharmacokinetics of tenofovir disoproxil fumarate/emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy. AIDS 2020;34:1989-91. doi: 10.1097/QAD.0000000000002633 | 33009014 |
| 103 | Rogge MC, Solomon WR, Sedman AJ, et al. The theophylline-enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition. Clinical Pharmacology and Therapeutics 1988;44:579-87. | 3180639 |
| 3184 | Rokx C, Blonk M, Verbon A, et al. The efficacy, pharmacokinetics, adn safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1 infected patients. J Acquir Immune Defic Syndr 2015;68:36-39 | 25247434 |
| 2668 | Rolf, P. G., Heeswijk, v., Bourbeau, M., Campbell, P., Seguin, I., Chauhan, B. M., Foster, B. C. and Cameron, D. W. Time-Dependent Interaction Between Lopinavir/Ritonavir and Fexofenadine. Journal of Clinical Pharma 2006;46:758–767. | |
| 1373 | Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clinical Infectious Diseases 2003;37(12):e174-6. | 14689363 |
| 1008 | Romanelli F, Jennings HR, Nath A, et al. Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology 2000;54(7):1404-7. | 10751246 |
| 1348 | Romanelli F, Pomeroy C. Concurrent use of antiretrovirals and anticonvulsants in human immunodeficiency virus (HIV) seropositive patients. Curr Pharm Des 2003;9:1433-9. | 12769723 |
| 3179 | Romero-Leon JM, Galvez-Contreras MC, Diez-Garcia LF. Symptomatic bradycardia and heart failure triggered by ivabradine in a patient receiving antiretroviral therapy. Rev Esp Cardiol (Engl Ed) 2016;69:529-30. | 27012681 |
| 3472 | Rosebush J, Best B, Chadwick EG, et al. Maraviroc safety and pharmacokinetics in HIV-exposed neonates [abstract 00842]. Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020. Boston, Massachusetts. | https://www.croiconference.org/abstract/maraviroc-safety-pharmacokinetics-in-hiv-exposed-neonates/ |
| 3473 | Rosebush JC, Best BM, Chadwick EG, et al. Pharmacokinetics and safety of maraviroc in neonates. AIDS 2021;35(3):419-27. | 33252481 |
| 531 | Rosecan LR, Stahl-Bayliss CM, Kalman CM, et al. Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethyl guanine. American Journal of Ophthalmology 1986;101(4):405-18. | 3008560 |
| 294 | Rosenbaum JT, Rahn DW. Prevalence of Lyme disease among patients with uveitis [letter; comment]. American Journal of Ophthalmology 1991;112(4):462-3. | 1928255 |
| 304 | Rosenblatt MA, Cunningham C, Teich S, et al. Choroidal lesions in patients with AIDS. British Journal of Ophthalmology 1990;74(10):610-4. | 2285685 |
| 3246 | Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:317-23. | 9070594 |
| 164 | Rosenstock IM. Historial origins of the Health Belief Model. Health Education Monographs 1974;2(4):328-35. | |
| 163 | Rosenstock IM. The Health Belief Model and preventive health behaviour. Health Education Monographs 1974;2(4):354-86. | |
| 1208 | Rosenzweig JC, Jordan J, Pathak D, et al. Patient perspectives on potential adherence to triple combination antiretroviral regimens [abstract 121]. Fifth International Congress on Drug Therapy in HIV Infection, October 22-26, 2000, Glasgow, Scotland. | |
| 2881 | Roskam-Kwint M, Bollen P, Colbers A, Duisenberg-van Essenberg M, Harbers V, Crevel R, Burger DM. Crushing of dolutegravir combination tablets increases dolutegravir exposure [abstract 429]. Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle, WA. | http://www.croiconference.org/sites/default/files/posters-2017/429_Bollen.pdf |
| 439 | Rossero R, McKinsey D, Green S, et al. Open label combination therapy with stavudine, didanosine, and hydroxyurea in nucleoside experienced HIV-1 infected patients [abstr. 653]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 457 | Rossero R, Nokta M, Andron L, et al. Open label combination therapy with stavudine, didanosine, and hydroxyurea in nucleoside experienced HIV-1 patients. 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 2126 | Rossi DR, Rathbun RC, Slater LN. Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Pharmacother 2002;22:1312-6. | 12389881 |
| 3572 | Rossi DR, Rathbun RC, Slater LN. Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. Pharmacotherapy. 2002;22(10):1312-1316. | 12389881 |
| 1297 | Roszko PJ, Curry K, Brazina B, et al. Standard doses of efavirenz, zidovudine, tenofovir, and didanosine may be given with tipranavir/ritonavir [abstract 865]. 2nd IAS Conference on HIV and Pathogenesis, July 14-17, 2003, Paris, France. | |
| 2249 | Rothman MS, Bessesen MT. HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options. Curr Osteoporos Rep 2012;10(4):270-7. | 23100110 |
| 3484 | Rough K, Sun Jenny W, Seage 3rd, GR, et al. Zidovudine use in pregnancy and congenital malformations. AIDS 2017;31(12):1733-1743. | 28537936 |
| 1357 | Roxane Laboratories I. Orlaam Product Monograph. Columbus, OH 2001. | |
| 1737 | Roy P, Tretyakov O, Wright J, et al. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favourable metabolic properties of (R)-enantiomer. Drug Metab Dispos 1999;27:1309-18. | 10534317 |
| 1695 | Roy P, Yu LJ, Crespi CL, et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999;27:655-66. | 10348794 |
| 230 | Royal Pharmaceutical Society of Great Britain. From compliance to concordance: towards shared goals in medicine taking. London: Royal Pharmaceutical Society1997. | |
| 1714 | Royer I, Monsarrat B, Sonnier M, et al. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996;56:58-65. | 8548776 |
| 1317 | Ruane P, Luber A, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrobial Agents and Chemotherapy 2007;51:560-5. | 17088488 |
| 291 | Rubin M. New drug application for lamivudine (EpivirTM). FDA Division of Antiviral Drug Products and Antiviral Drugs Advisory Committee Meeting, November 6, 1995, Washington, D.C. | |
| 2406 | Rudek MA, Chang CY, Steadman K, et al. Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure. Cancer Chemother Pharmacol 2014 Apr;73(4):729-36. | 24488374 |
| 1987 | Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011;12:905-12. | 21570912 |
| 3138 | Rudek MA, Moore PC, Mitsuyasu RT et al. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer 2014;120:1194-202. | 24474568 |
| 1017 | Ruedy J, Schechter M, Montaner JS. Zidovudine for early human immunodeficiency virus (HIV) infection: who, when, and how? Annals of Internal Medicine 1990;112:721-3. | 1970465 |
| 3510 | Ruel T, Acosta EP, Singh R, et al. Pharmacokinetics and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to <6 years: results from IMPAACT P1093 [abstract) AIDS 2018, Amsterdam, Netherlands, July 23-27, 2018 | http://regist2.virology-education.com/presentations/2018/10PED/16_ruel.pdf |
| 3506 | Ruel TD, Capparelli EV, Tierney C, et al. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Lancet HIV 2021; 8(3):e149-e157. | 33242457 |
| 971 | Ruiz NM, Labriola DF, Fiske WD, et al. Efavirenz plasma levels and therapeutic response are affected in patients concomitantly receiving selective serotonin reuptake inhibitors [abstract 1635]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. | |
| 456 | Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS. 1998 May 28;12(8):F71-7. | 9631134 |
| 442 | Rutschmann OT, Opravil M, Iten A, et al. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. Antivir Ther. 1998;3 Suppl 4:65-7. | 10723515 |
| 1330 | Ruxrungtham K, Boyd M, Bellibas SE, et al. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. Journal of Clinical Pharmacology 2004;44(7):793-803. | 15199084 |
| 1530 | Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 2008;9(10):883-96. | 18795960 |
| 2257 | S Wason, DiGiacinto JL, Davis MW. Clinically significant drug interaction between colchicine and ritonavir in healthy adults. 14th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, July 19-21, 2012, Washington, DC. | |
| 762 | Saag M, Knowles M, Chang Y, et al. Durable effect of Viracept (nelfinavir mesylate) in triple combination therapy [abstract I-101]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 2051 | Saag MS. HIV now firmly established in the middle ages. Clin Infect Dis 2011;Advance Access published October 13, 2011:1-3. | 21998283 |
| 719 | Saah A, Riddler S, Havlir DV, et al. Co-administration of indinavir and nelfinavir: pharmacokinetics, tolerability, anti-viral activity, and preliminary viral resistance [abstract 22352]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 988 | Saah A, Winchell G, Rhodes R, et al. Multiple-dose pharmacokinetics and tolerability of indinavir with ritonavir and efavirenz combinations in a once-daily regimen in healthy volunteers (Merck 093) [P284]. 5th International Congress on Drug Therapy in HIV Infection, October 22-26, 2000, Glasgow, Scotland: AIDS. | |
| 916 | Saah AJ, Winchell G, Seniuk M, et al. Multiple-dose pharmacokinetics and tolerability of indinavir and ritonavir combinations in a once-daily regimen in healthy volunteers (Merck 089) [abstract 329]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-28, 1999, San Francisco, CA. | |
| 786 | Saah AJ, Winchell G, Seniuk M, et al. Multiple-dose pharmacokinetics and tolerability of indinavir ritonavir combinations in healthy volunteers [abstract 362]. 6th Conference on Retroviruses and Opportunistic Infections, January 31-February 4, 1999, Chicago IL. | |
| 3382 | Saari TI, Laine K, Leino K, et al. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 2006;80:502-8. | 17112806 |
| 3656 | Saberi P, Phengrasamy T, Nguyen DP. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports, and clinical management. HIV Med 2013; 14: 519-529. | 23590676 |
| 2657 | Saberi P, Ranatunga DK, Quesenberry CP et al: Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy Mar, 2011; 31(3):253-261. | |
| 2713 | Sabo J, Elgadi M, Wruck J, et al. The pharmacokinetic interaction between atazanavir/ritonavir and steady-state tipranavir/ritonavir in healthy volunteers [abstract 41]. 7th International Workshop on Clinical Pharmacology of HIV Therapy, April 20-22, 2006, Lisbon. | |
| 2334 | Sabo J, Kashuba A, Ballow C, et al. Cytochrome P450 (CYP) interactions with the HCV protease inhibitor BI 201335 in healthy volunteers [abstract A-1248]. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 9-12, 2012, San Francisco. | |
| 2277 | Sabo J, Kort J, Ballow C, et al. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz and tenofovir. Clin Infec Dis 2014;Aug 4. pii: ciu616. [Epub ahead of print]. | 25091302 |
| 2354 | Sabo J, Lang B, Elgadi M, et al. Effect of multiple oral doses of faldaprevir on the multiple dose pharmacokinetics of a combination oral tablet of ethinylestradiol and levonorgestrel in healthy premenopausal female volunteers [abstract 482]. Hepatology 2013;58(4 (suppl)):440A. | |
| 1065 | Sabo J, MacGregor T, Lamson M, et al. Pharmacokinetics of tipranavir and nevirapine [abstract 249]. 10th Annual Canadian Conference on HIV/AIDS Research, May 31-June 3, 2001, Toronto. | |
| 2757 | Sabo J, Macha S, Oksala C, et al. Stereoselective pharmacokinetics of methadone after co-administration with steady-state tipranavir/ritonavir 500/200 mg BID in healthy volunteers [abstract 42]. 7th International Workshop on Clinical Pharmacology of HIV Therapy, April 20-22, 2006, Lisbon. | |
| 1520 | Sabo JP, Cong XJ, Haas D, et al. Lack of a pharmacokinetic effect between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers [abstract A-967]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington, DC. | |
| 214 | Sackett DL, Haynes RB. Compliance with therapeutic regimens. Baltimore MD: Johns Hopkins University Press; 1976. | |
| 173 | Sackett DL, Snow JC. The magnitude of compliance and non-compliance. In: Haynes RB, Taylor WD, Sackett DL, editors. Compliance in Health Care. Baltimore: Johns Hopkins University Press; 1979. p. 11-22. | |
| 356 | Sacks SL, Aoki FY, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group [see comments]. Jama 1996;276(1):44-9. | 8667538 |
| 2567 | Sadarangani S, Berg ML, Mauck W. Iatrogenic cushing syndrome secondary to ritonavir-epidural triamcinolone interaction: an illustrative case and review. Interdiscip Perspect Infect Dis 2014;2014:849432. | 24895495 |
| 205 | Sadler BM, Caldwell P, Scott JD, et al. Drug interaction between rifampin and atovaquone in HIV+ asymptomatic volunteers [abstr]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco. | |
| 651 | Sadler BM, Eron J, Wakeford J, et al. Pharmacokinetics of 141W94 and indinavir after single-dose coadministration in HIV-positive volunteers [abstract A-56]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 707 | Sadler BM, Gillotin C, Chittick GE, et al. Pharmacokinetic drug interactions with amprenavir [abstract 12389]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 1088 | Sadler BM, Gillotin C, Lou Y, et al. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrobial Agents and Chemotherapy 2001;45:3663-68. | 11709366 |
| 924 | Sadler BM, Piliero PJ, Preston SL, et al. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS. 2001 May 25;15(8):1009-18. | 11399983 |
| 3582 | Saeheng T, Na-Bangchang K, Siccardi M et al. Physiologically-based pharmacokinetic modeling for optimal dosage prediction of quinine coadministered with ritonavir-boosted lopinavir. Clin Pharmacol Ther 2020;107:1209-20. | 31721171 |
| 3603 | Sage Therapeutics, Inc. Zulresso (brexanolone) Prescribing Information. Cambridge, MA. March, 2019. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf |
| 134 | Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir (SQV) and nevirapine (NVP). 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 1021 | Sahai J, Gallicano K, Garber G, et al. Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. Clinical Pharmacology and Therapeutics 1992;52:464-70. | 1424420 |
| 50 | Sahai J, Gallicano K, Oliveras L, et al. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993;53:292-7. | 8453847 |
| 822 | Sahai J, Gallicano K, Pakuts A, et al. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus [see comments]. Journal of Infectious Diseases 1994;169(5):1103-7. | 8169401 |
| 1366 | Sahai J, Gallicano K, Seguin I, et al. Interaction between zidovudine (ZDV) and didanosine (ddI) [abstract 82]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 4-7, 1994, New Orleans. | |
| 823 | Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Annals of Internal Medicine 1997;127(4):289-93. | 9265429 |
| 37 | Sahai J, Garber G, Gallicano K, et al. Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. Annals of Internal Medicine 1995;123:584-7. | 7677298 |
| 820 | Sahai J, Narang PK, Hawley-Foss N, et al. A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1995;9(3):274-9. | 7788425 |
| 193 | Sahai J, Stewart F, Swick L, et al. Rifabutin reduces saquinavir plasma levels in HIV-infected patients [abstract A027]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996, New Orleans. | |
| 28 | Sahai J. Avoiding the ciprofloxacin-didanosine interaction [letter]. Ann Intern Med 1995;123:394-5. | 7625638 |
| 237 | Sahai J. Risks and synergies from drug interactions. AIDS 1996;10((suppl 1)):S21-5. | 8970672 |
| 2826 | Sahajpal R, Ahmed R, Hughes CA, Foisy MM. Probable interaction between levothyroxine and ritonavir: Case report and literature review. Am J Health-Syst Pharm. 2017;74:587-92. | 28389458 |
| 3557 | Salama E, Hill L, Patel N, et al. Brief report: pharmacokinetics of bictegravir and tenofovir in combination with darunavir/cobicistat in treatment-experienced persons with HIV. JAIDS 2021;88:389-92. | 34285156 |
| 3531 | Salama E, Hill L, Patel N, et al. Pharmacokinetics of bictegravir and tenofovir in combination with darunavir/cobicistat in treatment-experienced persons with HIV. J Acquir Immune Defic Syndr 2021; Jul 19. | 34285156 |
| 1255 | Salmon-Ceron D, Chauvelot-Moachon L, Abad S, et al. Mitochondrial toxic effects and ribavirin.[comment]. Lancet 2001;357(9270):1803-4. | 11407389 |
| 1014 | Salmon-Ceron D, Fontbonne A, Saba J, et al. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of pneumocystis carinii pneumonia. Journal of Infectious Diseases 1995;172:656-64. | 7658056 |
| 360 | Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrobial Agents & Chemotherapy 1994;38(10):2454-7. | 7840587 |
| 147 | Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. American Journal of Medicine 1992;92:495-502. | 1580296 |
| 1906 | Samineni D, Desai P, Sallans L, et al. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol 2012;52(6):922-31. | 21712498 |
| 841 | Sampol E, Lacarelle B, Rajaonarison JF, et al. Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. British Journal of Clinical Pharmacology 1995;40(1):83-6. | 8527274 |
| 349 | Sampson M, Torres RA, Stein AJ, et al. Ritonavir-saquinavir combination treatment in protease inhibitor experienced patients with advanced HIV disease [abstr. I-104]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 350 | Sampson MS, Barr MR, Torres RA, et al. Viral load changes in nelfinavir treated patients switched to a second protease inhibitor after loss of viral suppression [abstr. LB-5 ]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 2836 | San C, Le M, Gervais A et al. Pharmacokinetic interaction between ledipasvir/sofosbuvir and etravirine containing regimen [abstract P_46]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL. | http://regist2.virology-education.com/Abstractbook/2017_5.pdf |
| 3257 | Sanchez RI, Yee, KL, Fan L, et al. Evaluation of the pharmacokinetics of metformin following coadministration with doravirine in healthy volunteers. Clin Pharmacol Drug Dev 2020;9:107-114. | 30973682 |
| 3426 | Sanchez-Rubio Ferrandez J, Lopez Garcia A, Gaspar Alonso-Vega G et al. Successful bictegravir/emtrictabine/tenofovir alafenamide treatment in a HIV patient with swallowing difficulties. Ann Pharmacother 2021;55(4):556-7. | 32862660 |
| 2715 | Sandhu P, Lee W, Xu X et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005;33(5):676-82. | |
| 3071 | Sandkovsky U, Swindells S, Moore R, Acosta EP, Fletcher CV. Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection. Pharmacotherapy 2012: 32(2):142–147. | 22392423 |
| 3570 | Sandow N, Diesing D, Sarrafzadeh A, et al. Nimodipine dose reductions in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2016;25(1):29-39. | 26690937 |
| 1828 | Sandoz Canada Inc. Fluorouracil (5-fluorouracil) Product Monograph. Boucherville, QC. September 26, 2016. | https://www.sandoz.ca/sites/www.sandoz.ca/files/Ondansetron%20TAB%26INJ%20Monograph.pdf |
| 3379 | Sandoz Canada Inc. Sufentanil Citrate Injection (sufentanil) Product Monograph. Boucherville, QC. August 17, 2018. | https://pdf.hres.ca/dpd_pm/00047506.PDF |
| 2745 | Sandoz Inc. Mefloquine Hydrochloride Product Monograph. Princeton, NJ. 2003-2009. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf |
| 687 | Sandoz Canada Inc. Loxapac (loxapine) Product Monograph. Boucherville, QC. July 7, 2014. | https://www.sandoz.ca/sites/www.sandoz.ca/files/Loxapac%20IM%20PMe%202014%2007%2007.pdf |
| 3014 | Sandstrom M, Karlsson MO, Ljungman P et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of bulsulphan in bone marrow transplantation recipients. Bone Marrow Transplant 2001;28:657-64. | 11704788 |
| 2703 | Sanis Health Inc. Terazosin product monograph. Dieppe, New Brunswick. August 7, 2015 | https://pdf.hres.ca/dpd_pm/00031794.PDF |
| 1225 | Sanne I, al. e. Comparative results of atazanavir vs. nelfinavir in combination with stavudine and lamivudine in treatment-naïve, HIV infected patients [abstract I-667]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 1222 | Sanne I, Piliero P, Squires KE, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. Journal of the Acquired Immune Deficiency Syndrome 2003;32(1):18-29. | 12514410 |
| 104 | Sano M, Kawakatsu K, Ohkita C, et al. Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans. European Journal of Clinical Pharmacology 1988;35:161-5. | 3191935 |
| 3234 | Sanofi Aventis Canada. Jevtana (cabazitaxel) Product Monograph. Laval, QC. September 7, 2017. | |
| 2487 | Sanofi Aventis Canada. Plavix (clopidogrel) Product Monograph. Laval, QC. December 7, 2016. | http://products.sanofi.ca/en/plavix.pdf |
| 2527 | Sanofi Aventis Canada. Primaquine (primaquine phosphate) Product Monograph. Laval, QC. March 13, 2017. | http://products.sanofi.ca/en/primaquine.pdf |
| 3453 | Sanofi Genzyme. Caprelsa (vandetanib) Product Monograph. Mississauga, ON. April 15, 2020. | |
| 3313 | Sanofi Genzyme. Kevzara (sarilumab) Product Monograph. Mississauga, ON. August 8, 2019. | |
| 3680 | Sanofi-Aventis Canada Inc. Cyclomen (danazol) Product Monograph. Laval, QC. May 18, 2017. | https://pdf.hres.ca/dpd_pm/00039595.PDF |
| 3037 | Sanofi-Aventis Canada Inc. Taxotere (docetaxel) Product Monograph. Laval, QC, November 3, 2017. | https://pdf.hres.ca/dpd_pm/00041993.PDF |
| 1831 | Sanofi-Aventis Canada Inc. Eloxatin (oxaliplatin) Product Monograph. Laval, QC. March 13, 2015. | http://products.sanofi.ca/en/eloxatin.pdf |
| 3376 | Sanofi-Aventis Canada Inc. Imovane (zopiclone) Product Monograph. Laval, QC. September 27, 2018. | https://pdf.hres.ca/dpd_pm/00047597.PDF |
| 3587 | Sanofi-aventis Canada Inc. Largactil (chlorpromazine) Product Monograph. Laval, QC. October 13, 2006. | https://pdf.hres.ca/dpd_pm/00002958.PDF |
| 3340 | Sanofi-Aventis Canada Inc. Plaquenil (hydroxychloroquine) Product Monograph. Laval, QC. August 26, 2019. | |
| 3271 | Sanofi-Aventis Canada Inc. Zaltrap (aflibercept) Product Monograph. Laval, QC. August 5, 2016. | https://pdf.hres.ca/dpd_pm/00035933.PDF |
| 2744 | Sanofi-Aventis U.S. Priftin (rifapentine) Product Monograph. Bridgewater, NJ. June 2018. | http://products.sanofi.us/priftin/priftin.pdf |
| 2508 | Sanofi-Aventis. Aralen (chloroquine phosphate) Product Monograph. Bridgewater, NJ. March 2013. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/006002s043lbl.pdf |
| 3593 | Sanofi-Aventis. Piportil (pipotiazine) Product Monograph. Laval, Quebec. October 2011. | https://products.sanofi.ca/en/piportil-l4.pdf |
| 1409 | Sansone-Parsons A, al. E. The addition of tipranavir has no impact on the pharmacokinetics of vicriviroc when coadministered with a potent CYP3A4 inhibitor such as ritonavir [abstract 57]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2007, Budapest, Hungary. | |
| 3387 | Santos JR, Merino A, Haefeli WE, et al. Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension: minimal removal by hemodialysis-a case report. BMC Nephrol 2020;21:24. doi: 10.1186/s12882-019-1659-5. | 31992232 |
| 1556 | Santoscoy M, Cahn P, Gonsalez C, et al. TMC278 (rilpivirine), a next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naive patients: 96 week results of study C204 [abstract TUAB0103]. XVIIth International AIDS Conference, August 3-8, 2008, Mexico City, Mexico. | |
| 1617 | Saraga M, Preisig M, Zullino DF. Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient. Bipolar Disord 2006;8(4):415-7. | 16879143 |
| 420 | Saran BR, Maguire AM. Retinal toxicity of high dose intravitreal ganciclovir [see comments]. Retina 1994;14(3):248-52. | 7973120 |
| 97 | Sarma GR, Kailasam S, Nair NGK, et al. Effect of prednisone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrobial Agents and Chemotherapy 1980;18:661-6. | 7447424 |
| 2284 | Sauvageon H, Grinsztejn B, Arnold V, et al. Pharmacokinetics of two doses of raltegravir in combination with rifampin in HIV-TB coinfected patients, an ANRS 12180 Reflate TB substudy [abstract 539]. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA. | |
| 2506 | Savarino A, Lucia MB, Rastrelli E, et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. Journal of acquired immune deficiency syndromes (1999) 2004 Mar 1;35(3):223-32. | 15076236 |
| 2106 | Saxena V, Terrault N. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant 2012 Jun;17(3):216-24. | 22476221 |
| 256 | Scadden DT, Zon LI, Groopman JE. Pathophysiology and management of HIV-associated hematologic disorders. Blood 1989;74:1455-63. | 2676010 |
| 2628 | Scarsi K, Darin KM, Nakalema S, et al. Correlation between efavirenz and levonorgestrel plasma concentrations during a drug-drug interaction study [abstract 70]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC. | |
| 1310 | Scarsi K, Postelnick M, Murphy R. Comparison of lopinavir/r plasma levels with and without tenofovir as part of HAART in HIV-1 infected patients [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome. | |
| 3180 | Scarsi KK, Cirrincione L, Nakalema S, et al. Double-dose levonorgestrel implant does not fully overcome interaction with efavirenz [abstract 51]. Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 4-17, 2019. | http://www.croiconference.org/sessions/double-dose-levonorgestrel-implant-does-not-fully-overcome-interaction-efavirenz |
| 3034 | Scarsi KK, Cramer YS, Gingrich D, et al. Vaginal contraceptive hormone exposure profoundly altered by efavirenz- and atazanavir/ritonavir-based ART [abstract 141]. 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018), Boston, March 4-7, 2018. | http://www.croiconference.org/sessions/vaginal-contraceptive-hormone-exposure-profoundly-altered-efv-and-atvr-based-art |
| 3355 | Scarsi KK, Darin KM, Chappell CA, et al. Drug-drug interactions, effectiveness and safety of hormonal contraceptives in women living with HIV. Drug Safety 2016;39:1053-72. | 27562873 |
| 2465 | Scarsi KK, Darin KM, Nakalema S, et al. Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks. Clin Infect Dis 2016:62(6):675-82. | 26646680 |
| 2574 | Scarsi KK, Darin KM, Nakalema S, et al. Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks. Clin Infect Dis 2016:62(6):675-82. | 26646680 |
| 3495 | Scarsi KK, Smeaton LM, Podany AT, et al. PK of dose-adjusted emergency contraception with EFV-based ART in ACTG 5375 [abstract 91]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, March 6-10, 2021. | |
| 730 | Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Annals of Internal Medicine 1998;128(1):21-8. | 9424977 |
| 2223 | Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease. Ann Intern Med 2012;157:94-103. | 22801672 |
| 3045 | Schalkwijk S, Colbers A, Best B, et al. Pharmacokinetics of Efavirenz 600 mg QD during Pregnancy and Postpartum [abstract 433]. Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb 22-25, 2016. | http://www.croiconference.org/sites/default/files/posters-2016/433.pdf |
| 3471 | Schalkwijk S, Colbers A, Konopnicki D, et al. Lowered rilpivirine exposure during the third trimester of pregnancy in human immunodeficiency virus type-1-infected women. Clin Infect Dis 2017;65(8):1335-1341. | 28595298 |
| 3062 | Schalkwijk, S, Colbers, A, Konopnicki, D et al. First reported use of elvitegravir and cobicistat during pregnancy. AIDS 2016, 30(5):807-808. | 26913711 |
| 1203 | Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. Journal of the Acquired Immune Deficiency Syndrome 2002;31(3):257-75. | 12439201 |
| 29 | Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50. | 8633817 |
| 2192 | Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins). Focus on drug-drug interactions. Clin Pharmacokinet 2010;49(9):573-88. | 20690781 |
| 2199 | Scheen AJ. Drug interactions of clinical importance with antihyperglycemic agents: an update. Drug Safety 2005;28:601-31. | 15963007 |
| 2195 | Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46:93-108. | 17253883 |
| 2196 | Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007;46:1-12. | 17201456 |
| 2197 | Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58. | 20590741 |
| 2101 | Schering Corporation a subsidiary of Merck & Co. Victrelis (boceprevir) prescribing information. Whitehouse Station, NJ April, 2012. | |
| 1996 | Schering Corporation a subsidiary of Merck & Co. Victrelis (boceprevir) Product Monograph. Whitehouse Station, NJ May, 2011. | |
| 3591 | Schering Corporation. Trilafon (perphenazine) Prescribing Information. Kenilworth, NJ. April 2002. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf |
| 20 | Scheven J, Scheven ML. Interaction between azoles and amphotericin B in the treatment of candidiasis [letter]. Clin Infec Dis 1995;20:1079. | 7795064 |
| 865 | Scheven M, Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrobial Agents & Chemotherapy 1995;39(8):1779-83. | 7486918 |
| 2100 | Schipani A, Waters L, Siccardi M, et al. Use of an in vitro to in vivo extrapolation to choose the best strategy for patients switching from efavirenz to maraviroc [abstract P_17]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 1090 | Schippers EF, Hugen PW, den Hartigh J, et al. No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients. AIDS 2000;14(17):2794-5. | 11125902 |
| 3513 | Schneider A, Ramesh M. Angioedema following initiation of glecaprevir/pibrentasvir while on sitagliptin. J Allergy Clin Immunol Pract 2019;7:2068-9. | 30779957 |
| 1394 | Scholler M, Hoetelmans RM, Bollen S, et al. No significant interaction between TMC125 and didanosine in healthy volunteers [abstract 29]. 6th International Workshop on Clinical Pharmacology of HIV Therapy April 28-30, 2005, Quebec. | |
| 1527 | Scholler-Gyure M, Boffito M, Pozniak A, et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacother 2008;28(10):1215-22. | 18823217 |
| 1452 | Scholler-Gyure M, Debroye C, Aharchi F, et al. No effect of TMC125 on the pharmacokinetics of oral contraceptives [abstract 57]. Eighth International Congress on Drug Therapy in HIV Infection, November 12-16, 2006, Glasgow. | |
| 1659 | Scholler-Gyure M, Kakuda TN, Akuma SH, et al. Pharmacokinetic interaction between etravirine and lopinavir/ritonavir [abstract A1-1298]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco. | |
| 1472 | Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV–volunteers. British Journal of Clinical Pharmacology 2008;66(4):508-16. | 18492125 |
| 1528 | Scholler-Gyure M, Kakuda TN, De Smedt G, et al. Pharmacokinetic interaction between the non-nucleoside reverse transcriptase inhibitor TMC125 and atorvastatin in HIV-negative volunteers [abstract WEPEA 106]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 22-25, 2007, Sydney, Australia. | |
| 1549 | Scholler-Gyure M, Kakuda TN, De Smedt G, et al. Pharmacokinetics of TMC125 in HIV-1 negative volunteers with mild and moderate hepatic impairment [abstract A-1428]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007, Chicago, IL. | http://www.natap.org/2007/ICAAC/ICAAC_17.htm |
| 1548 | Scholler-Gyure M, Kakuda TN, De Smedt G, et al. Pharmacokinetics of TMC125 in QD and BID regimens in HIV-1 negative volunteers [abstract A-1427]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007, Chicago, IL. | http://www.medadvocates.org/resources/conferences/icaac/47/etravirine/jd122018%20scholler%20poster%2006%2009%2007.pdf |
| 1512 | Scholler-Gyure M, Kakuda TN, Stevens T, et al. Effect of etravirine on cytochrome P450 isozymes assessed by the Cooperstown 5+1 cocktail [abstract A-955]. . 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington, DC. | |
| 1658 | Scholler-Gyure M, Kakuda TN, Van Solingen-Ristea R, et al. Pharmacokinetic interaction between etravirine and fluconazole or voriconazole in HIV-negative volunteers [abstract A1-1299]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco. | |
| 1469 | Scholler-Gyure M, Kakuda TN, Van Solingen-Ristea RM, et al. No clinically relevant effect of etravirine on digoxin pharmacokinetics in HIV-negative volunteers (abstract P22). 9th International Workshop on Clinical Pharmacology of HIV Therapy April 7-9 2008, New Orleans, LA. | |
| 1844 | Scholler-Gyure M, Kakuda TN, Woodfall B, et al. Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception 2009;80(1):44-52. | 19501215 |
| 2158 | Scholler-Gyure M, Van den Brink W, Kakuda TN, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol 2008;48:322-9. | 18195053 |
| 2684 | Scholler-Gyure M, Woodfall B, Bollen S, et al. Pharmacokinetics of amprenavir and TMC125 in HIV-infected volunteers receiving TMC125 with fosamprenavir/ritonavir [abstract A-0370]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27-30 2006, San Francisco, CA. | |
| 2953 | Scholten S, Mauruschat S, Hindermann S et al. Administration of darunavir tablets in patients with difficulties in swallowing - two case reports. Journal of the International AIDS Society 2010 13(Suppl 4):P114. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112889/ |
| 2816 | Schulman S. Inhibition of warfarin activity by ribavirin. Ann Pharmacother 2002;36(1):72-74. | 11816263 |
| 1059 | Schutz M, Nangah S, Merry C. The effect of gastric proton pump inhibitors on delavirdine absorption: four case reports [abstract 1.15]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4, 2001, Noordwijk, the Netherlands. | |
| 1280 | Schvarcz R, Rudbeck G, Soderdahl G, et al. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000;69(10):2194-5. | 10852623 |
| 2518 | Schwartz A, Brown JR. Quinidine-rifampin interaction. American heart journal 1984 Apr;107(4):789-90. | 6702573 |
| 102 | Schwartz J, Jauregui L, Lettieri J, et al. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum. Antimicrobial Agents and Chemotherapy 1988;32:75-7. | 3348614 |
| 2805 | Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi’s sarcoma. AIDS 1999;13:283-4 | 10202837 |
| 3228 | Seattle Genetics, Inc. Adcetris (brentuximab vedotin) Product Monograph. Bothell, WA. May 2, 2019. | https://pdf.hres.ca/dpd_pm/00051061.PDF |
| 1994 | Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010;65:1079-85. | 20335191 |
| 2107 | Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Current Opinion in HIV and AIDS 2011;6(6):514-26 10.1097/COH.0b013e32834b54dc. | 22001895 |
| 588 | Seidel EA, Koenig S, Polis MA. A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet. AIDS 1993;7:941-5. | 8357555 |
| 1025 | Seifert RD, Stewart MB, Sramek JJ, et al. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. British Journal of Clinical Pharmacology 1994;38:405-10. | 7893580 |
| 3518 | Sekaggya-Wiltshire C, Nabisere R, Musaazi J, et al. PK and safety of high-dose rifampicin in TB-HIV co-infected patients on EFV or DTG [abstract 90]. Conference on Retroviruses and Opportunistic Infections (Virtual CROI), March 6-10, 2021. | |
| 3497 | Sekaggya-Wiltshire C, Nabisere R, Musaazi J, et al. Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with tuberculosis and human immunodeficiency virus receiving high-dose rifampicin. Clin Infect Dis 2023;76(3)e910-e919 | 35861296 |
| 2954 | Sekar V et al. Bioavailability and food effect of darunavir following administration of an oral suspension [abstract H-233]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: September 12-15th, 2009. | http://www.hivandhepatitis.com/2009icr/icaac/pdfs/3_ICAACBioavai_Sekar.pdf |
| 1623 | Sekar V, De Paepe E, De Marez T, et al. Pharmacokinetic interaction between darunavir (TMC 114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine and sertraline (abstract P295). 8th International Congress on Drug Therapy in HIV Infection, November 12-16, 2006, Glasgow, Scotland. | |
| 2691 | Sekar V, De Paepe E, Vangeneugden T, et al. Absence of an interaction between the potent HIV protease inhibitor TMC114 and the fusion inhibitor enfuvirtide in the POWER 3 analysis [abstract 54]. 7th International Workshop on Clinical Pharmacology of HIV Therapy April 20-22, 2006, Lisbon. | |
| 2680 | Sekar V, De Pauw M, Marien K, et al. No clinically significant pharmacokinetic drug-drug interaction is observed between the HIV protease inhibitor TMC114 and the non-nucleoside reverse transcriptase inhibitor efavirenz [abstract 55]. 7th International Workshop on Clinical Pharmacology of HIV Therapy April 20-22 2006, Lisbon. | |
| 2955 | Sekar V, Kestens D, Spinosa-Guzman S, De Pauw M, De Paepe E, Vangeneugden T, Lefebvre E, Hoetelmans RM. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol. 2007 Apr;47(4):479-84. | 17389557 |
| 1522 | Sekar V, Lavreys L, Van de Casteele T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob Agents Chemother 2010;54:4440-5. | 20660678 |
| 2643 | Sekar V, Lefebvre E, Boogaerts G, et al. Pharmacokinetic interaction between the protease inhibitors TMC114 and lopinavir/ritonavir [abstract A-0367]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27-30 2006, San Francisco, CA. | |
| 1510 | Sekar V, Lefebvre E, De Marez T, et al. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects. Clin Drug Invest 2008;28(8):479-85. | 18598093 |
| 1450 | Sekar V, Lefebvre E, De Marez T, et al. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers. Drugs in R & D 2007;8(4):241-8. | 17596110 |
| 1473 | Sekar V, Lefebvre E, De Pauw M, et al. Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. British Journal of Clinical Pharmacology 2008;66(2):215-21. | 18460033 |
| 1458 | Sekar V, Lefebvre E, Marien K, et al. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers. Ther Drug Monit 2007(29):795-801. | 18043478 |
| 1635 | Sekar V, Lefebvre E, Marien K, et al. Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2009;68(1):116-9. | 19660009 |
| 1511 | Sekar V, Lefebvre E, Spinosa Guzman S, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antiviral Ther 2008;13(4):563-9. | 18672535 |
| 1399 | Sekar V, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetic interaction trial between darunavir in combination with low-dose ritonavir and didanosine [abstract WEPEB012]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 22-25, 2007, Sydney, Australia. | |
| 1405 | Sekar V, Spinosa-Guzman S, De Paepe E, et al. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment. Clin Pharmacokinet. 2010 May;49(5):343-50. | 20384396 |
| 1398 | Sekar V, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between Prezista and pravastatin [abstract 54]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2007, Budapest, Hungary. | |
| 1482 | Sekar V, Spinosa-Guzman S, Meyvisch P, et al. Cocktail study to investigate the in-vivo drug interaction potential of darunavir co-administered with low-dose ritonavir (DRV/r) on cytochrome P450 enzymes 2D6, 2C9 and 2C19 [abstract P23]. 9th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9 2008, New Orleans, LA. | http://www.medadvocates.org/resources/conferences/iwcphiv/9th/iwcphiv%202008%20cocktails%20final.pdf |
| 1589 | Sekar V, Tomaka F, Lavreys L, et al. Pharmacokinetic interaction between darunavir in combination with low-dose ritonavir (DRV/r) and carbamazepine (CBZ) [abstract TUPE0083]. XVII International AIDS Conference, August 3-8, 2008, Mexico City. | |
| 1660 | Sekar V, Tomaka F, Lefebevre E, et al. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenace therapy using methadone or buprenorphine/naloxone. J Clin Pharmacol 2011;51(2):271-8. | 20421512 |
| 2075 | Sekar V, Verloes R, Meyvisch P, et al. Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers [abstract 1076]. 45th Annual Meeting of the European Association for the Study of the Liver (EASL), April 14-18, 2010, Vienna, Austra. | |
| 2280 | Sekar V, Verloes R, Meyvisch P, et al. Evaluation of metabolic interactions for TMC435 via cytochrome P450 enzymes in healthy volunteers [abstract 1076]. 45th Annual Meeting of the European Association for the Study of the Liver (EASL), April 14-18, 2010, Vienna, Austria. | |
| 2956 | Sekar VJ, Lefebvre E, De Paepe E, De Marez T, De Pauw M, Parys W, Hoetelmans RM. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007. | 17210768 |
| 774 | Selik RM, Karon JM, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. Journal of Infectious Diseases 1997;176(3):632-6. | 9291308 |
| 914 | Sellers E, Lam R, McDowell J, et al. The pharmacokinetics of abacavir and methadone following coadministration: CNAA1012 [abstract 663]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-28, 1999, San Francisco, CA. | |
| 760 | Sension M, Elion R, Green L, et al. An open label study to assess the 48-week efficacy and safety of BID Viracept (nelfinavir mesylate) combined with 2 NRTI's in HIV-infected treatment-naive patients [abstract I-218.]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 24-27, 1998, San Diego. | |
| 3584 | Seo S, Englund JA, Nguyen JT, et al. Combination therapy with amantadine, oseltamavir and ribavirin for influenza A infection: safety and pharmacokinetics. Antiviral Therapy 2013:18:377-386. | 23264438 |
| 1603 | Sepracor I. Lunesta (eszopiclone) Prescribing Information. Marborough, MA February, 2008. | |
| 3278 | Serrao A, Santoro C, Foa R, Chistolini A. Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients. HIV Med 2020;21:e7. doi: 10.1111/hiv.12803 | 31618519 |
| 3178 | Servier Canada Inc. Lancora (ivabradine) Product Monograph. May 14, 2018, Laval, Canada. | |
| 2875 | Servier Canada Inc. Lixiana (edoxaban) Product Monograph. Laval, Quebec, July 26, 2017. | |
| 1166 | Servier Canada Inc. Starnoc Product Monograph. Laval, Quebec 2000. | |
| 1513 | Sevinsky H, Eley T, He B, et al. Effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther 2011;16(2):149-56. | 21447863 |
| 1463 | Sevinsky H, Eley T, Yones C, et al. Effect of atazanavir with and without ritonavir on the pharmacokinetics of the CYP2C8 probe rosiglitazone in healthy subjects [abstract O5]. 9th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9, 2008, New Orleans, LA. | http://www.natap.org/2008/Pharm/Pharm_15.htm |
| 2852 | Sevinsky H, Magee M, Ackerman P, et al. The effect of fostemsavir on methadone and buprenorphine pharmacokinetics [abstract MOPEB0338]. 9th IAS Conference on HIV Science (IAS 2017). July 23-26th, 2017, Paris, France. | http://programme.ias2017.org/Abstract/Abstract/3300 |
| 2920 | Sharma GK, Megaly M. Etravirine as a culprit of recurrent drug-eluting in-stent restenosis in an HIV patient. Int J Cardiol 2016;219:117-8. | 27318755 |
| 3526 | Sheehan NL, Brouillette M-J, Delisle M-S, Allan J. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother 2006;40:147-50. | 16368918 |
| 1894 | Sheehan NL, Kelly DV, Tseng AL, et al. Evaluation of HIV drug interaction web sites. Ann Pharmacother 2003;37:1577-86. | 14565802 |
| 1389 | Sheehan NL, Richter C, Koopmans P, et al. Efavirenz 600 mg is not associated with subtherapeutic efavirenz concentrations when given concomitantly with rifampin [abstract 28]. 6th International Workshop on Clinical Pharmacology of HIV Therapy April 28-30, 2005, Quebec. | |
| 1279 | Sheikh AM, Wolf DC, Lebovics E, et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999 July 27;68(2):307-9. | 10440408 |
| 4 | Shelton J, Morse GD, Hewitt RG. Gastric hypoacidity among HIV-infected outpatients [abstract 495]. 2nd National Conference on Human Retroviruses, 1995, Washington, D.C. | |
| 968 | Shelton MJ, Cloen D, Becker M, et al. Evaluation of the pharmacokinetic interaction between phenytoin and nelfinavir in healthy volunteers at steady state [abstract 426]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. | |
| 1079 | Shelton MJ, Cloen D, Berenson C, et al. Pharmacokinetics (PK) of once daily (QD) saquinavir/ritonavir (SQV/RTV): effects on unbound methadone and alpha1-acid glycoprotein (AAG) [abstract A-492]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 1092 | Shelton MJ, Cloen D, Berenson C, et al. Pharmacokinetics of once daily saquinavir/ritonavir: effects on unbound methadone and alpha1-acid glycoprotein [abstract A492]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 1060 | Shelton MJ, Cloen D, DiFrancesco R, et al. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. Journal of Clinical Pharmacology 2004 April 2-4;44(3):293-304. | 14973306 |
| 1382 | Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr. 2006 May;42(1):61-7. | 16639341 |
| 1173 | Shelton MJ, Giovanniello AA, Cloen D, et al. Effects of didanosine formulations on the pharmacokinetics of amprenavir. Pharmacotherapy 2003;23(7):835-42. | 12885096 |
| 677 | Shelton MJ, Hewitt RG, Adams JM, et al. Delavirdine mesylate pharmacokinetics during combination therapy with ritonavir [abstract A-63]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 912 | Shelton MJ, Mei JH, Hewitt RG, et al. If taken 1 hour before indinavir, didanosine does not affect indinavir exposure, despite persistent buffering effects. Antimicrobial Agents and Chemotherapy 2001;45:298-300. | 11120981 |
| 1316 | Shelton MJ, Wire MB, Lou Y, et al. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob Agents Chemother. 2006 Mar;50(3):928-34. | 16495253 |
| 913 | Shelton MJ, Wynn H, Hewitt RG, DiFrancesco R. Effect of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. J Clin Pharmacol 2001;41(4):435-42. | 11304900 |
| 2738 | Sherman KE. High frequency of anemia in HCV-HIV coinfected persons receiving weight-based ribavirin and zidovudine [abstract 67955]. 56th Annual Meeting of the American Association for the Study of Liver Diseases, November 11-15, 2005, San Francisco, CA. | |
| 2899 | Sheth AN, Evans-Strickfaden T, Haaland R, et al. HIV-1 Genital Shedding is Suppressed in the Setting of High Genital Antiretroviral Drug Concentrations Throughout the Menstrual Cycle. The Journal of Infectious Diseases. 2014;210(5):736-744. doi:10.1093/infdis/jiu166. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202306/ |
| 3326 | Shibayama T, Sugiyama D, Kamiyama E, et al. Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab pharmacokinet 2007;22:41-7. | 17329910 |
| 1780 | Shibutani S, Ravindernath A, Suzuki N, et al. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000;21:1461-7. | 10910945 |
| 3097 | Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. British Journal of Clinical Pharmacology. 2006;62(3):372-376. | 1885140 |
| 3064 | Shiomi M, Matsuki S, Ikeda A, et al. Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: A randomized, three-way crossover study. Journal of Clinical Pharmacology. 2014;54(6):640-648. | 24615728 |
| 2825 | Shire. Intuniv XR (guanfacine) Product Monograph. Saint-Laurent, QC, June 24, 2016. | |
| 3523 | Shytaj IL, Tolba MM, Lucic B et al. Cobicistat syndergizes with remdesevir to suppress SARS-CoV-2 replication in vitro [abstract 394]. Conference on Retroviruses and Opportunistic Infections (virtual CROI), March 6-10, 2021. | |
| 47 | Shyu WC, Knupp CA, Pittman KA, et al. Food-induced reduction in bioavailability of didanosine. Clinical Pharmacology and Therapeutics 1991;50:503-7. | 1934863 |
| 3464 | Sibiude J, Mandelbrot L, Blanche S, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort (ANRS Co1/Co11) | 24781315 |
| 2897 | Siccardi M, D'Avolio A, Simiele M, Sciandra M, Baietto L, et al. Intracellular pharmacokinetics of boosted and unboosted atazanavir in HIV infected patients [abstract 17]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7th, 2010, Sorrento, Italy. | http://regist2.virology-education.com/11th/docs/07_Siccardi.pdf |
| 3621 | SIGA Technologies Inc. TPOXX (tecovirimat) Product Monograph. Corvallis, OR. November 29, 2021. | https://pdf.hres.ca/dpd_pm/00063782.PDF |
| 3622 | SIGA Technologies, Inc.TPOXX (tecovirimat capsules and injection) Prescribing Information. Corvallis OR. May 2022. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214518s000lbl.pdf |
| 3598 | Sim BZ, Smith LK, Yarwood T, Smith S. Successful treatment of HIV-associated progressive multifocal leukoencephalopathy with pembrolizumab. AIDS 2022;36:483-5. | 35084387 |
| 1129 | Sim SM, Hoggard PG, Sales SD, et al. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. AIDS Research and Human Retroviruses 1998;14(18):1661-7. | 9870320 |
| 318 | Simpson AE. The cytochrome P450 4 (CYP4) family. General Pharmacology 1997;28(3):351-9. | 9068972 |
| 881 | Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1995;9(2):153-61. | 7749792 |
| 2445 | Singh G, Jackson A, D'Avolio A, et al. No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals.[Letter]. AIDS 2014;28(13):1993-5. | 25259708 |
| 1415 | Singh K, Dickinson L, Back DJ, et al. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther 2008 Jun;83(6):867-72. | 17898705 |
| 149 | Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996;8(3):261-9. | 8827119 |
| 639 | Singh N, Squier C, Sivek C, et al. Determinants of nontraditional therapy use in patients with HIV infection. A prospective study. Archives of Internal Medicine 1996;156(2):197-201. | 8546553 |
| 3297 | Singh R, Chandasana H, Dooley KE, et al. Population pharmacokinetic analysis of dolutegravir in HIV/TB co-infected people with and without rifampicin [abstract PE35/9]. 17th European AIDS Conference, November 6-9, 2019, Basel, Switzerland. | |
| 3427 | Singh R, Shaik J, Wolstenholme A et al. Comparison of relative bioavailability of Tivicay neonatal liquid formulations to pediatric dispersible tablets [abstract 8]. Int Workshop Clin Pharmacol HIV Hepatitis Antivirals 2020, Sep 28-30. | |
| 2134 | Sinicco A, Raiteri R, Rossati A, et al. Efavirenz interference in estradiol ELISA assay. Clin Chem 2000;46:734-5. | 10794766 |
| 776 | Skiest DJ, Chiller T, Chiller K, et al. Protease inhibitor therapy is associated with markedly prolonged time to relapse and improved survival in AIDS patients with cytomegalovirus retinitis. Int J STD AIDS. 2001 Oct;12(10):659-64. | 11564333 |
| 619 | Skoutelis AT, Murphy RL, MacDonell KB, et al. Indwelling central venous catheter infections in patients with acquired immune deficiency syndrome. Journal of the Acquired Immune Deficiency Syndrome 1990;3(4):335-42. | 2313561 |
| 383 | Skowron G, Leoung G, Kerr B, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 1998;12(10):1243-4. | 9677174 |
| 603 | Skowron G, Stein D, Drusano G, et al. Safety and anti-HIV effect of GM-CSF in patients on highly active anti-retroviral therapy [abstract 615]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 1235 | Slain D, Amsden JR, Khakoo RA, et al. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Pharmacotherapy. 2005 Feb;25(2):165-70. | 15767232 |
| 797 | Slater L, Sension M, Feinberg J, et al. Fortovase BID regimens in HIV-1 infected patients: combination with 2 nucleoside analogs or with nelfinavir plus 1 nucleoside analogue [abstract 390]. 6th Conference on Retroviruses and Opportunistic Infections, January 31-February 4, 1999, Chicago IL. | |
| 322 | Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Annals of Pharmacotherapy 1995;29(6):619-24. | 7663035 |
| 2488 | Small DS, Farid NA, Payne CD, et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clinical pharmacokinetics 2010 Dec;49(12):777-98. | 21053990 |
| 3318 | Smit JW, Duin E, Steen H, et al. Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br J Pharmacol 1998;123:361-70. | 9504375 |
| 77 | Smith AG. Potentiation of oral anticoagulants by ketoconazole. Br Med J 1984;288:188-9. | 6318877 |
| 143 | Smith D. Compliance packaging: a patient education tool [letter]. American Pharmacist 1989;NS29:127. | 2929419 |
| 139 | Smith DL. Patient compliance: an educational mandate. McLean, Virginia: Norwich Eaton Pharmaceuticals Inc., Norwich, New York and Consumer Health Information Corporation; 1989. | |
| 1132 | Smith DM, Puoti M, Sulkowski M, et al. Symptomatic hyperlactatemia during a large Hepatitis C treatment trial in HIV/HCV co-infected participants on stable antiretroviral therapy [abstract MoOrB1059]. XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain. | |
| 201 | Smith JA, Hardin TC, Patterson TF, et al. Rifabutin decreases itraconazole plasma levels in patients with HIV infection [abstract 126]. 2nd National Conference on Human Retroviruses and Related Infections, January 29-February 2, 1995, Washington DC. | |
| 1919 | Smith NF, Mani S, Schuetz EG, et al. Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2. Ann Pharmacother 2010;44(11):1709-17. | 20959500 |
| 1295 | Smith P, Kearney BP, Liaw S, et al. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Pharmacotherapy 2004;24(8):970-7. | 15338845 |
| 1078 | Smith PF, Booker BM, Difrancesco R, et al. Effect of methadone or LAAM on the pharmacokinetics of nelfinavir & M8 [abstract A-491]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 2682 | Smith PF, Robbins GK, Shafer RW, et al. Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors Antimicrob Agents Chemother 2005;49(8):3558-61. | |
| 2841 | Smolders E, Burger D, van Seyen M, et al. Treating the "untreatable": adjusted doses of daclatasvir with the anti-epileptic drug carbamazepine (HepNED study 003) [abstract P36]. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL. | http://regist2.virology-education.com/Abstractbook/2017_5.pdf |
| 2796 | Smolders EJ, Kanter CT, Grintjes K, et al. Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir. AIDS 2016 Jun 1;30(9):1491-3. | 27167014 |
| 3399 | Smolders EJ, Willemse SB, El-Sherif O, Khoo S, and Burger DM. The Observed Effect of Gastric Bypass Surgery onDirect-acting Antiviral Treatment: a Case Report. Annals of Hepatology 2018;17(3):525-29 | 29735803 |
| 889 | Snider DE, Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61(4):191-6. | 6269259 |
| 882 | Snodgrass SR. Vitamin neurotoxicity. Molecular Neurobiology 1992;6(1):41-73. | 1463588 |
| 874 | Snyder DC, Mohle-Boetani JC, Chandler A, et al. A population-based study determining the incidence of tuberculosis attributable to HIV infection. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1997;16(3):190-4. | 9390571 |
| 2711 | Sockalingam S, Tseng A, Giguerre P, Wong D. Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterology 2013;13:86. p. 1-10. | |
| 1960 | Solas C, Garraffo R, Gagnieu MC, et al. Pharmacokinetic interaction between maraviroc and etravirine: a multicentre study in HIV-patients receiving an antiretroviral regimen without PI [abstract O_13]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April13-15, 2011, Miami, USA. | |
| 2150 | Solas C, Pambrun E, Winnock M, et al. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS 2012;26(17):2193-9. | 22781224 |
| 1101 | Solas C, Quinson AM, Couprie C, et al. Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy [abstract 440-W]. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA. | |
| 2394 | Song I, Borland J, Arya N, et al. Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects. The Journal of Clinical Pharmacology 2015, 55(5) 490–496. | 25449994 |
| 2983 | Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012;56:1627-9. | 22183173 |
| 1947 | Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol 2011;72(1):103-8. | 21342217 |
| 1949 | Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor, dolutegravir (S/GSK1349572) [abstract P_12]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, May 13-15, 2011, Miami, USA. | |
| 2042 | Song I, Borland J, Chen S, et al. Effect of fosamprenavir/ritonavir on the pharmacokinetics of dolutegravir in healthy subjects. Antimicrob Agents Chemother 2014;58(11):6696-700. | 25155604 |
| 2335 | Song I, Borland J, Chen S, et al. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2013;57: 4394-7. | 23817375 |
| 2088 | Song I, Borland J, Chen S, et al. Metabolism and drug-drug interaction profile of dolutegravir (DTG, S/GSK1349572) [abstract O_07]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 1943 | Song I, Borland J, Lou Y, et al. Effects of enzyme inducers, tipranavir and efavirenz, on the pharmacokinetics of the integrase inhibitor, dolutegravir (S/GSK1349572) [abstract O_02]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13-15, 2011, Miami, USA. | |
| 1948 | Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 2011;55(7):3517-21. | 21555764 |
| 2982 | Song I, Borland J, Savina P et al. Pharmacokinetics of single-dose dolutegravir in HIV-seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clinical Pharmacology in Drug Development 2013;2:342-8 | 26097786 |
| 2622 | Song I, Jerva F, Zong J, et al. Evaluation of drug interactions between dolutegravir and daclatasvir in healthy subjects [abstract 79]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC. | |
| 2281 | Song I, Mark S, Borland J, et al. Dolutegravir has no effect on pharmacokinetics of methadone or oral contraceptives with norgestimate and ethinyl estradiol [abstract 535]. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA. | |
| 1945 | Song I, Min S, Borland J, et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr 2010;55(3):365-7. | 20585260 |
| 1946 | Song I, Min S, Borland J, et al. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol 2011;51(2):237-42. | 20489027 |
| 2436 | Song I, Weller S, Patel J, et al. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. Eur J Clin Pharmacol 2016;72:665-70. | 26898568 |
| 2466 | Song IH, Zong J, Borland J, Jerva F, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr 2016;72(4):400-7. | 26974526 |
| 2957 | Soon G, Dickinson L, Shen P, Li J, Yong EL, Pham PL, Flexner C, Lee L. Coadministration of efavirenz increases intracellular concentrations of once-daily ritonavir-boosted darunavir in healthy volunteers [abstract P_02]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | |
| 1564 | Soon GH, Shen P, Yong EL, et al. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers. Antimicrob Agents Chemother 2010;54(7):2775-80. | 20385850 |
| 1250 | Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel. AIDS 2002;16:813-28. | 11919483 |
| 1254 | Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.[see comment]. Journal of Hepatology 1997;26(1):1-5. | 9147999 |
| 3357 | Souza MCO, Marques MP, Duarte G et al. Pharmacokinetics and placental transfer of bupivicaine enantiomers in HIV-infected parturient women on antiretroviral therapy. J Clin Pharmacol 2020;60:566-72. | 31696528 |
| 2032 | Soyinka JO, Omoruyi SO, Adegbenga RS, et al. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol 2009;61:439-43. | 19298689 |
| 1518 | Soyinka JO, Onyeji CO, Owolabi AR, et al. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol 2010;69(3):262-70. | 20233197 |
| 2547 | Soyinka JO, Onyeji CO. Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2010 Feb 19;39(4):213-8. | 19961932 |
| 423 | Spaide RF. Ganciclovir intraocular device and patient survival [letter; comment]. Archives of Ophthalmology 1994;112(1):19-20; discussion 20-1. | 8285883 |
| 1477 | Spak CW, Dhanireddy S, Kosel B. Clinical interaction between efavirenz and phenytoin. AIDS 2008;22(1):164-5. | 18090412 |
| 1491 | Spector R, Park GD, Johnson GF, et al. Therapeutic drug monitoring. Clin Pharmacol Ther 1988;43(4):345-53. | 3281773 |
| 489 | Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. Journal of Infectious Diseases 1995;171(6):1431-7. | 7769276 |
| 485 | Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group [see comments]. New England Journal of Medicine 1996;334(23):1491-7. | 8618603 |
| 533 | Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. Journal of Infectious Diseases 1993;168(3):557-63. | 8394858 |
| 1619 | Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4-22. | 17214606 |
| 2189 | Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4-22. | 17214606 |
| 1257 | Spradling P, Drociuk D, McLaughlin S, et al. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. Clinical Infectious Diseases 2002;35(9):1106-12. | 12384845 |
| 3293 | Sprout Pharmaceuticals Canada, Ltd. Addyi (flibanserin) Product Monograph. Oakville, ON. October 2, 2019. | |
| 364 | Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group [see comments]. Archives of Internal Medicine 1996;156(15):1729-35. | 8694673 |
| 710 | Squires K, Currier J, Clark R, et al. Final 48-week results of a phase II, randomized study of the safety, efficacy, and pharmacokinetics of BID vsTID nelfinavir and saquinavir in combination with lamivudine and stavudine in HIV-positive women (Women First Trial) [abstract 330]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago IL. | |
| 1220 | Squires KE, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9. | 15247553 |
| 552 | Squires KE. Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS: results of two randomized studies. Aids 1996;10(Suppl 4):S13-8. | 9110065 |
| 1612 | Sriwiriyajan S, Mahatthanatrakul W, Ridtitid W, et al. Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. Eur J Clin Pharmacol 2007;63(5):479-83. | 17345073 |
| 288 | Stagg RJ, Gathe J, Lieberman RM, et al. The Vistide (Cidofovir Injection) treatment IND for relapsing CMV retinitis. 4th National Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 629 | Stalder N, Sudre P, Olmari M, et al. Cytomegalovirus retinitis: decreased risk of bilaterality with increased use of systemic treatment. Clinical Infectious Diseases 1997;24:620-4. | 9145735 |
| 541 | Stanat SC, Reardon JE, Erice A, et al. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrobial Agents & Chemotherapy 1991;35(11):2191-7. | 1666492 |
| 1433 | Stanfield-Oakley SA, Davison DK, Bowling TS, et al. Synergistic in vitro antiretroviral activity of enfuvirtide and elvitegravir [abstract H-1051]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, IL. | |
| 2878 | Stanford University. HIV Drug Resistance Database. | http://hivdb.stanford.edu/ |
| 2489 | Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical pharmacokinetics 2008;47(5):285-95. | 18399711 |
| 1115 | Staszewski S, Dauer B, Stephan C, et al. Pharmacokinetic profile monitoring as an augmentation to therapy evaluation in patients taking a simple boosted double protease inhibitor regimen of lopinavir/r plus saquinavir without reverse transcriptase inhibitors [abstract 2.4]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | |
| 2755 | Staszewski S, Haberl A, Gute P, et al. Nevirapine/didanosine/lamivudine once daily in HIV-1 infected intravenous drug users. Antiviral Ther 1998;3(Suppl 4):55-6. | |
| 271 | Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Jama 1996;276(2):111-7. | 8656502 |
| 272 | Stazewski S, Bartlett I, Eron J, et al. Reductions in HIV-1 disease progression for AZT/3TC relative to control treatments: a meta analysis [abstr Th.B.948]. XI International Conference on AIDS, July 7-12, 1996, Vancouver. | |
| 2968 | Steffe EM, King JH, Inciardi JF et al. The effect of acetaminophen on zidovudine metabolism in HIV-infected patients. J Acquir Immune Defic Syndr 1990;3(7):691-694. | 2352121 |
| 848 | Stein DS, Graham NM, Park LP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Annals of Internal Medicine 1994;121(2):100-8. | 8017721 |
| 949 | Stein DS, Sadler B, Sale M. Pharmacodynamic effects of amprenavir + ritonavir on different viral populations [abstract 5.2]. First International Workshop on Clinical Pharmacology of HIV Therapy, March 30-31, 2000, Noordwijk, the Netherlands. | |
| 3690 | Sterman FL, Lalezari JP, Kowalczyk UM, et al. Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV. AIDS 2023; 37:1057-1064 | 36927740 |
| 1158 | Stevens RC, Rapaport S, Maroldo-Connelly L, et al. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. JAIDS 2003;33(5):650-1. | 12902812 |
| 1331 | Stevens RC, Rapaport S, Maroldo-Connelly L, et al. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. JAIDS 2003;33(5):650-1. | 12902812 |
| 1782 | Stiborova M, Borek-Dohalska L, Hodek P, et al. New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch Biochem Biophys 2002;403:41-9. | 12061800 |
| 1319 | Stocker H, Kruse G, Arasteh K, et al. Pharmacokinetic interaction between saquinavir/r and nelfinavir in HIV-infected patients [abstract A-454]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC. | |
| 1296 | Stocker H, Kruse G, Kreckel P, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 2004;48:4148-53. | 15504834 |
| 161 | Stockwell Morris L, Schulz RM. Medication compliance: the patient's perspective. Clinical Therapeutics 1993;15(3):593-606. | 8364951 |
| 167 | Stockwell Morris L, Schulz RM. Patient compliance: an overview. Journal of Clinical Pharmacy and Therapeutics 1992;17:283-95. | 1464632 |
| 1866 | Stone JA, Li S, Winchell GA, et al. Population pharmacokinetics of caspofungin in candidiasis patients [abstract no. A-1571]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003, Chicago, IL. | |
| 1865 | Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004;48:4306-14. | 15504857 |
| 2342 | Stray KM, Bam RA, Birkus G, et al. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother 2013;57:4982-9. | 23896476 |
| 693 | Strayhorn VA, Baciewicz AM, Self TH. Update on rifampin drug interactions, III. Archives of Internal Medicine 1997;157(21):2453-8. | 9385296 |
| 1928 | Stuart G, Moses A, Corbett A, et al. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. J Acquir Immune Defic Syndr 2011;58(2):e40-3. | 21921726 |
| 569 | Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Archives of Ophthalmology 1996;114(1):23-33. | 8540847 |
| 539 | Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Archives of Internal Medicine 1995;155(1):65-74. | 7802522 |
| 476 | Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. New England Journal of Medicine 1992;326(4):213-20. | 1345799 |
| 610 | Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Annals of Internal Medicine 1997;126:264-74. | 9036798 |
| 1047 | Suleiman J, Rhodes R, Campo R, et al. Preliminary results from indinavir and ritonavir in a once-daily regimen (Merck 103/104) [abstract 336]. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago IL. | |
| 560 | Sullivan SD, Mozaffari E, Johnson ES, et al. An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Clinical Therapeutics 1996;18(3):546-58. | 8829030 |
| 3494 | Sun HY, Cheng CN, Lin YT et al. Bicetegravir concentrations and virologic responses in PLWH receiving 1HP for LTBI [abstract 132]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, March 6-10, 2021. | |
| 3522 | Sun HY, Cheng CN, Lin YT, et al. Bictegravir concentrations and virologic responses in PLWH receiving 1HP for LTBI [abstract 132]. Conference on Retroviruses and Opportunistic Infections (virtual CROI), March 6-10, 2021. | |
| 3440 | Sun Pharma Canada Inc. Odomzo (sonidegib) Product Monograph. Brampton, ON, Canada. June 2020 | https://pdf.hres.ca/dpd_pm/00056602.PDF |
| 3442 | Sun Pharmaceuticals Industries Europe B.V. Odomzo (sonidegib) Summary of Product Characteristics. The Netherlands, 15/10/2020. | https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdf |
| 2176 | SungHee Kole A, Jones H, Christensen R, et al. A case of Kombucha tea toxicity. J Intensive Care Med 2009;24(3):205-7. | 19460826 |
| 3649 | Sunlenca (lenacapavir) Product Monograph. Gilead Sciences Canada. November 1, 2022. | |
| 3628 | Sunlenca (lenacapavir) Summary of Product Characteristics. Gilead Sciences Ireland UC. August 2022. | https://www.ema.europa.eu/en/medicines/human/EPAR/sunlenca |
| 3420 | Sunovion Pharmaceuticals Canada Inc. Xenleta (lefamulin) Product Monograph. Mississauga, ON. July 10, 2020 | https://pdf.hres.ca/dpd_pm/00057231.PDF |
| 2857 | Sunovion Pharmaceuticals Canada Inc. Aptiom (eslicarbazepine) Product Monograph. Mississauga, ON. March 27, 2017. | http://www.sunovion.ca/monographs/aptiom.pdf |
| 2581 | Sunovion Pharmaceuticals Canada Inc. LATUDA (lurasidone HCl) Product monograph. Mississauga ON, April 2018. | |
| 3119 | Sunovion Pharmaceuticals Inc. Arcapta (indacaterol) powder Prescribing Information. Marlborough, MA. March 2017. | |
| 13 | Suttmann U, Ockenga J, Selberg O, et al. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acq Immune Def Syndr Hum Retr 1995;8:239-46. | 7859135 |
| 2054 | Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011;53(7):716-24. | 21890776 |
| 3012 | Sweiss K, Quigley JG, Oh A, et al. A novel drug interaction between busulfan and blinatumomab. J Oncol Pharm Pract 2017 [epub ahead of print]. | 28857712 |
| 220 | Swindells S, Gendelman HE. The new non-nucleoside reverse transcriptase inhibitors. Infect Med 1996;13:715-19, 31. | |
| 1018 | Symonds WT, McDowell J, Chittick G, et al. The safety and pharmacokinetics of GW159U89, zidovudine (ZDV) and lamivudine (3TC) alone and in combination after single-dose administration in HIV-infected patients [abstract P19]. AIDS 1996;10(Suppl 2):S23. | |
| 85 | Symonds WT, O'Connor G, Nix DE. Focus on itraconazole: a broad-spectrum antifungal agent for treatment of blastomycosis and histoplasmosis. Hospital Formulary 1993;28:23-33. | |
| 3063 | Szwarcberg J et al. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) in HIV-Infected Patients with Mild to Moderate Renal Impairment [abstract]. 20th International AIDS Conference, Melbourne, Australia, July 20-25, 2014. | http://www.natap.org/2014/IAC/IAC_60.htm |
| 1822 | T.M. Wyeth Canada. Torisel (temsirolimus) Product Monograph. Kirkland, QC. January 6, 2014. | http://www.pfizer.ca/sites/g/files/g10017036/f/201410/TORISEL_0.pdf |
| 1143 | T.M. Wyeth. Effexor (venlafaxine) Product Monograph. Kirkland, Quebec. May 7, 2015. | http://www.pfizer.ca/sites/g/files/g10028126/f/201511/Effexor_XR_PM_182858_07May2015_E.pdf |
| 1329 | Taburet A, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 2004;48(6):2091-6. | 15155205 |
| 826 | Taburet A, Singlas E. Drug interactions with antiviral drugs. Clinical Pharmacokinetics 1996;30(5):385-401. | 8743337 |
| 2457 | Taburet AM, Piroth L, Paniez H, et al. Pharmacokinetics of asunaprevir, daclatasvir and raltegravir in HCV/HIV co infected patients, with or without cirrhosis, and previously null responders to pegylated interferon + ribavirin (ANRS HC30 - QUADRIH study) [abstract 1967]. American Association for the Study of Liver Diseases The Liver Meeting (AASLD), November 7-11, 2014, Boston, MA. | |
| 1179 | Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clinical Pharmacology and Therapeutics 2004;75:310-23. | 15060509 |
| 1299 | Tackett D, Child M, Agarwala S, et al. Atazanavir: a summary of two pharmacokinetic drug interaction studies in healthy subjects [abstract 543]. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston. | |
| 2958 | Taegtmeyer AB, Müller V, Kovari H, Kullak-Ublick GA, Corti N. Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube. AIDS 2011;25:1339-41. | 21659798 |
| 2363 | Tailor S, Foisy M, A T, et al. The role of the pharmacist in caring for persons living with HIV/AIDS: A Canadian position paper. Can J Hosp Pharm 2000;53(2):92-103. | |
| 1716 | Takanashi S, Bachur NR. Adriamycin metabolism in man. Drug Metab Dispos 1967;4:79-87. | 3405 |
| 1701 | Takanashi S, Bachur NR. Daunorubicin metabolites in human urine. J Pharmacol Exp Ther 1975;195:41-9. | 1181403 |
| 829 | Takano M, Hasegawa R, Fukuda T, et al. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. European Journal of Pharmacology 1998;358(3):289-94. | 9822896 |
| 3263 | Takeda Canada Inc. Alunbrig (brigatinib) Product Monograph. Oakville, ON. July 2018. | |
| 1604 | Takeda Pharmaceuticals America I. Rozerem (ramelteon) Prescribing Information. Deerfield, IL November, 2010. | |
| 2421 | Talaty JE, Caro L, Yeh W, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and efavirenz in normal healthy volunteers [abstract 492]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November, 2013, Washington, DC. | |
| 3213 | Tan LK, Thenmozhiyal JC, Ho PC. Stability of extemporaneously prepared saquinavir formulations. J Clin Pharm Ther 2003;28(6):457-63. | 14651667 |
| 3302 | Tanaka Y, Tateishi R, Koike K. Successful treatment of chronic hepatitis C virus infection with crushed glecaprevir/pibrentasvir administered via a percutaneous endoscopic gastrostomy tube: case report and review of the literature. Clin J Gastroenterol 2019;12(6):588-591. | 31134448 |
| 2892 | Tao X, Sevinsky H, Wang R et al. Atazanavir/cobicistat fixed-dose combination is bioequivalent to the separate agents [abstract]. Conference on Retroviruses and Opportunistic Infections, Boston MA, March 3-6, 2014. | http://www.croiconference.org/sites/default/files/abstracts/525.pdf |
| 1379 | Tappouni HL, Rublein JC, Donovan BJ, et al. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm. 2008 Mar 1;65(5):422-8. | |
| 846 | Tartaglione TA, Collier AC, Opheim K, et al. Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. Antimicrobial Agents & Chemotherapy 1991;35(11):2225-31. | 1803995 |
| 923 | Tashima K, Bose T, Gormley J, et al. The potential impact of efavirenz on methadone maintenance [abstract P0552]. 9th European Congress of Clinical Microbiology and Infectious Diseases, March 21-24, 1999, Berlin, Germany. | |
| 3529 | Tashiro M, Naito T, Kagawa Y, et al. Influence of cytochrome P450 genotype on the plasma disposition of prochlorperazine metabolites and their relationships with clinical responses in cancer patients. Ann Clin Biochem 2018;55(3):385-393. | 28853295 |
| 3383 | Taskar K, Patel P, Cozen S, et al. Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of cabotegravir [abstract 18]. 20th Int Workshop Clin Pharmacol HIV Hepatitis and Other Antiviral Drugs, May 14-16, 2019, Noordwijk, the Netherlands. | http://regist2.virology-education.com/presentations/2019/20AntiviralPK/34_Patel.pdf |
| 386 | Taskintuna I, Banker AS, Rao NA, et al. An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects. Experimental Eye Research 1997;64(5):795-806. | 9245910 |
| 388 | Taskintuna I, Rahhal FM, Arevalo JF, et al. Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1997;104(6):1049-57. | 9186448 |
| 474 | Taskintuna I, Rahhal FM, Rao NA, et al. Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Ophthalmology 1997;104(11):1827-36; discussion 36-7. | 9373113 |
| 1699 | Tattersall MHN, Sodergren JE, Sengupta SK, et al. Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 1975;17:701-8. | 1139861 |
| 2237 | Taylor G, Clayden P, Dhar J, et al. British HIV Association guidelines for the management of HIV infection in pregnant women 2012. HIV Med 2012;13(Suppl 2):87-157. | 22830373 |
| 2256 | Taylor S, Boffito M, Khoo S, et al. Stopping antiretroviral therapy. AIDS 2007;21:1673-82. | 17690564 |
| 2959 | Taylor S, Jayasuriya A, Berry A, Gilleran G, Dufty N, Else L, et al. Darunavir concentrations exceed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1-infected men. AIDS 2010;24:2583-6. | 20736813 |
| 987 | Taylor S, Reynolds H, Drake SM, et al. A pharmacokinetic study of ritonavir 200 mg BID and indinavir 600 mg BID in plasma and semen of HIV-1 infected men [P278]. 5th International Congress on Drug Therapy in HIV Infection, October 22-26, 2000, Glasgow, Scotland: AIDS. | |
| 2759 | Tayrouz Y, Ganssmann B, Ding R, et al. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther, 2001, 70: 405-414 | 11719726 |
| 3113 | TB Ejsing, AD Pedersen, K Linnet P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments Hum Psychopharmacol, 20 (2005), pp. 493-500 | 16118767 |
| 3077 | Tebas P, Bellos N, Lucasti C, Richmond G, Godofsky E, Patel I et al. Enfuvirtide does not require dose-adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. JAIDS Journal of Acquired Immune Deficiency Syndromes. 47(3):342-345, March 1, 2008. | 18091608 |
| 3516 | Teegen EM, Dürr M, Maurer MM, et al. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: therapy of HCV-recurrence. Transpl Infect Dis 2019;21:e13020. | 30375710 |
| 1451 | Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007;46(11):941-52. | 17922559 |
| 3540 | Tempestilli M, D\'Avolio A, De Nicolo A et al. Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. J Antimicrob Chemother 2021; 76:3320-3322.. | 34450632 |
| 2599 | Teng R, Butler K. Effect of the CYP3A4 inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess 2013;2:30-9. | |
| 2600 | Teng R, Mitchell P, Butler K. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. Eur J Clin Pharmacol 2013 Apr;69(4):877-83. | 23093043 |
| 2490 | Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clinical pharmacokinetics 2012 May 1;51(5):305-18. | 22489610 |
| 574 | Tenney DJ, Yamanaka G, Voss SM, et al. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase. Antimicrobial Agents & Chemotherapy 1997;41(12):2680-5. | 9420038 |
| 3200 | Teppler H, Thompson K, Chain A, et al. Crushing of raltegravir (RAL) chewable tablets for administration in infants and young children. 9th Int Workshop on HIV Pediatrics [abstract 37]. Paris, France, July 23-26, 2017. | http://regist2.virology-education.com/Abstractbook/2017/2017_7.pdf |
| 3252 | TEST | 5566. |
| 2156 | Tetrault JM, Tate JP, McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res 2012;36(2):318-24. | 21797892 |
| 3275 | Teva Canada Limited. Leucovorin calcium Product Monograph. Toronto, ON. August 10, 2018. | |
| 3286 | Teva Canada Limited. Treanda (bendamustine) Product Monograph. Montreal, QC.January 10, 2018. | |
| 2859 | Teva Canada Ltd. Alertec (modafinil) Product Monograph. Montreal, QC. June 13, 2017 | http://www.tevacanadainnovation.com/downloads/Alertec_PM_EN.pdf |
| 3592 | Teva Pharmaceuticals. Orap (pimozide) Prescribing Information. Sellersville, PA. January 2008. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017473s041lbl.pdf |
| 3532 | Thakkar N, Magee M, Nguyen D et al. Clinical application for coadministration of fostemsavir and HCV medications [abstract 21]. International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs (virtual), September 20-22, 2021. | |
| 3660 | Thakkar N, Magee M, Nguyen D, et al. Clinical drug interaction of coadministration of FTR and raltegravir in HIV-1 infected subjects [abstract 20]. International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Drugs. Sep 19-20, 2022, Barcelona, Spain. | |
| 2233 | Tharao W, Logie C, James L, et al. “These are some of the things we need”: women living with HIV discuss issues in their daily lives as research priorities [abstract]. Canadian Association for HIV Research Annual Conference, April 14-17, 2011, Toronto, Canada. | |
| 2364 | The Canadian HIV/AIDS Pharmacists Network. 2014; Available from: http://hivclinic.ca/chap/ accessed February 6, 2014. | |
| 203 | The Datri Study Group. Clarithromycin plus rifabutin for MAC prophylaxis: evidence for a drug interaction [abstr]. 1st National Conference on Human Retroviruses and Related Infections, December, 1993, Washington DC. | |
| 204 | The Datri Study Group. Coadministration of clarithromycin alters the concentration-time profile of rifabutin [abstr]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, October, 1994, New Orleans. | |
| 2037 | The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Network (NEAT) consensus conference. AIDS 2011;25(4):399-409. | 21139491 |
| 880 | The Indinavir (MK 639) Pharmacokinetic Study Group. Indinavir (MK 639) drug interaction studies [abstract Mo.B.174]. XI International Conference on AIDS, July 7-12, 1996, Vancouver. | |
| 558 | The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS 1995;9(5):471-7. | 7639972 |
| 3678 | Theratechnologies Inc. Egrifta (tesamorelin) Product Monograph, Montreal, QC, March 26, 2015. | https://pdf.hres.ca/dpd_pm/00029988.PDF |
| 3188 | Theratechnologies, Inc. Trogarzo (ibalizumab) prescribing information. Montreal, QC. December 2023. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761065s020lbl.pdf |
| 805 | Thompson M, Torres G, Enstrom T, et al. Single-dose plasma profiles of abacavir in HIV-1-infected individuals with renal failure [abstract 42278]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 1850 | Thuret I, Chaix M-L, Tamalet C, et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS 2009;23(17):2364-6. | 19823069 |
| 1395 | Timpone J, King J, Qaqish R, et al. Pharmacokinetics of indinavir and ritonavir +/- efavirenz in HIV-infected patients [abstract 33]. 6th International Workshop on Clinical Pharmacology of HIV Therapy April 28-30, 2005, Quebec. | |
| 3083 | Tiraboschi JM, Niubo J, Ferrer E, Barrera-Castillo G, Rozas N, Maso-Serra M, Podzamczer D. Etravirine concentrations in seminal plasma in HIV-infected patients. J Antimicrob Chemother. 2013 Jan;68(1):184-7. | 22954493 |
| 1726 | Tjuljandin SA, Doig RG, Sobol MM, et al. Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res 1990;50:5095-101. | 2379173 |
| 1834 | Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin’s lymphoma. Ann Oncol 2004;15(12):1805-9. | 15550586 |
| 1013 | Toffoli G, Errante D, Corona G, et al. Interactions of antineoplastic chemotherapy with zidovudine pharmacokinetics in patients with HIV-related neoplasms. Chemotherapy 1999;45:418-28. | 10567772 |
| 392 | Tognon MS, Turrini B, Masiero G, et al. Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis. European Journal of Ophthalmology 1996;6(2):179-82. | 8823593 |
| 3614 | Tolbert D, Larsen F. A comprehensive overview of the clinical pharmacokinetics of clobazam. J Clin Pharmacol 2019;59:7-19. | 30285275 |
| 2670 | Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Advanced drug delivery reviews. 2010;62(13):1238-1249. | |
| 2632 | Tomilo DL, Smith PF, Ogundele AB, et al. The effect of lansoprazole acid suppression on the pharmacokinetics of atazanavir in healthy volunteers [abstract A-1192]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2005, 2005, Washington, DC. | |
| 1704 | Tomlinson ES, Lewis DFV, Maggs JL, et al. In vitro metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochem Pharmacol 1997;54:605-11. | 9337077 |
| 2548 | Tommasi C, Bellagamba R, Tempestilli M, et al. Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. Malaria journal 2011;10:141. | 21600016 |
| 2960 | Tommasi C, Nicastri E, Gallo AL, Tempestilli M, Bellagamba R, Fezza R et al. Raltegravir and darunavir pharmacokinetics in HIV-1 infected patients with advanced liver disease [abstract 10]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7th, 2010, Sorrento, Italy. [page 11] | http://regist2.virology-education.com/abstractbook/2010_2.pdf |
| 1569 | Tommasi C, Tempestilli M, Bellagamba R, et al. Pharmacokinetics of darunavir/ritonavir, raltegravir and etravirine coadministered in HIV-1-infected patients [abstract O_11]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 3549 | Toomey CB, Lee J, Spencer DB. Rifabutin-cobicistat drug interaction resulting in severe bilateral panuveitis. Case rep ophthalmol 2020; 11:156-160 | 32399018 |
| 555 | Torgovnick J. Oral ganciclovir for cytomegalovirus retinitis [letter; comment]. New England Journal of Medicine 1996;334(1):55-6. | 7494578 |
| 2961 | Torres R, Anderson P, Kiser J, et al. No influence of CYP3A5 and ABCB1 polymorphisms on darunavir and ritonavir pharmacokinetics in HIV-negative Caucasian volunteers [abstract P_21]. 12th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, USA, April 13-15, 2011. [page 41] | http://regist2.virology-education.com/abstractbook/2011_3.pdf |
| 1500 | Torti C, Quiros-Roldan E, Regazzi M, et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin Infec Dis 2005;40:1828-36. | 15909273 |
| 2639 | Touzot M, Le Beller C, Touzot F, et al. Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient. AIDS 2006;20(8):1210-12. | |
| 2563 | Towner W, Kerrigan HL, LaRiviere M, et al. Efficacy of a once daily (QD) regimen of nevirapine (NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naive HIV infected patients: a pilot study [abstract P49]. 7th International Congress on Drug Therapy in HIV Infection November 14-18, 2004, Glasgow UK. | |
| 1932 | Toy J, Giguère P, Kravcik S, et al. Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia. AIDS 2011;25(4):541-2. | 21293201 |
| 2901 | Toy J, Harris M, la Porte C, Guillemi S, Harrigan P, Montaner J. Therapeutic drug monitoring and clinical outcome after acute atazanavir overdose in an HIV-positive adult male [abstract P_29]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18th, 2012, Barcelona, Spain. | http://regist2.virology-education.com/abstractbook/2012_3.pdf |
| 2246 | Toy J, Zhang G, Giguere P, et al. Therapeutic drug monitoring of antiretrovirals in HIV-1 infected patients: A review of the Ottawa Hospital Program Database [abstract 183]. Ontario HIV Treatment Network Annual Research Conference, November 15-16, 2010, Toronto, ON. | |
| 3227 | Trahan MJ, Lamarre V, Metras ME, Kakker F. Use of triple combination antiretroviral therapy with raltegravir as empiric HIV therapy in the high-risk HIV-exposed newborn. Pediatr Infect Dis J 2019; 38(4):410-412.. | 30882734 |
| 3469 | Tran AH, Best BM, Stek A, et al. Pharmacokinetics of Rilpivirine in HIV-infected pregnant women. J Acquir Immune Defic Syndr 2016;72(3):289-96. | 26918544 |
| 1126 | Tran JQ, Garrett M, Hee B, et al. Pharmacokinetic interactions between delavirdine, lopinavir, and ritonavir during co-administration in healthy volunteers [abstract 7.17]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | |
| 1085 | Tran JQ, Petersen C, Garrett M, et al. Delavirdine significantly increases exposure of low dose ritonavir in healthy volunteers [abstract A494]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 984 | Tran JQ, Petersen C, Garrett M, et al. Delavirdine significantly increases plasma concentrations of amprenavir in healthy volunteers. AIDS 2000;14 (supplement 4):S92. | |
| 980 | Tran JQ, Petersen C, Garrett M, et al. The pharmacokinetics and tolerability of indinavir and delavirdine administered twice-daily in the absence and presence of food in healthy volunteers [abstract 1634]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. | |
| 279 | Trapnell C, Jamis-Dow C, Klecker R, et al. Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrobial Agents and Chemotherapy 1997;41:924-6. | 9145845 |
| 65 | Trapnell CB, Lavelle JP, O'Leary CR, et al. Rifabutin does not alter fluconazole pharmacokinetics. Clinical Pharmacology and Therapeutics 1993;52:196 [abstract PII-06]. | |
| 66 | Trapnell CB, Narang PK, Li R, et al. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Annals of Internal Medicine 1996;124:573-6. | 8597321 |
| 1875 | Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009;9(8):1946-52. | 19519819 |
| 2707 | Troost J, et al. Effects of strong CYP 2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol. 2011;72(2):247-56. | 21496064 |
| 1998 | Tsapepas DS, Webber AB, Aull MJ, et al. Managing the atazanavir-tacrolimus drug interaction in a renal transplant recipient. Am J Health Syst Pharm 2011;68(2):134-42. | 21200061 |
| 123 | Tseng A, Fletcher D, Gold W, et al. Precipitous declines in hemoglobin with combination AZT/3TC. 4th National Conference on Retroviruses and Opportunistic Infections, January, 1997, Washington. | |
| 2640 | Tseng A, Fletcher D. Interaction between ritonavir and levothyroxine. AIDS 1998;12:2235-6. | 9833871 |
| 2063 | Tseng A, Foisy M, Bajcar J, et al. Development of an HIV pharmacy practice specialty residency. Am J Health Syst Pharm 2001;58:591-4. | 11296608 |
| 2062 | Tseng A, Foisy M, Hughes CA, et al. Development of a national HIV/AIDS pharmacists network in Canada [abstract E11553]. XIV International AIDS Conference, July 7-12, 2002, Barcelona. | |
| 2204 | Tseng A, Foisy M, Hughes CA, et al. The role of the pharmacist in caring for patients with HIV/AIDS: clinical practice guidelines. Can J Health-Syst Pharm 2012;65(2):125-45. | 22529405 |
| 960 | Tseng A, Foisy M, Park-Wyllie L, et al. Development of a post-Pharm.D. HIV specialty residency program [abstract WePpD1327]. XIII International AIDS Conference, July 9-14, 2000, Durban, South Africa. | |
| 437 | Tseng A, Foisy M. Adverse Drug Reactions in HIV. In: Fanning MM, editor. HIV Infection: A Clinical Approach. 2nd ed. Philadelphia: W. B. Saunders Company; 1997. p. 180-3. | |
| 2086 | Tseng A, Foisy M. Development of a handbook and website on HIV drug therapy: comprehensive drug information resources for health care professionals [letter]. Am J Health Syst Pharm 2012;69:1284-6. | |
| 2061 | Tseng A, Foisy M. Handbook and website on HIV drug therapy [poster P101]. 20th Annual Conference on HIV/AIDS Research, April 14-17, 2011, Toronto, ON. Can J Infect Dis Med Microbiol 2011;22 (suppl B):72B. . | |
| 2294 | Tseng A, Foisy M. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep 2012;14:67-82. | 22125049 |
| 2491 | Tseng A, Foisy M. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep 2012;14:67-82. | 22125049 |
| 1277 | Tseng A, Nguyen ME, Cardella C, et al. Probable interaction between efavirenz and cyclosporine. AIDS 2002 February 15;16(3):505-06. | 11834972 |
| 955 | Tseng A, Patel M, Gallicano K, et al. A pilot study of nelfinavir therapeutic drug monitoring in HIV infected patients [abstract 210]. Canadian Journal of Infectious Diseases 2000;11(Suppl B):35-6-36B. | |
| 956 | Tseng A, Patel M, Gallicano K, et al. A pilot study of nelfinavir therapeutic drug monitoring in HIV-infected patients [abstract TuPeB3300]. XIII International AIDS Conference, July 9-14, 2000, Durban, South Africa. | |
| 2213 | Tseng A, Raboud J, Walmsley S, et al. Polypharmacy in older patients: Medication use and potential drug interactions in an aging ambulatory HIV clinic population [abstract O_08]. First International Conference on HIV and Aging, October 4-5, 2010, Baltimore, MD. | |
| 2389 | Tseng A, Szadkowski L, Walmsley S, et al. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother 2013 Nov;47(11):1429-39. | 24285760 |
| 870 | Tseng A, Walmsley S. Follow-up to management strategies for candidates for protease inhibitors and requiring treatment for Mycobacterium tuberculosis. Canada Communicable Disease Report 1998;24:129-32. | 9727271 |
| 3197 | Tseng A, Wong AY, McLelland C, Walmsley S. Drug interactions are not always predictable: the curious case of valproic acid and dolutegravir and a possible explanation. AIDS 2019;33:1677-9. | 31305336 |
| 2794 | Tseng A, Wong DK. Hepatotoxicity and potential drug interaction with ledipasvir/sofosbuvir in HIV/HCV infected patients. J Hepatol. 2016 May 19. pii: S0168-8278(16)30201-X. doi: 10.1016/j.jhep.2016.05.015. [Epub ahead of print] | 27210428 |
| 232 | Tseng AL, Dolovich L, Salit IE. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 1997;24:76-7. | 8994766 |
| 231 | Tseng AL, Foisy M. The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: pharmacological review and update on new developments. Canadian Journal of Infectious Diseases 1996;7(3):183-94. | 22514437 |
| 239 | Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Annals of Pharmacotherapy 1997;31:1040-58. | 9296246 |
| 827 | Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. Annals of Pharmacotherapy 1999;33(4):461-73. | 10332538 |
| 2823 | Tseng AL, Luetkehoelter J, Walmsley SL. Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal. AIDS 2017;31(1):175-6. | 27898595 |
| 828 | Tseng AL, Mortimer CB, Salit IE. Iritis associated with intravenous cidofovir. Annals of Pharmacotherapy 1999;33(2):167-71. | 10084411 |
| 2727 | Tseng AL, Salit IE. CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction. Ann Pharmacother 2007;41(3):512-7. | |
| 1 | Tseng AL, Walmsley SL. Rifabutin-associated uveitis. Annals of Pharmacotherapy 1995;29:1149-55. | 8573961 |
| 427 | Tseng AL. Anonymous HIV testing in the Canadian aboriginal population [see comments]. Canadian Family Physician 1996;42:1734-40. | 8828876 |
| 778 | Tseng AL. Compliance issues in the treatment of HIV infection. American Journal of Health-System Pharmacy 1998;55:1817-24. | 9775345 |
| 2231 | Tsunoda SM, Harris RZ, Mroczkowski PJ, et al. Preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women. J Clin Pharmacol 1998;38:1137-43. | 11301566 |
| 61 | Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clinical Infectious Diseases 1992;14:165-74. | 1315160 |
| 2081 | Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002;95(1):147-54. | 12115328 |
| 770 | Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 1998;177(4):1080-3. | 9534987 |
| 2989 | Turley S, Fulco P. Enteral Administration of Twice-Daily Dolutegravir and Rilpivirine as a Part of a Triple-Therapy Regimen in a Critically Ill Patient with HIV. JIAPAC 2017;16(2):117-119. | http://journals.sagepub.com/doi/abs/10.1177/2325957417692678 |
| 397 | Turrini B, Tognon MS, De Caro G, et al. Intravitreal use of foscarnet: retinotoxicity of repeated injections in the rabbit eye. Ophthalmic Research 1994;26(2):110-5. | 8196932 |
| 2517 | Twum-Barima Y, Carruthers SG. Quinidine-rifampin interaction. The New England journal of medicine 1981 Jun 11;304(24):1466-9. | 7231477 |
| 359 | Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group [see comments]. Annals of Internal Medicine 1995;123(2):89-96. | 7778840 |
| 717 | Tyring SK, Douglas JMJ, Corey L, et al. A randomized, placebo-controlled comparison of oval valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Archives of Dermatology 1998;134(2):185-91. | 9487210 |
| 2071 | U.S. Food and Drug Administration. HIV/AIDS Update - Important info about interactions between certain HIV drugs and cholesterol-lowering statin drugs. March 1, 2012. | |
| 1981 | U.S. Food and Drug Administration. Important updates to the Reyataz (atazanavir) label April 30, 2009; Accessed May 17, 2011. | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021567Orig1s019.pdf |
| 2803 | UCB Canada Inc. Vimpat (lacosamide) Product Monograph. Oakville, ON. February 27, 2017. | https://pdf.hres.ca/dpd_pm/00038267.PDF |
| 3519 | Ueaphongsukkit T, Gatechompol S, Sophonphan J et el. Efficacy and PK of dolutegravir 50mg QD with food versus 50mg BID with rifampicin.[abstract 370]. Conference on Retroviruses and Opportunistic Infections (Virual CROI), March 6-10, 2021. | |
| 2 | Unadkat JD, Agosti JM. Problems in pharmacokinetic investigations in patients with HIV infection. Clin Pharmacokinet 1990;19:172-76. | 2203578 |
| 1012 | Unadkat JD, Collier AC, Crosbys S, et al. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS 1990;4:229-32. | 2350441 |
| 1867 | Undre N, Stevenson P, Amakye D. Rifampicin and ritonavir do not affect the pharmacokinetics of micafungin (FK463), an echinocandin antifungal. 14th European Congress of Clinical Microbiology and Infectious Diseases, May 1-4, 2004, Prague, Czech Republic. | |
| 2268 | United Nations. World Contraceptive Use 2010. In: Department of Economic and Social Affairs PD, editor. 2011 Available from: http://www.un.org/esa/population/publications/wcu2010/Main.html. | |
| 3685 | Upjohn Canada ULC. Inspra (eplerenone) Product Monograph. Kirkland, QC. May 11, 2020. | https://pdf.hres.ca/dpd_pm/00056405.PDF |
| 3007 | Upreti W, Boulton DW, Li L et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol 2011;72:92-102. | 21651615 |
| 2513 | Uriel A, Lewthwaite P. Malaria therapy in HIV: drug interactions between nevirapine and quinine. International journal of STD & AIDS 2011 Dec;22(12):768. | 22174067 |
| 144 | Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Inf J 1988;22:363-78. | |
| 1488 | US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1 ed 2009. | |
| 2492 | US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. 2013. | https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm |
| 3411 | Usman S, Oreagba I, Akinyede A, et al. Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria. J Pharmacol Sci 2020;144:95-101. | |
| 819 | USPHS/IDSA Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials. 2001 Nov-Dec;2(6):493-554. | 11742438 |
| 512 | Ussery FMd, Gibson SR, Conklin RH, et al. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988;95(5):640-8. | 2845321 |
| 466 | Ussery FMI, Gibson SR, Conklin RH, et al. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988;95:640-8. | 2845321 |
| 458 | Ussery MA, Kunder SC, Zhang H, et al. The ribonucleotide reductase inhibitors hydroxyurea, didox and trimidox inhibit retroviral replication in the HIV-Infected HuPBMC SCID model and the Rauscher murine leukemia virus (RMuLV) model. 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington DC. | |
| 1820 | Uttamsingh V, Lu C, Miwa G, et al. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6 and 3A4, to the hepatic metabolism of the proteosome inhibitor bortezomib. Drug Metab Dispos 2005;33:1723-8. | 16103134 |
| 1833 | Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001;91(1):155-63. | 11148572 |
| 2125 | Valeant Canada LP. Tiazac (diltiazem) Product Monograph. Laval, QC. March 27, 2017. | https://pdf.hres.ca/dpd_pm/00038702.PDF |
| 1620 | Valeant Canada LP. Zyban (bupropion) Product Monograph. Laval, QC. August 10, 2016. | https://pdf.hres.ca/dpd_pm/00036009.PDF |
| 1608 | Valeant Canada. Ralivia (tramadol) Prescribing Information. West Laval, QC. December 21, 2016. | https://pdf.hres.ca/dpd_pm/00037549.PDF |
| 1974 | Valin N, De Castro N, Garrait V, et al. Cushing's syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature. J Int Assoc Physicians AIDS Care (Chic) 2009;8(2):113-21. | 19270151 |
| 94 | Valsalan VC, Cooper GL. Carbamazepine intoxication caused with isoniazid. British Medical Journal 1982;285:261-2. | 6807441 |
| 240 | Van Cleef G, Fisher EJ, Polk RE. Drug interaction potential with inhibitors of HIV protease. Pharmacotherapy 1997;17(4):774-8. | 9250556 |
| 1935 | Van den Eynde E, Quer J, Cubero M, et al. Abacavir co-administration does not interfere with the suppressive activity of ribavirin in an HCV replicon system [abstract 963]. 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011, Boston, USA. | |
| 1386 | Van der Lee MJ, Blenke A, Rongen G, et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 2007 Nov;51(11):4098-104. | 17846135 |
| 1385 | Van der Lee MJ, Dawood L, ter Hofstede H, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006 Aug;80(2):159-68. | 16890577 |
| 2181 | Van der Lee MJ, Dawood L, ter Hofstede H, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 2006;80(2):159-68. | 16890577 |
| 1392 | Van der Lee MJ, Sankantsing RR, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antiviral Ther 2007;12:1127-32. | 18018771 |
| 1648 | Van der Meer JWM, Keuning JJ, Scheijgrond HW, et al. Influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother 1980;6:522-4. | 6253434 |
| 615 | Van der Pijl H, Jos Frissen PH. Experience with a totally implantable venous access device (Port-A-Cath) in patients with AIDS. AIDS 1992;6:709-13. | 1503690 |
| 595 | Van der Pijl JW, Frissen PHJ, Reiss P, et al. Foscarnet and penile ulceration [letter]. Lancet 1990;335:286. | 1967736 |
| 716 | Van der Ryst E, Strydom W, Scott C, et al. A high rate of psychiatric comorbidity in South African HIV/AIDS patients [abstr 32258]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 1578 | Van der Walt J, Cohen K, McIlleron H, et al. The effect of rifampicin-based tubercular therapy on the population pharmacokinetics of lamivudine [abstract P_24]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 1553 | Van Gyseghem E, Pendela M, Baert L, et al. Power for reconstitution of the anti-HIV-1 drug TMC278 - formulation development, stability and animal studies. Eur J Pharm Biopharm 2008;70:853-60. | 18657611 |
| 1519 | Van Heeswijk R, Gysen V, Googaerts G, et al. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir [abstract A-966]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25-28, 2008, Washington, DC. | |
| 1543 | Van Heeswijk R, Hoetelmans R, Aharchi F, et al. The pharmacokinetic interaction between atorvastatin and TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor in HIV-negative volunteers [P4.3/04]. 11th European AIDS Conference, October 24-27, 2007, Madrid, Spain. | |
| 1544 | Van Heeswijk R, Hoetelmans R, Kestens D, et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor [abstract 74]. 7th International Workshop of Clinical Pharmacology of HIV Therapy, April 20-22, 2007, Lisbon, Portugal. | |
| 1410 | Van Heeswijk RP, al. E. The effects of TMC 278, a next generation non-nucleoside reverse transcriptase inhibitor, on the pharmacokinetics of acetaminophen and CYP2E1 activity in HIV-negative volunteers [abstract 67]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2007, Budapest, Hungary. | |
| 1400 | Van Heeswijk RP, Hoetelmans RM, Kestens D, et al. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers [abstract TUPDB01]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 22-25 2007, Sydney, Australia. | |
| 2712 | Van Heeswijk RP, hoetelmans RM, Kestens D, et al. The pharmacokinetic interaction between ketoconazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor in healthy, HIV-negative subjects [abstract TUPE0087]. XVI International AIDS Conference, August 13-18 2006, Toronto, Canada. | |
| 1429 | Van Heeswijk RP, Hoetelmans RM, Kestens D, et al. The pharmacokinetic interaction between TMC278, a next generation non-nucleoside reverse transcriptase inhibitor, and once daily darunavir/ritonavir in HIV-negative volunteers [abstract H-1042]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, IL. | |
| 2023 | Van Heeswijk RPG, Boogaerts G, De Paepe E, et al. The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor telaprevir [abstract PK_19]. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 22-23, 2011, Cambridge, MA. | |
| 2085 | Van Heeswijk RPG, Boogaerts G, De Paepe E, et al. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 23-24, 2010, Boston, MA. | |
| 2041 | Van Heeswijk RPG, Garg V, Boogaerts G, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers [abstract A1-1738a]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2011, Chicago, IL. | |
| 1930 | Van Heeswijk RPG, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers [abstract 119]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA. | |
| 2022 | Van Heeswijk RPG, Verboven P, Vandevoorde A, et al. Pharmacokinetic interaction between telaprevir and methadone. Antimicrob Agents Chemother 2013;57:2304-9. | 23478952 |
| 782 | Van Heeswilk RPG, Veldkamp AI, Hoetelmans RMW, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS. 1999 Oct 1;13(14):F95-9. | 10513637 |
| 1843 | Van Houtte M, Picchio G, Van Der Borght K, et al. A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. J Med Virol 2009;81:1702-9. | 19697398 |
| 1561 | Van Luin M, Colbers EPH, Verwey-van Wissen C, et al. Raltegravir has no influence on UGT1A4/2B7 when using lamotrigine as a phenotypic probe [abstract 693]. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2009, Montreal, Canada. | |
| 1573 | Van Luin M, Van der Ende ME, Richter C, et al. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. AIDS 2010;24(8):1223-6. | 20299957 |
| 556 | Van Natta ML, Holbrook J. Oral ganciclovir for cytomegalovirus retinitis [letter; comment]. New England Journal of Medicine 1996;334(1):55; discussion 55-6. | 7494577 |
| 78 | Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. European Journal of Clinical Pharmacology 1989;36:423-6. | 2544431 |
| 2109 | Vance DE, Mugavero M, Willig J, et al. Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care 2011;22(1):17-25. | 20471864 |
| 1892 | Vance DE. Aging with HIV: clinical considerations for an emerging population. Am J Nurs 2010;110(3):42-7. | 20179457 |
| 154 | Vanhove GR, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy. Journal of the American Medical Association 1996;276:1955-6. | 8971062 |
| 3483 | Vannappagari V, Albano JD, Koram N, et al. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry. Eur J Obstet Gynecol Reprod Biol 2016;197(6-10). | 26687320 |
| 1706 | Varis T, Kaukonen KM, Kivisto KT, et al. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998;64:363-8. | 9797792 |
| 1705 | Varis T, Kivisto KT, Backman JT, et al. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999;85:29-32. | 10426160 |
| 1709 | Varis T, Kivisto KT, Backman JT, et al. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000;68:487-94. | 11103751 |
| 1708 | Varis T, Kivisto KT, Neuvonen PJ. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. Eur J Clin Pharmacol 2000;56:489-93. | 11049012 |
| 1766 | Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000;56:57-60. | 10853878 |
| 837 | Vasquez JA. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy 1999;19:76-87. | 9917080 |
| 2763 | Vaughan DP, Beckett AH, Robbie DS. The influence of smoking on the intersubject variation in pentazocine elimination. Br J Clin Pharmacol. 1976 Apr;3(2):279-83. | 973961 |
| 23 | Veal GJ, Hoggard PG, Barry MG, et al. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation [letter]. AIDS 1996;10:546-8. | 8724049 |
| 927 | Veldkamp AI, Harris M, Montaner JSG, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human iImmunodeficiency virus type 1 infected persons. Journal of Infectious Diseases 2001;184:37-42. | 11398107 |
| 952 | Veldkamp AI, Hoetelmans RMW, Beijnen JH, et al. Ritonavir enables continued therapy with rifampin and saquinavir. Clinical Infectious Diseases 1999;29:1586. | 10585827 |
| 2154 | Vergara-Rodriguez P, Tozzi MJ, Botsko M, et al. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acq Immune Def Syndr 2011;56(Suppl 1):S62-7. | 21317596 |
| 3527 | Verity Pharmaceuticals. Ivozfo (fosfomycin sodium) Product Monograph. Mississauga, ON. May 1, 2019. | https://pdf.hres.ca/dpd_pm/00050889.PDF |
| 1552 | Verloes R, Van't Klooster G, Baert L, et al. TMC278 long acting - a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers [abstract TUPE0042]. XVIIth International AIDS Conference, August 3-8, 2008, Mexico City, Mexico. | |
| 1915 | Vermeulen JH, Gyurkovits K, Rauer H, et al. Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma. Respiratory Medicine 2007;101:2182-91. | 17614270 |
| 1995 | Vertex Pharmaceuticals Inc. Incivek (telaprevir) Product Monograph. Laval, QC December 17, 2013. | |
| 2647 | Vezina HE, Tschampa JM, Jennings C, et al. Steady state pharmacokinetics of lopinavir/ritonavir coadministered with atazanavir in HIV-infected subjects [abstract 48]. 7th International Workshop on Clinical Pharmacology of HIV Therapy April 20-22, 2006, Lisbon. | |
| 2984 | Viani R, Alvero C, Fenton T, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: forty-eight-week results from IMPAACT P1093. Pediatr Infect Dis J 2015;34:1207-13. | 26244832 |
| 2985 | Viani RM, Alvero C, Fenton T et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment- experienced HIV+ children [abstract]. Conference on Retroviruses and Opportunistic Infections, Boston MA, March 3-6, 2014. | http://www.natap.org/2014/CROI/croi_165.htm |
| 2404 | Vieira CS, Bahamondes MV, de Souza RM, et al. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. J Acquir Immune Defic Syndr 2014 May 4;66(4):378–85. | 24798768 |
| 1849 | Vigano A, Meroni L, Marchetti G, et al. Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. Antiviral Ther 2008;13:839-43. | 18839785 |
| 2330 | ViiV Healthcare ULC, Tivicay (dolutegravir) Prescribing Information. Laval, QC. October 14, 2022. | https://pdf.hres.ca/dpd_pm/00067834.PDF |
| 263 | ViiV Healthcare ULC. 3TC (lamivudine) Product Monograph. Laval, QC. May 3, 2023. | https://pdf.hres.ca/dpd_pm/00070533.PDF |
| 3371 | ViiV Healthcare ULC. 3TC (lamivudine) Product Monograph. Laval, QC. May 3, 2023. | https://pdf.hres.ca/dpd_pm/00070533.PDF |
| 1633 | ViiV Healthcare ULC. Celsentri (maraviroc) Product Monograph. Laval, QC, July 5, 2019. | https://pdf.hres.ca/dpd_pm/00029100.PDF |
| 2974 | ViiV Healthcare ULC. Juluca (dolutegravir/rilpivirine) Prescribing Information. Montreal, QC. August 29, 2022. | https://pdf.hres.ca/dpd_pm/00067267.PDF |
| 2886 | ViiV Healthcare ULC. Kivexa (abacavir/lamivudine) Product Monograph. Laval, QC. September 21, 2021. | https://www.viivhealthcare.com/media/125040/kivexa_pm-2017-05-12.pdf |
| 187 | ViiV Healthcare ULC. Rescriptor (delavirdine) Product Monograph. Montreal, QC. December 15, 2009. | https://www.viivhealthcare.com/media/32305/Rescriptor-MktPM-20130305Canada.pdf |
| 1037 | ViiV Healthcare ULC. Retrovir (zidovudine) Product Monograph. Montreal, QC. June 9, 2021. | https://pdf.hres.ca/dpd_pm/00037623.PDF |
| 3386 | ViiV Healthcare ULC. Rukobia (fostemsavir) Product Monograph. Montreal, QC. October 1, 2021. | |
| 1230 | ViiV Healthcare ULC. Telzir (fosamprenavir) Prescribing Information. Laval, QC. July 5, 2019. | https://pdf.hres.ca/dpd_pm/00037886.PDF |
| 2569 | ViiV Healthcare ULC. Telzir (fosamprenavir) Prescribing Information. Laval, QC. July 5, 2019. | https://pdf.hres.ca/dpd_pm/00037886.PDF |
| 2230 | ViiV Healthcare ULC. Tivicay (dolutegravir) Prescribing Information. Laval, QC. October 14, 2022. | https://pdf.hres.ca/dpd_pm/00067834.PDF |
| 3311 | Viiv Healthcare ULC. Vocabria (cabotegravir) and Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) Product Monograph. Laval, QC. December 7, 2022. | https://pdf.hres.ca/dpd_pm/00069696.PDF |
| 1041 | ViiV Healthcare ULC. Ziagen (abacavir) Product Monograph. Laval, QC. January 20, 2021. | https://pdf.hres.ca/dpd_pm/00037447.PDF |
| 3552 | ViiV Healthcare. Apretude (cabotegravir extended release injectable suspension) Package Insert. Research Triangle Park, NC. February 2023. | |
| 3501 | Viiv Healthcare. Dovato (dolutegravir/lamivudine) Prescribing Information. Research Triangle Park, NC. January 2023. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211994s014lbl.pdf |
| 3259 | Viiv Healthcare. Tivicay (dolutegravir) Prescribing Information. Laval, QC. October 14, 2022. | https://pdf.hres.ca/dpd_pm/00067834.PDF |
| 2790 | ViiV Healthcare. Tivicay (dolutegravir) Prescribing Information. Research Triangle Park, NC. October 2022. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204790s030,213983s003lbl.pdf |
| 3605 | ViiV Healthcare. Tivicay (dolutegravir) Prescribing Information. Research Triangle Park, NC. October 2022. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204790s030,213983s003lbl.pdf |
| 3604 | ViiV Healthcare. Tivicay (dolutegravir) Product Monograph. Laval, QC, Canada. October 14, 2022. | https://pdf.hres.ca/dpd_pm/00067834.PDF |
| 3258 | Viiv Healthcare. Tivicay (dolutegravir) Product Monograph. Research Triangle Park, NC. October 2022. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204790s030,213983s003lbl.pdf |
| 3261 | Viiv Healthcare. Triumeq (dolutegravir/lamivudine/abacavir) Prescribing Information. Laval, QC. September 23, 2022. | |
| 3607 | Viiv Healthcare. Triumeq (dolutegravir/lamivudine/abacavir) Prescribing Information. Laval, QC. September 23, 2022. | https://viivexchange.com/content/dam/cf-viiv/viivexchange/en_CA/open/pdf/triumeq.pdf |
| 3606 | Viiv Healthcare. Triumeq (dolutegravir/lamivudine/abacavir) Prescribing Information. Research Triangle Park, NC. March 2022 | https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG-IFU.PDF#page=1 |
| 3260 | Viiv Healthcare. Triumeq (dolutegravir/lamivudine/abacavir) Prescribing Information. Research Triangle Park, NC. March 2022. | |
| 2887 | ViiV Healthcare. Ziagen (abacavir sulfate) Prescribing Information. Research Triangle Park, NC. November 2020. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020977s035,020978s038lbl.pdf |
| 1093 | Vilaro J, Mascaro J, Colomer J, et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine in HIV-positive patients [abstract A497]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 1067 | Villani P, Viale P, Signorini L, et al. Pharmacokinetic Evaluation of Oral Levofloxacin in Human Immunodeficiency Virus-Infected Subjects Receiving Concomitant Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy 2001;45:2160-62. | 11408245 |
| 1795 | Villikka K, Kivisto KT, Maenpaa H, et al. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999;66:589-93. | 10613614 |
| 3632 | Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol 1998; 83:135-8. | 9783333 |
| 1044 | Vincent I, Paci-Bonaventure S, Batista R, et al. Antiretroviral drug removal by hemodialysis [abstract 8.2]. First International Workshop on Clinical Pharmacology of HIV Therapy, March 30-31, 2000, Noordwijk, the Netherlands. | |
| 1677 | Vingerhoets JH, Peeters M, Azijn H, et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Antiviral Ther 2008;13(Suppl 3):A26. | |
| 2973 | Vispo E et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS, epub 17 March 2010. | 20299955 |
| 1937 | Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008;13(3):429-37. | 18572756 |
| 2714 | Vivus Inc. Stendra (avanafil) Product Monograph. Mountain View, CA. September 2017. | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202276s017lbl.pdf |
| 1278 | Vogel M, Voight E, Wasmuth JC, et al. Drug to drug interactions between ritonavir and cyclosporine A in liver-transplanted HIV-infected patients [abstract 4.7]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 1920 | Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG Trial A5188 J Acquir Immune Defic Syndr 2010;55(4):473-82. | 20842042 |
| 852 | Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235(4794):1376-9. | 2435003 |
| 265 | Volberding P, Lagokos S, Koch M, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. New England Journal of Medicine 1990;322:941-9. | 1969115 |
| 1423 | Vourvahis M, Dumond J, Patterson K, et al. Effects of tipranavir/ritonavir on the activity of cytochrome p450 enzymes 1A2, 2C9 and 2D6 in healthy volunteers [abstract 52]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2007, Budapest, Hungary. | |
| 1958 | Vourvahis M, Fang J, Choo HW, et al. Lack of a clinically relevant effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers [abstract P_14]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13-15th, 2011, Miami, USA. | |
| 1634 | Vourvahis M, Fang J, Huyghe I. Hemodynamic effects of single-dose vardenafil in subjects receiving maraviroc [abstract WEPEB255]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009, Capetown, South Africa. | |
| 1581 | Vourvahis M, LaBadie R, Banerjee S, et al. The effect of raltegravir and darunavir/ritonavir on the pharmacokinetics of the next-generation NNRTI lersivirine (UK-453,061), and of lersivirine on the pharmacokinetics of raltegravir in healthy volunteers [abstract P_27]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 1580 | Vourvahis M, LaBadie R, Fang J, et al. Lack of a clinically relevant effect of lersivirine (UK-453,061), a next-generation NNRTI, on the pharmacokinetics of atazanavir +/- ritonavir and antacid on the pharmacokinetics of lersivirine in healthy subjects [abstract P_20]. 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15-17, 2009, Amsterdam. | |
| 2289 | Vourvahis M, Plotka A, Kantaridis C, et al. The effect of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers [O_17]. 14th International Workshop on Clinical Pharmacology of HIV Therapy, April 22-24, 2013, Amsterdam. | |
| 2377 | Vourvahis M, Plotka A, Kantaridis C, et al. The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: An open-label, fixed-sequence study in healthy volunteers. J Acquir Immune Defic Syndr 2014;65(5):564-70. | 24346637 |
| 2387 | Vourvahis M, Plotka A, Mendes da Costa L, et al. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects. Antimicrob Agents Chemother 2013 Dec;57(12):6158-64. | 24080663 |
| 2097 | Vourvahis M, Plotka A, Mendes da Costa L, et al. Pharmacokinetic interaction between maraviroc and fosamprenavir/ritonavir: an open-label, fixed-sequence study in healthy volunteers [abstract P_12]. 13th International Workshop on Clinical Pharmacology of HIV Therapy, April 16-18, 2012, Barcelona, Spain. | |
| 1901 | Vourvahis M, Vallun SR, Damle B, et al. Pharmacokinetics of QD maraviroc administered as part of a novel NRTI-sparing regimen with atazanavir/ritonavir in HIV treatment-naive patients [abstract 37]. 11th International Workshop on Clinical Pharmacology of HIV Therapy, April 5-7, 2010, Sorrento, Italy. | |
| 2029 | Vourvahis M, Wang R, Gruener DM, et al. Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers. Drug Alcohol Depend 2012;Jun 8 [Epub ahead of print]. | 22682979 |
| 2533 | Vugt MV, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. The American journal of tropical medicine and hygiene 1999 Jun;60(6):936-42. | 10403324 |
| 3609 | Waalewijn H, Szubert A, Wiesner L et al. TAF/TFV pharmacokinetics when given with PI/InSTI in the CHAPAS-4 pediatric trial. [abstract 734] CROI 2022, Feb 12-24, 2022, hybrid virtual/Denver CO. | https://www.croiconference.org/wp-content/uploads/sites/2/resources/2022/croi2022-program-guide.pdf |
| 109 | Wagner JC. Rifampin-phenytoin drug interaction [abstr]. Drug Intell Clin Pharm 1984;18:497 [abstract]. | |
| 2811 | Wai A, Naccarato M, Hall E, Ostrowski M, Carvalhal A. A probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy: a case report [abstract CSP11.05]. The 25th Annual Canadian Conference on HIV/AIDS Research, May 12-15, 2016, Winnipeg, Manitoba. | |
| 1656 | Wakeham K, Parkes-Ratanshi R, Watson V, et al. Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. J Antimicrob Chemother 2010;65(2):316-9. | 20032007 |
| 3559 | Waldman G, Bethea E, Gustafson J et al. Use of crushed glecaprevir/pibrentasvir in hepatitis C positive donor heart transplant recipients [abstract 211]. J Heart Lung Transplant 2020;39:S95-S96. | https://www.jhltonline.org/article/S1053-2498(20)30958-X/fulltext |
| 3011 | Walimbwa SI, Lamorde M, Waitt C et al. Drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine. Antimicrob Agents Chemother 2019;63:e01310-18. | 30420479 |
| 2251 | Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 2012;205(Suppl 3):S391-8. | 22577213 |
| 897 | Wallace RJ, Jr., Brown BA, Griffith DE, et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. Journal of Infectious Diseases 1995;171(3):747-50. | 7876634 |
| 757 | Walmsley S, Walach C, Moses A, et al. Salvage therapy with a combination including nelfinavir in patients failing treatment including a protease inhibitor (PI) [abstract 12285]. 12th World AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland. | |
| 604 | Walmsley SL, Chew E, REad SE, et al. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate (Foscarnet). Journal of Infectious Diseases 1988;157(3):569-72. | 2830347 |
| 1289 | Walmsley SL, Katlama C, Lazzarin A, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):429-40. | 18176328 |
| 767 | Walsh JC, Jones CD, Barnes EA, et al. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 1998;12:613-8. | 9583601 |
| 570 | Walton RC, Whitcup SM, Mueller BU, et al. Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. Ophthalmology 1995;102(12):1865-70. | 9098289 |
| 3615 | Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340–353. | 22422635 |
| 3610 | Wamalwa DC, Musiime V, Kekitiinwa AR et al. Living: 48-week data on LPV/r pellets in 990 children in resource-limited studies. CROI 2022 [abstract 721]. February 12-24, 2022, hybrid virtual/Denver CO. | https://ww2.aievolution.com/cro2201/index.cfm?do=abs.viewAbs&abs=2654 |
| 2240 | Wang B, Sanchez RI, Franklin RB, et al. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos 2004;32(11):1209-12. | 15304426 |
| 2930 | Wang C, Sun JH, O'Boyle DR, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 2013; 57: 2054-2065. | 23403428 |
| 1638 | Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002;46:160-5. | 11751127 |
| 1807 | Wang L, Christopher LJ, Cui D, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 2008;36:1828-39. | 18556438 |
| 2493 | Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug metabolism and disposition: the biological fate of chemicals 2010 Mar;38(3):448-58. | 19940026 |
| 1080 | Wang LH, Blum MR, Hui J, et al. Lack of significant pharmacokinetic interactions between emtricitabine and other nucleoside antivirals in healthy volunteers [abstract A 505]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2001, Chicago, IL. | |
| 623 | Wang LH, Lyogendran S, Weller S, et al. A phase I trial evaluating the tolerability and pharmacokinetics of 1263W94 following single oral administration of escalating doses in normal healthy volunteers [abstract H028]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 15-18, 1996, New Orleans. | |
| 1583 | Wang X, Boffito M, Zhang J, et al. Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients. AIDS Patient Care STDS 2011;25(9):509-15. | 21770762 |
| 3698 | Wang, X, Cerrone M, Ferretti F, et al. Pharmacokinetics of dolutegravir 100mg once-daily with rifampicin. Int J Antimicrob Agents 2019;54(2):202-206. | 31002950 |
| 559 | Ward-Able C, Phillips P, Tsoukas CM. The use of oral ganciclovir in the treatment of cytomegalovirus retinitis in patients with AIDS. Cmaj 1996;154(3):363-8. | 8564906 |
| 830 | Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1998;19(3):203-9. | 9803961 |
| 3084 | Wassner C, Maiti S, Kodroff K, Cohen H. Iatrogenic adrenal insufficiency secondary to combination therapy with elvitegravir/cobicistat/tenofovir disproxil fumarate/emtricitabine and interlaminar triamcinolone injection in an AIDS patient. J Int Assoc Provid AIDS Care 2017;16:535-9. | 28895486 |
| 3634 | Watkins PB, Murray SA, Winkelman LG et al. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 1989;83:688-97. | 2913056 |
| 2705 | Watson Laboratories, Inc. Rapaflo® (silodosin) product monograph. Mississauga, ON; June 10, 2013. | http://www.actavis.ca/NR/rdonlyres/70828090-3E89-46C1-9229-359531B4BB33/0/Rapaflo_Product_Monograph_English.pdf |
| 2136 | Watts DH, Park JG, Cohn SE, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 2008;77(2):84-90. | 18226670 |
| 1952 | Weatherley B, Vourvahis M, McFadyen L. Modeling of maraviroc pharmacokinetics in the presence of atazanavir/ritonavir in healthy volunteers and HIV-1-infected patients [abstract P_05]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13-15, 2011, Miami, USA. | |
| 3575 | Weber E, Graham H, West S et al. Pharmacokinetics of lenacapavir in participants with severe renal impairment [abstract 434]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, February 12-16, 2022. | |
| 1725 | Weenen H, Lankelma J, Penders PG, et al. Pharmacokinetics of 4-epi-doxorubicin in man. Invest New Drugs 1983;1:59-64. | 6590528 |
| 3403 | Weidlich S, Boesecke C, Schneider J, et al. Sufficient plasma levels within 24 weeks of antiretroviral HIV therapy of dolutegravir combined with boosted darunavir: A pharmacologic subgroup analysis of the DUALIS study [abstract PEB0242]. 23rd International AIDS Conference Virtual, July 6-10, 2020. | https://cattendee.abstractsonline.com/meeting/9289/Presentation/1155 |
| 562 | Weinberg DV, Murphy R, Naughton K. Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. American Journal of Ophthalmology 1994;117(6):776-82. | 8198162 |
| 2831 | Weiner M, Benator D, Peloquin P, et al. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin Inf Dis 2005;41(9):1343-9. | 16206114 |
| 2078 | Weiner M, Egelund EF, Engle M, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother 2014;69:1079-85. | 24343893 |
| 500 | Weisenthal RW, Sinclair SH, Frank I, et al. Long-term outpatient treatment of CMV retinitis with ganciclovir in AIDS patients. British Journal of Ophthalmology 1989;73(12):996-1001. | 2558708 |
| 2002 | Weiss J, Herzog M, Haefeli WE. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Clin Pharmacol 2011;660(2-3):298-304. | 21501604 |
| 3492 | Weiss J, Herzog M, Konig S et al. Induction of multiple drug transporters by efavirenz. J Pharmacol Sci 2009;109:242-50. | 19234366 |
| 2664 | Weiss J, Kerpen CJ, Lindenmaier H, et al. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther. 2003 Oct;307(1):262-7. | |
| 3230 | Weiss L, Wustmann K, Semmo M, et al. Elbasvir/grazoprevir, an alternative in antiviral hepatitis C therapy in patients under amiodarone treatment. Case Rep Gastroenterol 2018;12:92-8. | 29606942 |
| 1769 | Weiss RB. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 1982;66:427-38. | 6277485 |
| 2987 | Weller S, Borland J, Chen S, et al. Bioequivalence of a dolutegravir, abacavir and lamivudine fixed dose combination tablet and the effect of food. JAIDS 2014;66:393-8. | 24798770 |
| 2986 | Weller S, Borland J, Chen S, et al. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol 2014;70:29-35. | 24096683 |
| 1985 | Welzen MEB, Van den Berk GEL, Hamers RL, et al. Interaction between antiretroviral drugs and acenocoumarol. Antiviral Ther 2011;16:249-52. | 21447874 |
| 1430 | Wenning L, Anderson MS, Petry A, et al. Raltegravir dose proportionality and effect of food [abstract H-1046]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, IL. | |
| 1588 | Wenning L, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008 Sep;52(9):3253-8. | 18625763 |
| 1576 | Wenning L, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009 July;53:2852-6. | 19433563 |
| 1517 | Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009 Jul;53(7):2852-6. | 19433563 |
| 2210 | Werner CR, Egetemeyr DP, Lauer UM, et al. Short report: Telaprevir-based triple therapy in liver transplanted HCV patients: A 12 week pilot study providing safety and efficacy. Liver Transplantation 2012;Sep 1 [Epub ahead of print]. | 22941516 |
| 1748 | Wheeler GP, Johnston TP, Bowdon BJ, et al. Comparison of the properties of metabolites of CCNU. Biochem Pharmacol 1977;26:2331-6. | 145865 |
| 1526 | Wheeler W, Mahle K, Bodnar U, et al. Antiretroviral drug-resistance mutations and subtypes in drug-naive persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006 [abstract 648]. 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, 2007, Los Angeles, CA. | |
| 3560 | Whelchel K, Zuckerman AD, Koren DE et al. Crushing and splitting direct-acting antivirals for hepatitis C virus treatment: a case series and literature review. Open Forum Infect Dis 2021;8:ofab525. | 34805439 |
| 771 | Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis [letter]. Jama 1997;277(19):1519-20. | 9153364 |
| 1781 | White IN, De Matteis F, Gibbs AH, et al. Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol 1995;49:1035-42. | 7748182 |
| 2521 | White T, Clode S, Gaunt I, et al. Developmental toxicity of the antimalarial artesunate in rats and rabbits. Birth Defect Res Part A 2004;70:265. | |
| 2218 | Wiegman D-J, Brinkman K, Franssen EJF. Interaction of Gingko biloba with efavirenz. AIDS 2009;23:1184-5. | 19451798 |
| 1592 | Wilby KJ, Greanya ED, Ford JA, et al. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. [Research Support, Non-U.S. Gov't] 2012 Mar-Apr;11(2):179-85. | 22345334 |
| 116 | Wilcox JB. Phenytoin intoxication and cotrimoxazole [letter]. N Z Med J 1981;94:235-6. | 6975449 |
| 3463 | Williams PL, Crain MJ, Ylidirim C, et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr 2015;169(1):48-55. | 25383770 |
| 3460 | Williams PL, Yildirim C, Chadwick EG, et al. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study. Lancet HIV 2020; 7(1):e49-58. | 31740351 |
| 3046 | Winston A, Amin J, Clarke A, Else L, Amara A, Owen A, Barber T, Jessen H, Avihingsanon A, Chetchotisakd P, Khoo S, Cooper DA, Emery S, Puls R; ENCORE Cerebrospinal Fluid (CSF) Substudy Team; ENCORE Cerebrospinal Fluid CSF Substudy Team. Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial. Clin Infect Dis. 2015 Apr 1;60(7):1026-32. | 25501988 |
| 1507 | Winston A, Khoo S. Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy? Current Opinion in HIV & AIDS 2008;3(6):608-11. | 19373031 |
| 2560 | Winter HR, Trapnell CB, Slattery JT, et al. The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clinical pharmacology and therapeutics 2004 Oct;76(4):313-22. | 15470330 |
| 801 | Wintergerst U, Rolinski B, Solder B, et al. Lack of absorption of didanosine after rectal administration in human immunodeficiency virus-infected patients [In Process Citation]. Antimicrob Agents Chemother 1999;43(3):699-701. | 10049294 |
| 2614 | Wire MB, al. E. The pharmacokinetic interaction between fosamprenavir/ritonavir and atazanavir in healthy adult subjects (APC 10018) [abstract 4.3/9]. 10th European Conference on AIDS, November 17-20, 2005, Dublin | |
| 1315 | Wire MB, Baker KL, Jones LS, et al. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. Antimicrob Agents Chemother. 2006 Apr;50(4):1578-80. | 16569890 |
| 1237 | Wire MB, Baker KL, Moore KHP, et al. The pharmacokinetic interaction of GW433908 with atorvastatin and 908/ritonavir with atorvastatin (APV10013) [abstract A-1622]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003, Chicago, IL. | |
| 1314 | Wire MB, Ballow C, Preston S, et al. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 2004;18(6):897-907. | 15060437 |
| 2463 | Wire MB, Fang L, Hussaini A, et al. Lack of Clinically Significant Pharmacokinetic Interaction between the Thrombopoietin Receptor Agonist Eltrombopag and Hepatitis C Virus Protease Inhibitors Boceprevir and Telaprevir. Antimicrob Agents Chemother 2014 Nov;58(11):6704-9. | 25155600 |
| 1305 | Wire MB, Lou Y, Shelton MJ, et al. Evaluation of plasma amprenavir pharmacokinetics following administration of fosamprenavir formulations with a high fat breakfast [abstract A-448]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC. | |
| 3122 | Wire MB, McLean HB, Pendry C, et al. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrob Agents Chemother 2012;56:2846-51. | 22391553 |
| 1269 | Wire MB, Naderer OJ, Masterman AL, et al. The pharmacokinetic interaction between GW433908 and lopinavir/ritonavir (APV10011 and APV10012) [abstract 612]. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco CA. | |
| 79 | Wishart JM. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J Am Acad Dermatol 1987;17:220-3. | 3040815 |
| 3511 | Wiznia A, Alvero C, Fenton T, et al. IMPAACT 1093; dolutegravir in 6- to 12-year-old HIV infected children: 48-week results. Presented at CROI 2016, Boston MA. | https://www.croiconference.org/abstract/impaact-1093-dolutegravir-6-12-year-old-hiv-infected-children-48-week-results-0/ |
| 1125 | Wolfe PR, Anderson PG, Gunawan S. Simultaneous administration of amprenavir and saquinavir does not appear to lower plasma levels of either agent when coadministered with low-dose ritonavir [abstract 7.11]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | |
| 3545 | Wong A, Gryzb K, Fuchs D, et al. Safety and efficacy of E/C/F/TAF switch followed by SOF/VEL antiviral HCV therapy followed by B/F/TAF simplification in HIV-HCV co-infected subjects receiving opioid agonist therapy with methadone or buprenorphine/naloxone [abstract PE2/15]. 18th European AIDS Conference, October 27-30, 2021, London, UK and virtual. | https://eacs2021.abstractserver.com/program/#/details/presentations/634 |
| 3135 | Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 2013; 57: 6333-6340. | 23877691 |
| 2824 | Wood BR, Lacy JM, Johnston C, et al. Adrenal insufficiency as a result of ritonavir and exogenous steroid exposure: report of 6 cases and recommendation for management. J Int Assoc Provid AIDS Care 2015;14(4):300-5. | 25589302 |
| 1046 | Wood R, Eron J, Arasteh K, et al. A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. Clin Infect Dis. 2004 Aug 15;39(4):591-4. | 15356829 |
| 985 | Wood R, Trepo C, Livrozet JM, et al. Enhancement of pharmacokinetic parameters of amprenavir when combined with low dose ritonavir (APV 600 mg/RTV 100 mg BID) and preliminary efficacy results [P283]. 5th International Congress on Drug Therapy in HIV Infection October 22-26, 2000, Glasgow, Scotland: AIDS. | |
| 1113 | Wood R, Wire MB, Lancaster T, et al. An assessment of plasma amprenavir pharmacokinetics following administration of Agenerase and low dose ritonavir QD in combination with efavirenz in HIV-infected adult subjects (COL30500) [abstract 2.2]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | |
| 311 | Woods A, Wahlin H. The probable role of benign histoplasmosis in the etiology of granulomatous uveitis. American Journal of Opthalmology 1960;49:205. | 13845884 |
| 155 | Woodward WC. Should directly observed therapy be considered for treatment of HIV? Journal of the American Medical Association 1996;276. | 8971063 |
| 652 | Woolley J, Studenberg S, Boehlert C, et al. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94 [abstract A-60]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28-October 1, 1997, Toronto. | |
| 690 | Workman C, Mussen R, Sullivan J. Salvage therapy using six drugs in heavily pretreated patients [abstract 426]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 815 | Workman C, Whittaker W, Dyer W, et al. Combining ritonavir and indinavir decreases indinavir-associated nephrolithiasis [abstract 677]. 6th Conference on Retroviruses and Opportunistic Infections, January 31-February 4, 1999, Chicago IL. | |
| 2520 | World Health Organization. Assessment of the safety of artemisinin compounds in pregnancy. Report on two RBM/TDR informal consultations [WHO/CDS/MAL/2003]. . Geneva 2003. p. 1094. | |
| 2497 | World Health Organization. Malaria and HIV interactions and their implications for public health policy: report of a technical consultation. . Geneva, Switzerland: World Health Organization,. 2005 Available from: http://www.searo.who.int./LinkFiles/Reports_MalariaHIVinteractions.pdf. | |
| 2265 | World Health Organization. Sexual and reproductive health of women living with HIV/AIDS: guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Geneva, Switzerland 2006. | http://www.who.int/hiv/pub/guidelines/sexualreproductivehealth.pdf |
| 2266 | World Health Organization. Technical update on treatment optimization: use of efavirenz during pregnancy: a public health perspective. Geneva, Switzerland 2012 Available from: http://apps.who.int/iris/bitstream/10665/70920/1/9789241503792_eng.pdf. | |
| 2255 | World Health Organization. Women and health : today's evidence tomorrow's agenda. Geneva, Switzerland 2009 Available from: http://whqlibdoc.who.int/publications/2009/9789241563857_eng.pdf. | |
| 95 | Wright JM, Stokes EF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction. New England Journal of Medicine 1982;307:1325-7. | 7133069 |
| 314 | Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. Journal of Pharmacokinetics & Biopharmaceutics 1996;24(5):461-73. | 9131485 |
| 744 | Wu EY, Wilkinson JM, 2nd, Naret DG, et al. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. Journal of Chromatography B, Biomedical Sciences and Applications 1997;695(2):373-80. | 9300874 |
| 3446 | Wu F, Krishna G, Surapaneni S. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib. Cancer Chemother Pharmacol 2020;86:461-73. | 32886148 |
| 3359 | Wu YT, Kao YL, Lin LC et al. Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. Int J Pharm 2010;396:127-33. | 20600721 |
| 2590 | Wyen C, Fuhr U, Frank D, Aarnoutse RE, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.Clin Pharmacol Ther. 2008 Jul;84(1):75-82 | 18183034 |
| 2529 | Wynalda MA, Hutzler JM, Koets MD, et al. In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug metabolism and disposition: the biological fate of chemicals 2003 Jul;31(7):878-87. | 12814964 |
| 1267 | Wynn Vezina HE, Brundage RC, Bushman L, et al. Pharmacologic management of the drug-drug interaction between lopinavir/ritonavir and amprenavir [abstract 609]. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco CA. | |
| 2494 | Xu C, Desta Z. In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug metabolism and pharmacokinetics 2013;28(4):362-71. | 23385314 |
| 1967 | Yacoob Y, Bhigjee AI, Moodley P, et al. Sodium valproate and highly active antiretroviral therapy in HIV positive patients who develop new onset seizures. Seizure 2011;20(1):80-2. | 20952215 |
| 3500 | Yager JL, Brooks K, Brothers J et al. Exogenous hormone pharmacokinetics in transgender adolescents receiving oral TDF/FTC [abstract 366]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, March 6-10, 2021. | |
| 2012 | Yakiwchuk EM, Foisy MM, Hughes CA. Complexity of interactions between voriconazole and antiretroviral agents. Ann Pharmacother 2008;42(5):698-703. | 18413691 |
| 3065 | Yamada H, Ikushima I, Nemoto T, Ishikawa T, Ninomiya N, Irie S. Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects. Clin Pharmacol Drug Dev. 2018 Feb;7(2):132-142. | 28581645 |
| 3066 | Yamada H, Ikushima I, Nemoto T, Ishikawa T, Ninomiya N, Irie S. Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects. Clin Pharmacol Drug Dev. 2018 Feb;7(2):132-142. | 28581645 |
| 1764 | Yamashita SK, Ludwig EA, Middleton EJ, et al. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther 1991;49:558-70. | 1827622 |
| 1642 | Yan J, Marino MR, Smith RA, et al. The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. J Clin Pharmacol 2006;46:193-200. | 16432271 |
| 2669 | Yanakakis LJ, Bumpus NN. Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012 Apr;40(4):803-14. | |
| 1800 | Yao D, Ding S, Burchell B, et al. Detoxification of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 2000;294:387-95. | 10871337 |
| 3208 | Yap JE, Jaiswal P, Ton L, et al. Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube. J Clin Pharm Ther 2018;43(5):730-732. | 29906312 |
| 1672 | Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infec Dis 2009;49(9):1441-9. | 19814627 |
| 1545 | Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009 Nov 1;49(9):1441-9. | 19814627 |
| 3145 | Yee KL, Khalilieh SG, Sanchez RI et al. The effect of single and multiple doses of rifampin on the pharmacokinetics of doravirine in healthy subjects. Clin Drug Investig 2017;37:659-67. | 28353169 |
| 3148 | Yee KL, Sanchez RK, Auger P, et al. Evaluation of doravirine pharmacokinetics when switching from efavirenz to doravirine in healthy subjects. Antimicrob Agents Chemother 2017;61:pii: e01757-16. | 27872069 |
| 86 | Yeh J, Soo SC, Summerton C, et al. Potentiation of action of warfarin by itraconazole [letter]. British Medical Journal 1990;29:301. | 2171705 |
| 653 | Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrobial Agents and Chemotherapy 1998;42:332-8. | 9527781 |
| 1470 | Yeh R, Ajuoga E, Hou J, et al. Lack of pharmacokinetic interaction of ritonavir-boosted lopinavir and atazanavir with cranberry juice in HIV-positive individuals (abstract P28). 9th International Workshop on Clinical Pharmacology of HIV Therapy, April 7-9 2008, New Orleans, LA. | |
| 1274 | Yeh R, Gaver V, Patterson K, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acq Immune Def Syndr 2006;42(1):52-60. | 16639344 |
| 2149 | Yeh R, Gaver V, Patterson K, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acq Immune Def Syndr 2006;42:52-60. | 16639344 |
| 2423 | Yeh W, Caro L, Huang X, et al. No pharmacokinetic interaction between HCV protease inhibitor MK-5172 and HCV NS5A inhibitor MK-8742 in healthy volunteers [abstract 478]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC. | |
| 2621 | Yeh W, Feng HP, Auger P, et al. No pharmacokinetic interaction between HCV inhibitors grazoprevir/elbasvir with rilpivirine [abstract 63]. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC. | |
| 2772 | Yeh W, Feng HP, Dunnington K, et al. No clinically meaningful pharmacokinetic interactions between HCV inhibitors grazoprevir/elbasvir with tacrolimus, mycophenolate mofetil, and prednisone, but cyclosporine increases grazoprevir/elbasvir exposures in healthy subjects [abstract] American Association for the Study of Liver Diseases (AASLD), November 13-17, 2015, San Francisco, CA. | |
| 2573 | Yeh W, Feng HP, Guo Z, et al. Drug-drug interaction between HCV inhibitors grazoprevir/elbasvir with dolutegravir [abstract 522]. Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015, Seattle, WA. | |
| 2353 | Yeh W, Fraser IP, Bifano M, et al. Lack of pharmacokinetic interaction between HCV protease inhibitor MK-5172 and HCV NS5A inhibitor daclatasvir in healthy volunteers [abstract 464]. Hepatology 2013;58(4 (suppl)):430A. | |
| 2419 | Yeh W, Fraser IP, Caro L, et al. No meaningful PK interaction between HCV protease inhibitor MK-5172 and tenofovir or raltegravir [abstract 500]. 21st Conference on Retroviruses and Opportunistic Infections (CROI), Mar 3-6, 2014, Boston, MA. | |
| 2418 | Yeh W, Fraser IP, Reitmann C, et al. Pharmacokinetic interaction of HCV protease inhibitor MK-5172 and ritonavir in healthy subjects [abstract 52]. HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis, December 8-12, 2013, Big Island, Hawaii. | http://www.natap.org/2013/hepDART/hepDART_01.htm |
| 2383 | Yeh W, Marshall W, Mangin E, et al. Pharmacokinetic interactions between the HCV NS5A inhibitor MK-8742 and efavirenz [abstract 498]. Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014, Boston, MA. | |
| 2398 | Yeh W, Marshall WL, Caro L, et al. Pharmacokinetic interaction of HCV NS5A inhibitor MK-8742 and ketoconazole in healthy subjects [P_27]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC. | |
| 2424 | Yeh W, Smith C, Caro L, et al. No meaningful pharmacokinetic interaction between hepatitis c virus protease inhibitor MK-5172 and ethinyl estradiol and levonorgestrel [abstract 53]. HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis, December 8-12, 2013, Big Island, Hawaii. | |
| 2382 | Yeh WY, Marshall W, Ma J, et al. Ritonavir-boosted atazanavir, lopinavir, & darunavir increase HCV NS5A inhibitor MK-8742 levels [abstract 635]. Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014, Boston, MA. | |
| 1555 | Yeni P, Goebel F, Thompson M, et al. TMC278, a next-generation NNRTI demonstrates potent and sustained efficacy in antiretroviral-naive patients: week 48 primary analysis of study TMC278-C204 [abstract P7.2/07]. 11th European AIDS Conference, October 24-27, 2007, Madrid, Spain. | |
| 3047 | Yilmaz A, Watson V, Dickinson L, Back D. Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Antimicrob Agents Chemother 2012;56 4583-4585. | 22687515 |
| 2169 | Yiu P, Nguyen NN, Holodniy M. Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Pharmacother 2011;31(5):480-9. | 21923429 |
| 2374 | Yoganathan K, David L, Williams C, et al. Cushing's syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection. Int J STD AIDS 2012 Jul;23(7):520-1. | 22844010 |
| 1970 | Yombi JC, Maiter D, Belkhir L, et al. Iatrogenic Cushing’s syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol 2008;27(Suppl 2):S79-82. | 18827959 |
| 3124 | Yoong D, Naccarato M, Gough K. Extensive bruising and elevated rivaroxaban plasma concentration in a patient receiving cobicistat-boosted elvitegravir. Ann Pharmacother. 2017;51:713-4. | 28351160 |
| 395 | Yoshizumi MO, Roca JA, Lee DA, et al. Ocular iontophoretic supplementation of intravenous foscarnet therapy. American Journal of Ophthalmology 1996;122(1):86-90. | 8659602 |
| 114 | Youle MS, Clarbour J, Gazzard B, et al. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine [letter]. Lancet 1988;1:1455-6. | 2898602 |
| 470 | Young SH, Morlet N, Henry S, et al. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Medical Journal of Australia 1992;157:370-3. | 1333036 |
| 2161 | Yu C, Campbell S, Sponseller C, et al. Steady-state pharmacokinetic interactions of darunavir/ritonavir with pitavastatin in healthy adult volunteers [abstract TUPE053]. XIX International AIDS Conference, July 22-27, 2012, Washington, DC. | |
| 1697 | Yu L, Waxman DJ. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab Dispos 1996;24:1254-62. | 8937861 |
| 126 | Yuen G, Anderson R, Daniels R, et al. Investigations of nelfinavir mesylate pharmacokinetic interactions with indinavir and ritonavir. 4th National Conference on Retroviruses and Opportunistic Infections, 1997, Washington DC. | |
| 2007 | Zacà V, Metra M, Danesi R, et al. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. Ther Adv Respir Dis 2009;3(1):11-4. | 19293198 |
| 1853 | Zaccarelli M, Antinori A, Cozzi-Lepri A, et al. Is there any potential for first-line etravirine use? Analysis from a large dataset of ART-naive HIV-infected patients undergoing resistance test [abstract WEPEB211]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22,, 2009, Capetown, South Africa. | |
| 1142 | Zalma A, von Moltke LL, Granda BW, et al. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiatry 2000;47(7):655-61. | 10745059 |
| 3546 | Zanon D, Manca A, D Nicolo A et al. Data on the stability of darunavir/cobicistat suspension after tablet manipulation. Data Brief 2020 Jun;30:105552. | 32292805 |
| 3454 | Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. New Engl J Med 2019;381(9):827-40. | |
| 3248 | Zash R, Holmes L, Diseko M, Jacobson, DL, Brummel S, Mayondi G, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med 2019;381(9):827-840. | 31329379 |
| 3412 | Zash R, Holmes L, Diseko M, Jacobson, DL, Brummel S, Mayondi G, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. [abstract OAXLB0102]. 23rd International AIDS Conference Virtual. July 6-10, 2020. | https://cattendee.abstractsonline.com/meeting/9289/presentation/3500 |
| 3566 | Zash R, Holmes LB, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Abstract PEBLB14. Presented at: IAS 2021. Virtual Conference Available at: https://www.ias2021.org/wp-content/uploads/2021/07/IAS2021_Abstracts_web.pdf | |
| 2036 | Zembruski NC, Büchel G, Jödicke L, et al. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother 2011;66(4):802-12. | 21393174 |
| 2877 | Zepatier: Clinical Pharmacology and biopharmaceutics Review(s): https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000ClinPharmR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000ClinPharmR.pdf |
| 2239 | Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17 alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 2007;46(2):133-57. | 17253885 |
| 3267 | Zhang H, Custodio JM, Wei X, et al. Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir [abstract 40]. Conference on Retroviruses and Opportunistic Infections, Seattle, February 13-16, 2017. | http://www.croiconference.org/sessions/clinical-pharmacology-hiv-integrase-strand-transfer-inhibitor-bictegravir |
| 3694 | Zhang H, Martin H, Lin L, et al. Pharmacokinetics (PK), safety, and efficacy of bictegravir/emtricitabine/tenofovir alafanamide (B/F/TAF) in virologically suppressed pregnant women living with HIV. IAS 2023 Conference, Brisbane, Australia, July 23-26, 2023. | https://programme.ias2023.org/Abstract/Abstract/?abstractid=681 |
| 3576 | Zhang H, Mortensen E, Rhee M et al. Evaluation of potential drug-drug interactions between islatravir and lenacapavir [abstract 433]. Conference on Retroviruses and Opportunistic Infections (CROI) virtual, February 12-16, 2022. | |
| 2874 | Zhang H, Shao Y, Garner W, et al. The effect of hepatic or renal impairment on bictegravir pharmacokinetics [abstract 27[. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, Chicago, IL. June 14-16, 2017. | |
| 1435 | Zhang J, Chung E, Yones C, et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther 2011;16(2):157-64. | 21447864 |
| 1574 | Zhang J, Zhu L, Stonier M, et al. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother 2011;66:2075–82. | 21712242 |
| 2069 | Zhang X, Fettner S, Zwanziger E, et al. Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects. Antimicrob Agents Chemother 2011;55(2):680-7. | 21135186 |
| 1732 | Zhao XJ, Kawashiro T, Ishizaki T. Mutual inhibition between quinine and etoposide by human liver microsomes. Evidence for cytochrome P4503A4 involvement in their major metabolic pathways. Drug Metab Dispos 1997;26:188-91. | 9456308 |
| 33 | Zhi J, Rakhit A, Patel IH. Effects of dietary fat on drug absorption. Clinical Pharmacology and Therapeutics 1995;58:487-91. | 7586941 |
| 2495 | Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug metabolism and disposition: the biological fate of chemicals 2011 Apr;39(4):703-10. | 21177984 |
| 2264 | Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab 2008;9(5):394-409. | 18537576 |
| 1798 | Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993;53:5121-6. | 8221648 |
| 1560 | Zhu L, Mahnke L, Butterton J, et al. Pharmacokinetics and safety of twice daily atazanavir 300 mg and raltegravir 400 mg in healthy subjects [abstract 696]. 16th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2009, Montreal, Quebec. | |
| 1416 | Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol. 2011 Mar;51(3):368-77. | 20457590 |
| 2089 | Zhu, L., Brüggemann, R. J., Uy, J., et al. CYP2C19 Genotype–Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. [abstract O_08]. The Journal of Clinical Pharmacology 2017; 57: 235–246. | |
| 3663 | Zino L, Jacobs TG, Nieuwenstein T et al. Model-informed intermittent tenofovir disoproxil fumarate and emtricitabine dosing for HIV pre-exposure prophylaxis in subjects with renal impairment: a case report. AIDS 2023;37:363-5. | 36541648 |
| 3647 | Zino L, Kingma JS, Marzolini C, et al. Implications of bariatric surgery on the pharmacokinetics of antiretrovirals in people living with HIV. Clin Pharmacokinet. 2022;61:619-635. | |
| 1306 | Zong J, Chittick G, Blum MR, et al. Pharmacokinetic assessment of tenofovir DF and ritonavir-boosted saquinavir in healthy subjects [A-444]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC. | |
| 676 | Zorrilla C, Clark R, Currier J, et al. ***see Squires 98 (#710) for updated data!*** Women First: a study in HIV positive women of quadruple therapy: nelfinavir, saquinavir, stavudine (d4T) and lamivudine (3TC) [abstract 722]. 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, 1998, Chicago, IL. | |
| 2962 | Zorrilla C, Wright R, Osiyemi O, Yasin S, Baugh B, Brown K, et al. Total and unbound darunavir pharmacokinetics in HIV-1-infected pregnant women [abstract P74]. 11th Congress on Drug Therapy in HIV Infection, Glasgow, November 11-15, 2012. [page 11] | http://hivarchive.com/hiv11/uploads/Clinical%20Pharmacology%20-%20Part%20One.pdf |
| 1286 | Zucchi P, Cusato M, Villani P, et al. Pharmacokinetic evaluation of saquinavir boosted with ritonavir in patients receiving two different doses (1600/100 mg od or 1000/100 mg BID) [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 112 | Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clinical Pharmacokinetics 1986;11:299-315. | 3530584 |
| 3281 | Zykadia (ceritinib) prescribing information (US). Revised March 2019. | |
| 3253 | bbss | 56578 |
| 1056 | de Gast M, Burger D, van Crevel R, et al. Double trouble: a pharmacokinetic study of indinavir/ritonavir (800 +100 mg BID) and rifampin for patients co-infected with TB and HIV [abstract 1.10]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4, 2001, Noordwijk, the Netherlands. | |
| 3054 | de Hoon M, Colbers A, Burger D, et al. Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given with Drip Feed [abstract 431]. Conference on Retroviruses and Opportunistic Infections, Boston MA, Feb 22-25, 2016. | http://www.croiconference.org/sites/default/files/posters-2016/431.pdf |
| 692 | de Jong MD, Vella S, Carr A, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. Journal of Infectious Diseases 1997;175(4):966-70. | 9086161 |
| 2072 | de Kanter C, Blonk M, Colbers A, et al. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infec Dis 2013;56(2):300-6. | 23001704 |
| 2224 | de Knegt RJ, Bezemer G, Van Gool AR, et al. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2011;34(11-12):1306-17. | 21999489 |
| 2815 | de Lorenzo-Pinto A, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, et al. Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration. J Clin Pharm Ther 2016;41(4):444-446. | 27159430 |
| 1247 | de Maat MM, Ekhart GC, Huitema AD, et al. Drug interactions between antiretroviral drugs and comedicated agents. Clinical Pharmacokinetics 2003;42(3):223-82. | 12603174 |
| 943 | de Maat MMR, Hoetelmans RMW, Mathot RAA, et al. Drug interaction between St John's wort and nevirapine. AIDS 2001;15(3):420-1. | 11273226 |
| 844 | de Miranda P, Good SS, Yarchoan R, et al. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clinical Pharmacology & Therapeutics 1989;46(5):494-500. | 2582706 |
| 3348 | de Waal R, Kroon SM, Holgate S et al. Nevirapine concentrations in preterm and low birth weight HIV-exposed infants. Pediatr Infect Dis J 2014;33:1231-33. | 24945881 |
| 1753 | den Hartigh J, McVie JG, van Oort WJ, et al. Pharmacokinetics of mitomycin C in humans. Cancer Res 1983;43:5017-21. | 6411336 |
| 3457 | ford | |
| 3224 | gilead monograph | |
| 3225 | gilead monograph | |
| 2862 | khali | |
| 3586 | product monograph | |
| 2606 | rascino RJ, Gaines Griffy K, Jung D, et al. Mu ltiple dose crossover study of IV ganciclovir induc tion dose (5 mg/kg IV q12h) and didanosine (200 mg po q12h) in HIV-infected persons [abstract A-27]. 3 5th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco. | |
| 2553 | ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. The American journal of tropical medicine and hygiene 2004 Aug;71(2 Suppl):41-54. | 15331818 |
| 2173 | van den Bout-van den Beukel CJP, Bosch MEW, Burger D, et al. Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications. AIDS 2008;22(10):1243-4. | 18525278 |
| 2174 | van den Bout-van den Beukel CJP, Koopmans PP, van der Ven AJAM, et al. Possible drug metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metabolism Reviews 2006;38:477-514. | 16877262 |
| 861 | van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. New England Journal of Medicine 1997;337(1):15-21. | 9203426 |
| 547 | van der Meer JT, Drew WL, Bowden RA, et al. Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection. Antiviral Research 1996;32(3):119-40. | 8955508 |
| 434 | van der Ven AJ, Koopmans PP, Vree TB, et al. Adverse reactions to co-trimoxazole in HIV infection [see comments]. Lancet 1991;338(8764):431-3. | 1678095 |
| 432 | van der Ven AJ, Riegr A, Branten A, et al. Cutaneous reactions to trimethoprim-sulphametrole in AIDS patients treated for Pneumocystis carinii pneumonia. Aids 1996;10(3):341-2. | 8882678 |
| 431 | van der Ven AJ, Vree TB, Koopmans PP, et al. Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. Journal of Antimicrobial Chemotherapy 1996;37(Suppl B):55-60. | 8818829 |
| 1586 | van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007 Dec 15;13(24):7394-400. | 18094422 |
| 2572 | van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007 Dec 15;13(24):7394-400. | 18094422 |
| 1119 | van Heeswijk RP, Cooper C, Gallicano K, et al. The pharmacokinetics of saquinavir/ritonavir 400/400 mg BID before, and after short- and long-term co-administration of efavirenz 600 mg QD [abstract 7.4]. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 11-13, 2002, Washington DC. | |
| 1290 | van Heeswijk RP, Sabo J, Cooper C, et al. The pharmacokinetic interactions between tipranavir/ritonavir 500/200 mg BID and atorvastatin, antacid, and CYP3A4 in healthy adult volunteers [abstract 5.2]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 1321 | van Heeswijk RP, Sabo J, MacGregor TR, et al. The effect of tipranavir/ritonavir 500/200 mg BID on the pharmacokinetics of clarithromycin in healthy volunteers [abstract A-457]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC. | |
| 1281 | van Heeswijk RP, Sabo J, MacGregor TR, et al. The effect of tipranavir/ritonavir 500/200 mg BID on the pharmacokinetics of fluconazole in healthy volunteers [abstract]. 5th International Workshop on Clinical Pharmacology of HIV Therapy, April 1-3, 2004, Rome, Italy. | |
| 1320 | van Heeswijk RP, Sabo J, MacGregor TR, et al. The pharmacokinetic interaction between single-dose rifabutin and steady-state tipranavir/ritonavir 500/200 mg BID in healthy volunteers [abstract A-456]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, 2004, Washington, DC. | |
| 1302 | van Heeswijk RP, Veldkamp AI, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antiviral Therapy 2002;6:201-29. | 11878403 |
| 1898 | van Luin M, Colbers A, van Ewijk-Beneken-Kolmer EW, et al. Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J Acquir Immune Defic Syndr 2010;55:82-86. | 20395869 |
| 1869 | van Luin M, Colbers A, Verwey-van Wissen CP, et al. The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol 2009;49(10):1220-7. | 19717722 |
| 1788 | van Maanen MJ, Huitema AD, Beijen JH. Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate. Anticancer Res 2000;20(3A):1711-6. | 10928097 |
| 3362 | van Seyen M, Samson AD, Cullen L, et al. Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder. Int J Antimicrob Agents 2020;55:105934. | https://pubmed.ncbi.nlm.nih.gov/32156618/ |
| 3242 | van Seyen M, Smolders EJ, van Wijngaarden P, et al. Successful HCV treatment of patients on contraindicated anti-epileptic drugs: role of drug level monitoring. J Hepatol 2019;70:552-4. | 30473264 |
| 2532 | van Vugt M, Ezzet F, Nosten F, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. The American journal of tropical medicine and hygiene 1999 Dec;61(6):964-7. | 10674679 |
| 1914 | von Berg A, Engelslatter R, Minic P, et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily vs. budesonide 400 microg once daily in children with asthma. Pediatr Allergy Immunol 2007;18(5):391-400. | 17617808 |
| 2659 | von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9. | |
| 245 | von Moltke LL, Greenblatt DJ, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clinical Pharmacokinetics 1995;29(Suppl 1):33-43; discussion 43-4. | 8846621 |
| 1000 | von Moltke LL, Greenblatt DY, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. Journal of Clinical Pharmacology 1998;38:106-11. | 9549640 |